• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    opioid receptor ligands and methods of using and making them this application describes compounds that can act as opioid receptor ligands, the compounds of which can be used in the treatment of, for example, pain and pain related disorders.
    公开号:BR112013024136A2
    申请号:R112013024136
    申请日:2012-03-23
    公开日:2020-01-14
    发明作者:C K Yuan Catherine；Yamashita Dennis；Gotchev Dimitar；Liu Guodong；Pitis Philip；Chen Xiao-Tao
    申请人:Trevena Inc；
    IPC主号:
    专利说明:

    Invention Patent Descriptive Report for: LIGANDOS
    RECEIVER OF OPIOID AND METHODS OF USING AND MANUFACTURING THE
    SAME.
    FIELD
    This application relates to a family of compounds acting as opioid receptor ligands. Such compounds can provide a therapeutic benefit in the treatment of pain.
    BACKGROUND
    Opioid receptors (ORs) mediate the actions of morphine and morphine-type opioids, including most clinical analgesics. Three types of opioid receptor molecularly and pharmacologically distinct have been described: δ, κ and μ. In addition, each type is believed to have subtypes. All three types of this opioid receptor appear to share the same functional mechanisms at the cellular level. For example, activation of opioid receptors causes inhibition of adenylate cyclase, and recruits β-arrestin.
    When therapeutic doses of morphine are given to patients in pain, patients report that the pain is less intense, less uncomfortable, or that it passes completely. In addition to experiencing relief from distress, some patients experience euphoria. However, when morphine in a dose selected to relieve pain is given to a pain-free individual, the experience is not always pleasant; nausea is common, and vomiting can also occur. Drowsiness, inability to concentrate, difficulty in mental activity, apathy, decreased physical activity, reduced visual acuity, and lethargy can result.
    There is a continuing need for new OR modulators to be used as pain relievers. There is another need for OR agonists like painkillers having reduced side effects. There is still another need for OR agonists such as analgesics having reduced side effects for the treatment of pain, immune dysfunction, inflammation, esophageal reflux, neurological and psychiatric conditions, urological and reproductive conditions, drugs for alcohol and drug abuse, agents to treat gastritis and diarrhea, cardiovascular agents and / or agents for the treatment of respiratory diseases and cough.
    SUMMARY
    This application describes opioid receptor (OR) ligands. It also describes methods of modulating opioid receptor activity using the compositions described here. Some compositions described here act as opioid receptor agonists. Other compositions described here act as opioid receptor antagonists.
    This application describes compounds having the structure of formula I:
    In the structure above, the variables Ai, A 2 , A 3 , A4, A5, Bi,
    B 2 , B 3 , B4, B 5 , and Di can be selected from the respective groups of chemical portions described later. Derivatives of OR ligand and mimetics are also provided. Processes for preparing these compounds are also provided.
    This application also describes pharmaceutical compositions comprising one or more compounds, as described in this application, and a pharmaceutically acceptable carrier. Naturally, the compounds described here can be employed in any form, as a solid or a solution (for example, aqueous solution) as described below. The compounds described herein, for example, can be obtained and used in a lyophilized form alone or with appropriate additives.
    Methods for treating pain and pain-related disorders are also provided. Such a method should comprise administering a therapeutically effective amount of one or more compounds described herein to an individual in need thereof.
    DETAILED DESCRIPTION
    This application describes a family of compounds, ligands DE OR, with a unique profile. The compounds described here act as opioid receptor (OR) mediated signal transduction agonists or antagonists.
    The ligands of these receptors can be used to treat pathologies associated with ORs including pain and pain-related disorders.
    Compounds also comprise formula I:
    where: A, is null, CH 2 , CHRi, CR1R2, CH, CRi, O, S, SO,
    SO 2 , NH or NRi; A 2 is null, CH 2 , CHR 5 , CR 5 R 6 , CH, CR 5 , O, S,
    SO, SO 2 , NH or NR 5 ; A 3 is null, CH 2 , CHR 7 , CR 7 R 8 , O, S, SO,
    SO 2 , NH, NR 7 , CH or CR 7 ; A4 is null, CH 2 , formula cycle
    C (CH 2 ) n, where η = 2-5, CHR 9 , CR 9 Rio, 0, S, SO, S0 2 , NH, NR 9 ,
    CH or CR 9 ; and A5 is null, CH 2 , CHR11, CRnRi 2 , CH 2 CH 2 , CHRnCH 2 ,
    CH 2 CHRh, CHRhCHRi 2.0 , S, SO, SO 2 , NH, NRn, CH OR CRn.
    No more than 2 out of 5 Aa (specifically Ai, A 2 ,
    A3, A4, A 5 ) can be null at the same time. The number of heteroatoms from Ai to A5 cannot exceed 2 at the same time, and 0-0, S-0; SS; SN fragments in the ring structure are excluded from this composition.
    The ring containing Ai, A 2 , A3, A4, As and the carbon connected to Di can be fused with another ring, such as benzene, pyridine, pyrimidine, furan, thiophene or pyridazine, but not limited to these examples, where the resulting bicycle it is chemically stable and synthetically accessible. It should also be understood that the aforementioned fused rings 15 can be poly-substituted with cyano, halogen, alkyl, branched alkyl, halogenated alkyl, hydroxyl, alkyloxy, formyl, acetyl, amino, alkylamino, dialkylamino, mercaptanyl, alkylmercaptanyl, and other groups small replacement parts. The connections between Ai and A 2 , 2 0 A 2 and A3, A3 and A4, A4 and As can be independently a single connection or a double connection. The connections between Ai and A 2 , A 2 and A3, A3 and A4, A4 and A5 cannot be a double connection at the same time.
    A 2 and A 4 can be connected by a carbon bridge.
    Examples of such a bridge include -CH2-, and -CH2CH2-.
    Bi, is CH 2 , CHR13, CR13R14, O, S, SO, SO 2 , NH, NR13, CR13 or CO. B 2 is CH 2 , CHR15, CR15R16, CR15 or CO. B 3 is H, alkyl, branched alkyl, halogenated alkyl, aryl, arylalkyl, alkylcarbonyl, branched alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or alkylsulfonyl. B 4 is null, C 1 -C 6 alkyl, CH 2 , CH 2 CH 2 , CHR19, CR19R20 or CO. In some embodiments, when B 4 is alkyl, one or more of the hydrogens can be replaced with a deuterium. B5 is alkyl, branched alkyl, halogenated alkyl, alkyl substituted by carbocycle, aryl, carbocycle or arylalkyl.
    Aryl, carbocycle (non-aromatic) / heterocycle (non-aromatic with 1-3 heteroatoms, including O, N, S) are either unsubstituted, or substituted with small substitution groups. Small substitution groups can be cyano, halogen, alkyl, branched alkyl, halogenated alkyl, hydroxyl, alkyloxy, amino, alkylamino, dialkylamino, mercaptanyl, alkylmercaptanyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, alkylcarbonyl, alkoxycarbonyl, dialoxycarbonyl, dialoxycarbonyl, dialoxycarbonyl, dialoxycarbonyl , arylalkyl, carbocycle or carbocycloalkyl. In some embodiments, the small substitution groups are selected from among F,
    Cl, Br, CH 3 , CH2CH3, CH2F, CHF 2 , CF 3 , n-Pr, n-Bu, i-Bu, secBu, i-Pr, t-Bu, CN, OH, OMe, OEt, O-iPr , OCF 3 , NH 2 , NHMe,
    NMe 2 , methoxycarbonyl, methanesulfonyl, Ph, benzyl,
    MeSO 2 , formyl, and acetyl.
    Carbocycles may contain double bonds, but they must not be aromatic.
    Di is an aryl group or a carbocycle.
    An aryl group is either a monocyclic aromatic group or a bicyclic aromatic group, which may contain hetero atoms in the aromatic group (for example, heteroaryl). The following structures are some examples of representative aryl groups, but aryl groups are not limited to them:




    Carbocycle is either a monocyclic ring system or a non-aromatic bicyclic ring. The following structures are some examples of a representative carbocycle, but the carbocycle is not limited to these examples:

    wherein Xi, and X 2 in the carbocycle examples are independently 0, S, N, NH or NRie.
    The aryl groups can be independently mono- or poly-substituted with cyano, halogen, alkyl, branched alkyl, halogenated alkyl, hydroxyl, alkyloxy, amino, alkylamino, dialkylamino, mercaptanyl, alkylmercaptanyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, alkylcarbonyl, alkylcarbonyl, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonylyl, carbonyl, alkoxyl, carbonyl, alkoxyl, carbonyl, alkylcarbonyl. , alkylaminocarbonyl, dialkylaminocarbonyl, aryl, arylalkyl, carbocycle, carbocycle-alkyl, and / or other small substitution groups. In some embodiments, the small substitution groups are selected from F, Cl, Br, CH 3 , CH2CH3, CH 2 F, CHF2, CF 3z n-Pr, n-Bu, i-Bu, sec-Bu, i -Pr, t-Bu, CN, OH, OMe, OEt, 0-iPr, OCF 3 , NH 2 , NHMe, NMe 2 , methoxycarbonyl, methanesulfonyl, Ph, benzyl, formyl, and acetyl.
    Di is an aryl, or a carbocycle.
    Ri, R2, R5, Re, R7, Rs, R9, Rio, R11, R12, R13, R14, R15, R16, Ris, R19, and R 2 are independently: cyan, halogen, hydroxyl, alkyloxy, alkyl, alkyl branched, halogenated alkyl, branched halogenated alkyl, aryl, arylalkyl, carbocycle, carbocycle-alkyl, alkylcarbonyl, branched alkylcarbonyl, halogenated alkylcarbonyl, branched halogenated alkylcarbonyl, arylcarbonyl or alkoxycarbonyl. In some embodiments, Ri, R 2 , R 5 , Re, R , Rs, Rg, Rio, R11, R12, R13, Ri4, Ris, R16, Ris <Rig, and R 2 are independently F, Cl , Br, CH 3 , CH 2 CH 3 , CH 2 F, CHF 2 , CF 3 , n-Pr, n-Bu, i-Bu, sec-Bu, i-Pr, t-Bu, CN, OH, OMe , OEt, Oi-Pr, methoxycarbonyl, phenyl, benzyl, formyl or acetyl, whenever a resulting structure is stable.
    Ri θ R2, R5 6 Re, R7 and Rs, R9 θ Rio, Rue Ri 2 , R13 and R14,
    Rib and Ri6, Ria and R 2 o, or R15 and R19 can form a unicycle.
    Me is methyl; Et is ethyl; i-Pr is i-propyl; t-Bu is tbutyl; Ph is phenyl.
    In some embodiments, the following compounds can be excluded from the compound genus:
    1) 2 - [({2 - [2-Ethyl-2-methyl-4 - (4-methylphenyl) oxan-4-yl] ethyl} amino) methyl] phenol
    2) 2- [({2- [2-Ethyl-4- (4-fluorophenyl) -2-methyloxan-4-yl] ethyl} amino) methyl] phenol
    3) {2- [2,2-Dimethyl-4- (4-methylphenyl) oxan-4yl] ethyl} [(4-methoxyphenyl) methyl] amine
    4) {2 - [(4S *, 4R *) - 2,2-dimethyl-4- (4-methylphenyl) oxan-4-yl] ethyl} [(IR) -1-phenylethyl] amine
    5) {2- [(4S *, 4R *) -2,2-dimethyl-4 - (4-methylphenyl) oxan-4-yl] ethyl} [(IS) -1-phenylethyl] amine
    6) Benzyl ({2- [2,2-dimethyl-4- (4-methylphenyl) oxan-4-yl] ethyl}) amine
    7) 2 - [({2- [2-Ethyl-4- (4-fluorophenyl) -2-methyloxan-4-yl] ethyl} amino) methyl] phenol
    8) Benzyl [2- (2,2-dimethyl-4-phenyloxan-4-yl) ethyl] amine
    9) {2- [2-Ethyl-4- (4-fluorophenyl) -2-methyloxan-4-yl] ethyl} [(4-methoxyphenyl) methyl] amine
    10) [(3,4-Dimethoxyphenyl) methyl] ({2- [4- (4-fluorophenyl) 2,2-dimethyloxan-4-yl] ethyl}) amine
    11) {2 - [4- (4-Methoxyphenyl) -2,2-dimethyloxan-4-yl] ethyl} (1-phenylethyl) amine
    12) [(4-Chlorophenyl) methyl] ({2 - [4 - (4-methoxyphenyl) -2,2-dimethyloxan-4-yl] ethyl}) amine
    13) Benzyl ({2- [2-Ethyl-4- (2-methoxyphenyl) -2-methyloxan-
    4-yl] ethyl}) amine
    14) [(3,4-dimethoxyphenyl) methyl] ({2- [2-ethyl-4- (2methoxyphenyl) -2-methyloxan-4-yl] ethyl}) amine
    15)
    - [({2 - [4 - (2-Methoxyphenyl) -2,2-dimethyloxan-4-yl] ethyl} amino) methyl] -N, N dimethylaniline
    16) Benzyl ({2- [4- (4-fluorophenyl) -2,2-dimethyloxan-4yl] ethyl}) amine
    {2- [2,2-dimethyl-4- (4-methylphenyl) oxan-4-yl] ethyl} (1-phenylethyl) amine
    18) [2- (2,2-Dimethyl-4-phenyloxan-4-yl) ethyl] [(4methoxyphenyl) methyl] amine
    19) {2 - [4 - (4-Fluorophenyl) -2,2-dimethyloxan-4-yl] ethyl} [(4-methoxyphenyl) methyl] amine
    20) [(3,4-Dimethoxyphenyl) methyl] [2- (2,2-dimethyl-4-phenyloxan-4-yl) ethyl] amine
    This application also describes compounds having the structure of formula II-1 and II-2:
    & 3
    where A 2 is CH 2 , CHR5, CRsRe; A 4 is CH 2 , CHRg, CR9R10, or a cycle of formula C (CH 2 ) n, where n = 2-5.
    Even more R 5 Re, R9, and Rio are independently CH3,
    CH2CH3, CH 2 F, CHF 2 , CF3, n-Pr, n-Bu, i-Bu, sec-Bu, i-Pr, tBu, or phenyl. Furthermore, R 5 and Re, or R9 and Rio can form a monocyclic carbocycle.
    A 2 and A 4 can be connected by a carbon bridge. This bridge can be -CH 2 - or -CH 2 CH 2 -.
    Even more B3 is selected from the following: H, alkyl, branched alkyl, aryl, arylalkyl, alkylcarbonyl, branched alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, and alkylsulfonyl. In some embodiments, B3 is C1-C5 alkyl. In some embodiments, B3 is H.
    Even more B4 is null, Ci-Ce alkyl, CH2, CH2CH2, CHR19,
    CR19R20 or CO. Furthermore, R19 and R20 can form a monocycle of the formula (CH2) n, where n = 2-4. Bs is alkyl, branched alkyl, carbocycle, alkyl substituted by carbocycle, aryl or arylalkyl.
    Even more Di is an arila. Examples of the aryl groups are shown above.
    Each aryl group can be independently mono- or poly-substituted with F, Cl, Br, CH3, CH2CH3, CH2F, CHF2, CF3, n-Pr, n-Bu, i-Bu, sec-Bu, i-Pr, t -Bu, CN, OH, OMe, OEt, O-iPr, OCF3, NH 2 , NHMe, NMe2, me toxicarbonyl, Ph, benzyl, formyl, or acetyl. That is, each aryl group can be poly-substituted with the same substituent (ie, 2 chlorine groups) or just be poly-substituted, although with different groups (for example, an aryl group with 1 chlorine and 1 methyl group would be considered polysubstituted).
    This application also describes compounds having the structure of formula III:
    III where A2 is CH2, CHR5 or CRsRs; A 4 is CH2, CHR9, CR9R10 or a cycle of formula C (CH2) n, where n = 2-5.
    Even more R5, Rs, R9, and Rio are independently CH 3 , CH2CH3, CH 2 F, CHF 2 , CF 3z n-Pr, n-Bu, i-Bu, sec-Bu, i-Pr, tBu, or phenyl . R5 and Rs, or R9 and Rio can form a monocyclic carbocycle.
    A2 and A4 can be connected by a carbon bridge. The bridge can be -CH2- or -CH2CH2-.
    Even more B 3 is selected from H, alkyl, branched alkyl, aryl, arylalkyl, alkylcarbonyl, branched alkylcarbonyl, arylcarbonyl, alkoxycarbonyl or alkylsulfonyl.
    Even more B 4 is zero, C 1 -C 6 alkyl, CH 2, CH 2 CH 2, CHR 19, CR 19 R 20 or CO. Furthermore, R19 and R20 can form a monocycle of the formula (CH2) n , where n = 2-4. B5 is alkyl, branched alkyl, carbocycle, alkyl substituted by carbocycle, aryl or arylalkyl.
    Even more Di is an arila. Examples of the aryl groups are shown above.
    The aryl groups can be mono- or poly-substituted with F, Cl, Br, CH 3 , CH 2 CH 3 / CH 2 F, CHF 2 , CF 3 , n-Pr, n-Bu, iBu, sec-Bu, i-Pr, t-Bu, CN, OH, OMe, OEt, O-iPr, OCF 3 , NH2, NHMe, ΝΜβ2, methoxycarbonyl, Ph, benzyl, formula, or acetyl.
    This application also describes compounds having the structure of formula IV-1, IV-2, or IV-3, V, or VI:
    B 3
    wherein R21 and R22 are, independently, H or CH3; A4 is
    CH2, CR9R10 or a cycle of formula C (CH2) n, where n = 2-5.
    Even more R9 and Rio are independently CH 3 or CH2CH 3 .
    Even more B 3 is H, Ci-Ce alkyl or branched alkyl.
    Even more B 4 is zero, C 1 -C 6 alkyl, CH 2, CH 2 CH 2, or CHCH 3 .
    B5 is - (CH 2 ) nCH 3 , where n = 2-3, -C (CH 3 ) 3 , cyclohexyl, cyclopentyl, aryl or arylalkyl.
    The arila group can be selected from the list below:

    All aryl groups can be mono- or polysubstituted with F, I, Cl, Br, CH 3 , CN, OH, OMe, OEt, OCF 3 , CF 3 , or methanesulfonyl.
    Furthermore, in some embodiments, Di is a phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl that can be independently mono- or poly-substituted with F, Cl, Br, OCF 3 , CF 3 , or CH 3 .
    This application also describes compounds having the structure of formula V-1, V-2, V-3, VI-1, VI-2, or VI-3:
    VI-1
    VI-2, or
    where Di is an arila; Bs is an aryl or carbocycle.
    In some embodiments, each aryl group is independently selected from the list below:

    In some embodiments, each aryl group is independently mono- or poly-substituted. In some embodiments, each aryl group can be independently mono- or polysubstituted with I, F, Cl,
    Br, CH 3 , CN, OH, OMe, OEt, OCF 3 ,
    CF 3 , or methane sulfonyl.
    In addition, in some embodiments, the carbocycle is cyclohexyl, cyclohexenyl or cyclopentyl.
    In some embodiments, Di is an optionally mono- or poly-substituted aryl. In embodiment, B 5 mono- or poly-realization, Di or some forms is an optionally substituted aryl or carbocycle. In some forms of
    Bs is independently selected from the group consisting of:

    where the carbocycle is
    cyclohexyl, cyclohexenyl or cyclopentyl.
    In some embodiments, D1 is optionally mono- or poly-substituted phenyl, 2-pyridyl, 3pyridyl, or 4-pyridyl. In some embodiments,
    Di is optionally substituted with one or more of F, Cl, Br,
    I, OCF3, CH3, and CF3. In some embodiments, Di is not substituted.
    In some embodiments, B5 is optionally mono- or poly-substituted
    In some embodiments, B 5 is replaced with one or more of Cl, Br, F, I, OMe, CN, CH3, methanesulfonyl, and CF3. In some embodiments, B 5 is replaced with two or more of Cl, Br, F, I, OMe, CN, CH 3 , CF 3 , and methanesulfonyl, or a combination thereof. That is, B 5 may have two or more substituents, but z not all the plurality of substituents must be the same.
    In some embodiments, compounds having structures of formula VII-1, VII-2, or VII-3
    are provided, where Di is an optionally substituted heteroaryl or aryl, B3 is H or alkyl, B5 is an optionally substituted aryl or heteroaryl, and R26 and R27 are each hydrogen or an isotope thereof. In some embodiments, R26 and R27 are deuterium. In some embodiments, R26 or R27 are independently alkyl. In some embodiments, B3 is C1-C5 alkyl.
    In some embodiments, the compound has a structure of formula VIII or an enantiomer of the same
    B 3
    wherein Di is a heteroaryl or substituted aryl, B3 is H or alkyl, B5 heteroaryl hydrogen carrying out, carrying out, optionally an aryl or optionally substituted, and or an isotope thereof. In
    R26 and R27
    R26 OR R27 as described here. In
    C1-C5 alkyl.
    enantiomer is the one connected to Di.
    In some
    R26 and R27 are each some forms of are deuterium. In some ways they are independently alkyl. A4 some embodiments, B3
    In some enantiomer R forms or S embodiments, of the structure of formula IX or an enantiomer
    In some embodiments, carbon, this compound has the same enantiomer, an R enantiomer or
    S in carbon, that is, connected to Di.
    In some embodiments, a compound has a structure of formula X or an enantiomer of the same
    In some embodiments, the enantiomer is the R or S enantiomer on the carbon, this is connected to Di.
    In some embodiments of the structures described here, Di is a pyridyl group or an optionally substituted phenyl group. In some embodiments, Di is an optionally substituted 2-pyridyl, 3-pyridyl, or 4-pyridyl group or phenyl group. In some embodiments, Di is optionally substituted with one or more of, H, OH, alkyl alcohol, halo, alkyl, amide, cyano, alkoxy, haloalkyl, or alkylsulfonyl. In some embodiments, Di is optionally substituted with one or more of H, OH, Cl, Br, F, I, OMe, CN, CH 3 , CF 3 .
    In some embodiments of the structures described here, B 5 is an optionally substituted thiophene group. In some embodiments, Bs are replaced with an alkoxy group. In some embodiments, B 5 is substituted with a C 1 -C 5 alkoxy group. In some embodiments, B 5 is replaced with a methoxy group. In some embodiments, Bs are replaced with a methoxy group. In some embodiments B 5 is
    In some embodiments B 5 is


    ^ 23

    OH, cyclo, aryl, branched or unbranched alkyl alcohol, halo, branched or unbranched alkyl, amide, cyano, alkoxy, haloalkyl, alkylsulfonyl, nitrite, alkylsulfanyl, and R25 is H or alkyl. In some embodiments, R23 and R24 together form an aryl or cycle that is attached to one or more of the B5 atoms. R23, R24, and R30 can also be replaced. In some embodiments, R23, R24, and R30 are each independently H, phenyl, C3-C6 carbocycle, methanesulfonyl, CF3
    o where R29 is H or an alkyl. In some embodiments, R29 is a Ci-Cg alkyl. In some embodiments, one of R23, R24, and R30 is H. In some embodiments, at least one of R23, R24, and R30 is H. In some embodiments, two of R23, R24, and R30 are H.
    The following compounds and others described here have agonist activity for OR-mediated signal transduction:
    [(4-chlorophenyl) methyl] ({2- [4- (4-methoxyphenyl) -2,2dimethyloxan-4-yl] ethyl}) amine [(3,4-dimethoxyphenyl) methyl] [2- (2,2 -dimethyl-4-phenyloxan-4-yl) ethyl] amine
    - [({2 - [2-Ethyl-2-methyl-4- (4-methylphenyl) oxan-4-yl] ethyl} amino) methyl] phenol [2- (2,2-dimethyl-4-phenyloxan-4 -yl) ethyl] [(2-fluorophenyl) methyl] amine
    4- [({2- [4- (2-methoxyphenyl) -2,2-dimethyloxan-4-yl] ethyl} amino) methyl] -N, N-dimethylaniline
    - [({2 - [2-ethyl-4- (4-fluorophenyl) -2-methyloxan-4-yl] ethyl} amino) methyl] phenol [(3-methoxythio-2-yl) methyl] ({2- [(9R) -9- (pyridin-2yl) -6-oxasposp [4.5] decan-9-yl] ethyl}) amine.
    In some embodiments, compounds, such as those described herein, are provided. In some embodiments, a compound selected from the compounds described in the examples is provided. The compounds can be used in any of the methods described here, including, but not limited to, the treatment of pain.
    Thus, the application provides methods of generating agonist activity in OR-mediated signal transduction by administering one or more of the compounds recited above to an individual or an individual in need thereof.
    Several atoms in the compositions described here can be isotopes that occur less frequently. Hydrogen can be replaced at any position in the compositions described here with deuterium. Optionally, hydrogen can also be replaced with tritium. Carbon ( 12 C) can be replaced in any position in the compositions described here with 13 C or 14 C. Nitrogen ( 1 4 N) can be replaced with 1 5 N. Oxygen ( 16 0) can be replaced in any position in the described compositions here with 17 0 or 18 O. Sulfur ( 32 S) can be substituted in any position in the compositions described here with 33 S, 34 S or 36 S. Chlorine ( 35 C1) can be substituted in any position in the compositions described here with 37 C1. Bromine ( 79 Br) can be substituted in any position in the compositions described here with 81 Br.
    The selected compounds described here are opioid receptor agonists and antagonists (ORs). The ability of the compounds to stimulate OR-mediated signaling can be measured using any test known in the art to detect OR-mediated signaling or OR activity, or the absence of such signaling / activity. OR activity refers to an OR's ability to transduce a signal. Such activity can be measured, for example, in a heterologous cell, by copulating an OR (or a chimeric OR) to a downstream effector such as adenylate cyclase.
    A natural ligand-induced activity as used here, refers to the activation of the OR by a natural ligand of the OR. Activity can be assessed using any number of end points to measure the activity of
    OR.
    Generally, tests to test compounds that modulate OR-mediated signal transduction include the determination of any parameter, that is, indirectly or directly under the influence of an OR, for example, a functional, physical, or chemical effect.
    Samples or tests comprising ORs that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition. Control samples (not treated with inhibitors) are assigned a relative OR activity value of 100%. The inhibition of an OR is obtained when the OR activity value relative to the control is about
    80%, 50%, or 25%. The activation of an OR is obtained when the OR activity value relative to the control (not treated with activators) is 110%, 150%, 200-500% (that is, two to five times higher with respect to the control) or , 1000-3000% or higher.
    The effects of compounds through the function of an OR can be measured by examining any of the parameters described above. Any appropriate physiological change that affects OR activity can be used to assess the influence of a compound on ORs and natural ligand-mediated OR activity. When functional consequences are determined using intact cells or animals, a variety of effects can also be measured such as changes in second intracellular messengers like cAMP.
    Modulators of OR activity are tested using recombinant or naturally occurring OR polypeptides as described above. The protein can be isolated, expressed in a cell, expressed in a cell-derived membrane, expressed in tissue or in an animal. For example, neuronal cells, immune cells, transformed cells, or membranes can be used to test the GPCR polypeptides described above. Modulation is tested using one of the in vitro or in vivo tests described here. Signal transduction can also be examined in vitro with solid or soluble state reactions, using a chimeric molecule as an extracellular domain of a receptor covalently linked to a heterologous signal transduction domain, or a heterologous extracellular domain covalently linked to the transmembrane and or cytoplasmic domain of a receptor. In addition, ligand binding domains of the protein of interest can be used in vitro in solid or soluble state reactions to test for ligand binding.
    Binding of the ligand to an OR, a domain, or chimeric protein can be tested in a number of formats. The bond can be carried out in solution, in a bilayer membrane, fixed to a solid phase, in a lipid monolayer, or in vesicles. Typically, in a test described here, the binding of the natural ligand to this receptor is measured in the presence of a candidate modulator. Alternatively, the binding of the candidate modulator can be measured in the presence of the natural ligand. Often competitive tests that measure a compound's ability to compete with the binding of the natural ligand to the receptor are used. The bond can be tested by measuring, for example, changes in spectroscopic characteristics (for example, fluorescence, absorbance, refractive index), hydrodynamic changes (for example, shape), or changes in chromatographic or solubility properties.
    Modulators can also be identified using tests involving recruitment by β-arrestin, β-arrestin serves as a regulatory protein, that is, distributed throughout the cytoplasm in non-activated cells. Binding of the ligand to an appropriate OR is associated with redistribution of β-arrestin from the cytoplasm on the cell surface, where it is associated with the OR. Thus, receptor activation and the effect of candidate modulators on ligand-induced receptor activation can be assessed by monitoring recruitment by β-arrestin to the cell surface. This is often accomplished by transfecting a labeled β-arrestin fusion protein (eg, β-arrestin fluorescent green protein (GFP)) into cells and monitoring its distribution using confocal microscopy (see, for example, Groarke et al., J Biol Chem 274 (33): 23263 69 (1999)).
    Another technology that can be used to evaluate OR-protein interactions in living cells involves resonance energy transfer with bioluminescence (BRET). A detailed discussion for BRET can be found in Kroeger et al. , J. Biol. Chem., 276 (16): 12736 43 (2001).
    Other tests may involve determining the activity of receptors that, when activated by ligand binding, result in a change in the level of intracellular cyclic nucleotides, for example, cAMP, activating or inhibiting downstream effectors such as adenylate cyclase. Changes in intracellular cAMP may be measured using immunotests. The method described in Offermanns & Simon, J. Biol. Chem. 270: 15175 15180 (1995) can be used to determine the level of cAMP. Also, the method described in Felley-Bosco et al., Am.
    J. Resp. Cell and Mol. Biol. 11: 159 164 (1994) can be used to determine the level of cGMP. In addition, a test kit for measuring cAMP is described in U.S. patent number
    4,115,538, incorporated herein by reference.
    Transcription levels can be measured to assess the effects of a test compound on ligand-induced signal transduction. A host cell containing the protein of interest is contacted with a test compound in the presence of the natural ligand for a time sufficient to effect any interactions, and then the level of expression of the gene is measured. The amount of time to effect such interactions can be empirically determined, such as spending time and measuring the level of transcription as a function of time. The amount of transcription can be measured using any method known to the person skilled in the art as being appropriate. For example, the mRNA expression of the protein of interest can be detected using northern blots or its polypeptide products can be identified using immunotests. Alternatively, transcription-based tests using reporter genes can be used as described in U.S. Patent No. 5,436,128, incorporated herein by reference. The reporter genes can be, for example, chloramphenicol acetyltransferase, firefly luciferase, bacterial luciferase, β-galactosidase and alkaline phosphatase. In addition, the protein of interest can be used as an indirect reporter via attachment to a second reporter as a green fluorescent protein (see, for example, Mistili & Spector, Nature Biotechnology 15: 961 964 (1997)).
    The amount of transcription is then compared to the amount of transcription in or in the same cell in the absence of the test compound, or it can be compared to the amount of transcription in a substantially identical cell in which the protein of interest is missing. A substantially identical cell can be derived from the same cells from which the recombinant cell was prepared, but which were not modified by introducing heterologous DNA. Any difference in the amount of transcription indicates that the recombinant cell has in some way altered the activity of the protein of interest.
    Pharmaceutical Compositions / Formulations
    Pharmaceutical compositions can be formulated by standard techniques using one or more physiologically acceptable vehicles or excipients. The formulations can include a buffer and / or a preservative. The components and their physiologically acceptable salts and solvates can be formulated for administration by any appropriate route, including inhalation, topical, nasal, oral, parenteral (e.g., intravenously, intraperitoneally, intravesically or intrathecally) or rectally in a vehicle comprising one or more pharmaceutically acceptable vehicles, the proportion of which is determined by the solubility and chemical nature of the compound, route of administration and standard biological practice chosen.
    The pharmaceutical compositions can include effective amounts of one or more compound (s) described herein together with, for example, pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and / or other vehicles. Such compositions may include diluents of varying buffer levels (for example, TRIS or other amines, carbonates, phosphates, amino acids, for example, glycinamide hydrochloride (especially in the physiological pH range), N-glycylglycine, sodium or potassium phosphate ( dibasic, tribasic), etc. or TRIS-HC1 or acetate), pH and ionic strength; additives such as detergents and solubilizing agents (eg surfactants such as Pluronics, Tween 20, Tween 80 (Polysorbate 80), cremophor, polyols such as polyethylene glycol, propylene glycol, etc.), anti-oxidants (eg ascorbic acid, metabisulfite of sodium), preservatives (for example, Thimersol, benzyl alcohol, parabens, etc.) and volume-forming substances (for example, sugars such as sucrose, lactose, mannitol, polymers such as polyvinylpyrrolidones or dextran, etc.); and / or incorporation of the material in particle preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or in liposomes. Hyaluronic acid can also be used. Such compositions can be used to influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of a compound described herein. See, for example, Remington's Pharmaceutical Sciences, 18 a . edition (1990, Mack Publishing Co., Easton, Pa. 18042) pages 1435-1712 which is incorporated here by reference. The compositions can, for example, be prepared in liquid form, or they can be in a dry powder, as a lyophilized form. The particular methods of administering such compositions are described below.
    Where a buffer should be included in the formulations described here, the buffer can be selected from sodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginine, sodium dihydrogen phosphate, disodium dihydrogen phosphate, phosphate sodium, and tris (hydroxymethyl) aminomethane, or mixtures thereof. The buffer may also be glycylglycine, sodium dihydrogen phosphate, disodium dihydrogen phosphate, and sodium phosphate or mixtures thereof.
    Where a pharmaceutically acceptable preservative should be included in a formulation of one of the compounds described here, the preservative can be selected from phenol, m-cresol, methyl p-hydroxybenzoate, propyl phydroxybenzoate, 2-phenoxyethanol, butyl phydroxybenzoate, 2- phenylethanol, benzyl alcohol, chlorobutanol, and thiomerosal, or mixtures thereof. The preservative can also be phenol or m-cresol.
    Preservative is present at a concentration of about 0.1 mg / ml and at about 50 mg / ml, at a concentration of about 0.1 mg / ml and at about 25 mg / ml, or at a concentration about 0.1 mg / ml and about 10 mg / ml.
    The use of a preservative in pharmaceutical compositions is well known to the person skilled in the art. For convenience, reference is made to Remington. · The Science and Practice of Pharmacy, 19 a. edition, 1995.
    The formulation can further comprise a chelating agent where the chelating agent can be selected from salts of ethylenediaminetetraacetic acid (EDTA), citric acid, and aspartic acid, and mixtures thereof.
    The chelating agent can be present in a concentration of 0.1 mg / ml to 5 mg / ml, from 0.1 mg / ml to 2 mg / ml or from 2 mg / ml to 5 mg / ml.
    The use of a chelating agent in pharmaceutical compositions is well known to the person skilled in the art. For convenience, reference is made to Remington: The Science and Practice of Pharmacy, 19 a. edition, 1995.
    The formulation of the compounds described herein may further comprise a stabilizer selected from high molecular weight polymers and low molecular weight compounds where such stabilizers include, but are not limited to, polyethylene glycol (e.g. PEG 3350), polyvinyl alcohol (PVA) , polyvinylpyrrolidone, carboxymethylcellulose, different salts (e.g., sodium chloride), L-glycine, L-histidine, imidazole, arginine, lysine, isoleucine, aspartic acid, tryptophan, and threonine or any mixture thereof. The stabilizer can also be L-histidine, imidazole or arginine.
    The high molecular weight polymer can be present in a concentration of 0.1 mg / ml to 50 mg / m, from 0.1 mg / ml to 5 mg / ml, from 5 mg / ml to 10 mg / ml, from 10 mg / ml to 20 mg / ml, from 20 mg / ml to 30 mg / ml or from 30 mg / ml to 50 mg / ml.
    The low molecular weight compound can be present in a concentration of 0.1 mg / ml to 50 mg / ml, from 0.1 mg / ml to 5 mg / ml, from 5 mg / ml to 10 mg / ml, from 10 mg / ml to 20 mg / ml, from mg / ml to 30 mg / ml or from 30 mg / ml to 50 mg / ml.
    The use of a stabilizer in pharmaceutical compositions is well known to the person skilled in the art. For convenience, reference is made to Remington: The Science and Practice of Pharmacy, 19 a. edition, 1995.
    The formulation of the compounds described here can also include a surfactant. In some embodiments, the surfactant can be selected from a detergent, ethoxylated castor oil, polyglycolated glycerides, acetylated monoglycerides, sorbitan fatty acid esters, poloxamers such as 188 and 407, sorbitan and polyoxyethylene fatty acid esters polyoxyethylene derivatives such as alkylated and alkoxylated derivatives (for example, Tween-20, or Tween-80), monoglycerides or ethoxylated derivatives thereof, diglycerides or polyoxyethylene derivatives thereof, glycerol, cholic acid or derivatives thereof, lecithins, alcohols and phospholipids, glycerophospholipids (lecithins, cephalins, phosphatidyl serine), glyceroglycolipids (galactopyranoside), sphingophospholipids (sphingomyelin), and sphingoglycolipids (ceramides, gangliosides), DSS (sodium docusate, docusate sodium or sodium lauryl sulfate), dipalmitoyl phosphatidic acid, sodium caprylate o, bile acids and salts thereof and glycine or taurine conjugates, ursodeoxycholic acid, sodium cholate, sodium deoxycholate, sodium taurocholate, sodium glycolate, N-hexadecyl-N, N-dimethyl-3ammonium-1-propanesulfonate , anionic monovalent surfactants (alkyl aryl sulfonates), palmitoyl lysophosphatidyl-L-serine, lysophospholipids (eg 1acyl-sn-glycero-3-phosphate esters of ethanolamine, choline, serine or threonine), alkyl, alkoxyl (alkyl ester ), lysophosphatidyl and phosphatidyl choline (alkyl ether) derivatives, for example, lysophosphatidylcholine, lauroyl and myristoyl derivatives, dipalmitoyl phosphatidylcholine, and modifications of the polar head group, ie hills, ethanolamines, phosphatidic acid, serines, serine , glycerol, inositol, and DODAC, DOTMA, DCP, BISHOP, positively charged, lysophosphatidylserine and lysophosphatidyltreonin, zwitterionic surfactants (eg N-alkyl-N, N-dimethylammonium-1-propanesulfonates, 3-co lamido-l-propyldimethyl ammonium-l-propane sulfonate, dodecylphosphocoline, myristoyl lysophosphatidylcholine, chicken egg lysolecithin), cationic surfactants (quaternary ammonium bases) (eg, cetyl-trimethylammonium bromide, non-cetylpyridine chloride) , polyethylene oxide / polypropylene oxide block copolymers (Pluronics / Tetronics, Triton X-100, Dodecyl β-D-glucopyranoside) or polymeric surfactants (Tween-40, Tween-80, Brij-35), fusidic acid derivatives - (eg sodium tauro dihydrofusidate, etc.), long-chain fatty acids and salts of the same C6-C12 (eg oleic acid and caprylic acid), acylcarnitines and derivatives, acylated ados α derivatives of lysine , arginine or histidine, or acetylated lysine or arginine side chain derivatives, N - acylated dipeptide derivatives comprising any combination of lysine, arginine or histidine and a neutral or acidic amino acid, N a -ac derivative of a tripeptide comprising any combination of a neutral amino acid and two charged amino acids, or the surfactant may be selected from the group of imidazoline derivatives, or mixtures thereof.
    The use of a surfactant in pharmaceutical compositions is well known to the person skilled in the art. For convenience, reference is made to Remington: The Science and Practice of. Pharmacy, 19 a . edition, 1995.
    Pharmaceutically acceptable sweeteners can be part of the formulation of the compounds described here. Pharmaceutically acceptable sweeteners include at least one strong sweetener such as saccharin, sodium or calcium saccharin, aspartame, potassium acesulfame, sodium cyclamate, alitame, a dihydrocalcone sweetener, monelin, stevioside or sucralose (4, l ', 6 , - trichloro-4, l ', 6'trideoxygalactosaccharose), saccharin, sodium or calcium saccharin, and optionally a raw sweetener such as sorbitol, mannitol, fructose, sucrose, maltose, isomalt, glucose, hydrogenated glucose syrup, xylitol, caramel, and honey.
    Intense sweeteners are conveniently used in low concentrations. For example, in the case of sodium saccharin, the concentration can be in the range of 0.04% to 0.1% (w / v) based on the total volume of the final formulation, or is about 0.06% in the formulations low dosage and about 0.08% in high dosage. The raw sweetener can effectively be used in larger amounts in the range of about 10% and about 35%, or about 10% to 15% (w / v) ’.
    Formulations of the compounds described herein can be prepared by conventional techniques, for example, as described in Remington's Pharmaceutical Sciences, 1985 or in Remington: The Science and Practice of Pharmacy, 19 a . edition, 1995, where such conventional techniques of the pharmaceutical industry involve dissolving and mixing the ingredients as appropriate to give the desired final product.
    The phrase pharmaceutically acceptable ' 7 or therapeutically acceptable refers to molecular entities and compositions that are physiologically tolerable and preferably do not typically produce a similar allergic or adverse reaction, such as gastric disorder, dizziness and the like, when administered to a human. As used herein, the term pharmaceutically acceptable means approved by a regulatory agency of the Federal or State Government or listed in the American Pharmacopoeia or other generally recognized pharmacopeia (for example, Remington's Pharmaceutical Sciences, Mack Publishing Co. (AR Gennaro editors 1985)) for use in animals, and more particularly in humans.
    Administration of the compounds described herein can be performed using any method known in the art. For example, administration can be transdermal, parenteral, intravenous, intraarterial, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, intracerebroventricular, intrathecal, intranasal, aerosol, or by suppositories, by suppositories, oral. A pharmaceutical composition of the compounds described herein can be for administration for injection, or for oral, pulmonary, nasal, transdermal, ocular administration.
    For oral administration, the pharmaceutical composition of the compounds described herein can be formulated in unit dosage forms such as capsules or tablets. Tablets or capsules may be prepared, by conventional means, with pharmaceutically acceptable excipients, including binding agents, for example, pregelatinized corn starch, polyvinylpyrrolidone, or hydroxypropyl methylcellulose; fillers, for example, lactose, microcrystalline cellulose, or calcium hydrogen phosphate; lubricants, for example, magnesium stearate, talc, or silica; disintegrants, for example, potato starch or sodium starch glycolate; or wetting agents, for example, sodium lauryl sulfate. The tablets can be coated by methods well known in the art. Liquid preparations for oral administration can take the form of, for example, solutions, syrups, or suspensions, or they can be presented as a dry product for reconstitution with water or another suitable vehicle before use. Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives, for example, suspension agents, for example, sorbitol syrup, cellulose derivatives, or hydrogenated edible fats; emulsifying agents, for example, lecithin or acacia; non-aqueous vehicle, for example, almond oil, oily esters, ethyl alcohol, or fractionated vegetable oils; and preservatives, for example, methyl or propyl p-hydroxybenzoates or sorbic acid. The preparations can also contain buffer salts, flavor, color, and / or sweetening agents as appropriate. If desired, preparations for oral administration can be appropriately formulated to confer a controlled release to the active compound.
    For topical administration, the pharmaceutical composition of the compounds described herein can be formulated in a pharmaceutically acceptable carrier containing 0.1 to 10 percent, or 0.5 to 5 percent, of the active compound (s). Such formulations can be in the form of a cream, lotion, sublingual tablet, aerosols and / or emulsions and can be included in a transdermal or buccal adhesive dressing of the matrix or reservoir type as are conventional in the art for this purpose.
    For parenteral administration, the compounds described herein are administered by either intravenous, subcutaneous, or intramuscular injection, in compositions with pharmaceutically acceptable vehicles or carriers. The components can be formulated for parenteral administration by injection, for example, by bolus injection or continuous infusion. Injection formulations can be presented in unit dosage form, for example, in ampoules or in multi-dose containers, with an added preservative. The compositions can take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and can contain formulation agents, for example, suspending agents, stabilizers, and / or dispersants. Alternatively, the active ingredient may be in powder form for constitution with an appropriate vehicle, for example, sterile pyrogen-free water, before use.
    For administration by injection, the compound (s) can be used in solutions in a sterile aqueous vehicle that can also contain other solutes such as buffers or preservatives, as well as sufficient amounts of pharmaceutically acceptable salts or glucose to make the solution isotonic. The pharmaceutical compositions of the compounds described herein can be formulated with a pharmaceutically acceptable carrier to provide sterile solutions or suspensions for injectable administration. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspensions in prior liquid prior to injection or as emulsions. Suitable excipients are, for example, water, saline, dextrose, mannitol, lactose, lecithin, albumin, sodium glutamate, cysteine hydrochloride, or the like. In addition, if desired, injectable pharmaceutical compositions can include minor amounts of non-toxic auxiliary substances, such as wetting agents, pH buffering agents, and the like. If desired, absorption enhancing preparations (for example, liposomes) can be used. Suitable pharmaceutical carriers are described in Remington's pharmaceutical Sciences by E. W. Martin.
    For administration by inhalation, the components can be conveniently distributed in the form of an aerosol spray presentation of pressurized packages or a nebulizer, with the use of an appropriate propellant, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other appropriate gas. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, for example, gelatin for use in an inhaler or insufflator, can be formulated containing a mixture of powder of the compound and an appropriate powder base, for example, lactose or starch. For intranasal administration the compounds described herein can be used, for example, as a liquid spray, as a powder or in the form of drops.
    The components can also be formulated in rectal compositions, for example, suppositories or retention enemas, for example, containing conventional suppository bases, for example, cocoa butter or other glycerides.
    In addition, the components can be formulated as a deposit preparation. Such long-acting formulations can be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the components can be formulated with appropriate polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a poorly soluble salt.
    The compositions can, if desired, be presented in a packaging or dispensing device that can contain one or more unit dosage forms containing the active ingredient. The package may, for example, comprise metal or plastic foil, for example, a blister pack. The package or dispensing device may be accompanied by instructions for administration.
    The compounds described here also include derivatives referred to as prodrugs, which can be prepared by modifying functional groups present in the components in such a way that the modifications are cleaved, either in routine or in vivo manipulation, for the parent compounds. Examples of prodrugs include compounds of the invention as described herein which contain one or more molecular moieties attached to a hydroxyl, amino, sulfhydryl, or carboxyl group of the compound, and which when administered to a patient, cleaves in vivo to form the free hydroxyl group, amino, sulfhydryl, or carboxyl, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and derivatives of alcohol benzoate and functional amine groups in the components of the invention. The preparation and use of prodrugs is discussed in T. Higuchi et al. , Pro-drugs as Novel Delivery Systems, vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference in their entirety.
    Dosages
    The compounds described herein can be administered to a patient in therapeutically effective doses to prevent, treat, or control one or more diseases and disorders mediated, in whole or in part, by an OR ligand interaction. Pharmaceutical compositions comprising one or more of the compounds described herein can be administered to a patient in an amount sufficient to elicit an effective protective or therapeutic response in the patient. An adequate amount to achieve this is defined as a therapeutically effective dose. The dose will be determined by the effectiveness of the particular compound used and the condition of the individual, as well as the body weight or the surface area of the area to be treated. The dose size will also be determined by the existence, nature, and extent of any adverse effects that accompany the administration of a particular compound or vector to a particular individual.
    The toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, by determining LD50 (a lethal dose to 50% of the population) and ED50 (a therapeutically effective dose in 50% of the population) . The dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio, LD50 / ED50. In some embodiments, compounds that exhibit high therapeutic indexes are used. Although compounds that exhibit toxic side effects can be used, care must be taken to design a delivery system that directs such compounds to the target site of the affected tissue in order to minimize the potential damage to normal cells and thereby reduce the effects collateral.
    The data obtained from cell culture tests and animal studies can be used to formulate a dosage range for use in humans. In some embodiments, the dosage of such compounds is within a range of circulating concentrations that include ED50 with low or no toxicity. A dosage can vary within this range depending on the dosage form employed and the route of administration. For any compound described here, the therapeutically effective dose can be estimated initially from cell culture tests. A dose can be formulated in animal models to obtain a circulating plasma concentration in the range that includes the IC50 (the concentration of the test compound that achieves a half-maximum inhibition of symptoms) as determined in the cell culture. Such information can be used to more accurately determine useful doses in humans. Plasma levels can be measured, for example, by high performance liquid chromatography (HPLC). In general, an equivalent dose of a modulator is about 1 ng / kg to 10 mg / kg for a typical individual.
    The amount and frequency of administration of the compounds described herein and / or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinical physician considering such factors as age, condition and size of the patient as well as the severity of the symptoms being treated. A doctor or veterinarian skilled in the art can easily determine and prescribe the effective amount of the drug required to prevent, counteract or halt the progress of the condition. In general it is contemplated that an effective amount would be from 0.001 mg / kg to 10 mg / kg of body weight, and in particular, from 0.01 mg / kg to 1 mg / kg of body weight. It may be appropriate to administer the required dose as two, three, four or more underdoses at appropriate intervals throughout the day. Said sub-doses can be formulated as unit dosage forms, for example, containing 0.01 to 500 mg, and in particular, 0.1 mg to 200 mg of active ingredient per unit dosage form.
    In some embodiments, the pharmaceutical preparation is in a unit dosage form. In such a form, the preparation is subdivided into unit doses of appropriate size containing appropriate amounts of the active component, for example, an amount effective to achieve the desired purpose. The amount of active compound in a unit dose of preparation can be varied or adjusted from about 0.01 mg to about 1000 mg, about 0.01 mg and about 750 mg, about 0.01 mg and about 500 mg, or about 0.01 mg and about 250 mg, depending on the particular application. The actual dosage employed can be varied depending on the patient's requirements and the severity of the condition being treated. The determination of the appropriate dosage regime for a particular situation is in accordance with the knowledge of the person skilled in the art. For convenience, the total dosage can be divided and administered in portions during the day, as required.
    In some embodiments, one or more compounds described herein are administered with another compound. Administration can be sequentially or concurrently. The combination can be in the same dosage form or administered as separate doses. In some embodiments, the other compound is an analgesic or other pain relieving agent. In some embodiments, the other compound is a non-opioid pain reliever. Examples of usable non-opioid pain relievers include, but are not limited to, non-steroidal anti-inflammatory agents, such as aspirin, ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen, ketoprofen, indoprofen, piroprofen, carprofen, propropropane, oxprofen, oxpropro, propane, proprofa, proprofa, trioxaprofen, suprofen, aminoprofen, thiaprofenic acid, fluprofen, bucclic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidomethacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, flufenamic acid, flufenamic acid, flufenamic acid, flufenamic acid, flufenamic acid, flufenamic acid, flufenamic acid, flufenamic acid, flufenamic acid , flufenisal, piroxicam, sudoxicam, isoxicam, and pharmaceutically acceptable salts thereof, and mixtures thereof. Other suitable non-opioid analgesics include the following non-limiting chemical classes of analgesic, antipyretic, non-steroidal anti-inflammatory drugs: derivatives of salicylic acid, including aspirin, sodium salicylate, magnesium trisalicylate choline, salsalate, diflunisal, salicylic saline, sulfasalicylic acid, sulfasalicylic acid, sulfasalicylic acid, and salasylsalicylic acid, sulfasalicylic acid, and salasylsalicylic acid. ; para-aminophenol derivative including acetaminophen and denacetin; indole and indene acetic acids, including indomethacin, sulindac, and etodolac; heteroaryl acetic acids, including tolmetin, diclofenac, and ketorolac; anthranilic acids (phenamates), including mefenamic acid and meclophenamic acid; enolic acids, including oxicams (piroxicam, tenoxicam), and pyrazolidinediones (phenylbutazone, oxidentartazone); and alkanones, including nabumetone. For a more detailed description of NSAIDs, see Paul A. Insel, AnalgesicAntipyretic and Antiinflammatory Agents and Drugs Employed in the treatment of Gout, in Goodman &Gilman's The Pharmacological Basis of Therapeutics 617-57 (Perry B. Molinhoff and Raymond W. Ruddon eds .., 9 · to ed additional 1996); and Glen R. Hanson, Analgesic, Antipyretic and AntiInflammatory Drugs in Remington: The Science and Practice of Pharmacy vol II 1196-1221 (AR Gennaro ed. 19 a . supplementary ed. 1995), which are incorporated herein by reference in their entirety .
    The compounds described here can also be administered Cox-II inhibitors. Examples of usable Cox-II inhibitors and 5-lipoxygenase inhibitors, as well as combinations thereof, are described in US patent 6.13 6.83 9, which is incorporated herein by reference in its entirety. Examples of Cox-II inhibitors include, but are not limited to, rofecoxib and celecoxib.
    The compounds described here can also be administered with anti-migraine agents. Examples of usable anti-migraine agents include, but are not limited to, alpiropride, bromocriptine, dihydroergotamine, dolasetron, ergocornine, ergocorninine, ergocriptine, ergonovine, ergot, ergotamine, flumedroxone acetate, phonazine, ketansergine, methysergine, lysuride, lysuride , naratriptan, oxetorone, pizothiline, propranolol, risperidone, rizatriptan, sumatriptan, timolol, trazodone, zolmitriptan, and mixtures thereof.
    The compounds described here can also be administered with anti-constipation agents. Examples of anti-constipation agents include, but are not limited to, laxatives or emollients. Examples of anti-constipation agents include, but are not limited to, docusate, poloxamer 188, psyllium, methyl cellulose, carboxymethyl cellulose, polycarbophyl, bisacodyl, castor oil, magnesium citrate, magnesium hydroxide, magnesium sulfate, dibasic sodium phosphate, phosphate monobasic sodium, sodium bisphosphate or any combination thereof.
    Medical use
    The compositions described here can be used to treat pain or disorders associated with pain. The compositions described here can be used to treat immune dysfunction, inflammation, esophageal reflux, neurological and psychiatric conditions, urological and reproductive conditions, drugs for alcohol and drug abuse, agents to treat gastritis and diarrhea, cardiovascular agents and agents for treatment respiratory diseases and cough.
    In some embodiments, methods of treating pain are provided. In some embodiments, one or more compounds described herein are administered to an individual to treat pain. In some embodiments, the pain may be postoperative pain. In some embodiments, the pain is caused by cancer. In some embodiments, the pain is neuropathic pain. In some embodiments, the pain is caused by trauma, such as, but not limited to, blind force trauma. In some embodiments, the pain is caused by inflammation.
    In some embodiments, the one or more compounds described herein can be administered by any appropriate route, including, but not limited to, inhalation, topical, nasal, oral, parenteral (e.g., intravenously, intraperitoneally, intravesically or intrathecally) or rectally in a vehicle comprising one or more pharmaceutically acceptable vehicles, the proportion of which is determined by the solubility and the chemical nature of the compound, chosen route of administration and standard practice.
    Definitions
    Unless otherwise indicated, all technical and scientific terms used here have the same meaning as commonly understood by those skilled in the art. Although methods and materials similar or equivalent to those described herein can be used in practice or in testing the compositions and compounds described here, the appropriate methods and materials are described below. All publications, patent applications, patents, and other references mentioned here are incorporated by reference in their entirety. In the event of a conflict, this report, including definitions, will be the control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting. Other aspects and advantages of the compositions and compounds described here will be evident from the following detailed description and claims.
    The general chemical terms used here have their common meanings. For example, the term alkyl refers to a branched or unbranched saturated hydrocarbon group. The term n-alkyl refers to an unbranched alkyl group. The term C x -C y alkyl refers to an alkyl group having x and y carbon atoms, including the branched or unbranched hydrocarbon group. By way of illustration, but without limitation, the term C1-C4 alkyl refers to a portion of straight or branched hydrocarbon having 1 to 4 carbon atoms, including methyl, ethyl, npropyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl. The term C1-C4 n-alkyl refers to straight-chain hydrocarbon moieties having from 1 to 4 carbon atoms including methyl, ethyl, n-propyl, and n-butyl. C x C y x can be delal0eyéde2a20. The term C3-C6 cycloalkyl refers to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. The term C3-C7 cycloalkyl also includes cycloheptyl. Cycloalkylalkyl refers to cycloalkyl moieties linked through an alkyl bonding chain, such as, but not limited to, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclopentylmethyl, cyclopentylmethyl, cyclopentylmethyl, cyclopentylmethyl, cyclopentylmethyl, cyclopentylmethyl, cyclopentylmethyl, cyclopentylmethyl, cyclopentylmethyl, cyclopentylmethyl, cyclopentylmethyl, cyclopentylmethyl, cyclopentylmethyl, cyclopentylmethyl, cyclopentylmethyl, cyclopentylmethyl, cyclopentylmethyl, , and cyclohexylpropyl. Each alkyl, cycloalkyl, and cycloalkylalkyl group can be optionally substituted, as, but not limited to, as specified here. In some embodiments, the alkyl is a C1-C3, C1-C4, Ci-Ce, C 4 -Cg, or C1-C10 alkyl.
    The terms alkoxy, phenyloxy, benzoxy and pyrimidinyloxy refer to an alkyl group, phenyl group, benzyl group, or pyrimidinyl group, respectively, that is, linked via an oxygen atom. Each of these groups can be optionally substituted.
    The terms alkylthio, phenylthio, and benzylthio refer to an alkyl group, phenyl group, or benzyl group, respectively, that is, attached via a sulfur atom. Each of these groups can be optionally substituted.
    The term C1-C4 acyl refers to a formyl group or a C1-C3 alkyl group attached through a carbonyl moiety. The term C1-C4 alkoxycarbonyl refers to a C1-C4 alkoxy group attached through a carbonyl moiety.
    The term halo refers to fluorine, chlorine, bromine, or iodine. In some embodiments, the halo groups are fluorine, chlorine, and bromine. In some embodiments, the halo groups are fluorine and chlorine.
    As used herein, carbocycle or carbocycle ring is intended to mean, unless otherwise stated, any stable monocyclic, bicyclic or tricyclic ring of 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 members, any one of them can be saturated, unsaturated (including partially and completely unsaturated), or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptenyl, cycloheptyl; cycloheptenyl, adamantyl, cyclooctyl, cyclooctenyl, cyclooctadienyl, [3.3.0] bicyclooctane, [4.3.0] bicyclononane, [4.4.0] bicyclodecane, [2.2.2] bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, and -hydronaftila. As shown above, bridged rings are also included in the definition of carbocycle (for example, [2.2.2] bicyclooctane). A bridged ring occurs when one or more carbon atoms bonds two non-adjacent carbon atoms. In some embodiments, the bridges are one or two carbon atoms. It should be noted that a bridge always converts a monocyclic ring to a tricyclic ring. When a ring is a bridge, the substituents described for the ring may also be present on the bridge. Fused rings (eg, naphthyl and tetrahydronaphthyl) and spiro are also included.
    The term heterocycle is taken to mean a 5- or 6-membered saturated or unsaturated ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, referred to as an optionally benzofused ring. Exemplary heterocycles include furanoyl, thiophenyl (thienyl), pyrrolyl, pyrrolidinyl, pyridinyl, Nmethylpyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, triazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, pyridine, pyridine, thyrazolidinyl, pyridine, thyrazolidinyl, pyridine Benzofused heterocyclic rings include isoquinolinyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, quinolinyl, benzofuranoyl, benzothiophenyl, indolyl, and others - all of which can be optionally substituted, including, of course, optionally substituted on the benzo ring when the heterocycle is benzofused.
    The term cycle group is considered to mean a carbocyclic ring, a carbocycle or a heterocarbocycle.
    As used here, the expression a cycle of the formula refers to a ring that can be formed with the variable referred to. For example, in the structure ^^ where A can be a cycle of formula C (CH2) n, where n = 2-5, it means that A is a carbon and forms a ring with itself with 2-5 CH2 groups, which can also be represented structurally as
    The variable A is not limited to atom, as, but not limited to, carbon and may be another heteroatom, but the context in which the variable is used will indicate what type of atom A can be. This is just a non-limiting example. In addition, the ring that is formed with A can also be replaced. Exemplary substituents are described here.
    In some embodiments, heterocycles include, but are not limited to, pyridinyl, indolyl, furanoyl, benzofuranoyl, thiophenyl, benzodioxolyl, and thiazolidinyl, all of which can be optionally substituted.
    As used herein, the term aromatic or heteroaryl heterocycle is intended to mean a 5, 6, 7, 8, 9, 10, 11, or 12-membered monocyclic or bicyclic aromatic ring consisting of carbon atoms and one or more heteroatoms , for example, 1 or 1-2 or 1-3 or 1-4 or 1-5 or 1-6 heteroatoms, independently selected from nitrogen, oxygen, and sulfur. In the case of bicyclic heterocyclic aromatic rings, only one of the two rings needs to be aromatic (for example, 2,3-dihydroindole), although both can be (for example, quinoline). The second ring can also be fused or bonded as defined above for heterocycles. The nitrogen atom can be substituted or unsubstituted (that is,
    N or NR where R is H or another substituent, as defined).
    Nitrogen and sulfur heteroatoms can be optionally oxidized (ie, N-> 0 and S (0) p , where p = 1 or 2). In certain compounds, the total number of atoms of S and
    The in the aromatic heterocycle is not more than 1.
    Examples of heterocycles include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranoyl, benzothiofuranoyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazol, benzine, benzyl, benzyl, benzyl, benzyl, benzyl , decahydroquinolinyl, 2H, 6H-1,5,2-dithiazinyl, dihydrofuro [2,3-6] tetrahydrofuran, furanoyl, furazanil, imidazolidinyl, imidazolinyl, imidazolyl, IH-indazolyl, indolenila, indolinyl, indolizinyl, indolyl, indolyl, indolyl, 3 , isatinoil, isobenzofuranoyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinclinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroxyquinolyl, 1,2-oxadiazolyl, 1,2-oxadiazolyl, 1,2 , 5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxindolyl, pyrimidinyl, phenantridinyl, phenanthrolinyl, phenazinyl, phenothiazini la, phenoxatinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridoxyrol, pyridoxyrol pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, chiriolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranoyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-tiadziazyl, 1,2 2,4 thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thiantrenyl, 'thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl,
    1.2.3- triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl,
    1.3.4- triazolyl, and xanthenyl.
    Alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, or substituted alkylthio, means an alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, or alkylthio group, respectively, substituted one or more times independently with a substituent selected from the group consisting of halo, hydroxy, and C1- C3 alkoxy. By way of illustration, but without limitation, examples include trifluoromethyl, pentafluoroethyl, 5-fluoro-2-bromopentyl, 3-hydroxypropyloxy, 4-hydroxycyclohexyloxy, 2-bromoethylthio, 3-ethoxypropyloxy, 3-ethoxy-4-chlorocyclohexyl, and others. In some embodiments, substitutions include substitution 1-5 times with halo, each independently selected, or substituted 1-3 times with halo and 1-2 times independently with a group selected from hydroxy and C1-C3 alkoxy, or substituted 1 -3 times independently with a group selected from hydroxy and C1-C3 alkoxy, provided that no more than one hydroxy and / or alkoxy substituent can be fixed through the same carbon.
    The terms substituted phenyl and substituted heterocycle are taken to mean that the cyclic portion in both cases is substituted. They can be independently replaced with one or more substituents. They can be independently replaced with 1, 2, 3, 4, 5, 1-3, 1-4, or 1-5 substituents. The substitution may be, independently, halo, alkyl, such as, but not limited to, C1-C4 alkyl, alkoxy, such as but not limited to, C1-C4 alkoxy, and alkylthio, such as but not limited to, C1-C4 alkylthio, wherein each alkyl, alkoxy and alkylthio substituent can further be independently substituted with C1-C2 alkoxy or with one to five halo groups; or substituted with a substituent selected from the group consisting of phenyloxy, benzyloxy, phenylthio, benzylthio, and pyrimidinyloxy, wherein the phenyloxy, benzyloxy, phenylthio, benzylthio, and pyrimidinyloxy moiety may be further substituted with one to two substituents selected from among group consisting of halo, C1-C2 alkyl, and C1-C2 alkoxy; or substituted with a substituent selected from the group consisting of CiC 4 acyl and C1-C4 alkoxycarbonyl, and further substituted with zero to a substituent selected from the group consisting of halo, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 alkylthio. When a substituent is halo, in some embodiments, the halo groups are fluorine, chlorine, and bromine. The halo can also be iodine.
    DMF means N, N-dimethylformamide.
    As used herein, the term pharmaceutically acceptable refers to compounds, materials, compositions, and / or dosage forms that are within the specialty of reliable medical judgment, suitable for use in contact with the tissues of humans and animals without excessive toxicity , irritation, allergic response, or other problem or complication, considering it with a reasonable benefit / risk ratio.
    By pharmaceutical formulation it is also meant that the carrier, solvent, excipients and salt must be compatible with the active ingredient of the formulation (for example, a compound described here). It should be understood by the person skilled in the art that the terms pharmaceutical formulation and pharmaceutical composition are generally interchangeable, and so they are used for the purposes of this application.
    As used herein, pharmaceutically acceptable salts refer to derivatives of the described compounds in which the parent compound is modified by taking acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkaline or organic salts of acidic residues such as carboxylic acids; and others. Pharmaceutically acceptable salts include conventional non-toxic salts or quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include, but are not limited to, derivatives of inorganic or organic acids selected from 2 acetoxybenzoic, 2-hydroxyethane sulfonic, acetic, ascorbic, sulfonic benzene, benzoic, bicarbonic, carbonic, citric, edetic, disulfonic ethane, sulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, glycolliarsanilic, hexylresorcinic, hydrabamic, hydrobromic, hydrochloric, iodhydric, hydroximalic, hydroxynaphonic, isethionic, lactic, lactobionic, sulfuric, mossylic, maleic, sulphonic, maleic , nitric, oxalic, pamoic, pantothenic, phenylacetic, phosphoric, polygalacturonic, propionic, salicylic, stearic, subacetic, succinic, sulfamic, sulfanyl, sulfuric, tannic, tartaric, and toluenesulfonic. The present description includes pharmaceutically acceptable salts of any of the compound (s) described herein.
    Pharmaceutically acceptable salts can be synthesized from the parent compound which contain a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous medium such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, and others. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 18 a. ed. , Mack Publishing Company, Easton, PA, USA, p. 1445 (1990).
    Since prodrugs are known to improve the numerous desirable qualities of pharmacists (for example, solubility, bioavailability, manufacture, etc.) the compounds described here can be distributed in the form of prodrugs and can be administered in this form for the treatment of diseases . Prodrugs are intended to include any covalently linked vehicles that release an active parent drug in vivo as described herein, when such a prodrug is administered to a mammalian individual. Prodrugs are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. Prodrugs include compounds described herein in which a hydroxy, amino, or sulfhydryl group is attached to any group that, when the prodrug is administered to a mammalian individual, it cleaves to form a free hydroxyl, free amino or free sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate, and derivatives of alcohol benzoate and functional amine groups in the compounds described herein.
    Stable compound and stable structure are intended to indicate a compound, that is, sufficiently robust to survive isolation to a usable degree of purity from a reaction mixture, and formulation into an effective therapeutic agent.
    As used here, treating or treating includes any effect, for example, diminishing, reducing, modulating, or eliminating, which results in improving the condition, disease, disorder, etc. Treating or treating a disease state means treating a disease state in a mammal, particularly a human, and includes: (a) inhibiting an existing disease state, that is, stopping its development or its clinical symptoms; and / or (c) relieving the disease state, that is, causing regression of the sick state.
    As used here, preventing means causing clinical symptoms of the disease state to not develop, that is, inhibiting the onset of disease, in an individual who may be exposed to or predisposed to the disease state, but who has not yet experienced or exhibited symptoms of sickness.
    As used here, mammal refers to human and non-human patients.
    As used herein, the term therapeutically effective amount refers to a compound, or a combination of compounds, described herein present in or on a container in an amount sufficient to elicit biological activity, for example, pain relief. In some embodiments, the combination of compounds is a synergistic combination. Synergy, as described, for example, by Chou and Talai ay, Adv. Enzyme Regul. vol. 22, ρρ. 27-55 (1984), occurs when the effect of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at sub-optimal concentrations of the compounds. The synergy can be in terms of lower cytotoxicity, increased decrease in pain, or some other beneficial effect of the combination compared to the individual components.
    All percentages and ratios used here, unless otherwise stated, are by weight.
    Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes are described as having, including, or comprising specific process steps, it is contemplated that the compositions described herein also essentially consist of, or consist of, the recited components, and that the processes described here also consist essentially of, or consist of the described processing steps. In addition, it must be understood that the order of steps or order to perform certain actions is immaterial, as long as the process remains operable. In addition, two or more steps or actions can be conducted simultaneously.
    All enantiomers, diastereomers, and mixtures thereof, are included within the scope of compounds described herein. In some embodiments a composition comprising the R enantiomer is free or substantially free of the S enantiomer. In some embodiments, it is free or a composition comprising the S enantiomer substantially free of the R enantiomer. In some embodiments, a composition comprises an enantiomeric of at least, or about, 80, 85,
    90, 91,
    92, 93,
    94,
    95, 96, 97, 98, 99% both, the R enantiomer or
    S.
    As used throughout this description, singular forms one, o or -'a include reference in the plural, unless the context clearly indicates otherwise.
    Thus, for example, a reference to a composition includes a plurality of such compositions, as well as a single composition, and a reference to a therapeutic agent is a reference to one or more therapeutic and / or pharmaceutical and equivalent agents of the same known versions. on so on.
    Thus, for example, a reference to a host is a plurality of such host cells, and a reference to an antibody is a reference to one or the same antibodies and equivalents known to those skilled in the art below.
    The compounds claimed in this invention can be prepared from the procedures described in the schemes below.
    Schemes
    The following representative schemes illustrate how the compounds described herein can be prepared. The specific solvents and reaction conditions mentioned are also illustrative and are not intended to be limited. The compounds not described are either commercially available 10 or are readily prepared by the skilled artisan using available starting materials.
    Layout 1
    I feel s »of nttrita« splrocyclic
    NCCH ^ OjCHj
    AcOH, NH, OAc
    1-S
    RMsX, Cul <cal.)
    KOH, «4ll * r * o gecd
    Caíor
    Chiral HPLC separation

    R = fenüa, feni'a siíòstitutóa. aria, substituted aria, píndla, suhetífuida pyridia, heteroaryl, hwwotrila sub & Muidu. carbocycle, helerocide, etc.,
    Scheme 2: Convert nitrile to the opioid receptor ligand (approach 1)
    iae 2-1
    M 23
    Sr-1 2-4, twt-2
    R and R, are independent
    R a Ri = fonila, substituted fentla, aryl, substituted aryl, pyridyl, substituted pyridlla, heteroaryl, substituted heteroaryl, carbocycle, heterocicfoe etç.
    In some embodiments, the same scheme is applied to al-7el-8A.
    Scheme 3: Convert nitrile to the opioid receptor ligand (approach 2)
    1-βΒ 3-1 3. 2 η »1-2
    ReR>, are independent
    Re R>, = phenyl, substituted phenyl, aryl, substituted aryl, pyridyl, substituted pyridyl, heteraariia, substituted heteraariia, carbocycle, heterocycle and etc.
    In some embodiments, the same scheme is applied to 1-7 and 1-8A.
    selected from the group consisting of
    4-1A 4-1B 4 * 1C 4-1D 4-1E
    Following a sequence shown in scheme 2 or 3, intermediate 4-4 can be converted to opioid receptor ligands.
    Scheme 5: Synthesis of other spirocidal derivative opioid receptor ligands
    0-1 5-2 5-3 n = 1-2
    R and R), are independent
    R and Ri, = phenyl, substituted phenyl, aryl, substituted aryl, pyridyl, substituted pyridyl, heteroaryl, substituted heteroaryl, carbocycle, heterocycle, etc.
    Other schemes can also be used. For example, the following schemes can be used alone or in combination with other schemes to prepare the compounds described here.
    Scheme 6: Allyl trimethylBano approach to access the center of the çu-ammonium carbon
    RMgXor RM
    AlilSMe », TFA
    O}. DCM error PPhj
    RICCUJNH, MeOH. NaLH,
    η · ί · 2
    R and R i are independent of Re R ,, = feared, switchable phenyl, aryl, substituted atyl, plodila, substituted pyridyl, tieteroaryl, substituted sisteroaryl, carbocycle, heterocycle, etc.
    Figure 7: Ligating of the N-linked plrrazol optoid receptor

    Scheme d

    In some embodiments, a process for preparing a compound having the structure of IV-1
    is provided. In some embodiments, the process involves contacting
    »3 NH with appropriate to form a compound
    and 5th
    under having the
    In some embodiments, the structure conditions IV-1 the process is carried out at room temperature. In some embodiments, the process is carried out in the presence of borohydrate. In some embodiments, the salt process forms are carried out in the presence of sodium borohydrate. Solvents can also be used to facilitate preparation. The process can be modified to give different alkyl groups, such as, but not limited to, the scheme shown in scheme 10.
    Examples
    The following examples are illustrative, but not limiting, of the methods and compositions described here.
    Other appropriate modifications and adaptations to the variety of conditions and parameters commonly found in therapy and which are obvious to the person skilled in the art are within the spirit and scope of the compounds and methods described here.
    Example 1:
    Intermediate 1: Methyl 2-cyano-2- (oxan-4-ylidene) acetate
    A 50 ml round bottom flask equipped with a Dean-Stark distillation set and condenser was charged with tetrahydro-4H-pyran-4-one (4.61 ml, 50 mmol), methyl cyanoacetate (5, 3 ml, 60 mmol), ammonium acetate (1 g, 13 mmol), acetic acid (0.57 ml, 10 mmol) and benzene (30 ml). The mixture was refluxed until there was no more water collected in the Dean-Stark (2 h), cooled, benzene (30 ml) added and the organic layer washed with water (50 ml). The aqueous layer was extracted with CH2 Cl2 (3 x 50 ml). The combined organic phase was washed with sat. NaHCO 3 . (100 ml), brine (100 ml) dried (MgSCu), filtered and concentrated. Purified by normal phase SiO2 chromatography (10 to 60% EtOAc / hexanes) to give methyl 2-cyano-2- (oxan4-ylidene) acetocyte as a colorless oil (6.30 g, 70%, m / z: 181.1 [M + H] + observed).
    Intermediate 2: Methyl 2-cyano-2- [4- (4fluorophenyl) oxan-4-yl] acetate
    A round-bottom flask was equipped with a condenser, addition funnel and nitrogen-septum rubber septum was charged with a solution of p-fluorophenylmagnesium bromide (2.0 M in diethyl ether,
    1.99 ml, 3.97 mmol) and Cul (63 mg, 0.331 mmol) in 10 ml dry diethyl ether (10 ml). Methyl 2-cyano-2- (oxan-410 ilidene) acetate (600 mg, 3.31 mmol) in diethyl ether (10 ml) was added in drops over 30 min while cooling the reaction flask in an ice bath . The mixture was then stirred for 3 h. The reaction mixture was poured into a 50 g ice / 1 N HCl mixture (25 ml). The product was extracted with Et2G (3x50 ml), washed with brine (50 ml), dried (NA2SO4) and concentrated. Purified by SiO2 chromatography in normal phase (7% to 60%
    EtOAc / hexanes) to give methyl 2-cyano-2- [4- (4fluorophenyl) oxan-4-yl] acetate as a white solid (730 mg, 80%, l / z ·. 277.1 [M + Na] + observed).
    Intermediate 3:
    2- [4- (4-fluorophenyl) oxs.n-4-yl] acetonitrile
    To a pre-dissolved solution of KOH (441 mg ', 7.87 mmol) in ethylene glycol (20 ml) was added 2-cyano-2- [4- (4-fluorophenyl) oxan-4-yl] acetate methyl (1.09 g, 3.93 mmol). The mixture, was heated to 120 ° C for 3 h, and then cooled. H2O was added (50 ml), the product extracted with Et2 <D (3x50 ml), washed with H2O (50 ml), dried over NA.2SO4, filtered and concentrated. Purified by normal phase SiO2 chromatography (5 to 40%
    EtOAc / hexanes) to give 2- [4- (4-fluorophenyl) oxan-4yl] acetonitrile as a colorless oil (450 mg, 78%, m / z:
    219.1 [M + H] + observed).
    Intermediate 4: 2- [4- (4-fluorophenyl) oxan-4-yl] ethanamine
    To a solution of 2- [4- (4-fluorophenyl) oxan-4-yl] acetonitrile (450 mg, 2.05 mmol) in anhydrous ether (15 ml) at 0 ° C was added LAH in drops (1.0 M in EtzO, 4.1 ml, 4.11 mmol). After 2 h the reaction was quenched with 1 ml of II O, 0.1 ml of 15% IJaOH and then 1 ml of H2O. The reaction mixture was extracted with Et2O (3x20 ml), dried over NA2SO4 and concentrated to give 2- [4- (4-fluorophenyl) oxan-4-yl] ethan-l-amine as a yellow oil, which was used without another purification (450 mg, 94%, m / z: 223.1 [M + H] + observed).
    Example 2: Benzyl ({2- [4- (4-fluorophenyl) oxan-4-yl] ethyl}) amine (compound 8)
    To a solution of 2- [4- (4-fluorophenyl) oxan-4-yl] ethanl-amine (250 mg, 1.12 mmol) in anhydrous CH2Cl2 (5 ml) and NA2SÕ4 (159 mg, 1.12 mmol) at room temperature benzaldehyde (0.17 ml, 1.68 mmol) was added. The reaction was stirred overnight. The reaction mixture was filtered and concentrated. The residue was dissolved in 5 ml of MeOH at 0 ° C and NaEH 4 added in one portion (51 mg, 1.34 mmol). The reaction was stirred at 0 ° C for 1 h. The solution was then quenched with H 0 (10 ml), extracted with
    CH2 Cl2 (3x20 ml), washed with brine (10 ml) and dried over MA2SO4. Purified by normal phase S1O2 chromatography (0 to 10% MeOH / CH 2 C12) to give benzyl ({2- [4- (4fluorophenyl) oxan-4-yl] ethyl}) amine as a colorless oil (2 00 mg, 60%, m / zt 314.2 [M + H] + observed).
    Intermediate 5: 2,2-dimethyl-4- (4-methylphenyl) oxan-4ol n-EuLi (26.3 ml, 1.6 M in hexane, 42 mmol) was added dropwise to a solution of 4-bromo- toluene (7.70 g, 45 mmol) in THF (100 ml) at -73 ° C under M 2 . The resulting mixture was stirred at -78 ° C for 30 min and a solution of tetrahydro-2,2-dimethyl-4H-pyran-4-one (3.84 g, 30 mmol) in THF (20 ml) was added. The resulting mixture was stirred at -78 ° C for a further 20 min and quenched by adding MeOH (10 ml). The reaction was concentrated in vacuo and the resulting residue was diluted with EtOAc (50 ml) and washed with sat. NH4 Cl. (250 ml), brine (250 ml), dried and concentrated to give 2,2dimethyl-4- (4-methylphenyl) oxan-4-ol as a white solid, which was used without further purification '(5.41 g , 82%).
    iH RUN (400 MHz, CDCI3) δ 7.36 - 7.26 (m, 2H), 7.11 (d, J - 8.0, 2H), 4.10 (td, J = .12.0, 2.2, 1H), 3.71 (ddd,
    J - 11.8, 5.0, 2.1, 1 II), 2.2 8 (s, 3H), 211 (ddd, J = 13.7,
    12.2, 5.0, 1 H), 1.72 (dt, J = 14.2, 8.3, 2H), 1.58 (dq, J = 13.8, 2.2, 1 H) , 1.44 (s, 3H), 1.38 (s, 1 H), 1.14 (s,
    3H).
    Intermediate 6: 2,2-dimethyl-4- (4-methylphenyl) -4- (prop-
    2-en-l-yl) oxane
    Allyl trimethylsilane (4.34 ml, 27.2 mmol) was added to a solution of 2,2-dimel: yl-4- (4-methylphenyl) oxan-4-ol (3.0 g, 13.6 mmol) in Dry CI-I2CI2 (100 ml) at 0 ° C, followed by SF 3 -CEt 2 (3.42 ml, 27.2 mmol). The resulting mixture was stirred at 0 ° C for 1 h. The reaction was quenched with I { 20 (10 ml) and diluted with CH2 Cl2 (10 ml), and washed with sat. NaHCO 3 . (20 ml), brine (20 ml), dried and concentrated. Purified by normal phase SiO2 chromatography (5 to 40% EtOAc / hexanes) to give 2,2-dimethyl-4 (4-methylphenyl) -4- (prop-2-en-1-yl) oxane as a colorless oil, which was used crude (2.49 g, 75%).
    Intermediate 7: 2- [2,2-dimethyl 1-4- (4-methylphenyl) oxart 4-yl] acetaldeldu
    Gas O 3 was passed through a solution of 2,2dimethyl-4- (4-methylphenyl) -4- (prop-2-en- 1-yl) oxane (1.21 g, 5 mmol) in ÓH2C12 (50 ml ) at -78 ° C until the solution turns light blue (about 5 min). After an additional 5 minutes, the reaction mixture was purged with oxygen gas for 15 min before adding triphenylphosphine (2.62 g, 10 mmol). The reaction was stirred at room temperature for 4 hours and concentrated. Purified by normal phase SiO 2 chromatography (10 to 60% EtOAc / hexanes) to give 2- [2,2-dimethyl-4- (4-methylphenyl) oxan-4-yl] acetaldehyde as a colorless oil (641 mg, 52%).
    τ Η NMR (400 MHz, CDC1 3 ) δ 9.42 - 9.27 (m, 1 II), 7.26
    (dd, J = 9.9, 8.0, 2H), 7.20 ( t, J = 8.7, 2H), 3.94 - 3 , 75 (m, 2H), 2.69 (dd, J = 14.6, 2.5, 1 H), 2.51 - 2.38 (m, 2H), 2.35 (s, 3H), 2.26 (dd, J = 13.9, 2.3, 1H) , 1.84 (ddd, J = 14.3, 11.0, 4.6, 1H) , 1.76 (d, J = 13.9, 1 H), 1.23 (S t 3H), 0.73 (s, 3H).
    Example 3; {2- [2,2-dimethyl-4- (4-methylphenyl) oxan4-yl] ethyl} [(3-methylphenyl) methyl] amine (compound 32)
    A mixture of 2- [2,2-dimethyl-4- (4-methylphenyl) oxan-4yl] acetaldehyde (61.6 mg, 0.25 mmol), 3-methylbenzylamine (63 μΐ, 0.5 mmol) and acid acetic acid (50 μΐ, 8.6 mmol) in CH2 Cl2 (3 ml) was stirred at room temperature for 1 h before adding sodium triacetoxyborohydrate (106 mg, 0.50 mmol). The resulting mixture was stirred at room temperature for 18h. The mixture was concentrated and dissolved in MeOH and purified by HPLC to give {2- [2,2dimethyl-4- (4-methylphenyl) oxan-4-yl] ethyl} [(3-methylphenyl) methyl] amine as a white solid (35 mg, 40%, m / z: 352.3 [Μ + Η] + observed).
    Intermediate 8: Methyl 2-cyano-2 - [(9Z) -6oxaspospiro [4.5] decan-9-ylidene]
    A 10 ml round bottom flask equipped with a Dean-Stark distillation set and condenser was charged with 6-oxaspospiro [4.5] decan-9-one (6 g, 39 mmol, which was prepared according to Hanschke, E Chem. Ber. 1955, 88, 1053), methyl cyanoacetate (4.1 ml, 46.7 mmol), ammonium acetate (780 mg, 10.1 mmol), acetic acid (0.44 ml, 7, 8 mmol) and benzene (40 ml). The mixture was refluxed until there was no more water collected in the Dean-Stark set (2 h), cooled, benzene (30 ml) added and the
    organic washed with water (50 ml) . THE aqueous layer was extracted with CH2CI2 (3x5 0 ml). THE phase organic combined was washed with sat NaHCCh . (100 ml), brine (100 ml) dried (MgSO 4 ), filtered and concentrated. Purifi each per chromatography of SiO 2 in phase normal (7% to 60% in EtOAc / hexanes) to give acetate in 2-cyan-2 - [(9Z) -6-
    oxaspiro [4.5] decan-9-ylidene] as a colorless oil (8.93 g, 97.5%, m / z 235.1 [M + H] + observed).
    Through the procedure for the preparation of intermediate 8 substituting 2,2-diethyloxan-4-one for 6oxasposp [4.5] decan-9-one, 2-cyano-2 - [(42) -2,2diethyloxan-4-ylidene acetate ] de'methyl was prepared (m / z 237.1 [M + Η] + observed).
    Through the procedure for the preparation of intermediate 8 substituting 1-oxasposp [5.5] undecan-4-one for 6-oxasposp [4.5] decan-9-one, 2-cyano-2 acetate [(4Z) -1-oxasposp [ 5.5] methyl undecan-4-ylidene] was prepared (m / z 249.1 [M + H] + observed).
    Intermediate 9; Methyl 2-cyano-2.-i2- (4flvorophenyl) -6-oxaspiro [4.5] decan-9-yl]
    A round-bottom flask was equipped with a condenser, addition funnel and nitrogen septum rubber septum, which was charged with a 4-fluoromagnesium bromide solution (2.0 M in diethyl ether, 7.5 ml, 12.5 mmol) 'and Cul (200 mg, 1.0 mmol) in 35 ml of dry diethyl ether. Methyl 2-caryo-2- [(9Z) -6-oxasposp [4.5] decan-9-ylidene] acetate (2.5 g, 10.5 mmol) in diethyl ether (35 m2.) in drops for 30 min while cooling the reaction flask in an ice bath. The mixture was then stirred at room temperature for 1 h. The reaction mixture was poured into a mixture of 25 g of ice / 1 N 11C1 (20 ml). The product was extracted with Et2O (3 x 50 ml), washed with brine (50 ml), dried (N.A2SO4) and concentrated. Purified by normal SiO2 chromatography in normal phase (8% to 60% EtOAc / hexanes) to give 2-cyano-2- [9- (4-fluorophenyl) -6-oxaecpirus [4.5] decan-9-yl acetate ] methyl as a colorless oil (3.24 g, 93%, m / z 330.2 [M +
    1- I] + observed).
    By the procedure described in the preparation of intermediate 9 replacing methyl 2-cyano-2 - [(4Z) 2,2-diethyloxan-4-ylidene] acetate with 2-cyano-
    2- [(9Z) -5-oxaspospiro [4.5] decan-9-ylidene] methyl, 2-cyano-2- [2,2-diethyl-4- (4-fluorophenyl; oxan-4yl] acetate] was prepuived (m / z 333.2 [Μ + II] + observed;.
    By the procedure described in the preparation of intermediate 9 replacing 2-cyano acetate; o-2- '(4Z) -1oxaspiro [5.5] undecan-4-ylidene] with 2-cyano-2 acetate - [(9Z) - Methyl 6-oxaspiro [4.5] decan-9-ylidene], 2-cyano-2- [4- (4-flucrophenyl) -1oxasposp [5.5] v.ndecan-4-yl] acetate was prepared (m / z 345.2 [M + H] + observed).
    Intermediate__10_: 2 - [(9R) -9- (4-fluoropheni 1) - 5oxaspospiro [4.5] decan-9 -il] acetonitrile.
    To a pre-dissolved solution of KOH (1.1 g, 19.5 mmol) in ethylene glycol (50 ml) was added 2-cyano-2- [9- (4-flucrophenyl) -6-oxasposp [4.5] decan -9-1] methyl (3.24 g, 9.8 mmol). The mixture: 120 U 'O was heated for 3 h, then cooled. H 2 O was added (50 ml), the product extracted with Et 2 O (3x50 ml), washed with 'H 2 O (50 ml), dried over NA 2 SO.i, filtered and concentrated. (7% to 60%
    EtOAc / hexanes) to give methyl 2-cyano- 2- [9- (4fluorophenyl) -6-oxaspospiro [4.5] decan-9-yl] acetate (1.96 g, 73%, m / z 273.2 [M + H] + observed).
    1.96 g of the enantiomers were separated by SFC on an AD-3 column using 15% MeOH (0.05% DEA) as a modifier to give 2- [(9S) -9- (4-fluorophenyl) -6 -oxaspospiro [4.5] decan-9-yl] acetonitrile as a colorless oil (fastest eluting enantiomer, 635 mg, 24%, m / z 274.2 [M + H] + observed) and 2- [(9R) -9- (4-fluorophenyl) -6-oxasospiro [4.5] decan-9-yl] acetonitrile as a colorless oil (slower eluting enantiomer, 703 mg, 26%, m / z 273.2 [M + H] + observed).
    By the procedure described in the preparation of intermediate 10 replacing methyl 2-cyano-2- [2,2diethyl-4- (4-fluorophenyl) oxan-4-yl] acetate with 2-cyano-2- [9- ( 4- methyl fluorophenyl) -6-oxaspospiro [4.5] decan-9-yl], 2- [2,2-diethyl-4- (4-fluorophenyl) oxan-4-yl] acetonitrile was prepared (m / z 275 , 2 [+ H] + observed).
    By the procedure described in the preparation of intermediate 10 substituting methyl 2-cyano-2- [4- (4-fluorophenyl) -1-oxaspospiro [5.5] undecan-4-yl] with 2-cyano-2- [9- Methyl (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl], 2- [4- (4-fluorophenyl) -1oxaspiro [5.5] undecan-4-yl] acetonitrile was prepared (m / z 287 , 2 [Μ + H] + observed).
    Intermediate 11: 2 - [(9R) -9- (4-nuorophenyl) -6-oxasposp [4.5] decan-9-yl] ethan-l-amine
    To a solution of 2 - [(9R) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl] acetonitrile (500 mg, 1.8 mmol) in anhydrous ether (30 ml) at 0 ° C LAH was added in flavors (1.0 M in Et 2 O, 3.7 ml, 3.7 mmol). The reaction was then warmed up to room temperature. After 2 h the reaction was quenched with 1 ml H 2 0, 0.2 ml 15% NaOH and then 1 ml H 2 O. The reaction mixture was extracted with Et 2 O (3x30 ml), dried over NA 2 SC> 4 and concentrated to give 2 - [(9R) -9 (4-fluorophenyl) -6-oxaspospiro [4.5] decan-9-yl] ethan-1-amine as a yellow oil, which was used without further purification (500 mg, 100%, m / z 277.2 [M + H] + observed).
    By the procedure described in the preparation of intermediate 11 replacing 2- [2,2-diethyl-4- (4fluorophenyl) oxan-4-yl] acetonitrile with 2 - [(9R) -9- (4fluorophenyl) -6-oxasposp [4.5] decan-9-yl] acetonitrile, 2 [2,2-diethyl-4- (4-fluorophenyl) oxan-4-yl] ethan-1-amine was prepared (m / z 279.2 [M + H] + observed ).
    By the procedure described in the preparation of intermediate 11 replacing 2- [4- (4-fluorophenyl) -1oxasposp [5.5] undecan-4-yl] acetonitrile with 2- [(9R) -9- (4fluorophenyl) -6-oxaspiro [4.5 ] decan-9-yl] acetonitrile, 296 [4- (4-fluorophenyl) -1-oxaspospiro [5.5] undecan-4-yl] ethanamine was prepared (m / z 291.2 [M + H] + observed ).
    Example 4: Benzyl ({2 - [(9R) -9- (4-fluorophenyl) -6oxasposp [4.5] decan-9-yl] ethyl}) amine (compound 81)
    To a solution of amine 2 - [(9R) -9- (4-fluorophenyl) -6oxasposp [4.5] decan-9-yl] ethan-l-amine (100 mg, 0.361 mmol) in anhydrous CH2 Cl2 (6 ml) and NA2SO4 (256 mg, 1.80 mmol) at room temperature was added benzaldehyde (0.055 ml; 0.541 mmol). The reaction was stirred overnight. The reaction mixture was filtered and concentrated. The residue was dissolved in 6 ml of MeOH at 0 ° C and NaBH 4 added in one portion (16 mg, 0.433 mmol). The reaction was stirred at 0 ° C for 1 h. The solution was then quenched with
    H2O (20 ml), extracted with CH2CI2 (3x3 0 ml), washed with brine (10 ml) and dried about NA 2 SO 4 . THE mixture was HPLC purified for to give benzyl ({2 - [(9R) -9 - (4- fluorophenyl) -6-oxaspospiro [4. 5] decan- -9-il] ethyl} ) the mine how
    a white solid (121 mg, 92% ·, m / z 368.3 [M + H] + observed).
    Intermediate 12: 2,2-diethyloxan-4-ol.
    To a mixture of 3-butene-l-ol (19.8 ml; 233 mmol) and
    3-pentenone (12.3 ml; 116 mmol) was added 75% sulfuric acid (19.8; 334 mmol; prepared by diluting 79 ml of concentrated sulfuric acid to 100 ml with distilled water) in drops at 0 ° C . The reaction was allowed to warm to room temperature and stirred overnight. Water (70 ml) was added to the mixture then neutralized with NaOH (granules) at pH 8 and extracted with diethyl ether (3x150 ml). The ether extract was washed with an aqueous solution of sodium bisulfite (40 ml), dried over K2CO3 and the ether evaporated in vacuo. The residue was distilled under reduced pressure to give 2,2-diethyloxan-4-ol (4.89 g, 27%, B. Pt. 65-70 ° C at 1 mm Hg).
    NMR (400 MHz, CDCI3) δ 4.04 - 3.86 (m, 1H), 3.84 3.66 (m, 1H), 3.65 - 3.38 (m, 1 Η), 2.06 - 1.95 (m, 1 Η), 1.92 - 1.76 (m, 2H), 1.78 - 1.63 (m, 1 Η), 1.63 - 1.50 (m, 1 Η ), 1.51 - 1.31 (m, 3H), 1.28 - 1.10 (m, 1 Η), 0.92 0.68 (m, 6H).
    Intermediate 13: 2,2-diethyloxan-4-one
    To a solution of crude 2,2-diethyloxan-4-ol (500 mg, 3.2 mmol) in CH2 Cl2 (10 ml) was added NMO (750 mg, 6.41 mmol) and 4A molecular sieves (2 g). The solution was stirred for 30 min and then TPAP (34 mg, 0.096 mmol) was added in one portion. The reaction was allowed to stir for 10 h. After checking the TLC, the alcohol evaporated. It was filtered through a short pad of S1O2. The filtrate was concentrated and purified by normal phase S1O2 chromatography (0% to 50% EtOAc / hexanes) to give 2.2 diethyloxan-4-one (365 mg, 73%).
    Ή NMR (400 MHz, CDC1 3 ) δ 3.75 - 3.66 (m, 2H), 3.44 3.29 (m, 2H), 2.51 - 2.31 (m, 4H), 1, 25 - 1.4 (m, 4H), 0.75 (m, 6H).
    Intermediate 14: 2 - (bromomagnesium) pyridine
    In a flask 2.0 M isopropylmagnesium chloride in THF (6 mL, 12 mmol), 2-bromopyridine (1.2 mL, 12 mmol) in anhydrous EtaO (4 mL) was added in drops. The reaction mixture was stirred at room temperature for 3 h. The resulting mixture was used as such as a 1M Grignard solution.
    Example 5: Dibenzyl ({2 - [(9R) -9- (4-fluorophenyl) -6oxasposp [4.5] decan-9-yl] ethyl}) amine (compound 225)
    To a solution of 2 - [(9R) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl] acetonitrile (30 mg, 0.13 mmol) in anhydrous CH2Cl2 (3 ml) and NA2SO4 (92.3 mg, 0.65 mmol) at room temperature 2.3 eq of benzaldehyde (0.032 ml, 0.32 mmol) was added; The reaction was stirred overnight. NaBH (OAc) 3 (6.6 mg, 0.31 mmol) added in one portion. The solution was then quenched with H 2 O (10 ml), extracted with CH2 Cl2 (3x20 ml), washed with brine (10 ml) and dried over NA2SO4. The solvent was evaporated in vacuo and the residue was purified by HPLC to obtain dibenzyl ({2 [(9R) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl] ethyl}) amine (37 , 4 mg, 50%, m / z 458.3 [M + H] + observed).
    Example 6: {2 - [(9R) -9- (4-fluorophenyl) -6-oxasposp [4.5] decan-9-yl] ethyl} [(3-methylphenyl) methyl) amine (compound 122)
    Following an analogous procedure described for compound 81, compound 122 was obtained from the corresponding intermediate after a chiral HPLC separation (the slowest moving fraction on an AD-3 column. The absolute configuration of ex. 122 was determined by a X-ray crystallography.
    Example____7: {2 - [(9R) -9- (pyridin-2-yl) -6-oxasposp [4.5] decan-9-yl] ethyl} [2 - (pyridin-3-yl) ethyl] amine (compound 75 )
    1.0 M DIBAL solution in toluene (3.0 ml, 3 mmol) was added dropwise to a solution of 2 - [(9R) -9- (pyridin-2yl) -6-oxasposp [4.5] decan-9-yl] acetonitrile (350 mg, 1.4 mmol) in 7 mL of toluene at -78 oC. The resulting mixture was stirred at -78 ° C to complete (1.5 h). The reaction was then quenched with 5 eq MeOH (0.28 ml) and 0.1 ml water, stirring while heating, 175 mg of added NA2SO4, stirring at room temperature. 2h to give 310 mg (80%) of 2- [(9R) -9- (pyridin-2-yl) -6oxasposp [4.5] decan-9-yl] acetaldehyde. LCMS m / z 250.6 (M + 1) observed.
    100
    To a solution of 2- [(9R) -9- (pyridin-2-yl) -6-oxasospiro [4.5] decan-9-yl] acetaldehyde (50 mg, 0.19 mmol), 5 mL of DC and NA2SO4 (134 mg, 0.95 mmol) 2- (pyridin-3yl) ethan-1-amine (31 mg, 0.25 mmol) was added and the reaction was stirred overnight. NaBH 4 (9.5 mg, 0.25 mmol) added, stirring 10 minutes, 2 drops of MeOH were added, stirring 1 h, and cooling briskly with water, the organics separated and evaporated. The residue was passed through a Gilson reversed-phase HPLC to give {2 [(9R) -9- (pyridin-2-yl) -6-oxasposp [4.5] decan-9-yl] ethyl} [2- (pyridin -3-yl) ethyl] amine, 65.3 mg (71%). LCMS m / z 367.1 (M + 1) observed.
    Example 8: 2 - [(9R) -9- (2- {4H, 5H, 6H-thieno [2,3-c] pyrrol5-yl} ethyl) -6-oxasposp [4.5] decan-9-yl] pyridine (compound
    82)
    To a stirred solution of 2 - [(9R) -9- (pyridin-2-yl) -6oxasposp [4.5] decan-9-yl] ethan-1-amine (0.030 g, 0.115 mmol; prepared following a sequence described for compound 81 in dried ACN (5.8 ml) was added 2.3bis (bromomethyl) thiophene (31.1 mg, 0.115 mmol) followed by addition of K2CO3 (79.62 mg, 0.576 mmol). After 30 min, LCMS showed that the reaction was carried out and the main peak has the corresponding mass for the desired product. It was then subjected to HPLC purification.
    101 by HPLC: Luna acid column, 10-50% acetonitrile in H 2 O for 15 min, followed by instant distillation with 100% acetonitrile, 0.1% TFA modifier was employed. Fractions containing the desired product were pooled, basified with 2N NaOH and extracted with DCM (3x20 ml). The combined organics were concentrated and purified with flash chromatography (10 g silica gel column, eluted by 0-10% MeOH and DCM, based on TLC measurement: DCM / MeOH (10/1) Rf = 0.60 ) to give 5 mg of 2 [(9R) -9- (2- {4H, 5H, 6H-thieno [2,3-c] pyrrol-5-yl} ethyl) -6oxasposp [4.5] decan-9-yl ] pyridine as a colorless oil in 12% yield. LCMS m / z 369 (M + 1) observed.
    Example_____9: {2- [9- (IH-pyrazol-1-yl) -6-oxasposp [4.5] decan-9-yl] ethyl} (thiophen-2-ylmethyl) amine (compound 26)
    An oven-dried flask equipped with a Dean-Stack apparatus and a condenser was cooled to room temperature under a stream of N 2 and charged with 6oxaspospiro [4.5] decan-9-one (0.50 g, 3.24 mmol), (tert-butoxy) carbohydrazide (0.42 g, 3.24 mmol) and hexane (10 mL). The resulting solution was heated to reflux overnight.
    It was cooled to room temperature and the solid collected by vacuum filtration. The solid was washed with hexane and dried in air to give (tert-butoxy) -Ν '- [(9Z) -6102 oxaspiro [4.5] decan-9-ylidene] carbohydrazide (0.84 g, 96% yield). LCMS m / z 213 (M + 1-t-butyl) observed.
    An oven-dried flask was loaded with (tert-butoxy) -Ν '- [(9Z) -6-oxaspospiro [4.5] decan-9ilidene] carbohydrazide (0.42 g, 1.56 mmol) and THF. The solution was cooled to 0 ° C and allylmagnesium chloride (2.0 M, 1.60 ml) was added in drops. The reaction was stirred at 0 ° C during warming to room temperature overnight. LC-MS indicated that the reaction had not gone to completion. Another 2 equivalents of allylmagnesium chloride were added at room temperature. The solution was stirred for 1 h before being quenched with MeOH. The solution was diluted with DCM (60 ml) and H2O (20 ml). A batch of precipitates was formed and the solid was filtered through a pad of celite. The organic was then separated and the aqueous layer was extracted with 10 ml of EtOAc. The combined organic layers were concentrated and the residue was purified on a 25 g Snap column (0-20% tOAc in hex, 12 CV) to give (tert-butoxy) -Ν '- [9- (prop-2en-1 -il) -6-oxaspospiro [4.5] decan-9-yl] carbohydrazide (0.33 g, 68% yield). LCMS ra / z 333 (M + Na) observed.
    A solution of (tert-butoxy) -Ν '- [9- (prop-2-en-1-yl) -6oxasposp [4.5] decan-9-yl] carbohydrazide (0.33 g, 1.06 mmol) in 4 mL of EtOAc was added to 4M HCl in dioxane
    103 at room temperature. The solution was stirred at room temperature until completion of the reaction, monitored by LC-MS (30 h). The solvent was then removed to give [9- (prop-2-en-1-yl) -6-oxasospiro [4.5] decan-9-yl] hydrazine (250 mg). LCMS m / z 211.1 (M + 1) observed.
    To a solution of [9- (prop-2-en-1-yl) -6-oxasposp [4.5] decan-9-yl] hydrazine (250 mg, 1.0 mmol) in 4 ml of iPrOH was added Et3N and 3-dimethylaminoacrolein. The solution was refluxed for 3 h and then at 50 ° C for 2 days. The solvent was removed and the residue was purified on 25 g Biotage snap column, eluted with 0-18% EtOAc in hex (12HP) to give 1- [9- (prop-2-en-l-yl) -6- oxaspiro [4.5] decan-9-yl] -IH-pyrazole (80 mg, 31% yield). LCMS m / z 247.1 (M + 1) observed.
    A solution of 1- [9- (prop-2-en-1-yl) -6-oxasposp [4.5] decan-9-yl] -IH-pyrazole (80 mg, 0.32 mmol) in DCM (5 mL ) at -78 ° C was bubbled with O 3 until the solution turned blue. The resulting solution was bubbled with N 2 for 5 min. To this was added PPh3 (168 mg, 0.64 mmol). And the solution was stirred for 4 h at room temperature. After removing the solvent, the residue was purified by flash column chromatography to give 2- [9- (1H-pyrazol-1yl) -6-oxasposp [4.5] decan-9-yl] acetaldehyde (15 mg, 23% Yield). LCMS m / z 249 (M + 1) observed.
    104
    A mixture of 2- [9- (1H-pyrazol-1-yl) -6-oxasposp [4.5] decan-9-yl] acetaldehyde (15 mg, 0.06 mmol) and thiophen-2-methylmethanamine (19 µL, 0, 18 mmol) was stirred at room temperature for 1 h before NaBH (OAc) 3 (25.4 mg, 0.12 mmol) was added. The solution was stirred overnight. After removing the solvent, the residue was purified by HPLC to give {2- [9- (IH-pyrazol-1-yl) -6-oxasposp [4.5] decan-9-yl] ethyl} (thiophen-2-ylmethyl) amine (17 mg, 61% yield) as a TFA salt. LCMS m / z 34 6 (M + 1) observed.
    Example 10: Basic procedure for making compounds of the formula:
    Following the scheme 8 2 - [(9R) -9- (pyridin-2-yl) -6oxasposp [4.5] decan-9-yl] ethan-1-amine, which can be prepared following a sequence as described for compound 81 (Compound 4) and a similar sequence for intermediate 11 react with an appropriately substituted heteroaromatic aldehyde or appropriately substituted aromatic aldehyde (1 equivalent) in the presence of an organic solvent (i.e. DCM, MeOH, EtOH) to form
    105 a corresponding imine, which is reduced by an appropriate reducing agent for the compound. (R) n and Rm refer to optional substituents. In addition, phenyl groups can be substituted with other cycles or aryl groups as described here.
    Example 11; Basic procedures for making compounds of the formula:
    Following scheme 9, 9-1, which can be prepared following a sequence described for compound 81 (compound 4) and a similar sequence for intermediate 11, it reacts with an appropriately substituted heteroaromatic aldehyde or appropriately substituted aromatic aldehyde (1 equivalent) in the presence of an organic solvent (i.e. DCM, MeOH, EtOH and etc.) to form a corresponding imine, which is reduced by an appropriate reducing agent (i.e. NaBH 4 ) to give the compound. (R) n and Rm refer to optional substituents. In addition, the phenyl groups can be replaced with other cycles or aryl groups as described here.
    Example 12: Opioid receptor ligands
    Opioid receptor ligands and compounds
    106 listed in the following tables can be or have been prepared according to the procedures described above from appropriate starting materials and appropriate reagents. The compounds that were made list the 5 NMR data and the prophetic examples do not list the NMR data.
    Table 1: Compounds with chemical name and characterization data Compound Name IM + HJ 4 1H NMR 1 2- [9- (pyrldin-2-yl) -6oxasposp {4.5] decan-9 -yl] ethan-i-amine 261.1 δ 8 58 (ddd, J = 4.8,1.9,0.9,1H), 7.63 (m, 1H), 7.30 (m, 1H), 7.12 (ddd, J - 7.4,4.8,1.0,1H), 3.76 (m, 2H), 2.55 (td, J · 11.6, 5.1, 1H), 2.46 (ddd, J -13.7,5.1, 2.7.1H), 2.37 (dd, J = 13.7, 2.1.1H), 2.14 (td, 1 »11.6, 5.0.1H), 1.92 (m, 2H), 1.70 (m, 4H), 1.46 (m ,4H), 1.13 (m, 1H), 0-71 (dt, J * 13-4.8.8.1H).
    2 2 - {(9R) -8- (pMdin-2 - ») -6-oxaspospiro [4.5] decan9-yl] ethan-1-amine 261.2 δ 8.58 (ddd, J = 4.8,1.7,0.7,1H), 7.64 (td, J - 7.8, 1.9.1H), 7.28 (m, 1H), 7.12 (ddd, J = 7.4, 4.8.0.9, 1H) , 3.76 (m, 2H), 2.55 (m, 1H), 2.46 (ddd, J «13.7,5.1, 2.7.1H), 2.37 (m, 1H), 2.14 (m, 1H), 1.91 (m, 2H), 1.71 (m, 4H), 1.47 (m, 4H), 1.13 (m, 1H), 0.71 (m, 1H). 3 2- {9- (2-amylethyl) -6- 277.1 6 7.60 (d, J = 6.8.1H), 7.60 (d, J 6.8.1H), 7.21 (s,
    107
    -oxaspospiro (4.5] decan-9iljpiridin-4-ol•2H), 6.79 (d, J »532.9.3H), 6.54 (m, 5H), 6.37 (s, 1H), 6.29 (d, J = 6.5.1H), 5.97 (m, 6H), 4.84 ( d, J = 169.9.3H), 3.69 (dt, J = 23.7,11.7, 3H), 3.69 (dt, J =23.7,11.7,3H), 3.40 (s, 2H), 3.40 (s, 2H), 2.64 (s, 1H), 2.64 (s, 1H), 2.32 (d, J »12.0.1H), 2.26 ( dd, J «'46,7,13,0,2H), 2.20 (d, J« 13,9,1H), 2.09 (d, J ® 13,8,1H), 2.09 (d, J - 13,8,1H), 1.84 (t , J «15.9, 2H), 1.60 (m, 15H), 1.55 (m, UH), 0.89 (m, 2H), 0.89 (m,...... 1H). ................................. 4 6- [9- (2-aminoethyl) -6oxaspospiro (4.5] decan-9iqplrldln-3-ol 277.1 68 05 (m, 1H), 7.01 (d, J - 8.6.1H), 6.87 (dd, J - 8.6,2.9.1H), 5.37 (s, 2H), 3.66 (dd, J = 13.7, 7.2, 2H), 2.60 (ddd, J »12.3,10.1, 5.6.1H), 2.22 (m, 3H), 1.88 (tt , JI = 10.0, 7.9.1H), 1.77 (d, J = 13.6.1H), 1.58 (m, 4H), 1.37 (m, 5H), 1.08 (dd, J = 15.4, 4.9.1H), 0 63 (dt, J ~ 13.7, 8.9.1H). s 8 {9 «(2-amlnoetll) -6« oxaspiro (4.5] decan-9il] plricHn-2-ol 277.1 6 7.38 (dd, J - 9.0, 7.1.1H), 6.40 (d, J = 9.0.1H), 6.09 (d, J »7.1.1H), 5.28 (s, 1H), 3.73 (s, 2H), 2.69 (m, 1H). 2.37 (m, 2H), 2.13 (m, 2H), 1.66 (m, 12H), 0.97 (dt, J »12.4, 7.6.1H). 6 2 «9R) -9- (2-aminoethyl) -6oxaspospiro [4.5] decan-9IIJ-1-oxldopyridine-14o 277.1 δ 8.23 (m, 1H), 7.31 (dd, J ® 5.8, 2.0, 2H), 7.23 (m,1H), 4.03 | s, 2H), 3.81 (S, 2H), 3.27 (d, J - 13 9.1H),2.95 (td, J -12.8, 5.1.1H), 2.65 (td, J = 11.8, 5.1,1H), 2.25 ($, 2H), 1.6S (ddd, J »38.7,17.6,11.7,9H), 1.24 (s, 1H), 0.84 (dt, J · 13.1,8.8.1H). 1 beniil ({24H4. fluorophenyljocyclohextl] ethyl}) amlna 312.2 69.72 (t, J = 1.5.1H), 7.91 (m, 2H), 7.23 (m, 3H), 7.06 (m, 2H), 6.92 (m, 2H), 2.91 (t, 1 - 6.9, 2H), 2.44(m, 4H), 2.09 (dd, J »13.2, 5.3.2H), 1.68 (m, 4H), 1.46 (m, 1H), 1.33 (dd, J» 15.4.6.7.4H). 8 benzyl ({2- {4- (4f! uorophenyl) oxan-4yl] ethyl}) amine 314.2 6 7.38 - 7.16 (m, 7H), 7.09 - 6.99 (m, 2H), 3.79 (ddd, J «11.5, 5.7, 3.6, 2H), 3.64 (s, 2H), 3.56 (ddd, J -11.6.8.8 , 2.8.2H), 2.39-2.29 (m, 2H), 2.24-2.01 (m, 4H), 1.86 (ddd, J · 13.8,7.9,3.5, 2H). 9 methylfentl) matil] ({2- (4- (4methylphenyl) oxan-4iljetiljjamina 324.2 6 7.16 (m, 8H), 3.79 (ddd, J »11.5, 5-2.3-8, 2H), 3.58 (m, 4H), 2.41 (m, 2H), 2.36 ($, 3H), 2.27 ( s, 3H), 2.16(m, 2H), 1.86 (ddd, J = 12.3,8.6,4.6,4H |, 1.58 (s,1H) 10 N- {2- (2,2-dimethyl-4 (4-methylphenyl) oxan44l] ethyl} aniline 324.3 6 7.25 (dt, J »5.9.2.9.3H), 7.11 (m, 2H), 6.98 (dd, J = 25.0.8.2, 4H), 3.65 (dd, J« 8.9.6.7, 2H), 2.9S ( d, J • 4.6, 1H), 2.50 (d, J »4.7.1H), 2.23 (s, 3H), 2.10 (d, JI = 13.9.1H), 1.89 (m, 3H), 1.43 (m , 2H), 1.21 (m, 1H), 1.05 (s, 3H), 0.53 (S, 3H). 11 2 - ((((2- (4- (4metllfenll) oxan-4yl] ethyl} amino) methylphenol 326.2 67.15 (m, 5H), 6.88 (dd, J = 7.4,1,3,1H), 6.79 (dd,) = 8.1,10,1H), 6.73 (td, J - 7.4,1.1,1H), 3.76 ( m,4H), 3-54 (ddd, J - 11.7,9.4, 2.5, 2H), 2.37 (m, 5H),2.13 (m, 2H), 1.82 (m, 4H) 12 2 - (((2- (4- (4- 330.2 6 8.26 {$, 2H), 7.07 (m, 3H), 6.95 (dd, J »14.3,5.8,
    108
    fluorophenll) oxan-4iQethyl} amino) methyl] phenol2H), 6.86 (d, J ~ 6.3.1H), 6.78 (d, J ~ 8.1.1H), 6.71 (t, 1 »7.4.1H), 3.96 (d, J - 7.0.2H), 3 -80 (s, 2H), 3.64(dt, J »8.8,3.9.2H), 3.41 (t, J = 9.3.2H), 2.45 (s, 2H), 1.95 <d, J = 14.7.2H), 1.85 (m, 2H), 1.67 ( m, 2H). 13 benzyl ({2- [3- (pyridin-2-11) -1-oxaspira (4.4] nonan-2il] ethyl)} amine 337.1 δ 9.76 (s, 2H), 8.59 (d, J = 4.7.1H), 8.11 (t, J »7.8,1H), 7.69 (d, J »8.1.1H), 7.63 - 7.52 (m, 1H), 7.35 (s,SH), 4.13 (d, J - 9.7.1H), 4.03 (s, 2H), 3.91 (d, J - 9.7,1H), 2.92 (d, J = 26.5.2H), 2.53 (ddd, J »14.6.9.5, 5.4.1H), 2-38 (dd, J = 19.0.8-5.2H), 2.28 (d, J = 13.6,1H), 1.99 -1.81 (m, 1H>, 1.84 - 1.52 (m, 6H), 1.51 -1.35 (m, 1H). 14 benzll ({2- [2,2dimethyl-4- (4methyphenyl) oxan-4ll] ethyl}) amine 338.3 6 8.54 (d, J »226.0.2H), 7.22 (q, J · 6.7.3H), 7.03 (dd, i - 19.0, 8.3, 6H), 6.23 (d, J - 186-3, 2H), 3.69 (m, 4H), 2.66 (s, 1H), 2.25 (s, 4H), 2.10 (dd, 1 = 22.7, 13.3, 2H), 1.83 (m, 1H), 1.64 (m, 1H), 1.49 (m , 2H), 1.11 (s, 3H), 0.57 (s, 3H). 15 {2 * [2,2-dimethyl-4- {4-metllphenyl) oxan-4yl] ethyl} (pyridin-2-ylmethyl) amine 339.3 6 8.48 (dd, J »5.2.0.9.1H), 8.26 (s, 1H), 7.98 (dd, J = 7.8.1-6.1H), 7.59 (d, J = 7.9.1H), 7.54 (m, 1H), 7.07 (s, 4H), 4.17 (q, J «13.9.2H), 3.73 (m, 2H), 2.88 (d, J = 4.8.1H), 2.42 (d, J« 4.8, 1H), 2.21 (m, 4H),2.10 (dd, J = 13.9, 2.1.1H) ,, 2.00 (d, J = 4.6.1H), 1.78 (d, J = 4.6, 1H), 1.58 (m, 2H), 1.12 (s, 3H ), 0.59 (5, 3H). 16 {2- [2,2- <iimettM- (4methyphenyl) oxan-40Jetyl} (pyridin-3llmethyl) amine 3393 δ 8.92 (s, 1H), 8.52 (s, 1H), 8.25 (d, 1 - 8.0.1H), 7.67 (m, 1H), 7.08 (m, 4H), 5.92 (s, 4H), 4.09 (s, 2H), 3.71(m, 2H), 2.85 (dd, J = 12.0, 7.9.1H), 2.34 (m, 1H),2.23 (m, 4H), 2.10 (d, J - 13.9.1H), 1.94 (m, 1H),1.74 (dd, J = 12.5, 4.3.1H), 1.55 (m, 2H), 1.10 (s,3H), 0.57 (s, 3H). 17 [(2-methoxyifer »il) metll] ({2- (4- (4-methylphenyl) oxan * 4 * ll] ethyl}) amlna 3402 δ 7.21 (m, 1H), 7.13 (s, 4H), 7.07 (dd, J - ΊΑ, 1.7, 1H), 6.84 (ddd, J = 12.1,9.3,4.6,2H), 3.78 (m, SH), 3.63 (s, 2H), 3.54 (ddd, J = 11.6,9.1,2.7, 2H), 2.38 (d, 1 · 1.3.1H), 2.32 (m, SH), 2.10 (m, 2H), 1.84 (m , 4H) 18 (furan-Wlme »l) ({2 [(9R) -9- (plr1dln» 2-li) -6oxasposp (4.5] decan-9il] etll)) amlna 341.1 δ 8.72 (d, J - 4.6.1H), 8.23 (t, J = 7.3.1H), 7.84 7.57 (m, 2H), 7.46 (s, 1H), 7.38 (t, J 1.6.1H), 7.28 ( s, 1H), 3.89 (s, 2H), 3.82 (dt, 12.4.4.2.1H), 3.72 (dd, J - 16.1, 6.2.1H), 2.96 (d. J = 4.4.1H), 2.40 (ddd , J »36.0, 24.7,12.8, 4H), 2.20 (dd, J = 12.7,4.8, 1H), 2.01 (d, J ~ 14.2.1H), 1.95 - 1.77 (m, 2H), 1.69 (dd, J «9.6, 4.4.1H), 1.63 - 1.39 (m, 4H), 1.21 - 1.08 (m, 1H), 0.91-0.60 (m, 1H). 19 (1H-imidazole-2ilmetfl) ({2 * {(9R) -9 (pyridin-2-yl) -6oxasposp [4.5] decan-9il] ethyl}) amine 341.1 δ 8.70 (d, 1 = 5.1.1H), 8.40 (t, J «7.9.1H), 7.92 (d, J = 8.2.1H), 7.87 - 7.74 (m, 1H), 7.31 (d, J = 18.0, 2H),4.66 (d, J «14.3.1H), 4.49 (d, J = 14.3.1H), 4.02 -3.81 (m, 1H), 3.74 (d, J = 9.7.1H), 3.10 (d, J ~ 4.9, 1H), 2.84 - 2.48 (m, 2H), 2.37 (t, J = 12.7.3H), 2.17 -
    109
    2.00 (m, 1H), 2.00-1.82 (m, 2H), 1.70 (s, 1H), 1.6S -1.41 (m, 4H), 1.21 (S, 1H), 0.82 (d, J = 13.1.1H). 20 (1,3-oxazol-4ylmethyl) ({2 - [(9R) -9 (pWdln-24l) - «oxaspiro [4.5] decan-9il] etli}) amine 342.1 δ 8.77 (dd, 1 5.5, 1.4.1H), 8.26 (td, J «8.0,1.7,1H), 7.90 (s, 1H), 7.82 ($, 1H), 7.79 - 7.60 (m, 2H) , 4.08 (s, 2H), 3.86 (d, J = 12.9.1H), 3.81 - 3.66 (m, 1H), 3.13 (d, J «5.6.1H), 2.76-2.60 (m, 1H), 2- 48 (s, 1H), 2.42 - 2.25 (m, 3H), 2.16 - 2.01 (m, 1H), 1.89 (dd, J 9.6, 4.0.2H), 1.79 - 1.63 (ffl, 1H), 1.63 -1.35 ( m, 4H), 1.19 (s, 1H), 0.80 (d, J = 13.2.1H). 21 {2- {3- (plridin-2-H) -1oxasposp [4.4] nonan * 3il] ethyl} (thiophen-2ylmethyljamine 343 δ 10.01 (s, 3H), 8.62 (d, J = 4.5.1H), 8.11 (td, j = 8.0, 1.4.1H), 7.70 (d, J - 8.1.1H), 7.63 - 7.46 (m, 1H ),7.33 (dd, J · 5.1.1.0.1H), 7.16 (d, J = 2.8.1H), 7.00 (dd, J = 5.1.3.6.1H), 4.29 (s, 2H), 4.14 (d, J = 9.7, 1H), 3.92 (d, J »9.7.1H), 2 97 (qd, J = 18.1.12.2, 2H), 2.53 (ddd, J = 14.4.9.0, 5.7.1H), 2.45 -2.21 (m, 3H), 2.00 - 1.82 (m, 1H), 1.67 (tt, J = 22.6, 8.0.6H), 1.44 (dd, J = 14.3,10,0,1H). 22 {2- [3qplridin-2-IMoxoxospiro (4.4] ninth-3ll] etll) (ttofen-3ylmethyl) amine 343 δ 11.15 (s, 2H), 9.70 (s, 2H), 8.64 (d, J = 4.4.1H), 8.17 (td, J = 8.0.1.5.1H), 7.74 (d, J = 8.1.1H), 7.63 (dd, J = 6.7, 5.7.1H), 7.40 (dd, 1 = 2.8.1.1.1H), 7.33 (dd, J = 5.0, 3.0.1H), 7.10 (dd, J = 5.0 , 1.2.1H), 4.23 - 4.07 (m, 3H), 3.94 (d, J = 9.8.1H), 2.90 (d, J = 33 7, 2H), 2.67 - 2.50 (m, 1H), 2.50 - 2.24 (m, 3H), 1.91 (dd, J = 13.7.4.9.1H), 1.83 -1.52 (m, 6H), 1.43 (td, J = 7.7, 3.9.1H). 23 (clclopentylmethylX {2-((9R) -9- (plridin.2-ll) -6oxae8ptro [4.5] decan-9ll] ethyl}) amlna 343.3 δ 8.77 (d, J = 4.6, 2H), 8.26 (t, J = 7.6.1H), 7.89 7.60 (m, 2H), 3.85 (dd, J - 85.4.2.1H), 3.73 ( t, J = 10.1.1H), 3.00 (5.1H), 2.81 (s, 2H), 2.42 (dt, J = 23.0, 9.5.4H), 2.25. (t, J · 10.8.1H ), 2.19 - 1.98 (m, 2H), 1.98 - 1.33 (m, 13H), 1.16 (s, 3H), 0.76 (dt, J »13.1, 8.9.1H), 24 {2- [2,2-dimethyl-4- (4methylphenyl} oxan-4yl] etll) (thiophen «2« ilmethyljamin 344.2 δ 8.87 (d, J = 194.4.2H), 3.91 (s, 3H), 3.69 (m, 2H), 2.66 (d, J = 7.9.1H), 2.24 (m, 4H), 2.10 (ddd, J =30.6.14 0.2.1, 2H), 1.84 (td, J = 12,5,4,9,1H), 1.65 (m, 1H), 1.49 (m, 2H), 1.11 (d, J = 6.1 , 3H), 0.57 (s, 3H). 25 {2- (4- (4 (fluorophenyl) oxan-4yl] etll} [(2methoxyphenyl) metit] amine 344.2 δ 7.20 (ddd, J = 7.6.4.8, 2.0, 3H), 7.03 (m, 3H), 6.84 (ddd, J = 11.7,9.1,4,5, 2H), 3.77 (m, 5H), 3 61 (s,2H), 3.54 (ddd, J = 11.6, 8.8, 2.8, 2H), 2.27 (m, 2H), 2.08 (m, 2H), 1.84 (ddd, 1 = 10.5.8.4, 3.0.4H), 1.58 (s, 1H) 26 (2- (9- (1 H-pyrazol-1 -11) -6-oxaesfrtro (4.5] decan9-ilJe «l} (tiofen-2llmetll) amlna 346 6 9.87 (s, 1H), 9.00 (d, J · 145.4, 2H), 7.46 (dd, J = 12.7.2.1.2H), 7.28 (dd, J = 5.1,1.1,1H), 7.01 (d , J «0.8.1H), 6.93 (dd, J = 5.1.3.5.1H), 6.34 - 6.24 (m, 1H), 5.22 (s, 1H), 4.10 (q, J = 14.2, 2H), 3.68 ( d, j 2.7, 2H), 2.94 (s, 1H), 2.50 (s, 1H), 2.31 (s, 2H), 2.24- 2.08 (m, 1H), 1.99 (dt, J «14.7, 7.3.1H), 1.93-
    110
    1.76 (m, 2H), 1.75 -1.63 (m, 1H), 1.57 (ddd, J =23.2.14 0, 8.1.1H), 1.51 (s, 4H), 1.17 -1.04 (m, 1H),0.69 (dt, J = 13.3.8.7.1H), 27 benzJIK2 «i (9S)« Sl · (pyridin-2-yl) -6oxaspospiro [4.5] decan-9il] ethyl}) amine 351.1 δ 8.67 (d, 1 = 4.7.1H), 8.17 (t, J = 7.7.1H), 7.64 (m, 2H), 7.35 (m, 5H), 6.51 ($, 4H), 4.72 (s, 1H) , 3.94 (s, 2H), 3.75 (m, 2H), 2.95 (s, 1H), 2.49 (s, 1H), 2.33 (m, 3H), 2.19 (m, 1H), 1.98 (d, J - 14.1.1H), 1.81 (dt, J = 13.4, 7.5, 2H), 1.68 (m, 1H), 1.49 (ddd, J »20.8,14.7, 7.2.4H), 1.15 (s, 1H), 0.75 (m, 1H). 28 benzyl ({2 - [(9R) -9 (plridln-2-li) -eoxasposp [4.5] decan-9ll] etll}) amine 351.1 δ 8.61 (s, 1H), 8.18 | t, J - 7.7.1H), 7.65 (m, 2H), 7.26 (m, 5H), 6.90 (d, J = 26.0.4H), 3.88 (s, 2H) , 3.72 (d, J - 12.7.1H), 3.60 (t, J 10.0.1H), 2.90 (s, 1H), 2.39 (d, J - 34.6, 2H), 2.20 (t, 1 - 13.3, 3H) , 1.92 (d, J -14.8, 2H), 1.75 (m, 2H), 1.59 (d, J »4.9.1H), 1.41 (m, 4H), 1.08 ($, 1H), 0.68 (dt, J · 13.2.9.0.1H). 29 benzyl ({2- {3- (pyridin-2il> 1 ‘oxaspesp [4.5] decan-3yl] ethyl}) amine 351.1 δ 9.67 (s, 2H), 8.61 {$, 1H), 8.19 (t, J - 7.5.1H), 7.80 (d, J = 8.1.1H), 7.64 (s, 1H), 7.36 (s, 5H) , 4.22 (d, J = 10.0.1H), 4.0S (5.2H), 3.98 (d, J = 10.0.1H), 3.00 (s,1H), 2.84 (s, 1H), 2.64 (5.1H), 2.39 (d, J = 8.7.1H), 2.18 (d, J »136.1H), 2.09 (d, J = 13.6.1H), 1.75 -1.52 (m, 4H), 1.33 (dd, J - 28,9,16.2, 7H). 30 benzll ({2- {9- (pyridin-2-oxaeapiro [4.5] decan> 9> il] ethyl)) amine 351.2 δ 8.49 (S, 1H), 8.03 (s, 1H), 7.53 (d, J = 8.0, 2H), 7.18 (m, 5H), 3.82 (s, 2H), 3.63 (s, 1H), 3.53 (dd , J = 23.8, 13.7.1H), 2.84 (s, 1H), 2.38 (s, 1H), 2.27 (d, J = 7.4, 1H), 2.13 (d, J - 14.1.3H), 1.84 ( d, J = 14.2.1H), 1.67 (m, 2H), 1.52 (d, J = 5.0.1H), 1.32 (m, 4H), 1.01 (s, 1H), 0.61 (dt, Jr 13.0.8.9, 1H). 31 {2- {2,2 «dlmethyl-4- (4methylphenyl) oxan-4ll] ettl> [(2 · metllphenyljmetyl] amine 352.2 δ 7.09 (d, J »8.3.2H), 7.02 (ddd, J = 8.1, 61.3.3,6H), 3.69 (m, 2H), 3.47 (5, 2H), 2.41 (td, J '10.8, 5.4, 1H), 2.25 (m, 4H), 2.11 (m, 5H), 1.75 (ddd, J - 13.2,10.4, 5.2.1H), 1.56 (m, 4H), 1.11 (s, 3H), 0.59 (s, 3 H). 32 {2- [2J2-dllm * til «4- (4methylphenyl) oxan-4illeUIM (3.. Methylphenyl) methyl} amine 352.3 δ 9.13 (s, 1H), 8.69 ($, 1H), 7.04 (m, 6H), 6.86 (m, 2H), 3.65 (m, 6H), 2.59 (s. 1H), 2.12 (m, 9H), 1.83 (td, J - 12.4, 4.5, 1H), 1.64 (m, 1H), 1.48 (m, 2H), 1.10 (s, 3H), 0.57 (s, 3H). 33 {2- [2 ^ -dimettl-4- (4metllfenll) oxan * 4 * ylJetylMHmethylphenyl) methyl] amine 352.3 δ 8.68 (d, J »205.9.2H), 7.02 (dd, J» 16.8.9.0.6H), 6.93 (d, j - 8.1.2H), 3.67 (dd, J « 6 6, 2.7.2H), 3 57(s, 2H), 3.44 (s, 3H), 2.61 (s, 1H), 2.25 (d, J = 11.2, 3H), 2.17 (5.3H), 2-08 (dd, J = 20.3, 14.0, 2H), 1.84 (m, 1H), 1.67 (d, J = 7.6.1H), 1.48 (m, 2H), 1.09 ($, 3H), 0.56 (s, 3H). 34 {2- [2,2-dimethyl-4- (4methylphenyl) oxan-4ll] ethyl} ((1R) -1-phenyl] amine 352.3 6 9.07 (dd, J = 228.2,166.6, 2H), 7.24 (ddd, J - 9.3, 6.4, 3.4, 3H), 7.15 (m, 2H), 6.94 (m, 4H>, 3.91 (s, 1H), 3.61 (dd, J = 7.0, 4.0, 2H), 2.42 (d, J = 33.9.1H), 2.21 (d, J = 11.7, 6H), 2.00 (m, 2H), 1.82 (m, 1H), 1.62 (dd,
    Ill
    J - 8.6, 4.1, IH), 1.42 (m, 5H), 1.05 (s, 3H), 0.53 (d, J = 3.4.3H), 35 {2- (2,2- <imimethyl-4- (4methylphenyl) oxan-4il] etll} [(1S) -1phenyethyl] amine 352.3 δ 8.92 (dd, J «238.8,174.0,2H), 7.24 (m, 3H), 7.14 (td, J» 7.5.2.2, 2H), 6.95 (m, 4H), 3.89 (d, J »19.3,IH), 3.62 (m, 2H), 2.96 (s, '2H), 2.42 (m, IH), 2.21 (d, J' 11.6.3H), 2.00 (m, 3H), 1.82 (m, 1H), 1.63 (m, IH), 1.40 (m, 5H), 1.06 (s, 3H), 0.53 (d, J = 3.6.3H). 36 benzll ({2- [2,2dimethyl-4- (4methylphenyl) oxan-4yl] ethyl)) niethylamine 352.3 δ 11.09 (s, 2H), 7.39 (m, 3H), 7.23 (m, IH), 7.15 (m, SH), 4.19 (dd, J = 25.7,12.6, IH), 3.91 (dd, J »17.4, 8.4, IH), 3.78 (m, 2H), 2.91 (d, J »127.4, IH), 2.56(dd, J -17.7, 7.2, 3H), 2.37 (d,) - 4.8.3H), 2.24 (ddd, J »22.0,12.2,2.2,3H), 2.05 (m, IH), 1.88 (td, J = 12.5, 4.7, IH), 1.64 (m, 2H), 1.21 (s, 3H), 382-30-67 (d, J »1.2.3H). 37 {2- (2,2-dimethyl- (4methylphenyl) oxan-4yl] ethyl} (2phenylethyl) amlna 352.3 Ó 9.06 (d, J »128.6, 2H), 7.17 (m, 3H), 7.02 (m, 6H), 3.68 (dd, J« 11.8,10.1,2H), 2.77 (dt, J * 36.5,30.4,7H), 2.19 (m, 5H), 1.99 (m, IH), 1.89 (td, J = 12.5, 4.6, IH), 1.69 (m, 1H), 1.49 (m, 2H), 1.00 (s, 3H) , 0.52 (5.3H). 38 (pirazln-2-imethyl) ({2 - ((9R) -9 (plridin-24l) -6oxasposp [4.5] d®can-9il] etll)) amine 353.1 δ 8.79 (dd, J · 5.6.1.4,1H), 8.68 - 8.54 (m, 2H), 8 51 (dd, J »2.3.1.6.1H), 8.32 (td, J« 8.0.1-6, IH ), 7.93 7.66 (m, 3H), 4.30 (s, 2H), 3 85 (dt, J »12.3, 4.2, IH), 3.72 (t, J = 9.9, IH), 3.19 (td, J = 11.7.5.2, IH), 2.72 (td, J = 11-8.4.0.1H), 2 62 -2.45 (m, IH), 2.45 -2.27 (m, 3H), 2.10 (d, J = 14.2, IH), 2.00 - 1.79 (m, 2H), 1.69 (dt, J «9.9, 6.6, IH), 1.63-1.41 (m, 4H), 1.19 (dd, J = 12.6, 6.5, IH), 0.78 (dt, J »13.1,8.9,............................................... 1H) 39 bewril ({2- (2> diethyl4- (pyrldin-2-ll) oxan-4yl] ethyl)) amine 353.3 δ 8.71 (dd, J «5.5,1.4, IH), 8.21 (td, j - 8.0,1.7, IH), 7.67 (m, 2H), 7.33 (m, 5H), 3.95 (s, 2H), 3.79 ( m, IH),3.67 (d, i = 10.8, IH), 3.01 (d, J - 5.2, IH), 2.40 (m, 4H), 2.10 (s, IH), 1.73 (t, J «16-5, 2H), 1.55 (dd, J = 14.1, 7.5, IH}, 1.39 (dd, J ~ 14.1,7.4, IH), 0.81 (m, 5H), 0.56 (t, J «7.3.3H), 40 benzyl ({2- (2,2,6,6tetramethyl-4- (pyridyl2ll) oxan-4ll] ethyl}) amlna 353.3 6 8.74 -8.62 (m, IH), 8.24 (td, J = 8.1.15, IH), 7.87 (d, J «8.2, IH), 7.76 - 7.65 (m, IH), 7.47 - 7.18 (m, 7H ), 3.96 (s, 2H), 2.75 (s, 2H), 2.50 (d, J «14.7, 2H),2.43 - 2.28 (m, 2H), 1.89 (d, J «14.8, 2H |, 1.30 (s, 6H), 0.97 (s, 6H). 41 44 ({2- [2 t 2-dime «1-4. (4-methylphenyl) oxan4yl] ethyl] amino) methyl phenol 354.2 δ 8.58 (d, J = 187.3, 2H), 7.05 (q, J «8.3.4H), 6.91 (d, J« 8.3, 2H), 6.58 (d, J «8.4, 2H), 3.67 (d, J = 10.4, 2H), 3.58 (s, 2H), 2.63 (d, J »18.2, IH), 2.26 (s, 4H), 2.07 (d, J» 14.3.4H), 1.84 (t, J ~ 10.2, IH), 1.49 (d, 1 - 13.9.3H), 1.09 (s, 3H), 0.S6 (s, 3H). 42 2 - [({2- [2,2-dimethyl-4 (4-metltfenlljoxan4- 354.3 δ 8.15 (d, JI «107.7, 2H), 7.03 (dt, J = 26.2, 8.3, SH),6.82 (m, 2H), 6 64 (t, J «7.4, IH), 3.68 (m, 6H), 2.58 (S, IH), 2.24 (d, J = 6.8.4H), 2.05 (dd, J = 21.0,14.9,
    112
    il] ethyl} arnlno) metiq phenol2H), 1.78 (d, J »4.4.1H), 1.58 (s, 1H), 1.44 (dd, J =21.2.9.8, 2H), 1.10 (d, J = 18.7.3H), 0.57 (d, J - 24.3, 3H). 43 (4 * «neÃllfenll) oxan>4-il] ethyl} amino) methyl] phenol 354.3 6 8.50 (d, J «165.4,2H), 7.02 (m, SH), 6.68 (d, 1» 7.5, 2H), 6.47 (d, J »7.4.1H), 367 (d, J« 9.4 , 2H), 3.59 (s, 2H), 2.63 ($, 2H), 2.23 {$, 4H), 2.09 (dd, J = 27.3,13.5, 2H), 1.84 (d, J - 7.8.1H), 1.66 (d, J = 8.6, 1H), 1.52 (d, J - 13.9.2H), 1.09 (s, 3H), 0.56 (s, 3H). 44 [(5-metllfuran-2yl) methyl] ({2 - {(9R) -9 (pyridin-2-yl) -6oxae «pyro (4J5] decan-9> yl] ethyl}) amine 355.1 δ 8.73 (d, J = 4.2.1H), 8.18 (td, J »80.15.15H), 7.80 -7.53 (m, 2HL 7.29 (s, 1H), 4.00 (d, J = 1.4, 2H), 3.83 (dt, i «12.4,4.3,1H), 3.79 - 3.63 (m, IHj, 3.10 2.86 (m, 1H), 2.64-2.44 (m, 1H), 2.45-2.27 (m, 3H), 2.27 - 2.11 (rp, 4H), 2.02 (d, J = 14.2.1H), 1.95-1.77 (m, 2H), 1.68 (dd, J «9.5, 4.1.1H), 1.62 -1.39 (m, 4H), 1.26 - 1.05 (m, 1H), 0.77 (dt, J = 13.3,9.0, 1H ). 45 [(5-metiffuran-2yl) methyl] ({2- [9 (plrazin * 2 * ll} 4> oxaspiro (4.5] decan-9ll] ethyl}) amine 356.1 δ 8.66 (s, 1H), 8.56 (s, 1H), 8.50 (s, 1H), 6.27 (d, J 3.2.1H), 6.05 - 5.83 (m, 1H), 3.94 (d, J «1.9, 2H ), 3.85-3.59 (m, 2H), 2.89 (d, J - 5.0.1H), 2.49 (d, J 5.1.1H), 2.38 (t, J - 16.0, 2H), 2.24 (s, 4H), 2.02 (dd,J «18.2, 6.8, 2H), 1.96-1.88 (m, 2H), 1.59 - 1.37 (m, 5H), 1.09 (s, 1H), 0.66 (d, J = 13.4.1H). 46 benzyl ({2- [9- (tk> fen2-) 1) -6oxaspospiro [4.5] decan-9ll] ethyl}) amine 356.2 δ 9.56 (S, 1H |, 9.11 ($, 1H}, 7.31 (m, 3H), 7.23 (m, 2H), 7.19 (dd, J = 5.1,1.0,1H), 6-91 (dd, J = 51.3.6, 1H), 6.74 (d, J »3.5.1H), 3.72 (m, 4H), 2.74 (m, 1H),2.44 (m, 1H), 2.01 (d, J = 13.9, 2H), 1.95 (dd, 1 = 11.7, 5.0.1H), 1.87 (m, 2H), 1.73 ($, 5H), 1.66 (m , 2H), 1.50 (m, 3H), 1.00 (dd, J * 13.6.8.5.1H). 47 {2 <2.2-dlmetIM- (4 »methylphenyl) oxan-4yl] ethyl} [(2fluorophenyl) met) 1] amine 356.3 δ 7.15 (m, 1H), 7.06 (m, 5H), 6.94 (dt, J = 18.3.8.1, 2H), 3.69 (t, J = 7.7, 2H), 3.60 (s, 2H), 2.44 (dd, J = 11.0.5.2.1H), 2.22 (d, J = 20.4, 4H), 2.11 (m, 2H),1.77 (dd, J = 6.6.4.0.1H), 1.57 (qd, J - 10.9, 5.5.3H), 1.11 (s, 3H), 0.59 (s, 3H). 48 {2- [2,2-dimethyl-4- (4 · methylphenyl) oxan-4-fluorophenyl) methyl] amine 356.3 Ô 8.79 (d, J «198.9.2H), 7.19 (m, 2H), 7.05 (d, J = 8.2.2H), 7.00 (d, J» 8.4.2H), 6.94 (td, J = 8.4.2.2 ,1H), 6.86 (d, j = 7.6.1H), 6.79 (d, J = 8-9.1H), 6.36 (s,2H), 3.69 (m, 4H), 2.65 ($, 1H), 2-24 ($, 3H), 2.11 (ddd, 1 «18.3,15.7,11.3, 3H), 1.81 (dt, J» 12.3, 6.2 , 1H), 1.63 (m, 1H), 1.48 (m, 2H), 1.10 (s, 3H), 0.56 (s, 3H). 45 {2- {2,2-dimethyl-4- <4methylphenyl) oxan-4yl] ethyl} [(4fluorophenyl) methyl] amine 356.3 Õ 8.73 (d, J «173.6, 2H), 7.03 (m, 6H), 6.88 (t, 1 = 8.5, 2H), 5.32 (s, 2H), 3.68 (m, 4H), 2.61 (s, 1H) , 2.24 (s, 3H), 2.11 (m, 3H), 1.78 (dt, J 12.3, 6.2.1H), 1.61 (m, 1H), 1.47 (m, 2H), 1.10 (s, 3H), 0.56 ( s, 3H). 50 benzll (2- {9-cyclohexll-6-oxaospiro [4.5] decan * 356.3 δ 9.09 (d, J - 38.9, 2H), 7.35 (m, SH), 6-43 (s, 2H),3.93 (s, 2H), 3.54 (m, 2H), 2.85 (s, 2H), 1.63 (m.
    113
    9yl) ethyl) amine16H), 1.10 (m, 7H), 0.84 (q, J '11.8, 2H). 51 {2- [3- (pyridin-2-tl) -1 · oxaspiro [4.5] decan-3yl] ethyl) (thiophene-2ylmethyl) amine 357 69.79 (s, 2H), 8.66 (s, 1H), 8.21 (t, J - 7.5, IH), 7.80 (d, J - 8.1, IH), 7.66 (s, 1H), 7.33 (d, J = 5.0 , IH), 7.16-(s, 1H), 7.06 - 6.98 (m, IH), 4.29 (s, 2H), 4.23 (d, J »9.9, IH), 3.99 (d, J» 10.0, IH), 3.00 ($, IH) , 2.87 (s,1H), 2.63 (t, J = 9.5, IH), 2.39 (d, J ® 8.6.1H), 2.20 (d,J »13.5.1H), 2.10 (d, J = 13.6.1H), 1.77 -1.49 (m, 4H), 1.47-1.19 (m, 6H). 52 {2- (3- (pyridin-24l) -1oxaspospiro [4.5] decan-3ll] etll) (tlofen-3 · ilmethyljamina 357 6 9.72 (s, 2H), 8.64 (s, 1H), 8.21 (t, J = 7.5.1H), 7.80 (d, 1 · 8.1.1H), 7.66 (t, J «5-9, IH), 7.44 - 7.31 (m, 2H), 7.09 (d, J - 4.8, IH), 4.23 (d, JI «9.9, IH), 4.10 (s, 2H), 3.99 (d, J» 10.0, IH), 2.95 (s, 1H), 2.80 (s, IH), 2.64 (s, IH), 2.39 (d, J = 8.7.1H), 2.21 (d, i = 13 7, 1H), 2.10 (d, J · 13.6 , IH), 1.77 - l.SO (m, 4H), 1.49 “1.22 (m, 6H). 55 {2 <Hplridin-2-IIHoxae5plro [4.5] decan-9IIJatHXtylophen-2ylmethyljamine 357.1 6 8.67 (d, J - 4.3, IH), 8.14 (s, IH), 7.66 (d, J = 8.2, IH), 7.59 ($, IH), 7.33 (dd, J »5.1.1.1, IH), 7.12 (d, J»2.7, IH), 7.00 (dd, J» 5.1.3.5, IH), 4.22 (s, 2H),3.80 (s, IH), 3.72 (t, J = 9.8, IH), 3.33 - 2.70 (m, IH),2.70 - 2.50 (m, IH), 2.30 (d, J = 14.0.3H), 2.19 (dd, J = 18.0.7.1, IH), 1.98 (d, J = 14.1, IH), 1.83 (d, J »4.6, 2H), 1.76-1.62 (m, IH), 1.50 (dd, J - 20.1,13.3, 5H), 1.16 (s, IH), 0.75 (dt, J »13.1, 9.1, IH). 54 {2 - {(9R) -9- (pyridin-2-(1) -6oxaspiro [4.5] decar> -9HJa «l> (ti0fen-2ilmetlljamina 357.2 6 8.67 (d, 1 »4.3, IH), 814 ($, IH), 7.66 (d, J» 8.2, IH), 7.59 (s, IH), 7-33 (dd, J = 5.1.1.1 , IH), 7.12 (d, J 2.7, IH), 7.00 (dd, J «5.1, 3.5, IH), 4.22 (s, 2H),3.80 (s, IH), 3.72 (t, J »9.8, IH), 3.33 - 2.7Ô (m, IH), 2.70 - 2.50 (m, IH), 2.30 (d, J - 14.0, 3H), 2.19 ( dd, J• 18.0, 7.1, IH), 1.98 (d, J »14.1, IH), 1.83 (d, J =4.6, 2H), 1.76 -1.62 (m, IH), l.SO (dd, J «20,1,13.3, 5H), 1,16 (s, IH), 0.75 (dt, J« 13.1, 9.1, IH). 55 (2 - ((9R) -9- (pyridin-2-il) -6oxaspospiro [4.5] decan-9H] «eiXeofen-3ilmetiljamlna 357.2 δ 8.73 (d, J «5.0, IH), 8.27 (t, J 7.5, 2H), 7.88 7.62 (m, 2H), 7.48 -7.23 (m, IH), 7.04 (dd, J» 4.9 , 1.0, IH), 4.02 (s, 2H), 3.90 - 3.76 (m, IH), 3.69 (t, J =10.0, IH), 2.95 (s, IH), 2.62 - 2.12 (m, 4H), 2.13 1.95 (m, IH), 1.95 -1.76 (m, 2H), 1.68 (dt,) »13.5, 7.9, IH) , 1.62 -1.30 (m, 5H), 1.16 (dd, J = 13.2, 6.6,IH), 0.76 (dt, J - 13.0.8.9, IH). 55 {2 - [(9R) -9- (pyridin-2ίΙ) -βoxaspospiro [4.5] decan-9H] etllX1,3-tlazol-2ylmethyljamina 358 õ 8.77 (d, J = 4.3.1H), 8.27 (t, J = 7.3, IH), 7.86 -7.65 (m, 2H), 7.43 (d, J »3.1, IH), 7.28 (s, IH), 4.56 -4.39 (m, 2H), 3.79 (dddd, J = 21.9.19.5,10 8.7.1, 2H), 3.19 (td, J -11.5.5.3, IH), 2.81 - 2.63 (m, IH),2.62 - 2.43 (m, IH), 2.43 - 2.26 (m, 3H), 2.14 -1.99(m, IH), 2.00 - 1.79 (m, 2H), 1.79 -1.63 (m, IH),1.63 - 1.38 (m, 4H), 1.20 (dd, J »13.0.6.5, IH), 0.79(dt, J »13.0.8.9, IH).
    114
    57 (2 - [(9R) -9- (pirtdin-2-11) -6oxaesplro [4.5] decan-9IJatiQ (1,3- «azole-5Hmetiljamlna 358 δ 8.76 (d, J = 4.7.1H), 8.37 (td, J ® 84, 1.4, 1H), 8.12 - 7.72 (m, 3H), 7.29 (S, 1H), 4.37 ($, 2H), 3.93 - 3-58 (m, 2H), 3.05 {td, J «11.7.54.1H), 2.66 - 2.43 (m, 2H), 2.42 - 2.22 (m, 3H), 248 -1.96 (m, 1H) , 1.96 1.79 (m, 2H), 1.79 -1.39 (m, 5H), 148 (dd, J '124, 5.5.1H), 0.77 (dt, J = 12.9.8.9.1H). 58 (2- {Hpirazin-2-ylHoxaa «piro {4.5] decar> ^ IHetHXttofen-2ylmethyl) amine 358 6 8.63 (s, 1H), 8.55 (s, 1H), 8.49 (d, J «2.3.1H), 7.33 (dd, J« 51.14.1H), 7.08 (d, J «2.6.1H), 7.05 - 6.97(m, 1H), 3.73 (d, J - 36.7.2H), 347 - 2.73 (m, 1H),2.54 - 2.43 (m, 1H), 2.35 (d, J = 13.0, 2H), 2.24 -241 (m, 1H), 2.05-245 (m, 4H), 1.51 (s, SH), 144 -1.01 (m, 1H), 0.66 (s, 1H). 59 {2- [2,2-diethyl-4 (pyridin-2-yl) oxan-4ll] ethyl} (thiophen-3ylmethyljamine 359.2 6 8.72 (dd, J = 5.5,1.4,1H), 8.21 (td, J = 8.0,1.7,1H), 7.68 (m, 2H), 7.35 (dd, J = 2.9,1.2,1H), 7.30 (m , 2H), 7.04 (dd, J = 5,0,1,3,1H), 4.02 (s, 2H), 3.80 (dd, J »10.0, 6.3.1H), 3.68 (d, J« 10.8.1H), 3.00 (m, 1H), 2.42 (m, 4H), 2.08 (d, J - 4.4.1H), 1.78 (s, 1H), 1.71 (d, J - 14.5.1H), 1.56 (dd, J «144.7.5.1H), 1.40 (dd, J« 14.1, 7.4.1H), 0.81 (m, 5H), 0.57 (t,) «7.3, 3H). 60 {242,2-dtotyl-4 · (pMdln «24l) oxan <4 * il) ethyl} (thiofan-2HmetiQamine 359.2 δ 8.70 (dd, J = 5.4.1.4.1H), 845 (d, J = 16.1H), 7.66 (d, J »8.2.1H), 7.60 (dd, J» 6.7.5.5, 1H), 7.33 (dd, 1 «54.1.2.1H), 741 (d, J« 2.6.1H), 6.99 (dd, J - 54, 3.6.1H), 3.73 (d, J = 44.0.4H) , 4.02 ($, 2H), 3.80 (dd, J · 10.0.6.3.1H), 3.68 (d, 1 »10.8.1H), 3.00 (m, 1H), 2.42 (m, 4H), 2.08 (d, J »4.4.1H), 1.78 (s, 1H), 1.71 (d, J« 14.5.1H), 1.56 (dd, J = 144.7.5.1H), 1.40 ( dd, 1 «14,1,7,4,1H), 0.81 (m, 5H), 0.57 (t, J = 7.3, 3H). 61 (242,2.6,6.tetramethyl-4- (piiMin-2-yl) oxan-4 ·IQatil) {tlofen-2ilmatiljamina 359.2 68.63 (dd, J = 5.6.1.3.1H), 848 (td, J = 84.1.6.1H), 7.81 (d, J «8.2.1H), 7.63 (dd, J = 6.8, 5.8 , 1H), 7.36 -746 (m, 2H), 7.05 - 6.96 (m, 2H), 6.88 (dd, J = 5.1, 3.6, 2H), 443 ($, 2H), 2.80-2.60 (m, 2H), 2.43 (d , 1 = 14.7.2H), 2.33 - 2.17 (m, 2H), 1.81 (d, J - 14.8, 2H), 1.21 (d, J »12.2.6H), 0.89 ($, 6H). 62 {2- (2,2,6,6tetnunatll <44plrld) n * 2-ll) oxan-4iI ethyl} (thiophen-3ylmethyljamine 359.2 δ 8.62 (dd, J - 5.6,1.4,1H), 849 (td, J = 8.0,1.7,1H), 7.81 (d, J - 8.2.2H), 7.67 - 7.60 (m, 1H), 7.27 (dd , J =2.9.14.1H), 743 - 747 (m, 2H), 6.95 (dd, J = 5.0, 1.3.1H), 3.95 (s, 2H), 2.62 (d, J = 84.2H), 2.41 (d , J = 14.7.2H), 2.34 - 2.08 (m, 2H), 1.82 (d, J '14.8, 2H), 1.21 (d, J - 13.1, 6H), 0.89 (s, 6H). 63 {2- [9- (thiophen-2-ylH · oxasposp [4.5] decan-9ll] eUI} (tfofen-2 · ilmatiljamina 362.2 δ 9.60 (s, 1H), 9.27 (s, 1H), 7.29 (dd, J = 5.1.1.1, 2H), 7.21 (dd, J = 54.1.0.1H), 7.03 (d, J «2.6.1H ), 6.94 (ddd, J = 9.9, 54, 3.6.2H), 6.77 (dd, J - 3.6.14, 1H), 4.03 (s, 2H), 3.74 (m, 2H), 2.80 (td, J ~ 11.9.4.9,1H), 2.50 (td, J = 11.8, 5.0.1H), 1.96 (m, 4H), 1.71 (m, 4H), 1.48 (m, 6H), 1.00 (dt, J 12.7.84.1H) .
    115
    64 (2- [9- (tlofen-2-ll) -6oxasposp [4.5] decan-9iqettl} (tlofen «3 * ilmatil) amlna 362.2 6 9.46 (s, 1H), 9.23 (s, 1H), 7.27 (m, 2H), 7.21 (dd, J = 5.1.1.0.1H), 7.00 (dt, J »7.5.4.4.1H), 6.93 ( dd, J = 5.1,3.5,1H), 6.75 (dd, J «3.6,1.1,1H), 3.85 (s, 2H), 3.74 (m, 2H), 2.73 (m, 1H), 2.43 (s, 1H ), 2.12 (m, 1H), 2.03 (m, 2H), 1.96 (dd, J · 12.4, 7.6.1H), 1.87 (m, 2H), 1.70 (m, 3H), 1.48 (m, 5H), 1.00 (dt, J = 12 8, 8.1.1H). 65 (clclopentllmetll) ({2 «[2,2-diatU-4- {4fluorophenll) oxan-4yl] ethyl)) amlna 362.3 6 9.23 (m, 1H), 8.73 (m, 1H), 7.25 (dd, J »8.9.5.2, 2H), 7.07 (t, J = 8.6, 2H), 3.73 (d, J» 10.9, 2H), 2.69 (s, 2H), 2.10 (m, 4H), 1.78 (d, J »18.1.3H), 1-64 (m, 7H), 1.38 (s, 2H), 1.28 (s, 1H), 1.10 ( d, J (16.3, 3H), 0.84 (s, 4H), 0.53 (s, 3H). 66 (cyclopentylmethyl) ({2 (4- (4-fluorophenyl) 2,2,6,6tetramethyloxan-4yl] ethyl}) amine 362.3 δ 8.64 (5, 2H), 7.22 (dd, J 8.9, 5.1.2H), 6.95 (t, J «8.6.2H), 3.25 (s, 2H), 2.61 (s, 2H), 2.43 (s, 2H ), 2.24 (d, J = 14.3, 2H), 1.91 (m, 2H), 1.68 (m, 2H), 1.60 (d, J«14.3, 2H), 1.49 (m, 4H), 1.18 (s, 6H), 1.03 (dd, J = 12.4,7.3, 2H), 0.93 ($, 6H). 67 (2- {9-cyclohexyl-6oxaesplra [4.5) decan-9il) ethyl) (thiophen-2ilmeUIJamlna 362.3 δ 9.21 (d, J »25.7, 2H), 7.33 (dd, J» 5.1.1.1, 2H), 7.14 (d, J »2.7.1H), 7.00 (dd. J» 5.1.3.6.1H), 4.19(s, 2H), 3.56 (m, 2H), 2.92 (s, 2H), 1.65 (m, 17H), 1.12 (m, 7H), 0.87 (dd, J = 23.8.11.9.2H). 68 (2 * {9 »cyclohexyl-6 * oxaspiro [4.5] decan-9ll) ethyl) (thiophen-3ylmethyl) amine 362.3 6 9.07 (d, J »31.8.2H), 7.37 (ddd, J = 7.9.3.9.2.1, 2H), 7.10 (dd, J> 5.0.1.3, IK), 6.37 (s, 2H), 4.04 (s, 2H), 3.55 (m, 2H), 2.87 (s, 2H), 1.64 (m, 16H), 1.12 (m, 7H), 0.85 (q, J «11.8.2H). 69 2- {2 - {(9R) -9- (plridln-211) -6oxaesp) ro [4.5Jdecan «9 * iqeUI) -2,3-d! Hydro1H-I» oindot 363.1 6 8.77 (d, J «4.0.1H), 8.09 (td, J» 8.0.1.7.1H), 7.64 (d, J «8.1.1H), 7.55 (dd, J = 7.1, 5.8.1H), 7.35 (dd, J• 5.6, 3.2.2H), 7.24 (d, J «3.6.2H), 4.76 (m, 4H), 4.21 (bra, 1H), 3.77 (m, 2H), 3.30 (m, 1H), 2.80 (td , J »12.3,4.4,1H), 2.49 (td, J» 12.9,4.5.1H), 2.38 (t, J= 15.1, 2H), 2.23 (td, J «12.9.4.2.1H), 2.07 (d, J = 14.0.1H), 1.87 (ddd, 1« 24,1,11.9, 7.1, 2H), 1.69 (m,1H), 1.51 (dt, J = 24.2.10.9.4H), 1.15 (m, 1H), 0.78 (dt, J ~ 13.4,9.0.1H). 70 (2- (2,2-dletyl-4- (4fluorophenyl) oxan-4yl] ethyl} dipropylamlna 364.4 6 11.44 ($, 1H), 7.28 (m, 2H), 7.20 (m, 2H), 3.75 (m, 2H), 2.88 (m, 5H), 2.27 (m, 3H), 1.97 (td, J = 12.7 , 3.9.1H), 1.80 (td, J = 12.6.4.9.1H), 1.66 (m, 2H), 1.46 (m, 6H), 1.04 (m, 1H), 0.88 (m, 10H), 0.55 (m , 3H). 71 (2-phenylethyl) ({2 [(9R) -9- (pyridin-2-yl) -6oxasplro [4.5] decan-9il] ethyl)) amine 365.1 δ 8.51 (dd, J - 5.3,1.3,1H), 8.04 (td, J = 7.9,1.7,1H), 7.56 (d, J = 8.1.1H), 7.49 (dd, J «7.1, 5.8.1H) , 7.25 -7.12 (m, 6H), 7.10-7.03 (m, 2H), 3.88 - 3.47 (m,3H), 3.01 (d, J 7.5, 2H), 2.85 (t, J - 7.8, 2H). 2.44 ($,1H), 2.38 - 2.17 (m, 3H), 2.17 -1.99 (m, 1H), 1.92 (d, J - 14.1.1H), 1.84 -1.66 (m, 3H), 1.58 (d, J ~ 5-1,1H), 1.40 (ddd, 1 = 15.2.12.1, 8.9.4H), 1.05 (d, J = 6.5.1H), 0.65 (d, J = 13.4.1H).
    116
    72 (2-phenylethyl) ({2- {9 (pyridin-2-tl) -6oxasposp [4.5] decan-9ll] «til}) amlna 365.3 6 8.58 (d, J - 4.8.1H), 8.07 (t, J = 7.9, IH), 7.61 (s, IH), 7.52 (dd, J = 12.0.6.3, IH), 7.27 (m, 3H), 7.20 (m, 2H), 4.04 (d, J - 3.2.2H), 3.76 (ddd, J «19.4,12.6.8.9, 2H), 3.05 (s. IH), 2.S3 (m, 2H), 2.29 (d, J »43.6, SH), 1.96 (d, J = 13.9, IH) , 180 (m, 2HJ, 1.68 (s,1H), 1.50 (ddd, J '20.5,13.1, 7.0.4H), 1.17 (s, IH), 0.75 (m, IH). 73 benzll ({2- [9- {6methylpyridin-2-yl) -6oxasposp [4.5] decan-9il] ethyl}) amine 365.7 6 9.49 (s, 2H), 8.18 (t, J · 7.9, IH), 7.55 (dd, J = 23.1, 7.8, 2H), 7.35 (s, 5H). 5.87 (s, 3H), 4.00 (s, 2H), 3.88 - 3.66 (m, 2H), 3.00 (s, 1H), 2.80 (s, 3H), 2.65 (d, J 12.5, IH), 2.53 (s, IH), 2.31 (d, J = 14.3.2H), 2.20 (d, J »13.5, IH), 2.11 - 2.00 (m, IH), 1.97 -1.80 (m, 2H), 1.70 ( d, J - 5.3, IH), 1.52 (ddd, J «29.7.17.1, 7.4.4H), 1.28 (t, J · 7.1, IH), 0.95 - 0.79 (m, 1H). (ddd, J = 29.7,17.1, 7.4.4H), 1.28 (t, J «7.1, IH), 0.92 - 0.77 (m, IH). 74 (2 »{2,methylphenyl) oxan-4yl] ethylX2-phenylpropan-2iljamlna 366.3 1H NMR (400 MH1324.3, CDCI3) δ 8.50 (d, J »223.4, 2H), 7.25 (s, 5H), 6-95 (d, 338.3 J 8.1, 2H), 6.87 (d, J« 8-3, 2H), 5.69 (s, 3H), 3.62 (dd, J * 6.8, 2.5, 2H), 2.38 (dd, J «15,7,13.2, IH), 2.22 (s, 3H), 1.98 (m,2H), 1.80 (m, 2H), 1.63 (m, 1H), 1.56 (s, 3H), 1.51 (s, 3H), 1.47 (d, J - 14.1, IH), 1.39 (dd, J = 10.5, 4.0, 1H), 1.06 ($, 3H), 0.53 (s, 3H). 75 {24 (9RHHplridlri-2. OxaMplno [4.Qdecan4lU> tll} [2- (plr1dln-3fl) atH [amlna 367.1 δ 8.90 (s, IH), 8.75 (d, J »4.4, IH), 8.61 (d, J« 5.2,IH), 8.41 - 8.28 (m, 2H), 7.87 -7.70 (m, 3H), 3.81 (s, IH), 3.71 (s, IH), 3.29 (t, J = 10.5.3H), 2.97 (d, J »7.3, IH), 2.44 (s, 2H), 2.33 (t, J - 11.9, 2H), 2.21 (dt, J - 24.1,11.9, IH), 2.07 (d, 1 -14.3, IH), 1.88 (d , J =10.3, 2H), 1.65 (dd, J »16.4, 9.9.1H), 1.60 -1.44 (m, 5H), 1.19 (s, 1H), 0.81 (d, J · 13.1.1H). 76 ((2-methylpyrimidin-5ll) methyl] «2 - ((9R) -9 (pyridir» -2-yl) -6oxaaspiro [4.5] decan-9il] ethyl}) amine 367.1 δ 8.57 (s, 2H), 7.83 -7.66 (m, 1H), 7.33 (s, 4H). 7.21 (dt, J = 10.8, 2.9, IH), 3.93 (s, 1H), 3.69 (s, 2H), 2.65 (s, IH), 2.40-2.20 (m, 3H), 2.09 (s, 2H), 1.87 ($, 2H), 1.76-1.50 (m, 3H), 1.42 (ddd, J = 33.3,13.0,3.9, 2H), 1.22 (td, J = 7.3,1.9, IH), 1.02 (s, IH) , 0.71 0.54 (m, IH). 77 {2- (2,2-dirnetyl-4- (4. Methylphenyl} oxan-4lljetyl} i {2methoxyphenyl) material] amine 368.3 5 7.16 (m, 6H), 6.85 (dd, J - 18 0, 7.8, 2H), 3.80 (s, 3H), 3.61 (d, J «1.9, 2H), 3.51 (s, 2H), 2.45 (d , J 5.2, IH), 2.35 (s, 4H), 2.15 (m, 2H), 1.81 (m, IH), 1.66 (s, 4H), 1.20 (5.3H), 0.69 (5.3H) . 78 {2- [2Jl-dime «l-4- (4methylphenyl) oxan-4yl] etH} [<3methoxyphenyl> methyl 368.3 δ 9.28 (5, IH), 8.80 (s, IH), 7.10 (m, IH), 7.01 (q, J = 8.4.4H), 6.74 (dd, J - 8.2, 2.0, IH), 6.65 (dd, J = 15.6, 4.8.2H), 3.66 (m, 7H), 2.64 (s, 4H), 2.24 ($, 3H), 2.09 (m, 3H), 1.82 (m, IH), 1.64 (m, IH) , 1.48 (ddd, J 13.4, 9.8, 8.8, 2H), 1.10 (s, 3H), 0.57 (s, 3H). 79 benzyl ({2- {9- {4- 368.3 6 8.82 (d,) - 134.2, 2H), 7.31 (m, 3H), 7.16 (m, 4H),
    117
    fluorophenyl »* oxaspospiro [4.5] decan-9iljetil} (amine7.00 (dd, J = 10.7.6.5, 2H), 3.72 (m, 4H), 2.70 (s,1H), 2.28 ($, 1H}, 1.92 (m, 6H), 1.62 (m, 2H), 1.46 (m, 4H), 1.23 (m, 1H), 0.77 (dt, J 13.6,8,8,1H ) _____ 80 benzyl ({2-í (9S) -9- (4fluorophenylHoxaesplro [4.5jdecan-9il] ethyl}) amine 368.3 6 9 09 (s, 1H), 8.74 (s, 1H), 7.31 (m, 3H), 7.16 (m, 4H), 7.00 (t, J = 8.6, 2H), 3.73 (m, M 2.67 (s, 1H), 2.26 (s, 1H), 2.02 (s, 2H), 1.94 {td, J * 12.6,4.7, IHj, 1.85 (d, J »13.9.3H), 1.62 (s, 2H), 1.46 (dd , J - 7.8, 4.0.4H), 1.24 (d, J «12.7.1H), 0.77 (dt, J« 13.6.8.7, 1H) 81 benzyl ({24 (»R) -9-44fluorophenyl-B · oxaspiro [4.5} dacan-9ll] etlf}) amine 368.3 δ 7.24-7.17 (m, 2H), 7.16-7.09 (m, 3H), 7.01 (d, J = 7.8.2H), 6.89 (d, J = 80 0, 2H), 3.68 (ddd, J = 11.8,5.0.1.3.1H), 3.62 - 3.49 (m, 3H), 2.32 (t, 1 = 7.3, 2H), 2.25 (s, 3H), 2.22 - 2.13 (m, 1H), 1.93 (dtd, 1 «15.7,7.7,3.8,1H), 1.81 -1.66 (m, 2H), 1.65 -1.56 (m, 1H), 1.37 (d, J = 20.2.1H), 1.20 -1.05 (m, 2H), 1.01- 1.02 (m, 2H), 0.86 (t, J »12.7.1H). 82 2 <(9R) -e- (2 · {4Η, 5Η, 6Η-ββπο [2 »3c] pyrrol-5-yl} ethyl) -6oxasposp [4.5] decan-9IQpIridlna 369 6 8.59 (ddd, J * 4.8,1.9,0.9.1H), 7.64 (m, 1HL 7 32 (t, J = 5.9.1H), 7.15 (d, J «4.9.1H), 7.12 (ddd, i 7.5 , 4.8.1.0.1H), 6.74 (d, 1 «4.9.1H), 3.80 (m, 4H), 3.68 (m, 2H), 2.63 (td, J · 11.6, 5.1.1H), 2.49 ( dd, J · 13.8, 2.2.1H), 2.37 (dd, J - 13.7, 2.0.1H), 2.16 (td, J »11.6.4.4.1H), 2.05 (m, IHJ, 1.79 (m, 3H ), 1.62 (d, J = 7.8, 2HL 1.50 (m, 3H), 1.40 (m, 1H), 1.14 (ddd, J = 9.7.7.6, 3.2.1H), 0.72 (dt, J «13.4,8.9, 1H), 83 [(4,6-dlmetltfuran-2> yl) methyl] ((2 - {(9R) -9 (plridin-2-IIHoxasespiro [4.5) decan-9il} ethyl}) amine 369.1 6 10.28 (brs, 1H), 9.39 (brs, 1H), 8.70 (d, J «4.6,1H), 8.12 (t, J »7.5.1H), 7.65 (d, J« 8.1.1H), 7.58 (m, 1H), 644 (s, 1H), 3.91 (q, J = 14.4.2H), 3.75 (m, 2H), 2.95 (dd, J = 10.9, 5.9.1H), 2.51 (t, J »9.7.1H), 2.33 (m, 3H), 240 (s, 3H), 1.99 (d, J 144.1H), 1.82(m, 5H), 1.68 (m, 1H), 1.48 (m, 4H), 1.15 (m, 1H),0.74 (dt, J «13.2.8.9.1H). 84 {2 - [(9R) -9- (4 fluorophenyl) -6 * oxaspospiro [4.5] decan-9ÍI] etiQ (pyridin-4llmetil) amlna 369.2 δ 8.53 (5, 2H), 7.78 (s, 3H), 7.29 - 7.05 (m, 6H), 6.96 (t, J - 8.4.3H), 4.07 (s, 2H), 3.66 (d, J »12.5, 2H),2.83 (s, 1H), 2.37 (s, 1H), 241 (d, J »13.7.1H), 2.01 (d, J» 13.3.2H), 1.83 (d, 1 = 14.0, 2H), 1.49 (t , J 61.9.9H), 147 (s, 2H), 0.70 (dt, J - 17.4, 8.9.1H). 85 2 <({2- [4- (4tethoxyphenyl) -2,2dimethyloxan-4ll] ethyl} amlno) methyl] phenol 370.3 δ 8.05 (d, J «152.9, 2H), 7.08 (m, 1H), 7.01 (d, J · 8.9.2H), 6.82 (m, 2H), 6.76 (d, J = 8.8, 2H), 6.69 (t, J »7.3.1H). 4.00 (5, 2H), 3.77 (s, 2H), 3.70 (s, 3H),3.65 (dd, J «6.9,2.6.2H), 2.61 (s, 1H), 2.23 (s, 1H), 2.04 (dd, J» 23.7,13.9, 2H), 1.93 (s, 1H), 1.81 (td , J »12.5, 4.9.1H), 1.60 (td, J» 12.7,4.8.1H), 1.48 (d, J · 13.9, 2H), 1.08 U, 3H), 0.55 ($, 3H). 86 banzil ({2- [2,2-diethyl-4- (4ftuorophenyl) axan-4H] * til}) amlna 370.3 δ 7.26-7.14 (m, 3H), 7.13 -7.02 (m, 4H), 6.91 (t, J 8.6, 2H), 3.69- 3.47 (m, 4H), 2.51 (td, J »12.2, 4.7, 1H) , 244 -1.94 (m, 3H), 1.83 (td, J = 12.7, 4.3.1H), 1.64 (td, J · 12.6, 4.7.1H), 1.56 - 1.35 (m, 3H), 1.27
    118
    (tt, J = 27.2,13.7,1H), 0-95 (dq, J = 14.7,7,4,1H), 0.84 -0.58 (m, 4H), 0.43 (t, J = 7.4.3H). 87 benzyl ({2- {4- (4fluorophenyl) -2,2,6,6tetramethyloxan-4ll] etll}) amine 3703 69.15 (s, 2H), 7.32 (m, 3H), 7.25 (m, 2H), 7.18 (dd, J - 7.3, 2.1, 2H), 6.99 (dd, J «12.0,53.2H), 3.72 (s , 2H), 234 (dd, J 53.2,23.4,2H), 1.91 (dd, J »10.4, 6.5, 2H), 1.68 (d, J = 14.3.2H), 1.27 ($, 6H), 1.02 (s , 6H). 88 [(2,3dimetoxlfenll) metiq ({2- (4- (4methylphenyl) oxan-4IIJetil}) amlna 370.3 5 7.13 (s, 4H), 6.95 (m, 1H), 6.80 (dd, J »8.2.1.4, 1H), 6.72 (dd, J - 7.6.1.4,1H), 3.83 (s, 3H), 3.75 (m, 5H), 3.63 (S, 2H), 3.54 (ddd, J «11.6,9.1, 2.7, 2H), 231 (m, 5H}, 2.10 (m, 3H), 1.Ç2 (ddd, J 133.83, 3.7.4H) 89 [(3-metlttlofen-2ll) matil] ({2 <(9R} -9 (pyridin-2-yl) -6oxa spectrum [4.5] decan -9il] ethyl}) amine 371.1 δ 9.68 (s, 1H), 8.75 (s, 1H), 8.16 (m, 1H), 7.74 (d, J «27.0, 2H), 7.27 (d, J = 1.5.1H), 6.85 (d, J - 5.1.1H), 4.10 (m, 2H), 3.84 (d, J = 12.7.1H), 3.66 (d, J = 103,1H), 2.96 (m, 1H), 2.69 (m, 1H), 2.54 (m, 3H), 235 (m, 4H), 2.11 (d, J · 14.0,1H), 1.87 (d, J · 103, 3H),1.57 (m, 5H), 1.06 (m 1H), 0.78 (d, J '12.8.1H). 90 {2 - [(9R) -9- (pyridin-2yl) -6oxae $ piro [4.5] decan-9il) ethyl} [2- (thiophen-2-yl) ethyljamin 371.1 δ 8.80 - 8.66 (m, 1H), 8.45-8.25 (m, 1H), 7.84 -7.63 (m, 2H), 7.16 (dd, J «5.1,1.1.1M), 6.91 (dd, J * 5,1,3.5,1H), 6.83 (dd, j» 3.4,0.9.1H), 3.83 ( tt, J »13.7, 6.9.1H), 3.69 (dd, J« 20.1,10.1,1H), 3.16 (s,4H), 3.02 (5.1H), 2.61 - 2.22 (m, 5H), 2.20-1.98 (m, 1H), 1.98-1.77 (Μ, 2H), 1.76-1.63 (m, 1H), 1.50 (tdd, J = 123,10.9,53,4H), 1.17 (dd, 1 - 7.9, 5.2,1H), 0.76 (dt, J = 13.0, 8.8.1H). 91 [(2-methyltophen-3it) metiq «2 - [(9R) -9 (plridin-2 <4oxasplro [4,5] decan-9il] ethyl}) amine 371.1 δ 8.68 (d, J - 5.4.1H), 8.26 (s, 1H), 7.82 - 7.63 (m, 2H), 7.05 (t, 1 «10 0.1H), 6.94 (d, J = S3.1H) , 3.96 (s, 2H), 3.82 (s, 1H), 3.72 (s, 1H), 3.03 (s, 1H), 2.50 (d, J = 15-9, 2H), 239 (s, 3H>, 2.30 (dd, J = 12.6, 7.5, 3H), 2.02 (d, J = 14.2.1H), 1.92 - 1.79 (m, 2H), 1.70(dt, J »14.S, 10.2.1H), 1.64-138 (m, 4H), 1.25 -1.13 (m, 1H), 0.79 (d, i -13.2.1H). 92 [(5-matiltiofen-2ll) metiQ ({2 <(9R> 9 (pyridin-2-íl) -6oxasposp [4.5] dacan-9 * ll] «tli}) amlna 371.2 δ 8.71 (d, J = 4.7.1H), 8.14 (t, J »7.6.1H), 7.78 -7.48 (m, 2H), 6.86 (d, J - 3.4.1H), 6.78 - 6.53 (m,1H), 4.09 (S, 2H), 3.76 (ddd, J = 40.6.143, 7.2, 2H), 3.17 - 2.85 (m, 1H), 2.64 - 2.23 (m, 4H), 2.16 (dd, J «16.4, 8.6.1H), 1.99 (d, J - 14.2.1H), 1.89 -1.75 (m, 2H), 1.75-1.61 (m, 1H), 1.61 - 135 (m, 4H), 1.24 -1.05 (m, 1H), 0.74 (dt, J -13.2, 8.9.1H). 93 (2- {9- (6-matílpíridln2-11) -6oxaaspiro {4.5] dacan-9il] etll} (thiophene-3ylmethyl) amine 371.2 δ 9.47 (d, J = 863, 2H), 8.17 (t, j - 8.0.1H), 7.58 (d, J = 8.0.1H), 7.52 (d, J «7.8.1H), 739 (d , J = 1.9, 1H),731 - 7.29 (tn, 1H), 7.08 (dd, J = 5.0,1.0,1H), 6.43 (s, 3H), 4.11 - 3.95 (m, 2H), 3 91 - 3.67 (m, 2H), 2.97 ( S, 1H), 2.81 (s, 3M), 2.61 (t, J = 12.6, IHj, 2.47 (t, J = 104.1H), 2.43-2.15 (m, 3H), 2.15-1-99 (m, 1H),1.87 (dd,} = 12.2.6.8.2H), 1.70 (dt, J = 12.7, 6.2,
    119
    1H), 1.63 -1.40 (m, 4H), 1.28 -120 (m, 1H), 0.84 (dt, J = 13.3,9.0.1H). 94 (2> {4 »(4 * fluorGphenyl) ·1-oxaesptro [5.5] undecan4-U> tyl) (1H-pyrrol-2llmethyl) amine 3713 δ 7.09 (dd, J - 8.9, 54, 2H), 6.93 (dd, J = 11.7.5.5,2H), 6.71 (d, J = 2.3.1H), 5.98 (s, 2H), 3.83 (s, 2H), 3.61 (m, 2H), 2.56 (m, 1H), 2.08 (t, J - 124, 3H), 1.68($, 3H), 1.48 (d, J -14.6.2H), 1.40 (d, J = 144, 2H), 1.29 (m, 3H), 1.05 (m, 3H), 0.58 (s, 1H). 95 (2- [9- (6-metll |> irldin2-ÍQ-6oxaesplro [4.5] decan-9il] ethyl} (ticfen-2Ilmetiljamina 371.3 δ 9.48 (s, 1H), 8.08 (t, J = 7.9.1H), 7.48 (d, J = 8.0, 1H), 7.42 (d, J »7.8.1H), 7.22 (dd, J» 54.0 , 8.1H), 7.04 | d, J »2.9.1H), 6.88 (dd, j = 54.3.5.1H), 5.95(S, 3H), 443 (s, 2H), 3.66 (ddd, J - 18.7,12.8,94, 2H), 2.91 (s, 1H), 2.71 (s, 3H), 2.60-2 2O (m , 2H), 248 (dd, J «48,6,144, 3H), 1.96 (d, J» 14,2,1H),1.88 -1.68 (m, 2H), 1.71 -1.54 (m, 1H), 1.56 -1.31 (m, 4H), 1.20 -1.05 (m, 1H), 0.83 - 0.63 (m, 1H). 96 [(4-metiltlofen-2yl) methyl) {{2 - {(9R) -9 (plridin * 2 «il} -6 <> oxaspiro [4.5] decan-9il] etll}) amlna 371.3 δ 9.63 | s, 1H), 8.61 (d, 1 44.1H), 8.08 (t, J »7.8, 1H), 7.61 (d, J = 84.1H), 7.53 (dd, J ~ 7.0, 5.6.1H), 6.91 (s, 1H), 6.88 (s, 1H), 444 (m, 2H), 3.75 (dt,) = 19.0,114.2H), 3.02 (m, 1H), 2.61 (m, 1H), 2.40 (brs,1H), 2.27 (m, 4H), 249 | d, J 0.8, 3H), 1-95 (d, J »14.0.1H), 1.79 (m, 2H), 1.66 (dd, J» 124.5.9, 1H),1.47 (m, 4H), 14 «(m, 1H), 0.74 (dt, J = 134.8.9,.................. 1H) .......... 97 {2 - [(9R) -9- (4fluorophenyl) -6oxaspane [4. S] decan -9yl] atyl) [(5methylfuran-2yl) methyl] amine 372 δ 742 (dd, J = 8.9.5.2.2H), 6.94 (t, J »8.6, 2H), 6-10 | d, J * 34.1H), 5.79 (dd, J - 34.0.9, 1H), 3-77 (m, 2H), 3.72 - 3.49 (m, 2H), 2.63 (s, 1H), 249 (s, 1H), 243 - 2.08 (m, 3H), 2.06 (s, 1H), 1.98 (dd, J = 13.8,1.3.1H), 1.89 ltd, J = 12.7.4.5.1H), 1.80 (dd, t * 134, 74, 2H), 1.71 (dd, J - 13.2, 6.0.1H), 1.59 (ddd,J «14.2,9.4, 5.4, 2H), 1.50 - 1.28 (m, 4H), 1.25 1.09 (m, 1H |, 0.71 (dt, J 13.5.8.8.1H). 96 [(4- «net il-1,3-ft'azol-24l) metll] ((2 - {(9R) -9 (pyridin-2-it) -6oxasposp [4.5] decan-9iQetil}) amlna 372.1 δ 8.68 (dd, J = 5.3.1.2,1H), 8.25 (s, 1H), 8.09 (td, J 8.0.1.7.1H), 7.63 (d, J = 8.1.1H), 7.54 (dd, J » 74, 5.7.1H), 6.94 (d, J = 0.9.1H), 4.37 (m, 2H), 3.76 (m,2H), 344 (td, J '11,2,5,9,1H), 2.73 (td, J = 11.4, 4.7.1H), 2.40 (m, 4H), 2.27 (m, 3H), 2.00 (m, 1H), 1.83 (ddd, J »13.8,9.3,4.4, 2H), 1.66 (m, 1H), 1.49(m, 4H), 1.19 (m, 1H), 0.78 (dt, J »13-3, 9.0.1H). 99 [(2-methyl-1,3-thiazol54l) metiq ({2 * {(9RHI (pyridin-2-yl) -6oxasplro {4.5] decan-9H] ethyl}) amine 372.1 δ 8.71 (d, J · 4.3.1H), 8.33 (td, J = 8.0.1.5.1H), 7.77 (m, 2H), 7.69 (s, 1H |, 5.53 (s, 1H), 4.28 (m, 2H), 3.78 (m, 2H), 3.04 (td, J '11.4, 5.4, 1H), 2.73 (5, 3H), 2.56(m, 2H), 2.30 | t, J »15.3, 3H}, 2.04 (m, 1H), 1.88 (ddd, J« 19.6,11.5, 7.0, 2H), 1.68 (m, 1H), 1.49 (m,4H), 148 (m, 1H}, O.77 (dt, J '134, 9.0.1H). 100 ((4-meHM, 3-thiazole-5-il> netiq {{2 - [(9R) -9- 372.1 δ 13.17 (s, 1H), 9.91 (s, 1H), 8.88 (s, 1H), 8.69 (d, J4.9.1H), 8.31 (t, J = 7.4.1H), 7.75 (t J = 7.9, 2H),
    120
    (pyridin-24l) -6oxaspospiro [4.5] decan-9il] ethyl}) amlna4.25 (m, 2H), 3-77 (m, 2H), 3.04 (td, J = 11.5,5.0, 1H), 2.57 (dt, J «10.7, 7.9.1H), 2.34 (m, 7H) , 2.02 (m, 1H), 1.86 (ddd, J · 26.5,13.3, 8.2.2H), 1.66 (dt, J = 13.6.8.4.1H), 1.50 (m, 4H), 1.15 (dd, J -13.2 , 6.6, 1H), 0.73 (dt, J - 13.0.8.9.1H). 101 [(2-chlorophenyl) methylj ({2- [2,2-dlmetll-4- (4methylf8nyl) oxan-4i [] etll)) amine ♦372.2 6 7.21 (m, 1H), 7.07 (m, 5H), 7.02 (d, J »8.2.2H), 3.69 (m, 2H), 3.58 (d, J« 1.0.2H), 2.37 (td, J -10 9, 5.3.1H), 2.22 (m, 4H), 2.07 (ddd, J = 14.2,9.9,3.8, 2H), 1.74 (ddd, J = 13.2,10.5,5.1,1H), 1.55 (m , 3H), 1.43 ($, 2H), 1.10 (s, 3H), 0.58 (5, 3H). 102 [(3chlorophenyl) methyl] ({2- {2,2-dimethyl-4- (4methylphenyl) oxan-4yl] ethyl}) amlna 372.2 6 9.27 (d, J -168.2, 2H), 7.19 (m, 2H), 7.11 (m, 2H),7.04 (d, J - 8.2, 2H), 6.99 (d, J = 8.2.3H), 3.67 (m,2H), 3.58 (s, 2H), 2.57 (5.1H), 2.33 (d, J - 12.1.2H),2.23 (s, 3H), 2.07 (m, 3H), 1.80 (td, J = 12.5,4.6,1H),1.62 (m, 1H), 1.47 (m, 2H), 1.09 (s, 3H), 0.56 (s, 3H). 103 [(4chlorophenit) metir] ({2-f2,2-di * netyl-4- (4methylphenyl) oxan-4 · yl] ethyl}) amine 372.2 6 8.80 (d, 1 »192.6, 2H), 7.19 (t, J» 4.2, 3H), 7.02 (m, 6H), 4.06 (s, 3H), 3.68 (dd, 1 «12.4,10.2,4H ),2.62 (s, 1H), 2.24 (d, J 13,6,3H), 2.11 (ddd, J = 21.2,15.6,7.6, 3H), 1.80 (dt, J = 12.3, 6.3.1H), 1.64(m, 1H), 1.49 (m, 2H), 1.11 (s, 3H), 0.57 (s, 3H). 104 6- [9- {2 - [(thiophen-2llmetll) amlno] ethyl} · 6-oxaMpiro [4.5) decan-9il] pyridin-3-ol 373 1H NMR (400 MHz, CD3CN) δ 8.18 (t, J * 1.7.1H), 8.11 (brs, 1H), 7.49 | dd, J - 5.1,1.1,1H), 7.34 (d, J 1.7, 2H), 7.18 (d, J »2.7.1H), 7.06 (dd, J 5.1.3.6, 1H), 4.24 (s, 2H), 3-67 (m, 2H), 2.95 (m, 1H), 2.73 ( brs, 1H), 2.51 (d, J = 4.3.1H), 2.29 (t, J - 11.0.2H), 2.08 (m, 2H), 1.84 (m, 2H), 1.72 (t, J «8.5.1H ), 1.62(dd, J »14.4, 6.5.2H), 1.48 (dt, J · 23.5.7.0.4H), 1.15 (m, 1H), 0.73 (dt, J» 12.7.8.7.1H). 105 6- [9- {2 - [(thiophen-2ylmethyl) amylno] ethyl) 6-oxasposp [4.5] decan9-ll] plridin-2-ol 373 δ 7.52 (d, J = 16.2,1H), 7.29 (d, J - 1.1.1H), 7.12 (d, J «2.7.1H), 6.97 (dd, J - 5.1, 3.6.1H |, 6 -51 (d, J = 8.9.1H), 6.27 (d, J «7.2.1H), 4.16 (s, 2H), 3.71 (s, 2H), 2.85 (dd, J« 13.9.7.6 , 1H), 268 (dd, J = 18.4, 9.5.1H), 2.31 (m, 2H), 1.94 (d, J = 13.6.2H), 1.59 (m, 10H), 0.90 (m, 1H). 106 [(5-methylthiophen-2yl) metll] ((2. [2,2,6,6tetramethyl-4- (pyridyl2-yl) oxan-4yl] ethyl}) amine 373.2 δ 8.73 (dd, J = 5-5,1.4, 2H), 8.24 (td, J - 8.0,1.6,1H), 7.87 (d, J = 82.1H), 7.69 (dd, J «7.0,6.1, 1H), 6.83 (dd, J - 20.2,3.4.1H), 6.67-- 6.48 (m, 1H), 4.09 (s, 2H), 2.83 - 2.69 (m, 2H), 2.52 (dd, J -19.1, 11.7, 3H |, 2.41 (d, J * 0.5.3H), 2.37 - 2.21 (m, 2H), 1.89 (d, J = 14.8, 2H), 1.31 (5.6H), 0 98 ($, 6H). 107 2- (9-} 2 - [(t »oferi-2ylmethyl) amino] ethyl} 6oxasplro [4.5] decan-9il) pyridin-4-ol 373.2 δ 9.46 (m, 2H), 7.95 (d, J «6.6.1H), 7.25 (d, J = 5-1, 1H), 7.10 (s, 1H), 7.03 (t, I ~ 5.8, 2H), 6.90 (dd, J =5.1, 3.6.1H), 4.10 (5, 2H), 3.62 (m, 2H), 2.84 ($, 1H),2.49 (s, 1H), 2.28 ($, 1H), 2.06 (dd, J - 44.3,14.1, 3H), 1.66 (m, 4H), 1.35 (ddd, J = 72.6,39.8,18-9, 6H), 0.68 (s, 1H). 108 [(4-metllttofen-2- 373.3 δ 8.75 (d, J = 4.6.1H), 8.35 (td, J = 8.1.1.3.1H), 7.96
    121
    yl) methyl] ({2- [2,2,6,6 * tetramethyl-4- (pyridin2-yl) oxan-4H] etll}) amine(d, J = 8.2, IH), 7.86 - 7.74 (m, IH), 6.95 - 6.80 (m, 2H), 4.14 (s, 2H), 2.87 - 2.68 (m, 2H), 2.52 (d, J ·14.8, 2H), 2.45 - 2.29 (m, 2H), 2.18 (d, J »0.7.3H), 1.93 (d, J« 14.9.2H), 1.31 (S, 6H), 0.98 (s, 6H). 109 dlbutil ((2 - ((9R) -9 (pirtdin-2-MHoxaesplro [4.5] decan-9il] ethyl}) amine 373.4 6 8.78 (d, i »4.6, IH), 8.05 (t, J = 7.5, IH), 7.62 (d, J = 8.0, IH), 7.50 (m, IH), 3.80 (m, 2H), 3.06 ( t, J 10.5, IH), 2.90 (s, 4H), 2.42 (m, 4H), 2.02 (m, 2H), 1.83 (m, 2H), 1.68 (tt, J -13.3.6.8, IH), 1.43 (m, 12H), 1.15 (dd, J -13.2, 5.7, IH), 0.91 (dt, J = 11.8, 7.1, 6H), 0.72 (dt, J - 13.3, 9.0, IH). 110 {2 * ((9R) -9- {4 fluorophenyl) -6oxasesplro {4,5] decan-9IIJetilXtlofen-3ilmatityamine 374.2 6 7.33 - 7.23 (m, 7H), 7.19 (dd, J - 8.9, 5.2, 2H), 7.04 (t, J «8.6, 2H), 6.98 (dd, J = 5.0.1.3, IH), 3.84 (s ,2H), 3.79 - 3.69 (m, 2H), 2.67 ($, IH), 2.19 -1.74 (m, 22H), 1.66 (ddd, J 14.0, 9.3,4.6,3H), 1.48 (ddd, J »23.7, 15.2, 8.6.4H), 1.28 ($, IH), 0.99 -0.64 (m, IH). 111 (2 - ((9R) -9- (4. fluorophanylHoxaweplro (4.5] decan-9 * yl] ethyl} (thiophen-2-Hmethyl) amine 374.2 δ 9.04 (d, J = 106.1, 2H), 7.21 (dd, J = 5.1,1.1, IH), 7.10 (m, 2H), 6.92 (m, 3H), 6.86 (dd, J «5.1, 3.6, IH ), 3.93 (s, 2H), 3.64 (m, 3H), 2.63 (d, J = 7.9, IH), 2.22 (t, J = 9.7, IH), 2.05 (d, J - 14.1, IH), 1.97 (d, J =13.9, IH), 1.88 (td, J »12.7,4.6, IH), 1.75 (m, 3H), 1.57 (m, 2H), 1.38 (m, 3H), 1.17 (dd, J» 14.1.6.1 , IH), 0.70 (dt, 1 «13.6.8.8, IH). 112 (clclopentllmetil) ({2 (4- (4-fluorophenyl) -1 oxaspiro [5.5] undecan4-yl] ethyl)) amine 374.3 fi 7.15 (dd, J «8.9, 5.2, 2H), 6.96 (s, 2H), 3.64 (d, J = 13.0.3H), 2.59 (s, 3H), 2.11 (m, 3H), 1.94 ( dd, J »10.4, 57.2H), 1.68 (dd, 1 = 12.4.4.8, 2H), 1.S3 (m, 8H), 1.31 (d, J = 19.9.4H), 1.03 (t, 7H) , 0.65 (m, IH). 113 {2- (2,2-di · til4- (4fluorof · nlí) oxarι-4il] ethyl} (tioferv3ilmetiljamina 376.2 δ 7.20- 7.13 (m, 8H), 7.09 (dd, J = 8.9, 5-2.2H), 6.93 (t, J = 8.6, 2H), 6.87 (dd, J · 4.9.1.3, IH), 3.70 (s, 2H), 3.61 (d, J - 2.3, 2H), 2.56 (s, IH), 2.02 (d, J 14.1.3H), 1.75 (S, UH), 1.44 (d, J · 14.2, 5H ), 0.95 (dd, J = 14.5,7.4, IH), 0.73 (t, J »7.5, 5H), 0.43 (t, J 7.4, 4H). 114 {2- [2,2-diethyl-4- (4fluorophenll) oxan-4IIJrtlXtlofan-2ilmatfl) amine 376.2 δ 7.25 - 7.15 (m, 3H), 7.1S - 7.02 (m, 4H), 6.91 (t, J = 8.6.2H), 3.82 - 3.36 (m, 4H), 2.51 (td, J »12.2, 47, IH), 2.12-1.94 (m, 3H), 1.83 (td, J - 127.4.3, IH), 1.64 (td, J «12.6, 47, IH), 1.55 -1.35 (m, 3H), 1.28(dq, J - 147, 7.4, IH), 0.95 (dq, J = 147.7.4, IH),0.80 - 0.64 (m, 4H), 0.43 (t, J - 7.4, 3H), 115 {2- {4- (4-fluorophenyl) 2,2,6,6tetrametlloxan-4il] ethyl) (tiofan-3llmetlljamlna 376.2 6 7.28 (m, 4H), 7.00 (ddd, i = 67.6.3, 3.2.3H), 3.82 (S, 3H), 2.46 (S, IH), 2.28 (d, J = 14.3, IH), 1.92 ( m,IH), 1.57 (m, 2H), 1.69 (d, J '14.4, 2H), 1.28 (s, 6H), 1.02 (s, 6H). 116 (2- [4- (441uor0ftHilt) 2,2,6,6tetramethyloxan-4yl] ethyl) (thiophen-2- 376.2 δ 7.29 (m, 3H), 7.01 (s, 4H), 3.98 (s, 2H), 2.50 (m, 2H), 2.30 (d, J «14.2.2H), 1.94 (m, 2H), 1.69 (d , J = 14.4, 2H), 1.28 (s, 6H), 1.03 (s, 6H).
    122
    IlmetiQamina 117 banzil ({2- [9- (2methoxyphenyl) -6oxasposp (4.5] decan-9il] etll}) amine 380.3 68.86 (d, J -149.6, 2H), 7.25-7.19 (m, 3H), 7.18-7.12 (m, 1H), 7.09 (dd, 1 - 7.4, 2-0, 2H), 6.96 (dd, J «7.8,1.5,1H), 6.8S - 6.75 (m, 2H), 3.74 - 3.63 (m , 7H), 2.55 (dd, J «15.6,7.9.3H), 2.11 (d, J» 14.8,2H), 1.75 -1.46 (m, 5H), 1.46 -1.32 (m, 3H), 1.32 1.22 (m, 1H), 1.17 (d, i = 4.1.1H), 0.74 - 0.60 (m, 1H). 118 baradl ({2- {9- (6metoxÍplridln-2ál) 6oxasospiro [4.5] decan-9iljatiljjamlna 381.3 6 9.43 (s, 1H), 9.20 (s, 1H), 7.52 (m, 2H), 7.30 (dd, J - 5.1,1.8,3H), 7.21 (m, 2H), 6.78 (d, J · 7.3, 1H), 6.57 (d, J «8.1.1H), 3.83 ($, 3H), 3.77 (s, 2H), 3.71 (dd, J« 7.8, 2.7, 2H), 2.77 (s, 1H ), 2.32 (d, J »13.6, 2H), 2.25 (d, J = 11.5.1H), 2.06 (td, J 11.9.4.8.1H), 1.76 (m, 3H), 1.59 (m, 3H), 1.47 (m, 3H), 1.38 (m, 1H), 1.15 (m, 1H), 0.70 (m, 1H). 119 (2- (2,2-dimethyl-4- (4metiffenll) oxan-4-methoxyphenyljmethyl] methylamine 382.3 6 10.17 (m, 3H), 7.41 (tdd,) · 8.3, 4.8,16,1H), 7.13 (m, 5H), 6.93 (m, 2H), 4.20 (dd, J = 14.9,5.8,1H),3.98 (ddd, J = 32.2,12.9,4.8,1H), 3.80 (dd, J «7.4, 2.6.5H), 2.94 (d, 1 - 114.3.1H), 2.35 (m, 9H), 2.05 (ddd, J = 17.1,12.7,6.5,1H), 1.89 (dt, J »12.8, 6.2, 1H), 1.67 (ddd, J« 22.2,14.2, 5.0.2H), 1 23 (d, J =10.7, 3H), 0.69 (t, J »9.5.3H). 120 {2- {9- (4-fluorophenll) -6-oxaspospiro (4.5] decan9yl] ethyl} ((3m «tilphenyl} methyl] amine 382.3 6 8.90 (d, J · 138.8, 2H), 7.15 (tt, J = 13.7, 7.6, 4H),6.97 (m, 4H), 3.70 (m, 4H), 2.67 (s, 1H), 2.27 (s, 4H), 2.00 (m, 3H), 1.82 (m, 3H), 1.63 (m, 2H), 1.46 (m,4H), 1.24 (d, J = 9.6.1H), 0.78 (dt, J - 13.6.8.8.1H) 121 {2 - ((98) -9- (4fluorophenyl) -6oxaspospiro [4.5] decan-9ll> tilH (3methylphenyljmetyl] amine 382.3 δ 8.73 (d, J = 138.2, 2H), 7.16 (m, 4H), 7 00 (dd, J = 10,5,6.7, 2H), 6.94 (m, 2H), 3.72 (m, 4H), 2.69 (m,1H), 2.27 (s, 4H), 2.05 (m, 2H), 1.94 (td, J = 12.6,4.7,1H), 1.83 (m, 3H), 1.63 (ddd, J = 14.1,9.6,4.6,2H), 1.47 (m, 4H), 1.23 (m, 1H), 0.78 (dt, J »13.9, 8.9 , 1H) 122 {2 <(9R} -9- (4fluorophenyl) -6oxaesplro [4.5] decan-9IQetll} [(3methylphenyl) material] amine 382.3 δ 8.96 (d, J «123.7, 2H), 7.15 (m, 4H), 6.98 (m, 4H), 3.71 (m, 4H), 2.66 (s, 1H), 2.25 (d, J» 14.0, 4H), 2.05 (m, 2H), 1.94 (td, J »12.7.4.6.1H), 1.81 (m, 3H),1.63 (ddd, J = 14.2, 7.7, 3.4, 2H), 1.47 (m, 4H), 1.23 (m, 1H), 0.77 (dt, J - 13.7, 8.9, 1H) 123 benzyl ({2- [4- (4fluorophenyl) -1oxasplro [5.5] undecan44l] atll}) amine 382.3 6 7.23 (m, 3H), 7.10 (dd, J - 4.6.2.6.4H), 6.92 (s, 2H), 3.64 (s, 2H), 2.63 (m, 1H), 2.07 (t, J * 13.9, 3H),1.74 ($, 2H), 1.48 (d, J = 8.3, 3H), 1.40 (d, J -14.0, 2H), 1.29 (m, 3H), 1.06 (m, 4H), 0.57 (m, 1H ). 124 {2 - [(9R) -9- (4fluorophenll) -6oxaspospiro [4.5] decan-9- 382.3 δ 7.47 - 7.32 (m, 3H), 7.31 - 7.22 (m, 2H), 7.11 (dd, J = 8.9, 5.2, 2H), 6.98 (t, J - 8.6.2H), 6.28 (s, 2H ), 4.03 (s, 1H), 3.79 - 3.58 (m, 2H), 2.51 (s, 1H), 2.19 (d, J »
    123
    lfletH} [(1R) .1phenylfljamina14.5, IH), 2.07 -1-90 (m, 3H), 1.89 -1.71 (m, 3H),1.72 -1.32 (m, 9H), 1.32 -1-10 (m, IH), 0.78 (dt, J ® 13.6.8.8, IH). 125 {2 - [(9R) -9- (4fluorophenyl) -6oxaesplro [4.5] decan-9il] ethyl) [(1S) -1fenltettQamlna 3823 δ 7.47 - 7.32 (m, 3H), 7.31 - 7.22 (m, 2H), 7.11 (dd, J = 8.9, 5.2, 2H), 6.98 (t, 1 »8.6.2H), 6.28 (s, 2H ), 4.03 (5, IH), 3.79 - 3.58 (m, 2H), 2.51 (s, IH), 2.19 (d, J 14.5, IH), 2.07 -1.90 (m, 3H), 1.89 -1.71 ( m, 3H), 1.72 -1.32 (m, 9H), 1.32 -1.10 (m, IH), 0.78 (dt, J »13-6.8.8, IH). 126 {2- [2,2-dlmetll-4- (4methylphenit) oxan-4IQeW) [(2nitrophenlljmetyl] amine 383.3 δ 7.94 (dd, J = 8.1.1.2, IH), 7.53 (td, J ~ 7.6.1.3, IH), 7.40 (m, 2H), 7.15 (m, 4H), 3.80 (m, 4H), 2.48 ( td, J = 10.9.5.4, IH), 2.32 (m, 4H), 2.18 (ddd, J 12.7, 7.8.3.7, 2H), 1.84 (ddd, J »13.2,10.4,5.1, IH), 1.63 (m , 4H), 1.21 (s, 3H), 0.69 (s, 3H). 127 {2 ^ 2,2-dmethyl-4- (4methylphenyl) oxan-4yl] etll} [(3nitrophenylmethyl] amine 383.3 δ 9.09 (d, J = 219.1, 2H), 8-12 (dd, J - 8.2.1.6, IH), 8.01 (S, IH), 7.45 (dt, J = 15.6,7.7, 2H), 7.03 (q , J =8.5.4H), 3.87 ($, 2H), 3.69 (m, 2H), 3.42 (s, IH), 3.22 (s, 2H), 2.73 (d, J = 4.5, IH), 2.24 (d, J » 8.2.4H), 212(m, 2H), 1.85 (m, IH), 1.69 (dd, J = 12.1.4.5, IH), 1.52 (m, 2H), 1.11 (s, 3H), 0.57 (s, 3H). 128 2 - (((2- (9- (4fl u oropheni 1) -6oxaspospiro [4.5) decan-9il] et) Qamino) metir] phenol 384.2 6 8.36 (d, J »129.4.2H), 7.20 (dd, J» 11.0,4.6, IH), 7.14 (dd, J »8.9, 5.1, 2H), 7.00 (t, J - 8.6.2H), 692 (m, 2H), 6.79 ft, J »7.1, IH), 3.88 (s, 2H), 3.68 (m, 2H), 2.67 (m, IH), 2.29 (m, IH), 198 (m, 3H) 1.79(m, 3H), 1.51 (m, 6H), 1.20 (s, IH), 0.74 (dt, i = 13.8, 89, IH) 129 (2- (4- (4methoxyphenyl) -2,2dlmethyloxan-4IIJettlX (2methoxyphenyl) methyl] amine 384.3 δ 8.47 (d, J = 196.5.2H), 7.36 (td, J · 8.3.1.7, IH),7.12 (dd, J = 9.5,2.6,2H), 7.08 (dd, J - 7.5,1.6, IH), 691 (td, J * 7.5,0.8, IH), 6.86 (d, J «8.8, 3H), 5.77 (S, 2H), 391 (S, 2H), 3.82 (s, 3H), 3.79 (s, 3H), 3.77(m, 2H), 2.76 (s, IH), 2.33 (s, IH), 2.16 (m, 2H), 196 (d, J »4.6, IH), 1.77 (d, J = 4.7, IH) , 1.59 (m, 2H),1.19 (s, 3H), 0.66 (s, 3H). 130 [(5-ethylthiophen-2yl) methyl] ({2 - ((9R) -9 (pllldln-20) -6oxae * plro (4.5] decan-9il] ethyl}) amine 385.1 6 8.73 (d, J = 4.6, IH), 8.20 (t, J = 7.7, 2H), 7.80 7.55 (m, 2H), 6 88 (d, J »3.4, IH), 6.64 (d, J - 3.4, IH), 4.11 (s, 2H), 3.81 (dd, J «8.4.4.3, IH), 3.70 (t, J = 10.0, IH), 3.00 | d, J» 4.6, IH), 2.86 - 2.70 (m, 2H), 2.53 (t, J - 10.1, IH), 2.45 - 2.25 (m, 3H), 2.18 (t, J 10.0, IH), 2.00 (d, J * 14.2, IH), 1.93 -1.75 (m, 2H), 1.68 (dd, J »9.5.4.4, IH), 1.62 -1.38 (m, 4H), 1.26 (t, J = 7.5, 3H), 1.20 -1.07 (m, IH), 0.75 (dt, J = 129, 8.8, IH). 131 [(3,5dlmetlltiofen-2yl) methyl] ((2 - [(9R) -9 (pyrldin-2-ll) -6oxasposp (4.5] decan-9- 385.1 δ 9.45 (brs, IH), 8.70 (d, J »5.0, IH), 8.26 (t, J» 7.7, IH), 7.75 (d, 1 - 8.1, IH), 7.70 (m, IH), 6.46 ( d, J 0.8, IH), 4.07 (s, 2H), 3.76 (ddd, J = 44.9,139,7.2, 2H), 3.05 (m, IH), 2.58 | m, IH), 2.43 (t, J - 10.6, IH),2.36 (d, J »0.7, 3H), 2.24 (dd, J« 319.17.7.3H),
    124
    ll] ethyl}) amine2.03 (m, 4H), 1.85 (m, 2H), 1.66 (dd, J * 13.8,8.8, 1H), 1.48 (m, 4H), 1.15 (d, J - 7.9.1H), 0.75 (dt, J = 13.1.8.9.1H). 132 {2- (2 ^ 2-dietll-4- (4fluorophenyl) oxan-4yl] ethyl} (((6methylpyridin-3yl) methyl] amine 385.3 6 8.84 (s, 1H), 8.24 (d, J - 8.2.1H), 7.53 (d, J »8.2, 1H), 7.17 (m, 3H), 6.96 (t, J» 8.6.2H), 4.08 (d, J 13.9.2H), 3.63 (d, J · 10.5, 2H), 2.84 (dd, J »12.0, 8.2.1H), 2.68 (S, 3H), 2.24 (m, 2H), 2.07 (d, J »14.1,1H), 1.96 (m, 1H), 1.74 (dd, J '12.5.8.6.1H), 1.57 (m, 1H), 1.48 (d, J * 14.2.1H), 1.41 (m, 1H), 1.28 ( dd,J = 14.0, 7.4.1H), 0.96 (dd, J - 14.5, 7.4.1H), 0.73 (td, J> 7.3, 3.9.4H), 0.44 (t, J »7.4, 3H). 133 {2 «[4 ~ (441uorophenyl) · 2,2,6,6tetrametlloxan-4-il) methyl] amlna 385.3 6 8.85 (s, 1H), 8.24 (d, J - 8.2.1H), 7.54 (d, J = 8.3, 2H), 7.24 (dd, J> 8.9.5-1.1H), 692 (m , 2H), 4.12 (s, 2H), 2.61 (m, 5H), 2.25 (d, J = 14.3.2H), 1.91 (dd, J = 10.4.6.2, 2H), 1.65 ( d, J - 14.4, 2H), 1.19 (d, J = 8.9, 6H), 0.94 (s, 6H). 134 (¢ 4,5dimethirtiophene-2yl) metll] ({2 - {(9R) -9 (pyridin-24l) -6oxasposp [4.5] decan-9n] ethyl}) amlna 385.3 5 9.46 (s, 1H), 8-62 (d, J - 4.2.1H), 8.07 (t, J = 7.3, 1H), 7.60 (d, J = 8.1.1H), 7.S2 (m, 1H ), 6.76 (s, 1H), 4.06 (q, J - 13.9.2H), 3.75 (m, 2H), 3.01 (m, 1H),2.57 (s, 1H), 2.29 (rn, 7H), 2.19 (m, 1H), 2.04 (s, 3H),1.95 (d, J = 14.0.1H), 1.81 (m, 2H), 1.67 (d, J b 8.2, 1H), 1.47 (m, 4H), 1.15 (m, 1H), 0.74 (dt, J = 13.1, 8-8.1H). 135 [(2,4-dimethyl, 3-thiazol-5-yl) methyl] ({2 [(9R) -9 (pyridin-2-yl) -eoxa & spiro [4.5] decan-9yl] ethyl}) amine 386.1 δ 9.59 (s, 1H), 8.68 (dd, J »5.6.1.4.1H), 8.35 (td, J« 8.0,1.6,1H), 7.80 (dd, J »12.0, 7.0.2H), 4.22 (m, 2H), 3.83 (dt, J = 12.5,4.4, 1H), 3.72 (m, 1H), 3.05(dt, J s 11.2,5.6,1H), 2.73 (s, 3H), 2.57 (m, 2H), 2.31 (m, 6H), 2.04 (m, 1 «), 1.88 (ddd, J» 19.2,11.4 , 6.9, 2H), 1.68 (m, 1H), 1.52 (m, 4H), 1.19 (dd, J - 12.2, 5.9.1H), 0.76 (dt, J »13.1.89.1H). 136 {2- {9- (pyrazin-24l) -6oxaesplro [4,5] decan-9il] ethyl} (thiophen-2ylmethyl) amlna 386.1 δ 8.90 (s, 1H), 8.55 ($, 1H), 8.40 (S, 1H), 6.60 (s, 1H), 3.88 (d, J = 12.3, 2H), 3.79 - 3.66 (m, 1H), 3.58 (dd, J - 16.8,6.5.1H), 2.81 (s, 1H), 2.40 (s, 1H), 2.35 - 2.22 (m, 2H), 2.16 (ί, 3H), 2.12 - 2.00 ( m, 1H), 1.97 -1.88(m, 4H), 1.85 (t, J = 9.1.1H), 1.75-149 (m, 3H),1.49 -1.27 (m, 4H), 0.98 (d, J = 11.4.1H), 0.55 (dt, J = 13.3.9.0.1H), 137 ((4,5-dlmethylfuran-2il) metll] ({2 - [(9R) «9 (4fluorophenll) -6oxasposp [4.5] decan-9IQ« tll}) amlna 386.1 6 9.14 (s, 1H), 8.85 (s, 1H), 7.24 (ddd, J - 11.5,6.2,3.3, 2H), 7.05 (5, 2H), 6.06 (s, 1H), 3.89-3.66 (m, 4H), 2.72 (s, 1H), 2.29 (s, 1H), 2.22 - 2.13 (m, 1H),2.11 (s, 4H), 1.85 (s, 7H), 1.76 -1.62 (m, 2H), 1.60 -1.36 (m, 4H), 1.33 - 1.24 (m, 1H), 0.82 (dt, J '13-6, 8.8.1H). 138 {2-PH2metoxifenll) -6oxaspospiro [4.5] decan-9- 386.2 δ 8.90 (d, J »150.1, 2H), 7.19 (dd, J = 3.7.1.4.1H),7.18 - 7.14 (m, 1H), 6 99 (dd, 1 * 7.8.1.5.1H), 6.94 -6.76 (m, 4H), 4.66 (s, 2H), 3.94 (s, 2H), 3.80 - 3.63
    125
    ll] ethylXtiofen-2> ilmetit) amine(m, 5H), 2.73 - 2.45 (m, 3H), 2.30 - 2.08 (m, 2H), 1.76 -1.48 (m, 5H), 1.39 (<Λ, J «7-0.6-3.3H) , 1.30 (d, J = 5.2.1H), 1.18 (d, 1 «4.1.1H), 0.68 (dd, J = 8.7, ________________________ S.0.1H) .________________________ 139 {2- (9- (2metoxtphenylM * oxaesplro [4.5] decan-9il] ethyl) (thiophen-3ylmetll) amlna 386.2 6 9.28 (d, 1 = 95.5, 2H), 7.18 - 7.12 (m, 3H), 6-97 (dd, J * 7.8.1.5,1H), 6.93 - 6.86 (m, 1H), 6.86-6.71 (m , 2H), 3.80 - 3.61 (m, 7H), 2.55 (dd, J »19.5, 5.1, 3H), 2.12 (d, J * 12.8.2H), 1.85 (s, 2H), 1.76 -1.47 (m, 5H), 1.46 -1-32 (m, 3H), 1.31 -1.22 (m, 1H), 1.17 (d, J = 4.2.1H), 0.74 - 0.60 (m, 1H). 140 (((3-methoxythiofen24l) medl] ({2 - {(9R) <0 (pyridin-2-ii) -6oxaespln> [4.5] deca n-9yl] ethyl)) amine 387 6 11.70 (hrs, 1H), 9.14 (d, J = 66.6.2H), 8.72 (d, J 4.3.1H), 8.19 (td, J · 8.0.1.4,1H), 7.70 (d, J «81, 1H), 7.63 (dd, J »7.0.5.8.1H), 7.22 (d, J * 5 5.1H), 6.78 (d, J = 5.6.1H), 4.08 (m, 2H), 3.80 (m, 4H), 3.69 (dd, J 11.2, 8.7, 1H), 2.99 (d, J »4.8.1H), 2.51 (t, J = 9.9.1H), 2.35 (m, 3H), 2.18 (td, J« 13.5,5.4,1H),1.99 (d, J = 14.2.1H), 1.82 (m, 2H), 1.65 (m, 1H), 1.47 (m, 4H), 1.14 (m, 1H), 0.73 (dt, J = 13-2, 8.9 , 1H). 141 [(3-methoxythiophen-2-yl) methyl) ((2- (9 (pyridin-2-yl> 6oxasplro [4.5] decan-9yl] ethyl)) amine 387 δ 9.03 (d, J »80.0, 2H), 8.75 (d, J = 5.3.1H), 8.31 (t, J = 7.9.1H), 7.76 (m, 2H), 7.26 (t, J» 4.0.1H ), 6.81(d, J = 5.6.1H), 4.12 ($, 2H), 3.82 (s, 4H), 3.69 (dd, J = 24.9,14.9.1H), 3.04 (s, 1H), 2.56 (s, 1H) , 2.45 (dd, J »17.7,7.6.1H), 2.29 (ddd, J - 17.8,13.5,5-8,3H),2.05 (d, J »14.3.1H), 1.87 (dt, J · 14.4, 6.7.2H), 1.67 (ddd, J = 27.6.16.0, 6.9.1H), 1.52 (m, 4H), 1.20 (m, 1H), 0.78 (dt, J = 13.0.8.9.1H). 142 {2- (9- (6metoxlplridin ^ -ll >> 6-oxaesplro [4.5] decan9iqeei} (tlofen-2ilmatil) amma 387.2 δ 9.37 (s, 1H), 9.11 (s, OH), 7.55 (dd, J »8.2.7.5, 1H), 7.30 (dd, J« 5.1,1.1,1H), 7.03 (d, J «2.6,1H ), 6.96 (dd, J «5.1, 3.6.1H), 6.81 (d, J - 7.3.1H), 6.60 (d, J - 8.0.1H), 4.07 ($, 2H), 3.86 (s, 3H) , 3.73 (dd, J =7.7, 2.7, 2H), 2.87 (m, 1H), 2.75 (brs, 1H), 2.47 (m, 1H), 2.32 (dd, J · 24.5,13.6, 2H), 2.09 (m, 1H), 1.80 ( m, 3H), 1.63 (dt, J »15.1, 7.4, 2H), 1.49 (m, 3H),1.39 (d, J = 4.5.1H), 1.16 (m, 1H), 0.72 (dt, J «13.4, 8.8.1H). 143 (2- (9- (6methoxypyridin-2-yl) 6-oxaspospiro [4.5] decan9iHetil} (thiophen-3ylmethyl) amine 387.2 δ 9.40 (s, 1H), 9.21 (s, 1H), 7.53 (m, 1H), 7.28 (d, J 3.0, 2H), 6.99 (dd, J. 4.8,1.4,1H), 6.80 (d, J = 7.4, 1H), 6-59 (d, J s 8.2.1H), 3.86 (d, J - 6.4, 5H), 3.72(dd, J = 7.7, 2.7, 2H), 2.78 (m, 1H), 2.30 (dd, J = 28.1, 12.5, 3H), 2.09 (m, 1H), 2.02 (brs, 1H), 1.79 (m, 3H), 1.61 (m, 2H), 1.47 (m, 4H), 1.16 (m, 1H), 0.71 (dt, J «13.4.8.7.1H). 144 {2- [4- (4-chlorophenyl) 2,2-dimethyloxan-4yl] ethyl} [(2methoxyphenyl) methyl] 388.2 δ 8.48 (d, J »152.7, 2H), 7.28 (td, J = 8.3,1.7,1H), 7.22 (dd, J = 6.6,4.8, 2H), 7.06 (m, 2H), 6.97 (dd, J «7.5.1.6.1H), 6.81 (ddd, J = 19.8.13.2, 4.6.2H), 6.03 (S, 1H), 3.82 (s, 2H), 3.66 (m, 5H), 2.64 (s, 1H) 2.15
    126
    the mine(s, 1H), 2.05 (ddd, i «22.5,14.1, 2.1, 2H), 1.85 (m,1H), 1.72 (dd, J = 12.5, 4.7.1H), 1.53 (m, 2H), 1.11 (s, 3H), 0.57 (s, 3H). 145 {2 - [(9R) -9 «{4 · ftuorophenyl) -6oxae * plro (4.5] decan-9-methyltiofen-2yl) metll] amlna 388 2 δ 7.28 (s, 4H), 7.25 - 7.15 (m, 2H), 7.04 (t, J - 8.6, 2H), 6.77 (d, J = 3.5.1H), 6.59 (dd, J = 3.4.1.1.1H ),3.91 (s, 2H), 3.85 - 3.64 (m, 2H), 2.73 (t, J = 9.7.1H),2.41 (d, J = 0.7, 3H), 2.37 -1.75 (m, 18H), 1.67 (dd, J «11.7, 7.1, 2H), 1.59 -1.34 (m, 4H), 1.26 ($, 1H) ,0.81 (dt, J = 14.0.8.9.1H). 146 {2 <4- (4-fluorophenll} -1oxaspospiro [5.5] unctecan-4il] ethyl} (ttofen-3IlmetiQamlna 388.2 δ 7.18 (s, 1H), 7.15 (s, 1H), 7.10 (dd, J = 8.9.5.2.2H), 6.92 (dd, J = 10.8.6.4.2H), 6.87 (m, 1H), 3.67 (d, J »35.8.3H), 2.66 (m, 1H), 2.07 (s, 3H), 1.83 (m, 2H),1.56 (s, 3H), 1.41 (d, 1 = 13-9.2H), 1.33 (m, 3H), 1.02 (m, 4H), 0.58 (m, 1H). 147 {2 - ((9 R) -9- (4 fluorophenyl) -6oxaesplro [4.5] decan-9 »l] ethyl} (((3meti! Thiophen-2 · ll) matil] amlna 388.2 S 9-01 (d, J = 137.9, 2H), 7.15 - 7.02 (m, 3H), 6.94 (t, J = 8.6, 2H), 6.77 - 6.63 (m, 1H), 4.82 (s, 1H), 3.83 (d,J = 19.1, 2H), 3.73 - 3 54 (m, 2H), 2.64 (s, 1H), 2.18 (d, J '10.4.1H), 2.12 -1.64 (m, 9H), 1.65 -1.50 ( m, 2H), l.SO-1.27 (m, 4H), 1.27 -1.08 (m, 1H), 0.69 (dt, J - 13.5.8.8.1H). 148 {2 - ((9R) -9- {4fluorophenyl) -6oxMspiro (4.5] clecan-9il] etll} [(4> methhiofen-2yl) methyl] amine 388.2 6 9.31 (d, J = 89.1, 2H), 7.15 - 7.05 (m, 2H), 6.93 (t, J - 8.6, 2H), 6.80 - 6.65 (m, 2H), 3.80 (s, 2H), 3.73 3 , 57 (m, 2H), 2.93 (s, 1H), 2.60 (s, 1H), 2.17 (5, 1H), 2.04 (dd, J = 16.0, 3.3.4H), 1.91 (ddd, J = 17.5, 16.7, 9.1, 2H), 1.84 - 1.65. (M, 3H), 1.57 (ddd, J = 13.2,9.0, 4.4, 2H), 1.50-1.25 (m, 4H), 1.17 (dd, J = 14.9 , 5.0, 1H), 0.70 (dt, J = 13.6.8.8.1H). 149 {2- (4- (4-fluorophenll) -1-oxaasplro [5.5] unclecan-4il] ethyl} (tiofen-2ilmetiQamlna 388.3 δ 7.28 (s, 3H), 7.22 (dd, J = 86.4.9, 2H), 7.01 (m, 2H), 4.01 (s, 2H), 3.74 (s, 1H), 2.26 ( m, 1H), 1.73 (m, 11H), 1.52 (d, J = 14.1, 2H), 1.39 (m, 2H), 1.13 (s, 2H), 0.69 (m, 1H). 150 {2 <(9RH <4. Fluorophenyl) -6oxaesplro [4.5] decan-9il] e0IX (4-methyl-1,3thiazo-2ll) methyl] amlna 389 δ 7.22 (dd, J = 8.9, 5.2, 2H), 7.02 (dd, J - 14.0,5.4, 2H), 6.92 (d, J = 0.9.1H), 4.25 (q, J = 14.7, 2H), 3.73 (m, 2H), 2.89 (td, J 11.8, 4.8.1H), 2.50 (td, J = 11.7, 5.0.1H), 2.38 (d, J = 0.8, 3H), 2.15 (m, 1H), 2.08 (m, 2H), 1.98 (m, 1H), 1.91 (d, J = 13.9.1H), 1.79 (d, J «9.3, 1H), 1.69 (m, 2K), 1.48 (m, 5H), 1.25 (m, 1H), 0.81 (dt, J = 13.3.8.7.1H), 151 {2- (2,2-dte «l-4- (4fluorof« nil) oxan-4-methyltiofen-2iljmetiljamina 390.2 δ 7.1S - 7.02 (m, 2H), 6.94 (t, J = 8.6, 2H), 6.67 (d, J »3.5.1H), 6.49 (s, 1H), 3.78 (s, 2H), 3 62 (dd, J =10.4.8.1, 3H), 2.61 ($, 1H), 2.30 (s, 4H), 2.08 (dd, J = 31.6.14.0.4H), 1.88 (d, J = 4.6.1H), 1.79 -1.34 (m , 19H), 1.29 (dd, J = 14.0,7.4, 2H), 0.96 (dd, J «14.5, 7.3.1H), 0.74 (t, J = 7.5.5H), 0.44 (t, J = 7 , 4.4H).
    127
    152 [(5-ktorothiophen-Zyl) methyl] ({24 (9R) -9 (pyridin-2-yl) -6oxasplro [4.5] decan-9il] ethyl}) amine 391 6 8.75 (d, J «4.8, IH), 8.24 (t, J = 7.7, IH), 7.86 7.58 (m, 2H), 6.44 (d, i · 3.3, IH), 6.28 (d, J = 3.3, IH), 4.07 (s, 2H), 3.94 - 3.79 (m, IH), 3.72 (t, J = 10.1, IH), 3.01 (dd, J = 11.1.6.0, IH), 2.56 (t, J * 9.9 , IH), 2.49-2.11 (m, 4H), 2.05 (d, J -14.1, IH), 1.88(ddd, 1 = 18.8.11.0.6.5.2H), 1.78-1.31 (m, 5H), 1.31 -1.07 (m, IH), 0.77 (dt, J »13.1.8.9, IH) 153 dibutll ({2- [444> fluorophenyl) -2,2,6,6tetra-methyloxan-4yl] etll}) amlna 392.4 δ 7.37 (m, 2H), 7.07 (m, 2H), 2.83 (dd, J = 16.3,9.4,4H), 2.68 (m, 2H), 2.38 (d, J «14.3.2H), 2.09 (s, 4H),1.93 (m, 2H), 1.77 (d, J · 14.3, 2H), 1.33 (m, 1OH),1.05 (d, J »8.6, 6H), 0.91 (t, J - 7.2, 6H). 154 {2 - ({9R) -9- (4 · fluorophenyl) -6oxaeaplro [4.5] decan-9ll] ethyl} (2fantlpropan-2iljamina 396.3 δ 7.37 (s, 5H), 7.28 (s, OH), 7.17 - 6.99 (m, 3H), 6.93 (t, J = 8.6.2H), 3.81 - 3.57 (m, 2H), 2.45 (d, J « 9.0,IH), 2.04-1.72 (m, 7H), 1.66 (t, J «10.7, 6H), 1.62 -1-53 (m, 2H), 1.52 -1.34 (m, 4H), 1.23 (s, IH), 0.78 (d, J = 13.8, IH). 155 {4H, 5H, 6Hclopenta [b] tlofen -2-ylmethyl} ({2 [(9R) -9- (pirtdln-2-ll) -6 · oxasposp (4.5] decan-9ll] «t»}) amlna 397.1 δ 9.57 (brs, IH), 8.62 (d, J = 3.9, IH), 8.02 (t, J = 7.1, 'IH), 7.57 (d, J - 8.1, IH), 7.48 (dd, J «6.9, 5.5, IH),6.80 (s, IH), 5.30 (brs, IH), 4.06 (q, Í - 14.1, 2H),3.74 (m, 2H), 2.99 (m, IH), 2.82 (t, J 7.2, 2H), 2.65 (t, J = 7.2.2H), 2.57 (m, IH), 2.34 (ddd, J - 33.3,21.0,10.4, 5H) ,. 2.16 (dd, J - 9.9.5-6, IH), 1.94 (d, J «13.9, IH), 1.78 (m, 2H), 1.66 (d, J ~ 8.0, IH ), 1.46(ddd, J - 16.6,12.7,5.7, 4H), 1.14 (m, 1H), 0.72 (dt, J «13.4,9.0, IH). 156 (2- {4- (4-fluorophen ΙΟΙoxaspospiro [5.5] undecan4 »methylpyridin-3ll) metll] amlna ; 397.3 6 8.22 (d, J · 8.0, IH), 7.49 (t, J = 16.4, IH), 7.17 (m, 8H), 6.96 it, J · 8.6, 2H), 4.09 (s, 2H), 3.66 (s , 4H), 2.84 (s, IH), 2.68 (s, 3H), 2.29 ($, 1H), 2.20 (d, J -13.2, IH), 2.10 (d, 1 - 14.1, IH), 1.93 (s, IH), 1.73 (s, IH), 1.59 (m, IH), 1.45 (d, J - 14.0.3H), 1.30 ( m, '2H), 1.10 (m, 3H), 0.62 (d, J = 11.1, IH). 157 [(2,3-dlmethoxyphenyljmetyl] ({2- (2,2-dinwtil4 »(4-methylphenyl) oxan44Qethyl}) amine 398.3 δ 7.05 (dd, J - 19.6.8.3,4H), 6.88 (m, IH), 6.74 (dd, J = 8.2.1.4, IH), 6.62 (dd, J 7.6.1.4, IH), 3.77 (s,3H), 3.68 (m, 5H), 3.55 (d, J «2.3, 2H), 2.37 (m, IH), 2.22 (m, 4H), 2.06 (ddd, J = 13.8, 8.6.4.1, 2H), 1.73 (dd, J »6.6.4.3, IH), 1.56 (m, 4H), 1.10 (s, 3H), 0.58 (s, 3H). 158 [(2,4dlmetoxtfenll) metll} ((2- (2,2-dίmetil-4 (4-methylphenyl) oxan44l] ethyl}) amine 398.3 δ 8.09 (s, IH), 7.68 (d, J »33.5, IH), 7.55 (s, IH), 7.02 (q, J * 8.4, 4H), 6.86 (m, IH), 6.32 (dd, J = 6.6, 2.2, 2H), 3.77 (d, I = 10.4.2H), 3.69 (m, 8H), 2.67 (s, IH), 2.24 (s, 4H), 2.10 (m, 2H), 1.87 (d, J = 4.5, IH), 1.67 (d,) = 4.4, IH), 1.51 (m, 2H), 1.10 ($, 3H), 0.57 (s, 3H). Ϊ59 (2- [9- (4-fluorophenyl).6-oxaospiro [4.5] decan- 398.3 5 9.06 (d, 1 -131.9.2H), 7.17 (m, 2H), 7.08 (d, J ·8.7.2H), 7.00 (t, J - 8.6, 2H), 6.79 (d, J = 8.7.2H),
    128
    9-yl] ethyl} [(4matoxif «nll) metll] amine3.69 (m, 7H), 2.62 (s, 1H), 2.20 (s, 1H), 1.99 (m, 3H),1.81 (m, 3H), 1.62 (ffi, 2H), 1.46 (m, 4H), 1.24 (d, J 9.5.1H), 0.77 (dt, J - 13.4, 8.8.1H) 16Q [(S-proplltlofen-2yl) methyl] ({2 - ((9R) -9 (pyridin-2-yl) -6oxasposp (4.5] decan-9il] atyl}) amine 399.1 δ 9.43 ($, 2H), 8.72 (d, J = 4.6.1H), 8.21 (t, J - 7.3, 1H), 7.72 (d, J - 8.1.2H), 6.88 (d, J = 3.5.1H) ), 6.63 (d, J = 3.5.1H), 4.11 (s, 2H), 3.87 - 3 65 (m, 2H), 3.00 (S, 1H), 2.71 (t, J «7.5.2H), 2.54 ( s, 1H), 2.32 (s, 3H), 2.27 - 2.11 (m, 1H), 2.02 (s, 1H), 1.84 (dd, J -16.6, 7.3.2H), 1.64 (dd, J »15.0.7.4 , 7H), 1.22 -1.10 (m, 1H), 0.95 (t, J = 7.3.3H), 0.83 - 0.72 (m, 1H). 161 (plridin «2-ilH> * oxaspospir (4.5] decan-9il] ethyl} amino) metii] t iofen-2-yl} and tan-Ιοί 401.1 δ 9.38 (s, 2H), 8.76 (d, J = 4.6.1H), 8.29 (t, J «7.9, 1H), 7.84 - 7.69 (m, 2H), 6.92 - 6.74 (m, 4H), 5.02 ( d,} - 6.4.1H), 4.13 (S, 2H), 3.87 - 3.60 (m, 2H), 3.03 (s, 1H), 2.52 (s, 1H), 2.34 (t, J = 15.7, 3H ), 2.20 (t, J · 12.6.1H), 2.03 (dd, J 14.2.4.7.1H), 1.96 -1.78 (m, 2H), 1.81 -1.65 (m, 1H), 1.65-1.43 (m, 7H ), 1.15 (s, 1H), 0.77 (S, 1H). 162 6- (9- (2 - (((4,5dimethylthiophen-2yl) methyl] amino} ethyl) -6-oxaesplro [4.5] decan9il] plridin-3-ol 401.1 1H NMR (400 MHt, C03CN) 68.18 (dd, J ® 2.3,1.2,1H), 7.72 (s, 1H}, 7.32 (d, J - 2.3.2H), 6.82 (s, 1H), 4.10 (s, 2H), 3.67 (m, 2H), 2.95 (m, 1H), 2.50 (m, 1H), 2.32 (s, 3H), 2.27 (d, J «13.9, 2H), 2.09 (m, 4H), 2.03 (m, 1H), 1.88 (m, 1H), 1.83 (t, J »9.2, 2H), 1.71 (m, 1H), 1.63 (rn, 2H), 1.48 (ddd, J» 16.6,12.3, 7.6,4H},1.13 (dd, J = 11.7, 5.4.1H), 0.72 (dt, J - 13.7, 9 0, .......................... .......... M ................................ 163 6- (9- (2 - ((((4,5dimatiltiophen-2yl) methyl] amlno} etH) -6-oxasposp (4.5] decan9-ll] plridln-2-ol 401.1 6 7.49 (m, 1H), 6.76 (s, 1H), 6.51 (d, J = 8.9.1H), 6.25 (d, J «7.0.1H), 3.99 (s, 2H), 3.71 (m, 2H) , 2-83 (dd, J - 16.5,11.3,1H), 2.61 (dd, J »17.0, 5.8.1H), 2.27 (d, J» 21.1.5H), 1.99 (m, 6H), 1.65 (m , 10H),0.98 (dd, J-18.1,5.5,1H). 164 2- (9- (24 ((4,5dimethylthiofen-2ll) metll] amlno} ethyl) 4-oxae «pirt> [4.5] decan9il] pyridin-4-ol 401.2 6 9.21 (d, J = 64.7.2H), 8.00 (s, 1H), 7.07 (m, 2H), 6-67 (s, 1H), 3.95 (s, 2H}, 3.62 (m, 2H), 2.84 ($, 1H), 2.44 (s, 1H), 2.27 (d, J = 12.2.1H), 2.16 ($, 4H), 2.03 (d, J = 13.5, 2H), 1.94 (s, 3H), 1.83 (d,) - 13.9.1H), 1.65 (m, 3H), 1.37 (m, 5H), 0.75 (s, 1H). 165 ((5-nitrothiophen-2yl) metiq «24 (9R) -9 (pyridin-211) -6oxaspirc [4.5] decan-9iq» tilde}) amine 402 6 8.59 (d, 4.0.1H), 8.15 (t, J - 7.0, 1H), 7.79 (d, J 4.1.1H), 7.66 (d, J - 8.2.1H), 7.60 (m, 1H), 7.16 (d,J - 4.2.1H), 4.23 (s, 2H), 3.78 (m, 2H), 3.04 (d, J = 6-0.1H), 2.65 (m, 1H), 2.43 (d, J = 9.8.1H ), 2.29 (m, 3H), 1.98 (d, J = 14.1, 1H), 1.83 (d, J - 5.4, 2H), 1.67 (m, 1H), 1.48 (m, 4H), 1.16 (m, 1H ), 0.75 (d, J «13.2, 1H). 166 [(3,5dimetlldofen-2H) methyl] ({2 - [(9R) -9- 402.1 δ 7.19 (dd, J «8.9, S.l, 2H), 7.01 (dd, J« 13.7, 5.0,2H), 6.43 (s, 1H), 3.87 (m, 2H), 3-72 (m, 2H), 3 02 (s,1H), 2.72 (dd, J »14.6, 8.9.1H), 2.31 (dd, J = 31.1,
    129
    (4-fluorophenyl) * 6 *oxaespiro [4.5] decan-9ii] etll}) amlna10.4.4H), 2.15 (d, i = 13.8.1H), 2.0S (d, J »14.0,1H), 1.98 (m, 4H), 1.87 (m, 2H), 1.77 (d, J 9.7.1H),1.67 (ddd, J = 15.6,10.3, 5.4, 2H), 1.46 (m, 4H), 1.25 (t, J = 7.1.1H), 0.79 (dt, J - 13.7, 8.9.1H). 167 [{5-ethylthiophen-2yl) metirj ({2 - {(9R) -9 (4 * fluorophenyl) -6oxasposp [4.5] decan-9ll] ethyl}) amlna 402.1 6 7.21 (dd, J «8.9, 5.2, 2H), 7.04 (t, J» 8.6, 2H), 6.79 (d, J 3.5.1H), 6.62 (d, J «3.5.1H), 3.92 (s, 2H), 3.80-3.67 (m, 3H), 2.82-2-67 (m, 2H), 2.32 (s, 1H), 2-16| d, J »14.3,1H), 2.06 ($, 1H), 2.00 (td, Í« 12.8,4.9, 1H), 1.91 (d, J = 13.9, 2H), 1.84-1.75 (m, 1H ), 1.® (s, 2H), 1.50 (d, J = 3.7.4H), 1.25 (t, J - 7.5, 4H), 0.81 (dt, 1 «13.4.8.7.1H). 168 {2- (4- (4-fluoroftnH) -1oxaspospiro (5.5) undecan4-®] atn} [(5metilticfen-2il) m «tlljamlna 402.3 6 7.12 (m, 2H), 6.93 (s, 2H), 6.66 (d, J = 3.4.1H), 6.49 (d, J »2.5.1H), 3.80 (S, 2H), 3.63 (s, 2H) , 2.65 (m,1H), 2.31 (s, 3H), 2.12 (m, 2H), 1.8S (m, 1H), 1.61 (s, 3H), 1.43 (d, J = 14.0, 2H), 1.33 (m, 3H), 1.03 (s, 4H), 0.59 (m, 1H). 169 [(4,5dimethylthiophen-2il) material] ({2 - {(9R) -9 (4. fluorophenyl) -6oxasposp [4,5] decan-9iljet H}) amine 402.3 δ 8.92 (d, J »108.6, 2H), 7.15 - 7.05 (m, 2H), 6.93 (t, J« 8.6, 2H), 6.51 (s, 1H), 5 31 ($, 1H), 3.75 (s , 2H),3.69 - 3.54 (m, 2H), 2.63 (s, 1H), 2.27 - 2.10 (m, 4H), 2.06 (d, J ~ 14.0.1H), 1.98 (d, J - 13.9.1H), 1.93 -1.84 (m, 4H), 1.84 -1.65 (m, 3H), 1.58 (ddd, J «17.0,8.4,3.8, 2H), 1.51 -1.27 (m, 4H), 1.17 (dd, J = 13.9, 6.2, 1H), 0.71 (dt, J «13.6.8.8.1H). 170 {[5-(maWaulfanil) thiophen-2-H] me «l} ({2l (9R) -9 (pyridin-2-0) -6oxaesplro [4.5] decan * 9irjatil}) amine 403 δ 9.54 (s, 1H), 8.71 (d, J - 4.5.1H), 8.26 (t, J = 7.2, 2H), 7.80 - 7.67 (m, 2H), 6.92 (dd, J «21.5,3.6.2H ), 4.15 (s, 2H), 3.76 (d, J »40.3, 2H), 3.02 (td, J = 11.4,5.3.1H), 2.62 - 2.51 (m, 1H), 2.48 (s, 3H), 2.42 (s, 1H), 2.31 (t, i = 13.3.3H), 2.03 (d, J = 14.2.1H ), 1.92 -1.78 (m, 2H), 1.78 - 1.63 (m, 1H), 1.64 -1.36 (m, 4H), 1.25 -1.12 (m, 1H), 0.79 (s, 1H). 171 6- (9- (2 - ((((3metoxiticdan-2il) metll] amlno) etll) -6-oxaspiro [4.5] decan9il] plridin-3-ol 403 1H NMR (400 MHz, CD3CN) 68.15 (d, J ~ 1.5.1H), 7.60 (s, 1H), 7.43 (d, J - 5.6.1H), 7.31 (m, 2H), 6.97(d, J - 5.6.1H), 4.11 (s, 2H), 3.86 ($, 3H), 3.66 (dd, J »7.8.2.9.2H), 2.97 (m, 1H), 2.51 (m, 1H), 2.28 (m,2H), 2.02 (m, 1H), 1.87 (m, 2H), 1.80 (d, J = 13.5,2H), 1.70 (d, J «9.8.1H}, 1.61 (dd, J -13 8.7.1.2H),1.49 (m, 4H), 1.12 (m, 1H), 0.71 (d, J = 13.5.1H). 172 649- (2 ^ ((3methoxythiophen-2yl) methyl] amnno} etll) -6-oxaspospiro (4.5] decan9iQpirtciln-2-ol 403 6 9.47 (brs, 1H), 7.51 (dd, J - 9.0, 7.2.1H), 7.23 (d, J «5.6.1H), 6.80 (d, J ® 5 5.1H), 6 52 (d, J = 8.9.1H), 6.27 (d, J = 7.1.1H), 4.10 (s, 2H), 3.82 (s, 3H), 3.73 (dd, J »6.8, 3.4, 2H), 2.83 (dd, J« 11.9, 5.7.1H), 2.60 (t, J = 10.0.1H), 2.27 (t, J = 15.0, 2H), 2.00 (t, i =12.3, 2H), 1.65 (m, 10H), 0.97 (d, J «13.4.1H). 173 2 - ((9R) -9- (2 - {[(3metoxttiophen-2yl) methyl] amino) ethyl) 403.2 δ 9.84 (s, ÍH), 8.76 (s, 1H), 8.32 (d, J - 5.3.1H), 7-60 (t, J = 7.7.1H>, 7.52 (m, 1H), 7.41 (m, 1H), 7.25 (d, J= 5.5.1H), 6.81 (d, J «5.5.1H), 4.16 (m, 2H), 3.82
    130
    -6-oxaesplro [4.5Jdecan-9-111-1oxidopirtdin-1-yl(m, 4H), 3.71 (m, 1H), 3.05 (d, J «13.4, 2H), 2.8S (d, J« 9.1.1H), 2.53 (s, 1H), 2.27 (d, J · 14.3 , 1H), 2.14 (m, 1H), 1.99 (t, J '11.3.1H), 1.85 (m, 2H), 1.66 (ddd, J s 18.0,10.0, 5.8.1H), 1.51 (m, 4H) , 1.22 (dd, J ® 12.3,6.0.1H), 0.90 (dt, J = 13.0.8.7.1H). 174 2- (9- (20metoxltlofen-2 * tl) matil] amino} ethyl) -6-oxaasphro [4> 5] decan9iQpiridin-4-ol 403.2 5 9.17 (d, J = 50.2.2H), 8.00 (d, j »6.5.1H), 746 (d, 1 5-6, 3H), 6.72 (d, J» 5.6.1H), 4.00 (s, 2H), 3.73 (s, 5H), 2.82 (S, 1H), 2.34 (d, 1 - 39 9, 2H), 241 (dd, J »51.0.13.1.3H), 1.84 (d, J« 13.9, 1H), 1.43 (m, 9H), 0.75 (s, 1H). 17S {24 (9RF944fluorophenyl) -6oxasposp [4.5] decan-9 * ll] ethyl} [(3-methoxytioten2yl) methyl] amlna 404 δ 7.24 (s, 3H), 7.03 (dd, J «11.7, 5.6.2H), 6.80 (d, j = 5.5.1H), 4.00 (S, 2H), 3 81 (m, 5H), 2.78 (m , 1H),2.39 (m, 1H), 247 (m, 1H), 2.06 (s, 2H), 1.86 (m, 2H), 1.66 (m, 3H), 1.51 (m, 3H), 1.26 (m, 2H), 0.80 (m, 1H). 176 {242,2-dlmethyl-4- (4methyphenyl) oxan-4yl] ethyl) ({[3 (trifluoromethyl) phenif] m «ti1}) amine 406.3 δ 9.43 (d, J - 141.7, 2H), 7.47 (d, J - 7.2.1H), 7.39 (s, 1H), 7.31 (m, 2H), 6.99 (q, J = 8.3.4H), 3.67 ( m, 4H), 2.54 (d,> »8.4.1H), 2.20 (d, J = 74, 3H), 2.06(m, 3H), 1.92 (s, 2H), 1.60 (td, J 12.5,4.7.1H), 1.46(m, 2H), 1.08 (s, 3H), 0.55 (s, 3H). 177 (1-benzothiophen-2llmethyl) ({2 - [(9R) -9 (pyridin-2-yl) -6oxasposp [4.5] decan-9ii] ethyl}) amine 407.1 6 8.51 (dd, 1 = 55.1.3.1H), 8.02 (d, J · 1.4.1H), 7.73 - 7.52 (m, 3H), 7.43 (d, J «1.0.1H), 7.35 - 7.23 (m , 3H), 3.67 (s, 3H), 2.96 (td, J - 11.5, 5.7.1H), 2.562.43 (m, 1H), 2.43 - 2.28 (m, 1H), 246 (d, J = 13.6, 3H), 1.89 (d, J = 14.2.1H), 1.73 (ddd, J «19.7,11.9, 7.2.2H), 1.55 (dt, J = 15.0, 5.7.1H), 1.48-1.22 (m, 4H), 1.06 (s, 1H), 0.66 (dt, J - 13.2.8.9.1H). 178 (1-benzothiophen-3llmetllX {24 (9R) -9. (Pyridin-2ilj-6 · oxasposp [4.5] decan-9ll} ethyl}) amlna 407.1 δ 11.71 (s, 2H), 9.34 (d, J · 85.8.1H), 8.48 (d, I = 5.0.1H), 8.10 (s, 1H), 7.71 (dd, 1 = 6.2, 2.8.1H), 7.58 (ddd, J »224,9.6,4.3,3H), 7.47 (s, 1H), 7.36 - 7.24 (m, 2H), 442 (s, 2H), 3.64 (s, 2H), 2.93 (s, 1H ), 2.51 -2.23 (m, 2H), 2.13 (t, i »14.3, 3H), 1.94 -1.83 (m, 1H), 1.80 -1.64 (m, 2H), 1.52 -1.49 (m, 1H), 1.37 (dd, J «39.4, 7.2.4H), 1.06 (d, J = 13.0.1H), 0.64 (dt,J = 134.9.0.1H). 179 [(5-chlorothiophen-2yl) metll) ((2 - [(9R) -9 (4 fluorophenll) -6oxasplro [4.5] decan-9il] ethyl)) amine 408.2 δ 741 (dd, J = 8.9, 5.2, 2H), 6.94 (dd, J> 15.9, 7.2, 2H), 6.75 - 6.56 (m, 2H), 3.79 (s, 2H), 3.71 - 3-52 (m, 2H), 2.61 (s, 1H), 248 (s, 1H), 1.84 (dddd, J = 31.4,25.9, 23.7,134,12H), 1.58 (td, J 9.4,4.6,2H), 1.39 (ddd, J = 23.7,14.8, 9.2, 5H), 147 (s, 2H), 0.69 (dd, J «8.7 , 54.1H). 180 2-f [(2- (2,2-dimethyl-4 [4-(trffluorwnetil) phenyl]oxan-4- 408.3 6 8.34 (d, J = 45-4.2H), 7.50 (d, J = 8.3, 2H), 7.24 (d, J - 8.2, 2H), 7.10 (s, 1H), 6.77 (m, 3H ), 3.80 (s, 2H), 3.66 (d, J '12.3, 2H), 3.31 (s, 3H), 2.63 {s, 1H), 2.09 (dd, 1 - 26.1,13.9, 3H), 1.87 (t , J ~ 10.4.1H), 1.71 (t.
    131
    ll) ethyl) amnno] inetll} phenolJ = 10.4.1H), 1.58 (d, J = 14.0.2H), 1.10 (s, 3H), 0.53 (S, 3H). 181 [(5-chlorothiophen-2-H) methyl] ({2- [2,2diethyl-4 (4-fluorophenyl) oxan4-yl] ethyl}) amine 410.1 fi 7.12 (dd, J »8.9, 5.2.2H), 6.96 (t, J = 8.6, 2H), 6.69 (q, 1 - 3.8, 2H), 3.79 ($, 2H), 3.63 (dd, J» 12.2 , 7.1, 2H), 2.63 (dd, J = 12.2, 7.5.1H), 2.29 -1.77 (m, 8H), 1.67 (td, J ® 12.5.4.7.1H), 1.44 (dd, J »24.5,10.8 , 3H), 1.31 (d, J * 7.5.1H), 0.95 ($, 1H), 0-74 (t, J »7.5, 4H), 0.44 (t, J» 7.4.3H). 182 {[5- (2methylpropyl) tlofen -2-ylJmetyl} «2 <(ÔR} 9 (pyridin-24l) -6oxasposp [4.5] decan-9ll] Tiro}) amlna 413-1 δ 9.56 (brs, 1H), 8.66 (d, J - 4.7.1H), 8.09 (t, J = 7.5, 1H), 7.62 (d, 1 »8.1.1H), 7.55 (m, 1H}, 6.87 (d, J -3.4.1H), 6.59 (d, J - 3.4.1H), 4.08 (m, 2H), 3.75 (m, 2H), 2.96 (d, J · 4.8.1H), 2.57 (d,) · 7.0, 2H ), 2.50 (t, J = 9-6.1H), 2.31 (m, 3H), 2.14 (td, J - 13.5,5.4,1H),1.96 (d, j - 14.1.1H), 1.80 (m, 3H), 1.66 (m, 1H),1.47 (m, 4H), 1.14 (d, J = 130.1H), 0.89 (d, J = 6.6, 6H), 0.73 (dt, J - 13.6, 9.0.1H). 183 [(5 * bu0ttiofen * 2 * il) methyl] ({2 - [(9R) -9 (pMdin-2it> -6oxaspospiro [4.5] decan-9ii) eer}) amine 413.1 δ 10.87 (brs, 1H), 9.42 (brs, 1H), 8.70 (d, J »4.8, IH), 8.17 (t, 1 - 7.7.1H), 7.68 (d, J = 8.1.1H), 7.62 ( m, 1H), 6.85 (d, J = 3.5.1H), 6.60 (d, J * 3.4.1H), 4.08 (s, 2H), 3.79 (m, 1H), 3.67 (t, J = 10.0.1H ), 2.97 (d, J * 4.3.1H |, 2.70 (t, 1 = 7.6, 2H), 2.50 (t, J «9.9,1H), 2.33 (m, 3H), 2.16 (td, J = 13.1, 5.0.1H), 1.98 (t, J - 9.4.1H), 1.80 (t, J = 9.6, 2H), 1.54 (m, 7H ), 1-33 (dq, J - 14.5, 7.3, 2H), 1.14 (m, 1H), 0.90 (t, J »7.3, 3H), 0.73 (dt, J» 13.0, 8.9.1H). 184 {4H.5H.6Hclcop «nta [b] tiofen[(9RW4fluorbfaflil) -6oxaesplro [4.5] decan-9iQetil}) amine 414 δ 7.20 (m, 2H), 7.01 (dd, J »13.5,4.7.2H), 6.65 (s, 1H), 3.88 ($, 2H), 3.72 (m, 3H), 2.78 (t, J - 7, 2.3H), 2.61 (t, J = 7.2, 2H), 2.34 (dt, J »14.5,7.3, 3H), 2-15 (d, J» 14.1.1H), 2.06 (d, J «13.9, 1H), 1.99 (m, 1H), 1.89 (m, 2H), 1.78 (m, 1H), 1.67 (ddd, J - 18.6,11.9, 7.0.2H), 1.46 (m, 4H), 1.25 (m, 1H), 0.79 (dt, J «13.4.8.7.1H). 185 {2 - [(9RHHpirtdln-2il) -6oxasposp [4.5] decan-9ilJatil} ({2H, 3Htleno [3,4b] (1,4] dloxln-5llmetil}) amlna 415 δ 9.37 (s, 1H), 8.65 (dd, J «5.3,1.3,1H), 8.12 (td, J 7.9,1.6,1H), 7.65 (d, J = 8.2,1H), 7.56 (dd, J« 7.1, 5.7.1H), 6.34 (S, 1H), 5.94 (s, 1H), 4.16 (dt, 1 = 8.2, 6.0.4H), 4.05 (m, 2H), 3.77 (m, 2H), 3.06 ( dd, J «17.1,11.1,1H), 2.61 (t, J - 8.9,1H), 2.29 (m, 4H), 1.99 (t, J = · 8.8.1H), 1.82 (ddd, J« 13.6,9.4 , 4.3.2H), 1.67 (m, 1H), 1.48 (ddd, J · 14.5,12.7, 6.9, 4H), 1.19 (m, 1H), 0.74 (dt, J »13.3,9.0.1H). 186 {2- [2,2-dimethyl-4- (4methylphenyl) oxan-4-matanoMutfonlIfanil) methyljamina 416.3 δ 8.66 (d, J -167.7, 2H), 7.92 (m, 1H), 7.52 (m, 3H), 7.05 ($, 4H), 4.21 ($, 2H), 3.71 (rtl, 2H), 3.49 (s , 1H), 3.06 ($, 3H), 2.85 (s, 1H), 2.47 (d, J «4.8.1H), 2.20 (m, 4H), 2.09 (dd, i · 13 9.2.1.1H), 1.94 (d, J = 4.6, 1H), 1.72 (s, 1H), 1.55 (m, 2H), 1.10 (s, 3H), 0 57 (s, 3H). 187 [(4-bromofuran-2- 419 δ 9.52 (s, 1H), 8.77 (s, 1H), 8.38 (s, 1H), 7.83 (d, J =
    132
    IIMnetll] ({2 - [(»R) -8 · (pyridin-211) -6oxaspospiro [4.5] decan-9H} atH}) amlna7.6, 2H), 7.40 (s, IH), 651 ($, IH), 4.09 (s, 2H), 3.78 (d, J = 48.0.2H), 3.03 (s, IH), 2.63 - 2.41 (m, 2H>, 2.33 (dd, J = 28.3,13.9, 3H), 2.09 (d, J »14.2, IH),1.90 (s, 2H), 1.82 - 1.63 (m, IH), 153 (ddd, J · 12.9, 10.9, 4.5, 4H), 1.19 (s, IH), 0.79 (dt, J = 13 0, 8-9 , IH). 188 {2 - [(9R) -9- (4-fluorophenyl) -6oxasposp [4.5] decan-9ll] ethyl} ({[5 (methylsulfanyl) thiophen2-yl] metll)) amine 420 δ 7.22 (dd, J «8.9.5.2.2H), 7.05 (t, J« 8.6, 2H), 6.85 (dd, J = 10.8, 3.7, 2H), 3.95 ($, 2H), 3.75 (d, J «4.6, 2H), 2.75 (S, IH), 2.47 ($, 3H), 2.32 (s, IH), 2.17 (d, J - 14.4, IH), 2.09 (d, J = 13.8, IH) , 1.99 (dt,) * 12.3, 6.4, IH). 1.91 (d, J «13.9.2H), 1.80 (d, J -105, IH), 1.74 -1.61 (m, 2H), 1.49 (dt, J - 18.7,11.7, 4H), 1.26 (s, IH) , 0.89-0.75 (m, 1H). 189 {2 - [(9R) -9- (pirldin-211) -6oxaspospiro [4.5] decan-9il] etii} ({[6 (trifluofXMnetll) pirldin34f | metlf}) amlna 420.3 6 8.83 - 856 (m, 2H), 8.35 (t, J = 7.6, IH), 7.96 (dd, J - 19.3, 8.7, IH), 7.87 - 7.75 (m, 2H), 7.71 (t, J «9.2 , IH), 4.16 (s, 2H), 3.84 (dd, J = 85.4.4, IH), 3.71 (t, J • 10.0, IH), 3.07 (dd, J «11.7, 6.8, IH), 255 (dt, J = 25.6,11.9,2H), 2.43-2.21 (m, 3H), 2.10 (d, J - 14.2,IH), 1.90 (ddd, J = 26.1,14.9,6.7, 2H), 1.76 -1.62 (m, IH), 1.60-1.34 (m, 4H), 1.33 -1.09 (m, IH), 0.76 (dtj-12.8 , 8.8, IH). 190 [(5-bromofuran-2-ll) metiq ({24 (»R) .9. (pyridin-2H) -6oxaspospiro [4.5Jdacan-9iQethyl}) amine 421 δ 8.75 (d, J - 4.8, IH), 8.24 (t, J »7.7, IH), 7.86758 (m, 2H), 6.44 (d, 1 = 3.3, IH), 6.28 (d, J« 3.3, IH ), 4.07 (s, 2H), 3.94 - 3.79 (m, IH), 3.72 (t, J «10.1, IH), 3.01 (dd, J« 11.1,6.0, IH), 256 (t, J = 9- 9, IH), 2.49 - 2.11 (m, 4H), 2.05 (d, J = 14.1, IH), 1.88(ddd, 1 «18.8,11.0,65, 2H), 1.78 -1.31 (m, 5H), 1.31-1.07 (m, IH), 0.77 (dt, J = 13.1, 8.9, IH) 191 (2- {2,2-dimethyl-4- [4 (trifluoromethyl) phenyl] oxan-4yl) ethyl) [(2methoxyphenyl) methyl] amine 422.3 δ 8.49 (d, J = 118.7.2H), 7.50 (d, i · 8.3, 2H), 7.25 (dd, J = 10.3,4.6, 3H), 6.96 (dd, J - 75.15, IH), 6.79 (ddd, J »22.1,14.4,4.4, 2H), 6.08 (s, IH), 3.84 (d, J =9.2, 2H), 3.68 (m, SH), 2.64 (s, IH), 2.09 (m, 3H),1.90 (m, IH), 1.77 (dd, J - 12.7.45, IH), 158 (ddd, J * 14.0,10.8,10.1, 2H), 1.12 (s, 3H), 055 (s, 3H). 192 {2- (2,2,6,6tetramethyl-4- {pyrldin2-yl) oxan-4yl] ethyl} ({[6 (trifluorometii) plridin -3-iq methyl}) amine 422.3 δ 8.79 - 8.63 (m, 2H), 8.31 (t, J «7.9, IH), 8.05 7.90 (m, 2H), 7.87 - 7.61 (m, 2H), 4.16 (s, 2H), 2.82 (dd, J »10.0, 6.6, 2H), 2.54 (d, J * 14.7.2H), 2.46 2.30 (m, 2H), 1.95 (d, J · 14.8, 2H), 1.32 (s, 5H), 0.98 (s, 5H ), 193 {[5-iforan-2ll) thiophen-2il] fnetll} ({2 - [(9R) -9 (plridin-2-yl) -6oxasposp [4.5] decan-9il] ethyl}) amine 423.1 δ 959 (5, IH), 856 (d, J «4.7, IH), 8.05 (t, J = 7.4, IH), 757 (d, J - 8.1, IH), 7.46 (dd, J -12.2, 6.3 , IH), 7.35 - 7.26 (m, IH), 6.93 (dd, 1 19.9, 3.7.2H), 6.46- 6.30 (m, 2H), 4.08 {s, 2H), 3.78 - 354 (m, 2H), 3.00- 2.81 (m, IH), 2.46 (t, J = 9.7, IH), 2.30 (t, J · 10.6,IH), 2.13 (ddd, J = 17.3,16.1,9.3,3H), 1.89 (d, J »
    133
    14.2, IH), 1.72 (ddd, J - 13.9,9.5.4.3.2H), 1.54 (dd, J 21.6,14.5, IH), 1.48 -1.23 (m, 4H), 1.06 (d, J = 13.2, IH ), 0.65 (dt, J «13.3.8.9.1H). 194 ((5-chlorothiophen * 2it) methyl] ({2- (4- (4fluorophenll) -1oxaatpiro [5.5) und «« an4ll] etll)) amine 423.2 δ 7.13 (dd, J = 8.9.5.1.2H), 6.95 (dd, J = 15.5.6.8, 2H), 6.69 (q, J «3.9, 2H), 3-81 ($, 2H), 3.62 (d, J 13.8.2H), 2.68 (m, IH), 2.11 (dd, J = 22.2.13.8,3H), 1.84 (m, IM), 1.54 (m, 4H), 1.30 (m, 4H), 1.05 (d, J »11.4, 4H), 0.63 (m, IH). 195 (1-benzothiophen-2-HmetilX {2 - [(9R) -9- (4fluorophenll) * 6 * oxaspiro (4.5] decan-9ll] ethyl}) amine 424 δ 9.53 (d, J - 105.8, 2H), 7.77 - 7.66 (m, 2H), 7.36 7.32 (m, 2H), 7.15 (dd, J - 8.8, 5.2.3H), 6.96 (t,) «8.6, 2H), 3.96 | s, 2H), 3.75 - 3.63 (m, 2H), 2.75 (s,1H), 2.33 (s, IH), 2.19 - 2.16 (m, OH), 2.15 - 1.71 (m, 6H), 1.71 -1.29 (m, 6H), 1.22 (s, 1H), 0-77 (dt, J = 13.5,9.0, IM). 196 (1-benzothiophen-3ylmethylX (2 - {(9R) -9- (4fluorophenll) -6oxasposp [4.5] dacan-9yl] ethyl}) amine 424 δ 8.67 (d, J = 139.8, 2H), 7.76 - 7.61 (m, IH), 7.56 7.39 (m, 1H), 7.34 - 7.25 (m, 3H), 6.98 (dd, J - 8.8,5.1, 2H), 6.84 (t, i - 8.6, 2H), 3.89 (s, 2H), 3.71 - 3.54 (m, 2H), 2.66 (s, 1H), 2.21 (s, IH), 2.07 - 1.89 ( m, 2H), 1.89 -1.60 (m, 4H), 1.60 -1-45 (m, 2H), 1.44 1.24 (m, 4H), 1.19 -1.07 (m, 1H), 0.67 (dt, J «13.8, 8.9.1H). 197 [(5-0uoro-1benzothiophen-2yl) methyl] ({2 - [(9R) -9 (ptridin-2-yl) -6oxasplro [4.5] decan * 9 * yl] ethyl)) amine 425 δ 8.47 (5, IH), 7.69 (s, 2H), 7.42 (d, J = 9.2, IH), 7.30 (dd, J = 10.5.9.5.3H), 7.13 (s, 2H), 4.21 (d, J »13.3, 2H), 3.73 (5, 2H), 3.16 - 2.91 (m, IH), 2.82 - 2.52 (m, 1H), 2.27 (d, J» 14.8, 2H), 2.21 - 2.09 (m, IH ), 2.08-1.94 (m, IH), 1.85 (d, J '13.6, IH), 1.65 (s, 4H), 1.43 (d, J »38.4.3H), 1.18 -1.02 (m, IH), 0-75 0.60 (m, IH). 198 [(5-cyclopantlltiofan-2ll) matil] ({2 - ((9R) -9 (pyridin-2-H) -6oxasposp (4.5] decan-9il] ethyl}) amine 425.1 δ 12.19 -12.13 (m, OH), 8.69 (d, J «4.7, IH), 8.18 (s, IH), 7.80 - 7.59 (m, 2H), 6.90 (d, J = 3.5, IH), 6.67 ( d, J = 2.9, IH), 4.14 (s, 2H), 3.82 (d, J «12.7, 2H),3.73 (d, J - 9.7, IH), 3-17 (t, J = 8.3, IH), 3.02 (s, IH), 2.58 (s, IH), 2.31 (d, J - 14.1.4H), 2.05 (dd, J = 33.0, 10.0.3H), 1.90 -1.74 (m, 4H), 1.68 (dt, J = 12.1.9.1, 3H), 1.51 (ddd, J = 13.4,10.8, 5.9.6H), 1.18 (s, IH),0.79 (s, IH). 199 [(4fanllfenll) metiq ((2 - ((9R) -8- (pyridin-2yl) -6oxasplro [4.5] decan-9yl] ethyl}) amine 427.3 δ 8.59 (d, J = 4.9, IH), 8.18 (t, J = 7.4, IH), 7.75 7.52 (m, 2H), 7.47 - 7.38 (m, 4H), 7.35 - 7.29 (m, 2H), 7.29 - 7.21 (m, 3H), 3.91 (s, 2H), 3.70 (dt, J =12.3, 4.2, IH), 3.57 (t, J = 9.7, IH), 2.92 ($, IH), 2.40 (dd, J = 26.0.12-7, 2H), 2.30-2.04 (m, 3H), 2.04 -1.84 (m, IH), 1.76 (ddd, J »27.2,15.3,6.8, 2H), 1.6S - 1.21 (m, 5H), 1.07 (dd, J - 14.4, 5.6, IH), 0.67 (dt, J -13.0,9.0, IH). 200 [(3-fenllfenll) metll] ( 427.3 6 8.44 (d, J «4.1, IH), 7.96 (t, j · 7.1, IH), 7.53 -7.43 (m, 5H), 7.42 - 7.26 (m, 3H), 7.19 (s, 3H), 3.94
    134
    {24 («R) -e- (pMdln-2-11) -6oxaspospiro [4.5] decan-9il] etll}) amine(s, 1H), 3.82 - 3.45 (m, 2H), 2.73 (s, 2H), 2.44 (s, 1H), 2.31 (d, J -10.6.1H), 2.15 (d, i 13.2.3H), 1.86 (d, J «14.1.1H), 1.70 (t, J = 9.7, 2H), 1.56 (s, 1H), 1.50 -1.22 (m, 5H), 1.06 (s, 1H), 0.66 (dd, J = 13.3, 9.0,1H). 201 benzll ({2- [9- (4 »bromophenyl) -6oxasposp [4.5] decan-9il] ethyl)) amlna 428.2 δ 9.51 (s, 1H), 9.15 (s, 1H), 7.42 (d, J «8.6.2H), 7.30 (m, 3H), 7.16 (dd, J = 7.3.2.1, 2H), 7.06 (d, J - 8.7, 2H), 3.68 (m, 4H), 2.62 (m, 1H), 2.19 (m, 1H), 2.04 (dd, J ~ 22.4,13.9, 2H), 1.93 (m, 1H), 1.85 ( m, 3H),1.60 (m, 2H), 1.45 (ddd,) »21.1.16.1.8-8.5H), 1.25 (m, 2H), 0.77 (dt, J» 13-2.8.7.1H). 202 2-amino-4-chloro-5 [({2 - {(9R) -9- (pirkjin-211) -6oxaesplro [4.5] decan-9i [| ethyl} amino) methyl] tlofan-3carbonltrila 431 1H NMR (400 MHz, CD3CN) 6 8.57 (dd, J - 4.9.1.0, 1H), 7.83 (m, 1H), 7.48 (d, J - 8.1.1H), 7.31 (ddd, i ~ 7.S, 4.9.0.9.1H), 6.13 (s, 2H), 4.06 (s, 2H), 3.69 (m, 2H), 2.96 (m, 1H), 2.42 | m, 2H), 2.08 (m, 2H), 1.92 (m, 1H), 1.87 (d, J = 13-5.1H), 1.57 (m, 8H), 1.10 (m, 1H), 0.71 (m, 1H). 203 (2 - [(9R) -9- {4fluorophan 11) -6oxaspospiro [4.5] decan-9ll] ethyl} ((2H, 3Hthene [3,4b] [1,4] dioxln-5ylmethyl)) amlna 432 δ 7.21 (dd, J 9.0, 5.1.2H), 7.03 (t, J = 8.6.2H), 6.33 (s, 1H), 4.13 (s, 4H), 3.90 (s, 2H), 3.74 (m, 2H ), 3.01 (brs, 1H), 2.77 (t, J = 13.7.1H), 2.35 (m, 1H), 2.17 (d, J = 14.0.1H), 2.02 (dt, J - 14.7,9.5, 2H) , 1.89 (m, 2H), 1.78 (d, J = 10.1.1H), 1.68 (ddd, J = 16.9,10-6, 5.8, 2H), 1.46 (ddd, 1 - 17.8,10.0, 5.9.4H) , 1.25 (m, 1H), 0.79 (dt, J = 13.5.8.8.1H). 204 [(4-phenylthiofan-2ll) metll] ({2 - {(9R) -9. (Pyridin-24l) -6oxasplro [4.5] decan-9il] ethyl}) amine 433.1 δ 9.71 (s, 4H), 8.53 (d, J - 5.0.1H), 8.09 (t, J »7.6, 1H), 7.62 (d, J = 8.1.1H), 7.54 - 7.44 (m, 1H), 7.43 7.35 (m, 2H), 7.32 - 7.19 (m, 5H), 4.12 (s, 2H), 3.77 -3.52 (m, 2H), 3.00 - 2.76 (m, 1H), 2.41 (dt, J - 25.0, 11.5.2H), 2.18 (t, J - 17.1.3H), 1.90 (d, J = 14.1.1H) , 1.73 (ddd, J «19.6,11.4,6.9, 2H), 1.55 (dd, J« 10.0,4.9.1H), 1.48 - 1.26 (m, 4H), 1.04 (s, 1H), 0.72 0.56 (m, 1H). 205 ((5-pheniitiophen-2ll) methyl] {{2 »[(9R) * 9 * (pyridin-2-yl) -6oxasposp [4.5] decan-9HJ * til})« nlna 433.1 δ 9.74 (brs, 1H), 7.62 (d, i - 8.1.1H), 7.50 (m, 3H), 7.37 (m, 2H), 7.31 (m, 1H), 7.12 (d, JI = 3.7, 1H), 7.04(d, 1 = 3.7.1H), 5.23 (brs, 1H), 4.19 (mz, 2H), 3 72 (m, 2H), 3.02 (d, J »6.5.1H), 2.59 (t, J« 9.1 , 1H), 2.39 (t, 1 »10.1,1H), 2.22 (dd, J« 29.2,10.0, 3H), 1.96 (d, J 14.1.1H), 1.80 (t, J »11.0, 2H), 1.62 (dd, J «14.1, 7.4, 1H), 1.44 (ddd, J = 16.8, 16.4, 7.5, 4H), 1.13 (m, 1H), 0.73 (dt, J = 12.7.8.8.1H). 206 [(5-methanesulfonlltiofen24l) metfl] ({2- «9RH (pyrldln-2-ll) -6oxasposp [4.5] decan-9il] ethyl)) amine 435 δ 8.67 (d, J «5.0.1H), 8.32 (t, J» 8.0.1H), 7.79 (d, J «7.9.2H), 7.59 (d, J« 3-8.1H), 7.22 (d , J «3.8,1H), 4.31 (d, J - 6.2, 2H), 3.84 (s, 1H), 3.74 (S, 1H), 3.18 (s,1H), 3.05 (s, 2H), 2.54 {t, J «10.3, 2H), 2.31 (d, J = 13.3, 2H), 2.14 - 2.00 (m, 2H), 1.89 (d, J« 13.8.3H ), 1.81 -1.64 (m, 1H), 1.64 -1.37 (m, 3H), 1.28 (s, 2H),
    135
    0.81 (d, J »13.2.1H). 207 [(4-brornothiophen-3yl) metH] ({2 - {(9R) -9 (plricfln-2il) -6oxasplro [4.5] decan-9il] ethyl)) amine 435 δ 11.51 (s, 1H), 9.44 (s, 1H), 8.69 - 8.58 (m, 1H), 8.14 (td, J ~ 8.0,1.6,1H), 7.68 - 7.56 (tn, 2H), 7.52 (d, 1 = 3.4.1H), 7.21 (d, J »3.3.1H), 4.01 (s, 2H), 3-82- 3.54 (m, 2H), 2.97 (td, J = 11.5.5.7.1H), 2.62 2.43 (m, 1H), 2.41 - 2.12 (tn, 4H), 2.02 -1.89 (m, 1H) , 1.78 (ddd, J - 18.6,11.9, 6.5.2H), 1.60 (dt, J = 13.5, 7.7.1H), 1.55 -1.30 (m, 4H), 1.10 (d, J = 4.1, OH) , 0.67 (dt, J = 13.1.89.1H). 208 [(4-bromthiophen-2yl) metiq ({2 - [(9R) -9 (pyridin-2il) -6oxasplro [4.5] decan-9il] ethyl}) amine 435.1 δ 8.59 (d, J »4.0.1H), 8.13 (t, J <7.1.1H), 7.65 (d, J« 8.2.1H), 7.59 (m, 1H), 7.23 (d, j »1.4 , 1H), 7-04 (d, J »1.2,1H), 4.19 (s, 2H), 3.75 (tn, 2H), 3.01 (tn, 1H), 2.84 ($, 1H), 2.60 (m, 1H ), 2.40 (m, 1H), 2.25 (d, J = 13.0, 3H), 1.97 (d, i »14.0.1H), 1.83 (d, J« 9.4, 2H), 1.67 (m, 1H) , 1.48 (dd, J = 24.0,15.8, 4H), 1.17 (brs, 1H), 0.77 (m, 1H). 209 (| 5-toromotiophen-2yl) methyl] ({2 - [(9R) -9 (pyridin-2yl) -6oxasposp [4.5] decan-9il] ethyl}) amine 435.1 δ 8.61 (d, J = 4.3.1H), 8.14 (t, J = 7.9.1H), 7.65 (d, J * 8.1.1H), 7.60 (tn, 1H), 6.94 (d, J »3.8 , 1H), 6.89 (d, J '3,8,1H), 4.14 (s, 2H), 3.76 (m, 3H), 2.99 (m, 1H), 2.58 (m, 1H), 2.38 (d, J = 9.8.1H), 2.26 (d, J «13.9, 3H), 1.97 (d, J = 14.1.1H), 1.82 (t, J = 9.7, 2H), 1.67 ($, 1H), 1.47 ( tn, 4H), 1.16 (s, 1H), 0.75 (dt, J = 13.4, 9.2.1H). 210 [(2-bromoeophen-3yl) metiq ({2 - [(9R) -9 (plrldln-2il) -6oxasplast (4.5] decan-9il] etll}) amine 436 δ 8.66 (d, J »5.3.1H), 8.21 (d, J» 7.2.1H), 7.85 7.58 (m, 2H), 7.33 (d, J «5.7.1H), 7.09 (d, J» 5.7,1H), 4.02 - 3.63 | m, 3H), 3.10 - 2.97 (m, 2H), 2.61 (t, J = 9.1.1H), 2.43 (d, J * 11.0.1H), 2.30 (d, J -13.6 , 3H), 2.04 | s, 1H), 1.94-1.80 (m, 2H), 1.69 (s, 1H),1.64 -1.40 (tn, 4H), 1.20 (s, 1H), 0.86 - 0.68 (m, 1H). 211 [(5-bromofuran-2ll) metiq ({2 - {(9R) -9 (4 fluoroferHI) -6oxaeaplro {4.5] decan-9iq »tll}) amine 436 6 9.07 (d, J «116.7.2H), 7.16 - 7 06 (m, 2H), 7.01 6.89 (m, 2H), 6.25 (d, J« 3.4.1H), 6.17 (s, 1H), 3.83 | s, 2H), 3.76-3.58 (m, 2H), 2.66 (s, 1H), 2.23 (s, 1H), 2.09 (d, J »14.0.1H), 2.04 -1.96 (m, 1H), 1.95 1.66 (m, 4H), 1.66-1.50 (m, 2H), 1.50 -1.28 | m, 4H), 1.28 -1.13 (m, 1H), 0.71 (dt, J = 13.6.8.8.1H). 212 {2 - ((9R) -9- {4fluorophenyl) -6oxospira [4.5) d ecan-9IIJetMMae (trffluoromethyl) plridln3iqmetil}) amlna 437.2 δ 8.63 (s, 1H), 7.83 (d, J = 8.3.1H), 7.68 (d, J '8.0, 1H), 7.29 (s, 1H), 7.21 (dd, J = 8.9, 5.1.3H), 7.05 (s, 2H), 3.93 (s, 2H), 3.75 (dd, J = 11.3,7.3, 2H), 2.84 2.58 (m, 1H), 2.44 - 2.04 (m, 10H), 2.02 -1.75 ( m, 5H), 1.74 -1.56 (m, 3H), 1.59-1.33 (m, 5H), 1.33 1.19 (m, 1H), 0.78 (d, J «13.6.1H). 213 [(4-bromofuran-2ll) metiq ({2 - {(»R) -9 (4-fluorophenyl) -6oxasposp [4.5] decan-9iq» tll}) amine 437.9 6 7.38 (d, J »0.6.1H). 7.28 (S, 1H), 7.22 (d, J «5.2, 2H), 7.08 (d, J = 8.5, 2H), 3.75 (dd, i« 11.7,7.1,2H),2.73 (s, 1H), 2.30 (d, f - 4.5.2H), 2.17 (d, J = 13.5,1H), 2.10 (d, J = 13.9.1H), 2.05 -1-95 (m, 1H), 194 (s, 2H), 1.79 (d, i = 9.8.1H), 1.74 -1.62 (m, 2H ), 1.49
    136
    (dt, J «16.4,10.6,4H), 1.28 (s, 2H), 080 (d, J“ 13.7, IH). 214 (2 - [(9R) -9- (pirtdln-211) -6oxasospiro [4.5] decan-9ll] etll} ({[5- (tlofen2-yl) thiophen2-yl] metiI)) amlna 439 δ 8.52 (d, J = 5.3, IH), 7.96 (t, J = 7.9, IH), 7.50 (d, J = »8.1, IH), 7.40 (dd, J - 16.2,10.4, IH), 7.24 - 7.10 (m, IH), 7.03 (dd, J · 3.6.1.0, IH), 6.98 - 6.81 (m, 3H), 4.07 (s, 2H), 3.80 - 3.49 (m, 2H), 2.90 (d , J * 111.2H), 2.16 (s, 5H), 1.87 (d, J = 14.0, IH), 1.71 (dd, J = 11.5.7.2.2H), 1.54 (d,) = 6.1, IH), 1.36 (ddd, J “16.8,12.9,6.1, 5 H), 1.05 (s, 1H), 0.82 0.54 (m, IH). 215 (2- [2 ^ -dletyl-4- (4fluorophenyl) oxan-4-(trifluoromethyl) pyridin-34QmeUI}) amine 439.3 δ 8.62 (5, IH), 7.84 (d, J = 8.2, IH), 7.66 (d, J = 8.2, IH), 7.20 (m, IH), 7.04 (s, 2H), 3.90 (s, 2H) , 3.71 (d, J - 12.1, 2H), 2.77 (m, IH), 2.19 (m, 3H), 1.98 (m, IH), 1.68 (Μ, 3H), 1.40 (d, J »7.6, 2H) , 1.04 (S, IH), 0.83 (t, J = 7.5.4H), 0.54 (d, J = 7.3, 3H). 216 ((5-chloro-1benzothiophen-3yl) metll] <(2 - [(9R) -9. (Plrldin-2-IIHoxasposp (4.5] decan-9il] ethyl}) amine 442 5 8.61 (d, J - 4.9, IH), 8.44 (s, IH), 8.17 (s, IH), 7.93 (d, J »5.5, IH), 7.69 (d, J« 8.1, IH), 7.60 (s, IH), 7.50 (d, J = 5.5, IH), 7.28 (s, IH), 3.82 (s, 3H), 3.17 (dd, J «16.8,10.9, IH), 2.75 (t, 1 · 8.9, IH), 2.47 (t, J = 9.7, IH), 2.32 (d, J - 13.9, 3H), 2.10-1.98 (m, IH) , 1.87 (dd, J - 12.1,7.1, 2H), 1.78 -1.62 (m, IH), 1.48 (dd,J s 23.5,18.9, 5H), 1.18 (s, IH), 0.77 (dt, i = 13.2, 9.0, IH). 217 [(5-bromo-4methyltophen-2yl) methyl] ((2 - {(9R) -9 (pyridin-2-i 1) -6oxaeaplro [4.5] decan «9il] ethyl}) amine 449 ’ δ 10.10 - 9.21 (m, IH), 8.53 (d, J »3.9, IH), 7.90 (td, J - 7.9.1.6, IH), 7.45 (d, J - 8.1, IH), 7.38 (dd , J =7.0.5.4, IH), 6.69 (s, IH), 4.02 - 3.86 (m, 2H), 3.74 -3.55 (m, 2H), 2.85 (dd, J * 11.4,5.9, IH), 2.47 -2.33 (m, IH), 2.31 - 2.09 (m, 3H), 2 09 -1.93 (m, 4H),1.87 (d, J = 14.0, IH), 1.69 (dt, J - 14.4, 6.1, 2H), 1.57 (d, J = 5.4, IH), 1.38 (ddd, J «26,7,14,6,8.4, 4H ),1.04 (s, IH), 0.73 -0.S6 (m, IH). 218 [(4-bromo-5metittiofen-2íl) methyl] ({2 - ((9R) -9 (pirtdln-2-yl) -8oxasposp [4.5] decan-9-H] etH)) amlna 449 δ 8.72 (d, J »4.9, IH), 8.26 (d, J« 7.7, IH), 7.74 (dd, J = 16.7, 7.1, 2H), 6.92 (s, IH), 4.21 (d, IH), 3.90 3.78 (m, 2H), 3.74 (d, J - 9.6, IH), 3.02 (s, IH), 2.51 (dd, J «52-4.11, 2H), 2.39 - 2-16 (m , 6H), 2.05 (d, J = 13.8, IH), 1.87 (d, J = 9.5.2H), 1.69 (S, IH), 1.63 -1.41 (m, 4H), 1.24 (d, J - 30.9, IH), 0.81 (s, IH). 219 [(3-bromo-5methyltiophen-2yl) n »tllJ ({24 (9R) -9 (plrldin-2-yl) -6oxasposp [4. $) Decan-9ll]« HI}) amlna 449 δ 8.61 (d, J - 4.9, IH), 8.02 (d, J - 7.9, IH), 7.69 - 7.41 (m, 2H), 6.68 (d, J = 1.0, IH), 4.23 (q, J = 14.2 , 2H), 3.90 - 3.59 (m, 2H), 3.10 (s, IH), 2.75 (m, 2H), 2.36 - 2.13 (m, SH), 1.96 (d, J - 13.9, IH), 1.82 (d , J »9.9, 2H), 1.75 -1.62 (m ; IH), 1.62 -1.38 (m, 4H), 1.24 -1.05 (m, IH), 0.74 (d, J = 13.2, IH). 220 [(4-bromo-3methyltophen-2yl) metll) {(2 - {(9R) -9- 449 5 8.61 (d, J «5.2, IH), 8.09 (t, J * 7.7, IH), 7.71 -7.49 (m, 2H), 7.30 (s, IH), 4.21 (d, J «4.3.2H), 4.00 -3.59 (rm, 2H), 3.05 (s, IH), 2.64 (s, IH), 2.31 (d, J =
    137
    (pyridin-Z-ylHb oxaspiro [4.5} decan-9il] ethyl}) amine14.5.2H), 2.25 (d, J «13.7, 2H), 2.18 (s, 3H), 1.96 (d, J» 13.9.1H), 1.82 (dd, J - 12.0, 7.2, 2H), 1.68 (s , 1H), 1.61 -1.40 (m, 4H), 1.17 (s, 1H), 0.92 -0.64 (m, 1H). 221 {2- {4- (4-fluoropher »ll).1-oxaesplro [5.5] undecarv 4-ÍI] 0tilX {[6 (trffluoromeetypiridln-3-H] rmrtil}) amine 451.2 6 8.52 (s, 1H), 7.73 (d, J = 9.6.1H), 7.57 (d, J - 8.0, 1H), 7.11 (dd, J »9.0.5.2, 2H), 6.94 (t, J «8.4, 2H), 3-83 (5, 2H), 3.63 (d, J - 18.0, 2H), 2.69 (m, 1H), 2.12 (t. J« 13.9.3H), 1.70 (m, 5H), 131 (d, J = 183.4H), 1.03 (s, 4H), 0.57 (m, 1H). 222 ((4-bromothiophen-3yl) metiQ ({2 - ((9R) -9 (44luorophenylH $> oxasposp | 4.5] decan-9yl] ethyl}) amtna 451.9 δ 9.26 (d, J = 136.7.2H), 739 (dd, J = 22.6.193, 2Hh 7.10 (dd, i «8.8.5.2.2H), 6.92 (dd, J -10.6.6.6,2H), 3.82 (s, 2H), 3.71-3 53 (m, 2H), 2.64 (s, 1H),2.20 (s, IHh 2.05 (d, J * 14.1.1H), 1.97 (d, J »13.9,1H), 1.89 (td, J · 12.6.4.6.1H), 1.83 -1.64 (m, 3H), 1.57 (ddd, J = 14.0, 9.6.4.7, 2H), 1.49 -1.25 (m, 4H),1.17 (d, J »13.2.1H), 0.69 (dt, J ~ 13.8.8.8.1H). 223 ((4-bromothiophen-2ll) metll] ({2 - ((9R) -9 (4fluorophenll) -6oxasposp [4.5} decan> 9ii] ethyl}) amine 452.1 δ 938 (d, J = 89.0, 2H), 7.16 - 7.03 (m, 3H), 6.96 (t, J ® 8.6.2H), 6.84 (d, J - 13.1H), 3 86 (s, 2H) , 3.70 3.55 (m, 2H), 2.62 (dd, J = 121, 7.7.1H), 2.18 (dd, J «11.9, 7.8.1H), 2.02 (dd, J - 32.5,14.0, 2H), 1.91 -1.63 (m, 4H), 1.64 - 1.50 (m, 2H), 1.49 - 1.25 (m, 4H), 1.16 (dd, J «14.0,6.1.1H), 0.69 (dt, J» 13.5, 8.8.1H) . 224 [(5-bromothiophen-2yl) methyl] ({2 - [{9R) -9 (4fluorophenif) -6oxaspospiro [4.5] denca-9ll] etll}) amlna 452.1 δ 931 (d, J »92.6, 2H), 7.15 - 7.04 (m, 2H), 6.95 (t, J» 8.6.2H), 6.82 (d, J - 3.8.1H), 6.67 (d, J «3.8 , 1H),3.82 (s, 2H), 3.70 - 3.53 (m, 2H), 3.44 (s, 1H), 2.62 (dd, J = 12.0.7.6.1H), 2.18 (dd, J «11.8, 7.9.1H), 2.02 (dd, j = 31.6,14.0, 2H), 1.93 -1.64 (m, 4H),1.57 (ddd, J · 12.1,8.5,3-8, 2H), 1.52 -1.25 (m, 4H),1.16 (dd, J = 14.9, 5.1.1H), 0.69 (dt, J = 13.6.8.8, 1H). 225 diberizil ({2 - [(9R) -9- {4fluorophenyl) -6oxaspospiro [4.5] decan-9- 4583 δ 7.27 (m, 17H), 7.00 (dd, J »8.9.5 2.2H), 6.86 (t, J = 8.6, 2H), 4.24 (s, 2H), 3.90 (m, 2H), 3.55 (d , J «3.4, 2H), 2.59 (m, 1H), 2.22 (m, 12H), 1.86 (dd, J« 75.2, 14.8, 7H), 1.59 (dd, J «44.S, 9.1.2H), 138 (m, 6H), 1.18 (s, 1H), 1.11 (s, 1H), 0.68 (m, 1H). 226 dibenztl ({2- [2,2diethyl-4- (4fluorophenyl) oxan-4yl] etll}) amlna 4603 δ 7.27 (d, J = 34.4, 7H), 7.18 (s, 4H), 6.98 (dd, J = 8.9, 5.2, 2H), 6.84 (t, J = 8.6, 2H), 4.25 (s, 2H), 3.85 (d, J · 46.4.2H), 3.53 (m, 2H), 2.57 (d, J = 4.7, 2H), 2.12 (d, J = 4.0, 2H), 1.97 (m, 3H), 1.73 (d , J = 4.8.1H), 1.44 (s, 1H}, 138 (dd, J = 13.8, 7.5, 3H), 1.23 (m, 1H),0.90 (m, 1H), 0.70 (dt, J = 10.8, 7.4, 4H), 0.40 (t, J »........................ ................................... 7> 4.3H) ......... ...... 227 [(4-bromo-3metiftlofen-2- 465.9 δ 7.19 (dd, J = 8.9.5.1.2H), 7.04 (t, J 8.6, 2H), 3.94 (d, J = 163, 2H), 3.72 (m, 2H), 2.72 (dd, J = 13.8, 6.5,
    138
    ll) methylJ ({2 - [(9R) -9 · (4-flucHrofen (l) -6oxaesplro [4.5] decan-9il] ethyl}) amineIH), 2.31 (m, IH), 2.15 (d, J = 12.1, 2H), 2-07 ($, 3H), 1.90 (m, 5H), 1.65 (m, 2H), 1.47 (m, 4H) , 1.25 (s, 1H), 0.78 (m, IH). 228 [(4-bromo-5methyltophen-2yl) metill ({2 - [(9R) -9 (4-fluorophenyl) -6oxaaspiro [4.5] decan-9iQetylDamine 465.9 6 9-06 (d, J = 100.4.2H), 7.15 - 7.04 (m, 2H), 6.95 (s, 2H), 6.68 (s, IH), 3.80 (s, 2H), 3.73 - 3.57 (m, 2H), 2.64 (s, IH), 2.21 (s, 4H), 2.07 (d, J = 14.1, IH), 1.99 (d, J * 13.9, IH), 1.94 - 1.64 (m, 4H), 164 - 1.51 (m, 2H), 1.51 -1.26 (m, 4H), 1.17 (dd, J - 13.9.6.3, IH), 0.70 (dt, J - 13.7.8.8, IH). 229 [(3-bromo-5methyltiophen-2ylknetil] ((2 - [(9R) -9 (4-fluorophenyl) -6oxa »plro [4.5] deam-9il] ethyl)) amine 466 δ 7.20 (m, 2H), 7.01 (dd, J - 11.1, 6.1, 2H), 6.61 (d, i - 1.1, IH), 4.01 (s, 2H), 3.72 (m, 2H), 2.75 (m, IH),2.61 (brs, IH), 2.41 (d, J »0.9.3H), 2.32 (m, IH),2.15 (d, J - 14.2, IH), 2.07 (d, J «13.9, IH), 1.99 (m, IH), 1.89 (m, 2H), 1.77 (m, IHf, 1.67 (ddd, / - 17.0, 10.6,5.6, 2H), 1.46 (m, 4H), 1.25 (m, IH), 0.78 (dt, J -13.9.8.9, IH). 230 [(5-bromo-4methyltophen-2yl) metifl ({2 - [(9R) -9 (4-fluorophenyl) -6oxasposp [4.5] decan-9il] etll}) amlna 466 9 δ 7.20 (d, J «5.2, 2H), 7.06 (d, J = 8.5, 2H), 6.85 (t, J - 3.6, IH), 3.91 (s, 2H), 3.81 - 3.62 (m, 2H), 2.71 (s, IH), 2.28 (s, IH), 2.07 (s, 6H), 1.91 (d, J = 13.8, 2H),1.79 (d, J = 10.3, IH), 1.69 (ddd, J = 14.1.9.4, 4.7, 2H), 1.59 -1.37 (m, 4H), 1.28 ($, IH), 0.80 (dd, J « 8.8,4.9, IH). 231 (2- [2Ç2-diethyl-4- (4fluorophenyl) oxan-4yljetyl} bts (tlofen2-ylmethyl) amine 472.2 δ 7.31 (d, J = 4.9.2H), 7.07 (dd, J = 8.9, 5.2, 2H), 6.99 ($, 2H), 6.9S (d, J «4.5, 2H), 6.89 (t, J = 8.6, 2H), 4.24 (s, 2H), 3.58 (dt, J = 23.8, 6.6, 2H), 2.66 (m, IH), 2.06 (d, J «14.0.4H), 1.82 (m, 2H), 1.51 (d, J - 14.3, 3H), 1.25 (m, 2H), 0.94 (dd, J = 14.6,7.4, IH), 0.74 (t, J = 7.5, 4H), 0.42 (t, J = 7.4, 3H). 232 [(4,5dibromothiophen-2yl) methyl] ({2 - {(9R) -9 (pyridin-24l) -6oxasposp [4.S] d «can-9il] etll}) amlna 514.8 δ 8.61 (dd, J - 5,3,1.3, IH), 8.13 (td, J «8.0,1.7, IH), 7.64 (d, J - 8.2, IH), 7-60 (m, IH), 6 94 (s, IH), 4.40 (brs, IH), 4.11 (s, 2H), 3.77 (ddd, J «36.9,13.7,7.2.2H), 2.98 (td, J - 11.3,6.0, IH), 2.54 (td, J «11.2,4.3, IH), 2.38 (m, IH), 2.22 (m, 3H), 1.98 (d, J »14.0, IH), 1.83 (dt, J = 18.5,9.2, 2H), 1.68 (m, IH),1.48 (m, 4H), 1.21 (d, J - 37.1, IH), 0.75 (dt, J = 13.1, 9.0, IH). 233 [(3,4-dibromotfofen-2il) metiQ ({2 - ((9R) -9 (plridin-2-ll) -6oxasplro [4.5] decan-9i (| etll}) amine 514.8 δ 8.39 (d, J - 4.0, IH), 7.67 (t, J - 7.0, IH), 7.38 (s, IH), 7.28 (d, J = 8.1, IH), 7.18 (s, IH), 4.22 ( d, / ·18.2, 2H), 3.65 (dd, i * 11.2, 7.1, 2H), 3 09 - 2.85 (m, IH), 2.60 (s, IH), 2.22 (dd, J = 25.9,13.8, 2H), 2.10 1.83 (m, 2H), 1.87 -1.50 (m, 4H), 1.36 (dd, J = 18.7,10.7.3H), 1.02 (s, 2H), 0.68 - 0.50 (m, IH). 234 [(4,5dibromothiophen-2H) methyl] ({2 - {(9R) -9 (4- 531.8 δ 7.20 (m, 2H), 7.05 (t, J «8.6.2H), 6.81 (s, IH),3.91 (s, 2H), 3.74 (m, 2H), 3.60 (brs, IH), 2.74 (m, IH), 2.31 (td, J = 12.1, 4.7, IH), 2.15 (d, J = 14.1, IH ),2.08 (d, J = 13.9, IH), 1.88 (m, 4H), 1.67 (ddd, J -
    139
    fluorophenll) * 6 *oxaespiro {4.5] cfecan-9-IQetll)) amine15.1,10.2,5.0,2H), 146 (ddd, J «27.4,14.5,7.2, 4H), 1.24 (dd, J = 10.5, 5.6.1H), 0.78 (dt, J 13 5, 8.8.1H). 235 [(3,4dibromothiophen-2yl) methyl) ({2 - {(9R) -9 (4 * fluorophenyl) -6oxaspospiro [4.5] decan-9 $ rj «tll}) amine 531.8 $ 7.35 (s, IH), 7.11 - 7.06 (m, 2H), 6.94 (dd, J »14.3, 5.7.2H), 4.05 (s, 2H), 3.75 - 3.56 (m, 2H), 2.70 (dd, J - 11.9,7.4, IH), 2.25 (dd, J = 11.7, 7.3.1H), 2.08 (d, J »14.7, IH), 1.99 (d, J -13.9.1H), 1.95 1.65 (m, 4H), 1.65 -1.50 (m, 2H), 1.50-1.29 (m, 4H), 1.16 (dd, J -14.8, 7.3, IH), 0-70 (dt, J = 13.6, 8-8 , IH). 236 [(2-fluorofenll} metll] ({2 - [(9R) -9- (pirldin2-11) -6oxaspospiro (4.5] decan94QeW}) amine 369 6 8.82 (s, 2H), 8.61 (dd, J * 4.8,1.2,1H), 7.85 (td, J = 7.8,1.8,1H), 7.51 (m, 3H), 7.30 (m, 3H), 5.22 ( S, 2H), 4.12 (d, J = 5.3, 2H), 3.66 (m, 2H), 2.90 (d, J · 4.5.1H), 2.39 (m, 3H), 2.08 (td, J «12.8, 4.4 , 1H), 1.54 (m, 7H), 1.02 (dd, J = 12.3, 5.8, IH), 0.68 (dt, J = 13.3, 8.9.1H). 237 [(2-bromophenyljnietyl] ({2 - [(9R) -9- (plridin2-11) -6oxae »piro [4.5] decan9-il] etll}) amlna 429 δ 8.93 (S, 2H), 8.60 (dd, J · 4.8.1.2.1H), 7.83 (td, J = 7.8.1.9.1H), 7.71 (dd, J = 8.0.1.1.1H),7.50 (m, 3H), 7.33 (m, 2H), 4.18 (s, 2H), 3.6S (m, 2H), 2.94 (s, 1H), 2.43 (t, J = 12.2, 3H), 2.11 (td , J - 12 8.4.4.1H), 1.89 (m, 2H), 1.55 (m, 7H), 1.01 (m, 1H), 0.67 (dt, J = 13.3, 8.9.1H). 238 [(2-chlorof »nll) matlQ ((2 <(9R) -9- (plridin241) -6oxaspospiro [4.5] decan94getil}) amine 385 δ 8.75 (dd, J »5.4,1.2,1H), 8.52 ($, 3H), 8.22 (td, J« 8.0,1.7, IH), 7.77 (d, J - 8.2.1H), 7.67 (ddd, J «7.5,5.4,0.9,1H), 7.42 (m, 4H), 4.20 (d,1 «14.0, 2H), 3.72 (m, 2H), 3.05 (td, J« 12.0, 5.1, IH), 2.53 (td, J · 12.0, 4.4.1H), 2.36 (m, 3H), 2.17 (m , 1H), 2.01 (d, J «14.2.1H), 1.79 (ddd,)« 9.3, 6.7, 3.4, 2H), 1.52 (m, 5H), 1.17 (m, 1H), 0.78 (dt, J = 12.9, 8.8, IH). 239 1 (2- |methylfenlljmetil] ({2 - [(9R) -9- (piit1din241) -6oxaesplro [4.5] decan-! 94T | atyl}) amine 365.1 δ 8.81 (dd, J «5.7,1.3, IH), 8.43 (td, J = 8.0,1.7, 1H), 7.98 (s, 1H), 7.92 (d, J» 8.2, 1H), 7.86 (ddd, J = 7.6.5.7.1.0.1H), 7.27 (m, 2H), 7.18 (m, 2H), 3.98 ($, 2H), 3.75 (m, 2H), 2.98 (d, J = 4.4, IH), 2.44 (m, 2H), 2.36 (m, 5H), 2.25 (dd, J = 13.5, 5.4, IH), 2.07 (d, J = 14.3, IH), 1.84 (m, 2H), 1.55 (m, 5H) , 1.23 (m, IH), 0.83 (dt, J = 13.0, 8.8, IH). 240 (2 - ((9R) -9- (pyridin-2-11) -6oxaaspiro [4.5] d «can9-(trifluoromethyl) phenitjm ethyl}) amlna 419.1 δ 8.71 (dd, J - 5.3.1.2, IH), 8.18 (td, J = 8.0,1.7, IH), 7.79 (d, J «7.8, IH), 7.75 (d, J = 8.2, IH) , 7.70 (m, 2H), 7.62 (ddd, J = 13.7, 6.8,1.2,2H),6.71 (s, 3H), 4.23 (s, 2H), 3.75 (ddd, J - 17.6, 8.8, 3.7, 2H), 3.08 (m, IH), 2.56 (m, IH), 2.36 (m, 3H ), 2.19 (m, IH), 1.79 (dq, J · 7.2, 4.7, 2H),
    140
    1.53 (m, 5H), 1.19 (m, 1H), 0.79 (m, 1H). 241 2 - [({2 - [(9R) -9 (plridin-2-ll) -6oxasposp [4.5] decan9-yl] ethyl) amino) methyl phenol 367 6 8.74 (m, 1H), 8.21 (td, J «8.0.1.8.1H), 7.75 (d, J = 8.2.1H), 7.66 (ddd, J = 7.6.5.4.1.0.1H), 7.27 (m , 1H), 7.20 (dd, J - 7.6,1.6,1H), 6.90 (m, 4H), 4.05 (S, 2H), 3.72 (ddd, J - 12.4,11.1, 5.4, 2H), 2.96 (d, J = 5.2.1H), 2.35 (m, 4H), 2.13 (m, 1H), 1.78 (m, 2H), 1.51 (m, 5H), 1.15 (dd, J = 4.0, 2.0.1H), 0.78 ( m, 1H). 242 [(2methoxyphenyl) methylj ({2 - ((9R) -9 (pyridin-2-oxae3piro [4.5] decan9-ll] ethyl)) amine 381.1 Ô 9.66 (S, 3H), 8.80 (dd, J = 5.5,1.2,1H), 8.31 (td, J = 8.0,1.7, 1H), 7.77 (m, 3H), 7.42 (ddd, J =15.9, 8.0,1.6,1H), 7.25 (dd, J = 7.5,1.6,1H), 7.04 (m, 1H), 6.96 (td, J = 7.5,1.0.1H), 4.04 (s, 2H), 3.85 (m, 4H), 3.73 (m, 2H), 2.97 (d, J = 4.9,1H), 2.37 (m, 4H), 2.19 (dd, i = 13.2.5.2.1H), 2.04 (d, J - 14.1.1H), 1.81 (ddd, J - 14.0, 9.5, 4.5, 2H), 1.81 (ddd, J = 14.0.9.5, 4.5.2H), 1.54 (m, 5H), 1.18 (m, 1H), 0.80 (m, 1H). 243 ((3-fluorofanll) m «tiq ({2 - [(9R) -9- (plridin241) -6oxaesplro [4.5] decan9-iQetil}) amlna 369 Ô 8.77 (dd, J = 5.4,1.5,1H), 8.38 (s, 1H), 8.29 (td, J «8.0,1.7,1H), 7.82 (d, J - 8.2.1H), 7.74 (dd, J = 7.1.6.1.1H), 7.43 (ddd, J = 13.8, 7.5,1.4.1H), 7.19 (m, 3H), 6.90 (s, 3H), 4.03 (d, J «2.0.2H), 3.74 (m, 2H), 2.98 (dt, J = 11.4,5.6,1H), 2.42 (ddd, J = 29.2.13.0, 3.8.4H), 2.18 (m,1H), 2.03 (d, J = 14.1.1H), 1.81 (ddd, J = 13.9, 9.4.4.5.2H), 1.55 (m, 5H), 1.20 (ddd, J = 9.9,6.9, 2.4.1H), 0.80 (dt, J = 12.9.8.8.1H). 244 1 (3-bromophenyljmetyl] ({2 - [(9RM4plridin. 2-11) -6oxaesp (ro [4.5] decan9-iqetiq) amine 431 δ 8.75 (dd, J »5.4.1.2.1H), 8.41 (s, 1H), 8.25 (td, J = 8.0.1.8.1H), 7.79 (d, J = 8.2.1H), 7.70 (ddd, J = 7.6.5.5, 0.9.1H), 7.59 (m, 2H), 7.36 (ddd, J ~ 22.8,10.9,4.6, 2H), 6.76 (s, 3H), 4.01(d, J = 2.3, 2H), 3.74 (ddd, J = 12.3, 11.0, 5.4,2H), 2.97 (d, J = 5.0.1H), 2.38 (m, 4H), 2.16 (m,1H), 2.00 (m, 1H), 1.79 (ddd, J - 8.6, 7.8.4.7, 2H), 1.53 (m, 5H), 1.20 [m, 1H), 0.80 (m, 1H). 245 ((3-chlorophenyl-methyl) ({24 (9R) -9- (pyridin2-11) -6oxasposp [4.S] decan9-iq «tn}) amine 385 δ 8.72 (dd, J - 5.4,1.1,1H), 8.57 (S, 1H), 8.19(td, J = 8.0, 1.8.1H), 7.74 (d, J = 8.2.1H), 7.64 (ddd, J = 7.6, 5.4.0.9, 1H), 7.37 (m, 5H), 3.99 (d, J = 2.3, 2H), 3.70 (m, 2H), 2.95 (m, 1H), 2.36 (m,4H), 2.12 (td, J «12.9, 5.1.1H), 1.76 (ddd, J -14.2.9.3, 5.1, 2H), 1.50 (m, SH), 0.77 (dt, J = 13.0, 8.9.1H). 246 [(3-methylphenyl) metiq 365 6 8.81 (dd, J = 5.7,1.3,1H), 8.43 (td, J = 8.0,1.7,1H), 7.98 (S, 1H), 7.92 (d, J - 8.2.1H), 7.86 (ddd,
    141
    ({2 - ((9RHHpirldln2-11) -6oxa © 3piro (4.5] decan94Qetil}) amlnaJ = 7.6, 5.7.1.0, IH), 7.24 (dq, J = 19.8,7,4,4H), 3.98 (s, 2H), 3.7S (m, 2H), 2.98 (d, J = 4.4, IH ), 2.44 (m, 2H), 2.36 (m, SH), 2.25 (dd, J «13-5, 5.4, IH), 2.07 (d, J - 14.3, IH), 1.84 (m, 2H), 1.55 (m, 5H), 1.23 (m, IH), 0.83 (dt, J = 13.0, 8.8, IH). 247 methyl benzoate 3 - [({2 [(9R) -9 (pyridin-2-yl) -6oxMsplro [4.5] «tecan-9il] etll} amlr» o) methyl] 409.1 6 8.78 (dd, J = 5.5,1.3, IH), 8.33 (td, J «8.0,1.7, IH), 8.24 ($, IH), 8.04 (m, 2H), 7.85 (d, J = 8.2, IH ), 7.78 (m, IH), 7.63 (m, 2H), 7.55 (d, J = 7.7, IH), 4.10 (d, J «2.0, 2H), 3.90 (s, 3H), 3.75 (ddd, J = 12.2,11.0,5.4, 2H), 3.00 (dd, J = 11.5, 7.1,IH), 2.40 (m, 4H), 2.21 (m, IH), 2.04 (d, J = 14.2,IH), 1.83 (ddd, J «13.9.9.2, 4.3.2H), 1.51 (dddd, J = 17.6,10.1, 8.1,3.0,5H), 1.21 (s, IH), 0.82 (dd, J« 15.6, 6.6, IH). 248 3 - {({2 - [(9R) -9 (plrldlr »-24l) -6oxasposp (4.5] decan9 · iljetiljaminojmetil] phenol 367 δ 8.77 (dd, J = 5.5,1.2, IH), 8.30 (td, J - 8.0,1.7, IH), 7.81 (S, IH), 7.75 (ddd, J = 7.6, S.5.1.0, IH) ,7.23 (t, J = 8.1, IH), 6.85 (dt, J «3.2, 2.1, 3H), 6.65 (S, 3H), 3.96 (s, 2H), 3.73 (dd, J = 13.8, 7.3,2H), 2.96 (S, IH), 2.36 (m, 4H), 2.15 (ddd, J = 9.9, 8.5, 4.7, IH), 2.03 (d, J »14.2, IH), 1.80 (dt,) = 11.2 , 4.8, 2H), 1.52 (ddd, / = 21.7,12.8, 7.4, 5H), 1.20 (m, IH), 0.80 (d, J - 13.3, IH). 249 {2-i (9R) -9- (pyridin-2-IIHoxaespiro [4.5] decan-9il] ethyl) ({(3 (trtfluoromethyl) methyl phen}}) 419.1 δ 8.66 (m, IH), 8.07 (td, J »7.9,1.8, IH), 7.72 (m, 2H), 7.65 (m, 2H), 7.54 (m, 2H), 6.22 (s, 2H),4.08 (d, J = 3.1, 2H), 3.71 (m, 2H), 2.97 (d, J =5.0, IH), 2.34 (dddd, J »25.4,19.6,16.7,4.4,4H), 2.09 (m, IH), 1.74 (m, 2H), 1.49 (m, 5H),0.76 (m, IH). 250 N-methyl-5 - (({2 [(9R) -9- {pyridin-2 * yl) 5oxaspiro (4.5) decan9yl] ethyl) amino) methyl] thiophene2-carboxamlda 414.1 6 8.78 (dd, J = 5.6,1.3, IH), 8.36 (td, J = 8.0,1.7, IH), 7.86 (d, J = 8.2, IH), 7.79 (ddd, J = 7.6, 5.6,1.0, IH), 7.38 (d, J - 3.8, IH), 7.14 (d, J = 3.8,IH), 7.06 (d, J = 3.9, IH), 4.21 (s, 2H), 3.72 (m, 2H), 2.97 (td, J = 12.0, 5.1, IH), 2.84 (d, J = 4.7,3H), 2.34 (m, 4H), 2.16 (m, IH), 2.03 (d, J ’14.2,IH), 1.80 (dd, J = 12.2, 3.0, 2H), 1.50 (m, 5H),1.20 (m, IH), 0.82 (s, IH). 251 N-etll * 5 - (({2 - ((9R} »9- (pyridin-2-yl) -6oxaspesp [4.5] decan9ll] ethyl} amlno) methyl] 428.1 δ 8.78 (dd, J = S.6,1.2, IH), 8.35 (td, J = 8.0,1.7, IH), 7.86 (d, J »8.2, IH), 7.79 (ddd, J * 7.6,5.6, 0.9, IH), 7.40 (d, 1 «3.8, IH), 7.14 (t, J = 10.7, 2H), 6.20 (S, 4H), 4.21 (d, J« 1.2.2H), 3.72 (m, 2H ), 3.34 (m, 2H), 2.97 (m, IH), 2.39 (m, 4H),
    142
    tlofen-2carboxamide2.18 (m, 1H), 2.03 (d, J = 14.2.1H), 1.81 (m, 2H),1.52 (m, 5H), 1.19 (m, 4H), 0.80 (m, 1H). 252 N-methyl-3 - «{2 [(9R> -9- <plridin-2-ll) 6oxasplro [4.5] decan9ll] etll} amino) methyl] benzamlda 408.1 δ 8.75 (dd, J «5.4,1.2,1H), 8.24 (td, J = 8.0,1.7,1H), 7.89 (s, 1H), 7.77 (m, 2H), 7.69 (ddd, J · 7.6, 5.5.0.9,1H), 7.49 (ddd, J - 18.3,10.6, 4.6, 2H), 7.33 (s , 1H), 4.07 (s, 2H), 3.73 (m, 2H), 2.98 (m, 1H), 2.88 (d, J »4.6.3H), 2.47 (t, J« 10.7,1H), 2.36 (dd, J = 12.8, 7.5.3H), 2.16 (d, J «4.8,1H), 1.79 (m, 2H), 1.50 (ddd, J «18.7,13.3, 6.9, 5H), 1.19 (ddd, J« 8.3,7.0,1.8,1H), 0.80 (d, J M-ΜΗ). 253 H-etll-3- [í {2 <(9R>9- (pírtóÍn-2-ÍI) -6 · oxasespiro [4.5] decan9ll] ethyl} amlno) methyl] benzamide 422.1 6 8.70 (dd, J = 5.3.1.2,1H), 8.43 (s, 1H), 8.14 (td, J = 7.9.1.8.1H), 7.89 (d, J = 1.4.1H), 7.76 (dt, J - 7.3.1.6.1H), 7.71 (d, J = 8.2.1H), 7.59 (ddd, J = 7.6, 5.3.0.9.1H), 7.46 (m, 2H), 7.37 (s, 1H), 6.55 ( $, 3H), 4.05 ($, 2H), 3.70 (m, 2H), 3.36 (qd, J - 7.2.5.7, 2H), 2.96 (d, J = 7.9.1H), 2.45 (t, J = 10.2 , 1H), 2.32 (dd, J = 21.2, 8.7.3H), 2.11 (d, J = 5.2.1H), 1.77 (m, 2H), 1.47 (m, 5H), 1.19 (m, 4H), 0.76 (d, J »13.3.1H). 254 [(4methoxyphenyl) methyl] ([2- «9R) -9 (pyridin-211) -6oxaspospiro [4.5] decan9-yl] ethylJ) amine 381.1 Ô 9.09 (d, J = 86.1, 2H), 8.69 (d, J = 5.0.1H), 8.29 (t, J = 7.7.1H), 8.06 (s, 3H), 7.75 (m, 2H), 7.20 ( d, J = 8.6.2H), 6.81 (d, J »8.6, 2H), 3.89 ($, 2H), 3.79 (m, 4H), 3.66 (m, 1H), 2.96 (s, 1H), 2.43 { dd, J = 23.4,11.5, 2H), 2.27 (t, J = 16.0, 3H), 2.01 (d, J = 14.2.1H), 1.83 (dd, J = 19.3,9.5, 2H), 1.66 (m, 1H), 1.47 (m, 4H), 1.14 (d, J = 7.0, 1H), 0.75 (m, 1H). 255 4 - [({2 - {(9R) -9 (plridin-24l) -6oxasposp [4.5] decan9yl] ethyl) amino) methyl] phenol 367 6 8.76 (dd, J = 5.5.1.2,1H), 8.26 (m, 1H), 7.80 (d, J - 8.2.1H), 7.72 (ddd, J «7.6, 5.5.0.9.1H), 7.65 (S , 1H), 7.22 (m, 2H), 6.82 (m, 2H), 3.93 (s, 2H), 3.73 (dd, J - 10.7, 7.6.2H), 2.94 (dd, J =11.1,5.9,1H), 2.36 (m, 4H), 2.13 (m, 1H), 2.01 (m, 1H), 1.80 (d, J = 3.6, 2H), 1.51 (dd, J · 9.7, 5.6.5H ), 1.19 (m, 1H), 0.81 (s, 1H). 256 «2.3-dlfluorofenlljmetll] ({2 <9R) -9 (pyridin-211) -6oxa © 8piro [4.5] decan94l] etll}) amine 387 6 8.75 (dd, J = 5.4, 1.3.1H), 8.26 (td, J - 8.0.1.7, 1H), 7.80 (d, J = 8.2.1H), 7.71 (ddd, J = 7.5, 5.5, 0.9, 1H), 7.34 (dtd, J = 10.0, 7.9.1.9.1H), 7.21 (m, 4H), 4.11 (s, 2H), 3.72 (m, 2H), 3.02 (td, J = 12.0, 5.1.1H ); 2.49 (td, J = 12.1, 4.3, 1H), 2.35(m, 3H), 2.16 (m, 1H), 2.01 (d, J «14.1.1H), 1.79 (ddd, J - 11.2,9.4,4.1, 2H), 1.52 (m, 5H), 1.17(m, 1H), 0.78 (dt, J - 12.9, 8.8, 1H).
    143
    257 1 (2,4dMorophanyl) methyl] ({2 - {(9R) -9 (pyridin-2-11) -6oxasospiro [4.5] decan9-8> tiD) amlna 387 δ 8.79 (dd, J = 5.5.1.3.1H), 8.38 (s, 1H), 8.32 (m, 1H), 7.84 (d, J = 8.2.1H), 7.76 (ddd, J - 7.6,5.5, 0.9.1H), 7.50 (dd, J = 14.8.8.3.1H), 7.03 (m, 2H), 4.08 ($, 2H), 3.74 (m, 2H), 3.02 (td, J = 12.0.5.0) , 1H), 2.42 (m, 4H), 2.18 (m, 1H), 2.03(d, J = 14.2, 1H), 1.82 (ddd, J «14.2,9.6,4.5, 2H), 1.56 (m, 5H), 1.19 (ddd, J = 7.0.6.2, 2.8,1H), 0.80 (dt, J = 12.9, 8.8.1H). 258 [(2,5 · diflu <mphenyl) m »tyl] ({2-K9RF9 (pyridin-2yl) -6oxae $ piro [4.5] decan« 94l] ethyl}) amine 387 6 8.74 (dd, J = 5.4,1.2,1H), 8.26 (td, J «8.0,1.7,1H), 7.72 (m, 2H), 7.21 (dddd, J = 8.4, 7.0, 4.8,1.8, 3H), 6.45 (S, 3H), 4.07 (s, 2H), 3.73 (ddd, J = 12.2,11.1,5.5, 2H), 3.02 (d, J - 5.2.1H), 2.49 (d, J = 4.3.1H), 2.36 (dt, i = 11.8.4.5.3H), 2.18 (dd,J = 12.3.5.2.1H), 2.00 (m, 1H), 1.79 (ddd, 1 = 13.9.9.3, 4.4, 2H), ^ .49 (m, 5H), 1.18 (m, 1H), 0.78 (d , i ~ 13.3.1H). 259 [(2,6difluoropheniQmethyl] ({2 - ((9R) -9 (pirldln-2-ÍI) -6oxaspospiro [4.5] decan9-itJ «til}) amine 387.1 δ 8.79 (dd, J = 5.6.1.3.1H), 8.36 (m, 1H), 8.20 (s, 4H), 7.86 (d, J = 8.2.1H), 7.79 (ddd, J = 7.6, 5.6, 1.0 , 1H), 7.50 (tt, J = 8.5.6.6.1H), 7.04 (m, 2H), 4.13 (s, 2H), 3.72 (m, 2H), 3.05 (td, J = 12.0, 5.1.1H) , 2.52 (td, J = 12.1.4.2.1H), 2.37 (m, 3H), 2.19 (m, 1H), 2.04 (d, J «14.2.1H), 1.81 (m, 2H), 1.53 (m, 5H), 1.18 (m, 1H), 0.79 (dt, J = 12.8, 8.8.1H). 260 [(3,4dlfiuorofenll} metiq ({2 - [(9R) -9 (plrfdÍn-2il) -6oxaaspiro [4.5] decan9-il] etlÕ) amlna 387.1 δ 8.84 (s, 1H), 8.79 (dd, J »5.6.1.3.1H), 8.41 (td, J = 8.0.1.6.1H), 8.25 (S, 1H), 7.86 (ddd, J = 13.3, 7.6 , 7.0, 2H), 7.30 (m, 3H), 3.99 (d, J - 1.7,2H), 3.73 (m, 2H), 2.96 (dd, J = 12.1, 7.4.1H), 2.38 (m, 4H), 2.21 (m, 1H), 2.05 (d, J - 14.2.1H),1.82 (ddd, J »12.6.9.0, 4.2.2H), 1.53 (m, 5H), 1.21 (m, 1H), 0.81 (dt, J» 12.9.8.8.1H). 261 [(3,5difluorophenyl) imethyl] ({2 - [(9RH (pyridin-2yl> 6oxasposp [4.5] decan9-ÍI] ethyl}) amine 387 δ 8.77 (d, J = 5.4.1H), 8.43 (s, 1H), 8.35 (d, J = 7.7.1H), 7.83 (m, 2H), 7.03 (m, 3H), 4.01 (s, 2H) , 3.74 (ddd, J = 27.7,13.8, 7.4, 2H), 2.96 (m, 1H),2.39 (m, 4H), 2.23 (dd, J - 13.3, 5.1.1H), 2.02 (m, 1H), 1.81 (m, 2H), 1.52 (m, 5H), 1.21 (dd, J = 9.4.5.3 , 1H), 0.80 (dt, J = 12.9, 8.9.1H). 262 [(2,3dlmethoxyphenyljmetll] «2 - [(9R) -9 (pyridin-2yl) -6-oxaspesp [4.5] decan-9-yl] ethyl)) amine 411.1 6 8.75 (dd, J = 5.4,1.2,1H), 8.21 (td, J - 8.0,1.8, 1H), 7.88 ($, 2H), 7.75 (d, J - 8.2.1H), 7.66 (ddd, J = 7.6, 5.4, 0.9.1H), 7.08 (dd, J «9.0, 5.6, 2H), 6.87 (dd, J - 6.2, 3.0.1H), 4.05 (s, 2H), 3.86 (d, J= 6.3, 6H), 3.73 (ddd, J “12.5,11.1, 5.4, 2H),
    144
    2.97 (s, 1H), 2.45 (s, 1H), 2.35 (m, 3H), 2.14 (m,1H), 1.78 (ddd, J = 14.2.6.0, 3.9.2H), 1.49 (m,5H), 1.16 (m, 1H), 0.77 (d, 1 - 13.3.1H). 263 [(3,4dlmetoxtfenll) metit] ({2 - {(9R) -9 (pyridin-211) -6oxaspospiro [4.5] decan94QedQ) aiTilna 411.1 6 8.73 (dd, J = 5.5,1.2,1H), 8.24 (td, J = 8.0,1.7, 1H), 8.00 (s, 1H), 7.78 (d, J - 8.2.1H), 7.69 (ddd, 1 «7.5, 5.5, 0.8.1H), 6.96 (d, 1 = 1.0.1H), 6.88 (d, 1 - 1.7, 2H), 6.55 (s, 3H), 3.93 (s, 2H), 3.78 (t, J = 7.5, 6H), 3.72 (m, 2H), 2.92 ($, 1H), 2.35 (m, 4H), 2.15 (m, 1H), 1.99 (d, J «14.2.1H), 1.79 (m, 2H), 1.49 (m, 5H), 1.18 (s, 1H), 0.79 (dd, 1 = 15.6.6.6.1H). 264 2-methoxy-4 - [({2 [(9R) -0- (pyri <iin-24l) 6oxasposp [4.5] decan9-H] ethyl} amino) methqphenol 397.1 6 8.62 (dd, 1 »5.0.1.0.1H), 7.94 (td, J = 7.9, 1.8, 1H), 7.57 (d, J - 8.1.1H), 7.42 (m, 1H), 7.00 (s, 1H ), 6.81 (d, 1 = 0-8, 2H), 3.93 (s, 2H), 3.84 (s, 3H), 3.70 (m, 3H), 2.93 (s, 1H), 2.36 (s, 3H), 2.17 (m, 1H), 1.90 (d, J »13.7.1H), 1.74 (m, 2H), 1.51 (s, 5H), 1.13 (m, 1H), 0.73 (dt, J · 13.2.8.9.1H ). 265 [(5-fluoroplridin-3yl) metll] ((2 - [(9R) -9 (pyridin-2H) -6oxasposp [4.5Jdecan9-yl] etll)) amlna 370 S 8.82 ($, 1H), 8.50 (dd, J «34.5, 26.7.3H), 7.93 (m, 2H), 7.74 (t, J = 9.7.1H), 4.12 (d, J = 10.8, 2H), 3.76 (dd, J = 25.7,11.8, 2H), 3-03 (d, 1 «7.9, 1H), 2.39 (m, 5H), 2.09 (t, J = 13.0.1H), 1.85 (d, J = 9.0, 2H), 1.60 (d, J = 44.8.5H), 1.24 (s, 1H), 0.86 (d, 1 »9.1.1H). 266 [(5-bromopyridin-3ll) metll} ({2 - [(9R) -9 (pyridin-211) -6oxM »pyro [4.5] decan9-yl] ethyl)) amine 430 δ 8.64 (m, 5H), 8.16 (s, 1H), 8.00 (d, J = 8.2.1H), 7.95 (m, 1H), 4.10 (m, 2H), 3.76 (m, 2H), 3.02 (td , 1 = 12.4, 5.0.1H), 2.49 (m, 2H), 2.29 (m, 3H), 2.12 (t, 1 = 10.2.1H), 1.88 (ddd, J «25.8, 12.8.8.1, 2H), 1.57 (m, 5H), 1.26 (m, 1H), 0.86 (dt, J = 12.9, 8.9.1H). 267 [(5-chloropyridin-3yl) methyl) ({2 - [(9R) -9 (pyridin-211) -6oxasposp [4.5] decan94I] ethyl)) amine 386 6 8.80 (S, 1H), 8.63 ($, 1H), 8.49 (dd, J = 17.4, 10.6, 3H), 7.93 (m, 3H), 4.08 (s, 2H), 3.75 (dd, J = 29.6, 6.9, 2H), 2.99 (d, J «11.6.1H), 2.45 (m, 2H), 2.28 (m, 3H), 2.08 (d, J - 14.3.1H), 1.85 (d, J = 7.5.2H), 1.60 (m, 5H), 1.23 (s, 1H), 0.84 (d, J = 5.6.1H). 268 [(5-matoxypyridin34!) MetlHX2 - {(9R) 9 (ptridln-241) · © · oxespospiro [4.5] decan9ll] ethyl)) amlna 382.1 δ 8.81 (d, J = 5.5.1H), 8.48 (m, 3H), 7.95 (m, 3H), 4.22 (d, J «13.4, 2H), 3.98 (s, 3H), 3.75 (ddd, J» 19.2,12.7,9.3, 2H), 3.04 (td, J = 11.6, 4.8.1H), 2.42 (m, 7H), 2.09 (d, J = 14.3.1H), 1.88 (m, 2H), 1.57 (m , 6H), 1.26 (d, J '10.9.1H), 0.85 (dt, 1 = 12.4.8.7.1H).
    145
    269 M ({2 - [(9R) -9 (pyrldin-2-ll) ^ 6oxaespin> [4.5] decan9 -yl] ethyl) amino) metif] pyridine-3carbonyl 377.1 δ 8.96 (d, J = 15.0.1H), 8.83 (t, J * 10.5.2H),8.53 (dt, J «15.9.8.0, 2H), 8.23 (d, J» 15.0.1H), 7.97 (ddd, J -13.4,11.9, 7.5, 2H), 4.13 (m, 2H), 3.77 ( m, 2H), 3.02 (m, 1H), 2.50 (ddd, J = 26.3, 14.4, 3.7.2H), 2.31 (m, 3H), 2.13 (dd, J = 19.3, 11.3.1H), 1.88 (ddd , J = 17.2,11.0, 7.0, 2H), 1.58 (m, 5H), 1.27 (m, 1H), 0.85 (dt, J = 12.8, 8.7.1H). 270 [(S-metilpIridin-Sil) metll] ({2 - [(9R) -9 (plridin-2ilJ-6 · oxasposp [4.5] decan94Qetil}) amine 366 δ 8.71 (dd, J = 50.6,19.3,3H), 8.37 (m, 2H), 7.85 (m, 2H), 4.20 (d, J = 13.3, 2H), 3.74 (ddd, J =11.9,11.1,5.6, 2H), 3.02 (m, 1H), 2.44 (m, 7H), 2.25 (dd, J = 12.5.5.0.1H), 1.84 (m, 2H), 1.57 (tdd, J = 24.6 , 15.7.8.5, 5H), 1.22 (d, J = 9.3, 1H), 0.83 (m, 1H). 271 {2-K9R) -9- (plrldin-2-il) -6oxaspospiro (4.5] decan-9il] ethyl} ({[5 (trifluoromethyl) pyridin-3HJmeti learning 420.1 δ 8.96 (s, 1H), 8.81 (m, 2H), 8.45 (td, J = 8.1.1.6, 2H), 8.21 (s, 1H), 7.90 (m, 2H), 4.16 (m, 2H), 3.77 (dtd, J = 12.7, 9.5.5.3, 2H), 3.04 (td, J 12.2, 5.1.1H), 2.50 (m, 2H), 2.31 (ddd, J = 21.7, 14.1, 7.0.3H), 2.12 ( d, J = 12.6,1H), 1.87 (ddd, J = 20.7,12.7,7.7, 2H), 1.58 (m, 5H), 1.26 (m, 1H), 0.85 (m, 1H). 272 {[6-cioro-5 (trifluoromethyl) pyrldin-3yl] methyl} ({2 - [(9R) -9 (pirtdin-24l) -6oxa spectrum [4.5] decan9-ll] etll}) amine 454.1 δ 8.70 (m, 1H), 8.60 (d, J = 2.1.1H), 8.28 (d, J = 2.2.1H), 8.16 (td, J ® 7.9.1.8.1H), 7.73 (d, J = 8.2 , 1H), 7.62 (ddd, J = 7.6, 5.3,1.0,1H), 4.12 (m, 2H), 3.73 (m, 2H), 3.18 (brs, 1H), 2.99 (td, J «12.0,5.1, 2H), 2.49 (td, J = 12.0.4.4.1H), 2.35 (dd, J «14.1,1.9, 3H), 2.13 (ddd, J = 14.2,12.1, 5.2.1H), 1.79 (dd, J« 5.6, 3.7, 2H), 1.62 (dd, J = 7.8, 2.8.1H), 1.51 (dd, J = 7.9, 4.1, 4H), 1.18 (m, 1H), 0.78 (dt, j · 13.2.8.9, 1H). 273 {[2-fluoro-5 (trifluoromethyl) plridin-3tl] methyl} (((24 (9R) -9 (plrldin-2-ll) -6oxasposp [4.5] decan94f] «til}) amlna 438.1 δ 8.73 (dd, J = 5.3,1.2,1H), 8.62 {s, 1H), 8.35 (dd, 1 = 8.5, 2.3.1H), 8.22 (td, J = 8.0.1.6.1H), 7.78 (d , J = 8.2.1H), 7.67 (dd, J «6,9,5.8,1H), 4.25 (brs, 1H), 4.13 (m, 2H), 3.74 (ddd, J = 12.3,11.0, 5.5, 2H), 3.05 (td, J = 11.9, 5.1.1H), 2.54 (td, J = 12.0, 4.4, 1H), 2.35 (dt, J = 9.7, 5.3, 3H), 2.16 (ddd, J = 9.9, 8.8.3.8.1H), 2.01 (d, J = 14.1,1H), 1.80 (m, 2H), 1.62 (m, 1H), 1.49 (m, 4H),1.19 (m, 1H), 0.79 (dt, J = 13.1.8.8.1H). 274 {[6-fluoro-5 (trifluorometll) plrldin-3- 438.1 δ 8.58 (d, J = 4.0.1H), 8.45 (s, 1H), 8.35 (d, J = 9.0.1H), 7.85 (m, 1H), 7.51 (d, J - 8.1.1H), 7.33 (dd, J = 7.4.4.9.1H), 4.12 (m, 2H), 3.70 (dd, J =
    6
    yl] methyl) ((2 - ((9R) -9 (pirlcfln ^ -IIHoxasespiro [4.5] decan9-ll] ethyl}) amine8.8, 2.9.2H), 2.98 (m, 2H), 2.47 (dd, J -12.1,7.4.2H), 2.38 (t, J = 11.7.2H), 2.18 (dd, J = 12.9, 4.8.1H), 1.90 (d, J «13.7.1H), 1.70 (m, 2H),1.60 (m, 1H), 1.50 (dt, J »39.4, 20.7.4H), 1.11 (m, 1H), 0.73 (dt, J = 13.5, 9.1.1H). 275 {2 - {(9R) -9- <pyridin-2 · yl) -6oxasposp (4.5] decan9. Il] ethyl} ({[3 (trifluoromatll) pHidyl-2yl] methyl}) amine 420.1 δ 9.29 (brs, 1H), 8.90 (s, 1H), 8.86 (d, J = 5.1,1H), 8.80 (dd, J = 5.7.1.2.1H), 8.49 (td, J - 8.0,1.7.1H), 7.98 (d, J = 8.2.1H), 7.91 (ddd, J - 7.6, 5.7, 1.0, 1H), 7.74 (d, J = 5.1.1H), 4.27 (m, 2H),3.81 (dt, J = 12.8,4.6,1H), 3.72 (m, 1H), 3.13 (td, J = 12.1, 5.1.1H), 2.60 (td, 1 = 12.3.4.1.1H), 2.49 (m, 1H), 2.33 (m, 3H), 2.10 (d, J = 14.3.1H),1.85 (m, 2H), 1.65 (m, 1H), 1.52 (m, 4H), 1.25 (m, 1H), 0.84 (dt, J »12.8, 8.8.1H). 276 {2 - [(9R) -9- (plridln-2il> -6oxaspospiro [4.5] decan9 ·(trlfluoromethyl) pyridin-3yl] methyl}) amine 420.1 δ 8.81 (dd, J = 5.5.1.2.1H), 8.75 (d, J = 4.4.1H), 8.32 (td, J = 8.0.1.7.1H), 8.16 (dd, J = 8.0, 0.7, 1H) , 7.S6 (d, J = 8.2.1H), 7.77 (ddd, J = 7.6, 5.5, 1.0.1H), 7.59 (dd, J = 7.5, 5.0.1H), 4.40 (m, 2H), 3.75 (m, 2H), 3.13 (td, J = 12.0, 5.3.1H), 2.66 (td, J = 12.1, 4.5, 1H), 2.49 (ddd, J = 13.7,11.9, 4.5.1H), 2-41 (m, 1H), 232 (m, 2H), 2.07 (d, J = 14.0.1H), 1.85 (ddd, J «93.7.7,4.5, 2H), 1.64 (m, 1H), 1.51 (m, 4H), 1.22 (m, 1H), 0.82 (dt, J = 13.1.8.9.1H). 277 {2 - ((9R) -9- {pyridin-2-il) -6oxaesplro [4.5] decan9yl] ethyl} ({[4 (trifluoromethyl) pyridin-2yl] metll}) amine 420.1 δ 8.80 (dd, J - 5.5.13.1H), 8.75 (d, J = 5.0.1H),831 (td, J «8.0,1.7,1H), 7.84 (d, J - 8.2,1H),7.75 (ddd, J = 7.6.5.5.0.9.1H), 7.65 (M, 2H),431 (m, 2H), 3.74 (m, 2H), 3.09 (td, J »12.0,5.2.1H), 2.60 (td, J »12.1.4.4.1H), 236 (m, 4H), 2.05 (d, J - 14.1.1H), 1.82 (m, 2H), 1.64 (m,1H), 1.50 (m, 4H), 1.20 (m, 1H), 0.81 (dt, J »12.8.8.8.1 H>. 500 «4-chlorophenikjmetyl) ({2- (4- (4methoxyphenyl) 23-dimethyloxan-4 4I] ethyl}) amlna 501 [βΛ · dimethoxyphenyl) m «ti0 [242,2-dlmettl-4fenlloxan-4il) ether] amine 502 24 {{2- [2-etii-2-methyl-4- (4-
    147
    methylphenyl) oxan-4i [) ethyl} amino) methyl] phenol S03 [2- (2,2-dlme «1-4-phenyloxan-4yl} ethyl] ((2-fluorophenyl-methyl] amine 504 4 - [{{2- [4- (2methoxyphenyl) -2,2dl * netlloxan-4ll] ethyl} amlno) methyl] -N, N-dimethylaniline •505 2 - [({2- [2-etll-4- (4fluorofanll> 2methyloxan-4iqetyl} amlno) metll] phenol
    Example 13: Opioid receptor ligands
    The following compounds in Table 2 can also be prepared according to the procedures described above from appropriate starting materials and appropriate reagents and would also be expected to have similar therapeutic properties and effects as the other compounds described here. In addition, for the specific structure shown, the other isomers or enantiomers are included with the description here. The compounds that were made relate NMR data and the prophetic examples do not relate NMR data.
    Table 2: Examples with chemical name and / or characterization data
    148
    Compound
    Name
    NMR Structure and / or Spectrum
    506.
    (2 - ((9R) -9- (pyridm-24l) -6oxae8piro [4.5] decan-9il] etHXpyrimidln-54lmethyl) amine
    MS: 353-2
    Ή NMR (400 MHz, CD3CN) δ 9.16 (s, IH), 8.78 (s, 2H), 8.70 (dd, J - S3, l.l, 1H), 8.16 (id, J - 8.0,
    I. 8.1H), 7.74 (d, J - 8.2, IH), 7.62 (ddd, J = 7.6.5.4, 0.9.1H), 4.27 (brs, IH), 404 (1, J- 7.7.2H) , 3.73 (m, 2H), 3.01 (td, J - 12.0, 5.1, IH), 2.50 (td, J = 12.0.4.4, IH), 2.33 (m, 3H), 2.12 (ddd, J - 19.0,
    II. 7.52, IH), 1.99 (d, J = 10.1, IH), 1.78 (m, 2H), 1.61 (m, IH), 1.48 (m, 4H), 1.17 (m, lH), 0.78 (dt, J = 13.1.8.9, IH).
    149
    Compound Name NMR Structure and / or Spectrum 507. [(2-methylplrimidin-54l) methyl] ((2 - {(9R) - 9- (pyridin-2-ll) -6-oxaeepiro [4 < 5] <te «an-9 * iqethyl}) amine 508. (2 - {(9R) -9- (plridln-24l) -6oxasposp [4.5] decan-94l] ethyl} ({[2 (trifluoromethyl) pyrimidin-5yl] methyl)) amlna QtojX 1 Uy509. [(2-methoxypyrimldin-54l) methyl] ({2I (9R) -9-{plrldin-24l> 6-oxaeeplro [4.5] decan-9il] ethyl)) amine MS: 383.3Ή NMR (400 MHz, CD3CN) IH), 8.54 (s, 2H), 8.10 (td, JJ = 8.1, IH), 7.56 (dd, J - 6.7, 3.71 (m, 3H), 3.50 (brs, 1H), 2 1H), 2.47 (td, J = 12.0.4.3, IH (tn, IH), 2.10 (tn, IH), 1.77 (n 1.47 (dddd, J - 14,1,12,4,8.4 1H), O, 77 (di, J - 13.1,8.9, IH Ο HSo -θ δ 8.69 (dd, J-5.2, 1.1, 7.9,1.7, IH), 7.69 (d, 5.3, IH), 3.98 (s, 5H), .98 (td, J - 12.0,5.0,), 2.37 (m , 2H), 2.27% 2HX1.62 (m, IH),4.9.4H), 1.17 (m,) · 5) 0. (ptridazin-44lmetilX (2 * {(9R) -9- (pMdin241) -6-oxaesplro [4.5] decan-94l] ethyl}) amlna Sil. [(6-metl Ipiddazin -4-ll) methyl] ({2 - [(9R) -9-(pirtdin-24l) -6-oxaesplro [4.5] decan-9l <] ettl)) amlna 4. ff H | πUy
    150
    Compound Name NMR Structure and / or Spectrum 512. {2 <(9R) -9- (pyrldln-2-ll) -eoxasospiro [4.5] decan-èIQeWX {^ - (trmuoromethyl) plrkl «tln-4 · iljmetiQJaminaCFj513. [(((6-methoxypyridazin-4-yl) methyl] ({2-[(9R) -9- (plridÍn-24l) <6-oxasplro [4.5] decan- 94l] ethyl}) amlnaOMe514. (pyrazfn-2-llmethylX {2 - {(9R) -9- (pyridin-2-oxaesplro [4.5] decan-94l] ethyl}) amine MS: 353.31 H NMR (400 MHz, CD 1H). 8.60 (d, 3 = 1.6.2H 7.9, 1.7, 1H), 7.73 (d, 3 * 5.3, 0.8.1H), 7.13 (brs, 2H), 3.09 (14.3 = 11.8, 5 4.6, IH), 237 (m, 3H), 2 IH). 1.99 (m, IH), 1.77 ((m, 1H), 1.48 (m, 4H), 1CV, «J3 3CN) 8 8.74 (dd, 3 = 5.3.1.1,), 8.55 (m, 1H), 8.16 (ld, J => 8.2.1H), 7.61 (ddd, 3 = 7.5, H), 4.25 (m, 2H ), 3.73 (m, 4.1H), 2.61 (td, 3- 11.9, 18 (ddd t J = 13.7,11.6,5.5, ddJ -9.6, 4.4.2H), 1.62 18 (m, 1H), 0.79 (dt, J- 515. [(6-methylpyrazin-2-yl) methyl] ({2 - [(9R) -9 (pyridin-2 ·ll) -6-oxaesplro [4.5] <tecan-9-yl] etir}) arnlna 516. {2 - {(9R) -9- <pyridin-2-yl) -6oxasplro [4.5] decan-9il) ethyl) ({[e- (trifiuoromethyl) pyrazin-2l] metll)) amlneCFj OH n '5c ^ Ns ^' n
    151
    Compound
    517.
    518.
    519.
    520.
    521
    Name [(6-methoxyplrazin ^ 4l) metH] ({24 (9R).
    9 (pyridin-2 -) * € -ox «kespiro [4.5] decan-9il] ethyl}) amine [(5-methylpyrazin-2-yl) metll] ({2 - [(9R) -9 (pyridin-2 -il) -6-oxaspospiro [4.5] decan-9il] ethyl}) amine {2 - {(9R) -9- (pyridin-2-yl) -6oxasplro [4.5] decan-9il] ethyl} ((í5- (trifluoromethyl> pi razin-2iQmetH}) amlna [(5-methoxypyrazin-2-yl) methyl] ({2 - ((9R) 9 * (pyridin-2-yl) -6-oxasposp [4.5] dflcan-9II ] etll}) amlna {2 - ((8R) ^ 4pírtdln-2 <ll) -6oxaspospiro [4.5] decan-9il] ethylXquinolin-3-! 1methyl) amine
    NMR Structure and / or Spectrum
    OMe

    MS: 402.3
    Ή NMR (400 MHz, CD3CN) δ 9.90 (brs. 1H), 9.15 (d, J »1.7.1H), 8.89 (s» 1H), 8.77 (dd, J - 5.6.1.3, IH), 8.40 (td , J - 8.0, 1.6.1H), 8.30 (d, J = 8.6.1H), 8.16 (d, J - 8.2.1H), 8.08 (ddd, J = 8.5.7.0, 1.3, IH), 7.90 (m , 2H), 7.81 (m, IH), 4.36 (m, 2H), 3.74 (m, 2H), 3.06 (td, J - 12.0,5.1, IH), 2.57 (id, J - 12.2, 4.1.1H) , 2.45 (m, IH), 2.29 (m, 3H), 2.08 (m, 1H),
    I. 98 (d, J »2.5, 1 Η), 1.83 (m, 2H), 1.64 (ddd, J»
    II. 6.8.7, 3.4, I H), 1.50 (m, 4H), 123 (ddd, J = 10.4, 4.4.2.4, IH), 0.82 (dt, J = 12.9.8.8. IH),
    152
    Compound Name NMR Structure and / or Spectrum 522. (1H-plrazol-3-ylmethyl) ({2 - [(9R) -9 * (pyrldin-2-yl} -6oxasplro (4.5] decan-9-yl] ethyl}) am Ina MS: 341.21H NMR (400 MHz, CD3CN) δ 8.76 (dd. 1 = 5.5, 1.2.1H), 8.28 (td, J »8.0,1.7.1 H), 7.80 (d, J« 8.2, 1H), 7.73 (ddd , J = 7.6,5.5,0.9, ÍH), 7.61 (d, J = 2.3, IH), 6.32 (d, J - 2.3, IH), 5.78 (bo. IH), 4.09 (m, 2H), 3.72 ( m, 2H), 2.98 (td, J = 12.0, 5.2, IH), 2 47 (tdj-12.1,4,3, IH), 236 (m, 3H), 2J6 (m, IH), 2.02 (d, J - 14.2, IH), 1.79 (m, 2H), 1.62 (m, IH),1.49 (m, 4H), 1.19 (m. 1H), 0.79 (Λ, J »12.9,8.8, Uík ....... ................ .. .. ui /523. [(1-methyl H-plrazol-3-ll) metll] ({2 [(9R) -9- (pyridin-2-yl) -e-oxasplro [4.5] decan-9-yl] ethyl}) amine MS: 355.3IH NMR (400 MHz, CD3CN) 6 8.98 (brs, IH), 8.73 (ddJ-5.3,1.1, IH), 8.73 (dd, J ** 5.3, ll, IH), 8.16 (m, 2H), 7.72 ( d, J · 8.2,! H), 7.72 (d, J = 8.2, IH), 7.62 (ddd, J = 7.5,5.4,0.8,1H), 7.62 (ddd, J - 7.5, 5.4.0.8, 1H) , 7.47 (d. J - 2.2.1H), 7.47 (d, J - 2.2. IH), 6.25 (d, J «2.2, IH), 6.25 (d, J - 2.2. IH), 4.02 (m, 2H ), 3.80 (s, 3H), 3.72 (m, 2H), 2.98 (td, J = 11.8.5.2, IH), 2.48 (td, J = 11.9.4.2.1H), 2.33 (m, 3H), 2.12 (ddd, J - 13.5, 11.9.5.4, IH). I.99 (m, IH), 1.77 (m, 2H), 1.62 (m, IH), I.48 (m, 4H), 1.17 (m, IH), 0.78 (dl, J = 13.1.8.9. IH ). Ο Η H524. [(5-methyl-1 H-plrazol-34l) metll] ({2 [(9R) -9-(plrldm-2-IIH-oxaesplro [4.5] decan-9-yl] ethyl)) amlna MS: 355.3IH NMR (400 MHz, CD3CN) δ 8.78 (dd, J “5.5, 1.2, IH), 8.34 (td, J - 80.1.7, IH), 7.79 (m, 2H), 6.07 (s, 1H), 5.95 (brs, IH), 4.02 (m, 2H), 3.72 (m, 2H), 2.97 (id, J = 120, 5.1, IH), 2.44 (ddd, J - 12.1, 10.0.4.2, IH), 2.34 ( m. 3H), 2.26 (s, 3H), 2.18 (td, J »13.1, 5.2, IH), 203 (d, J - 14.2, IH), 1.81 (ddd, J 8.7, 7.4, 3.8, 2H), 1.63 (ddd, 1 - 14.6,10.4,4.6, IH), 1.49 (m, 4H), 1.20 (m, IH), 0.81 (dt, J “12.9.8.9, 1H1 / 588 % H N-NH
    153
    Compound Name NMR Structure and / or Spectrum 525. [(1,5 <imimethyl-1H-p1ru »l-34l) motil] ({2 ·{pyridin-24l) -6-oxaspospiro [4.5] decan-9-yl] ethyl)) amine MS: 3693IH NMR (400 MHz, CD3 (dd, 3-5.4, I.2, IHX8.28 (brs, 1 H), 7.74 (m, 2H), 6. 3.73 (m, 5H), 2.96 (td, 3 12.1 , 4.2, 1H), 236 (m, 3b IH), 1.79 (tn, 2H), 1.63 (d 1.50 (m, 4H), 1.19 (ddd, J (dt, J-12 ^ 89.1H).Ό CN) 6 12.13 (brs, 1H), 8.77 (td, 3 = 8.0, 1.7, IH), 8.00 03 (s, lHX3.96 (m, 2HX 12.0,5.2,1HX 2.47 (ld, J <X2. 17 (m, 4H), 2.00 (m, dd, 3-8.4,7.6,33, IH), = 10,1,6,6,1.8, IH), 0.81 526. (1H-pyrazol-44lmethyl) ({2 - {(9R) -9-(piridln-2-il} -6-oxaespiro [4.5] decan-94qetll}) amlna MS: 341.21HNMR (4QQ MHz, CD3 1.1, IH), 8.21 (td, 3 = 8.0, IH), 7.66 (m, 3H), 7.56 (s, (m, 2H), 2.9I (m, IHX 23 1.99 (m, I HX 1.78 (m, 2H 4H), 1.19 (m, lH), O.78 (d CN) δ 8.73 (dd, 3 = 5.3, I.7.2HX 7.75 (d, 3 = 8.2,IHX 3.96 (s, 2H), 3.73 2 (m, 4HX2.08 (m, IH), Xl.62 (m, IH), i.49 (m, t, J-13.1,8.8, IHX 527. «1 -meei-1 H-plrazol> 44l) methyl] ({2 * [(9R) -9-(pyridin-2-yl) -6-oxaspane [4.5] decan4MI] ethyl)) amine MS: 355.2IHNMR (400MHz, CD3I. 3.1H), 8.32 (td.J-8.0, IH), 7.77 (ddd, 3-7.6, 5.5 7.55 (s, IH), 7.43 (s, IH),II. 7.3HX 3.73 (m, 2H), 2.2.35 (m, 4H), 2.14 (ddd, 3 (dj - 14.2, IH), 1.80 (m, 2.7, IH), 1.49 (m, 4H), L2 12.9.8.8, IH), CN) 68.78 (dd, J-5.5,1.7, IH), 7.84 (d, 3 = 8.2,, 0.9, IH), 7.71 (brs, IH).3.91 (s. 2H), 3-81 (d, 3 =90 (dt, 3 = 11.7.5.8, IH).- 10.8, 10,2,5.2, IH), 2.032H), 1.62 (tdd, 3 = 8.7.6.8.0 (m, 1HX 0.80 (dt, 3 = 528. [(5-methyl-1H-pyrazol-4-yl) methyl] ({2í (9R) ^ * {plrtdln-24l) * 6-oxaesplro (4.5] decan-94Qethyl}) amine
    154
    Compound Name NMR Structure and / or Spectrum 529. [(1,5-dimethyl-1H-pyrazol-4-yl) methyl] ({2 [(9R) -9-(pirith'n-2-yl) -6-oxaspospiro [4.5] decan-94l] ethyl}) arnine VVyA / ’530. [(5,6-dffluoropyridyl-34l) methylX {24 (9R) 9-(plridÍn-2-HH-oxasespiro [4.5] decan-9-yl] ethyl}) amine ^ tO531. [(5 * cioi ^ «flttoropyrindin-34l) metll] ({2 * í (9R) -9-(pyridin-2-ll) -6-oxaospiro [4 »5] decan-9-yl] ethyl} amine L g h f | T^ ° tO532, [(5-bromo-6-fluoropyridin-3Hl) metl!] ({2 ((9R) -9-(plrldin-2-ll) -6-oxaspospiro [4.5Jdecan-94l] ethyl}) amine «* <JM Fí g η r I533. [(6-fluoro-5-k> dopiridin-3-yl} methyl] ({2 · [(9R) -9- (pyridine * 24l) 6-oxasplro {4.5] decan-94l) ethyl}) amine 4, g η Γ T534. ((6-fluoro-5-methylpyridin-3-i) methyl] ({2 [(9R) -9-(pyridin-2-yl) -0-oxaspospiro [4.5] decan-9-ll] ethyl} amine MS: .384.3tHNMR (4O0MHz, CD3C8.36 (s, IH), 8.20 (d, J “7, í (', J-7.1, 2H), 7.66 (m, IH 2H), 2.98 (ddj = 11.6,6.9, ($, 3H), 2. I6 (<M, J = 13.2.21.51 (m, 6H), 1.2013-3, 1H)..........----- Π — F N) 8 «73 (d, J-4.4, IH),1, IH), 8.01 (s, IH), 7.77), 4.01 (s, 2H), 3.73 (m,IH), 2.36 (m, 5H), 2.26 1.80 (m, 2H),8.7.4 7,! HX 0.79 (d, J =
    155
    Compound Name NMR Structure and / or Spectrum 535. ((Mluoro-5- <n «toxiptrMln-3H) metlQ {{24 (9R)« 9 »(pyridin-2-yl) -6-oxasposp (4.5) decan-94l] etll}) amlnaand 536. 2-fluoro-5 - [((2 - [(9R) -9- (plridin-2-ll) -6oxasposp (4.5] decan-9IQethyl} amlno) metll] pyridine-3carbonitrile r - 4 tf Η Γ 1 «ίΟ537. [(6-clon> 5 «fluoroplridin <-34l) rne6l] ({2 · [(9R) -9-(pyridtn-2-yl) -6-oxasospiro [4.5] deean »9» il] etlf}) amine MS: 404.2IHNMR (400 MHz, CD3Cb 1.1, IHX 8.24 (d, 1 - 1.9, IH IH). 7.78 (dd, 1-90, 2.0.11 7.56 (ddd, 1-7.5,53,0.9. 1 (m, 2H) , 3.72 (m, 2H). 2.99 (2-48 (td, J-120.4.5, 1H), 2 IH), 1.77 (m, 2H), 1.62 (m, 1 (m, IH), 0.77 (dt , J- 13.1,8 Ç-bjiXÇ O6 8.68 (dd, J-5.2,X8.10 (td, J = 7.9, 1.8, 1), 7.69 (d, J-8.2, IH). H), 4.75 (brs, IH), 407 td, J = 11.9.5.2, IH), 32 (m, 3H). 2.11 (m, H), 1.49 (m, 4H), 1.179, IH). 538. [(5,6-dichloropyridin-3-yl) methyl] ({2 - [(9R) 9- (pyridin-2-yl) -6-oxasposp [4.5] decan-9-ll] ethyl}) amlna MS: 422.2IHNMR (400 MHz, CD3Cb (d, J-2.1, 1H), 8.12 (d, J =: IH), 7.49 (d, 1 = 8.1, IH), 714.26 (dj- 1.5.2H), 3.57 (dk (td. J “12.2,4.6, IH), 2.55 (12.27 (dddd, 1 * 25.5,17.3,14 IH), 1.59 (m, 2H), 1.34 (m, (5.0, IH), 0.60 (dt, 1-J3. ^ 9 CVjUX 1) 8 8.51 (m, IH), 833 LI, IH), 7.76 (l, J = 7.9, i3 (dd, J-7.4.4.9, IH),1, J -7.7.30.2H), 3.09 d, J-12.1.4.6, IH)..3.3.4,4H), 1.77 (m,> H), 0.98 (ddj-11.4.0. IH). 539. [(5-bromo-6-chloroplridin-3-JI) methyl] ({2 [(9R) -9-(pyridin-21l) -6-oxaesplro [4.5] decan-9-yl] ethyl}) amine MS: 466.1IH NMR (400 MHz, CD3CN) δ 8-64 (d, J - 5.1, IH),, 836 (d »J = 2.l, 1H), 8.24 (d, J-2.1, IH), 8.02 (m ,IH), 7.69 (d, J - 80.1H), 7.47 (m, IH), 3.59 (m, 2H), 3.17 (d, J = 4.7, IH), 2.63 (d, J - 4.5, IH), 2.34 (m, 4H), 2.12 (d, J -4.8, JH), 1.85 (d, J = 13.8, IH),1.66 (m, 2H), 1.35 (m, 6H), 102 (m, IH), 0.66 (s,
    156
    Compound Name NMR Structure and / or Spectrum IH).QçjiXÇ540. [(6-chloro-5-lodopyrldln-3-yl) metll] ({2 - ((9R) -9 (p (rWin-24l) -6-oxaesplro [4.5] decan-94l] ethyl}) amine 541. [(6-ck> ro-5-medlplridin-3-yl) methyl] ({2 [(9R) -9-(pirldln-24l) -6-oxaesplro | 4.5]decan-9-yl] ethyl)) amine MS: 400.2IH NMR (400 MHz, CD3C1 1.2, IH), 8.20 (tj = 2.4, IH, 1H), 7.74 (tj -5.2.2H), 7.6IH), 5.11 (s, 1H), 4.01 (m, 2 (td, J = 11.9.5.1, IH), 2.46 (2.33 (m, 6H), 2.12 (ddd, J = (d, J = 6.9 , IH), 1.78 (m, 2H 4H), 1.18 (m, 1H), 0.78 (dt, VVUJuCvQ 4) 5 8.70 (dd, J «5.3,>, 8.17 (dd, J = 7.9,1.7,» 3 (ddd, J = 7.5,5,3,0.9, H), 3.73 (m, 2H), 2.98 Id, J 12.0.4.2, IH), 14.7,10.5,5.3, IH), 1.99), 1.62 (m, IH). 1.48 (m,= 13.1.8.9, IH). 542. [(6-chloro-5-methoxypyridin-3ll) mettl] ({2 - [(9RF9 (pyridin-24l) -6-oxasplro {4> 5] decan4MI] etll}) amine MS: 416.21H NMR (400 MHz, CD3C1 1.2, IH), 8.26 (td, J = 7.9.1. 1H), 7.80 (dJ-8.2, IH), 7. 7.52 (d, J = 1.9, IH), 5.05 (b 3.90 (s, 3H), 3.74 (m, 2H), 2ΓΗ), 2.40 (dddd, J-19.5.12 (m, IH), 1.99 (m, IH), 1.80 (14.5,7.2,3.0, IH), 1.49 (m, (dt, J = 12.9.8.8, IH) ),«X. (4., 014 1 «Γ 1 4) 6 8.73 (dd, J = 5.4, 5, IH), 7.93 (d, J - 1.9, 70 (dd, J = 7.1, 5.9, IH), rs, 1 Hl 4.64 (m, 2H), .98 (td, J '12 .0, 5.1, .3,9.6,4.7,3H), 2.16 m, 2H), 1.63 (ddd, J · 4H), 1.20 (m, lH), 0. «0 543. 2-chloro-5 - [(((2 - ((9R) -9- (pyridin-2-yl) -6oxasposp [4.5] decan-9IOetll) amlno) metiI] pirtdlna-3carbonitrila 4 1 n JL 1
    157
    Compound Name NMR Structure and / or Spectrum 544. 34luoro-5 «[({24 (9R)« 9- (pMdln-24l) * 6oxaspospiro [4.5] decan-9il] ethyl} amino) methyl] pyridine-2carbonitrile 545. 3-chloro-5 - [({2 - [(9R) -9- (pyridin-2-yl) -6-oxaesplro [4.5] decan-9il] ethyl} amino) methyl] pyridine-2carbonttrfla 546. 3-bromo-5 - [({2 - [(9R) -9- {pyrldln-2-IIHoxasespiro [4.5) decan-9iqetil} amlno) metll] plridine <2 <· carbonitrile 547. 3-iodo-5 - {({2 - ((9R) -9- (pyridin-2-yl) -6oxasesplro [4.5] decan-9 · tl] ethyl} amino) metll] pyridine-2cartxmitrtla 548. 3-methyl-5 - [({2 - [(9R) -9. (Pyridin-2- (l) -6oxasposp [4.5] decan-9lq »dl} amino) methyl] pyridin-2 <> cartoonitrilaL a h r Y549. 3-methyl-5 - [({2 - [{9R) -9- (pyridin-2-yl) -6oxasposp [4.5] decan-9 * iqetfl} amino) metH] plridine-2carbonyltrylN CM350. 5 - [(€ 2-K9R) ^ - (pírtdm-24í) -6oxaspospiro [4.5] decan-9ll] ethyl} amino) methyl] plridine-2,3dicarbonftrila«Ssx N_.CN
    158
    Compound Name NMR Structure and / or Spectrum 551. 5 - [({2 - {(9R) -9- (pyridin-2-tl) -6oxafesp [4.5jdecan-9if) ethyl} amino) methyl] -3 (trifluoronrethyl) p4ridine-2carbonitrilepK r * N v ÕN N j552. {[5 * fluoro- € 4binuoromethyl) pyridyl-3-il] metiQ ({2 - [(9R) -9- (plridin-24l) -6-oxaspirus [4,5] decan-9-ll] ethyl)) amlnaP.................................. 'sÀçJXX^ ° ίΟ553. {($ -doro-6- (trtfluorom «tll) plrtdln-3-ll] me «l} ((2 - [(9R) -9- (pírtdlo-24l) -6-oxaespiro [4.5] decan-9-yl} ethyl}) amine 554. {[54> romo-6- (trifluoromethyl) pyridin-3iqmetylK {2 - [(9R) -9 <(plrtdin-2-IIH ’oxaspiro [4.S] <lecan-04l] edl}) amlna MS: 498.1IH NMR (400 MHz, CD3CN 1.2, IH), 8-64 (d, 3 = 1.6, IH) 8.26 (td, J = 8.0.1.6, IH). 7.8 (dd, 3-7.1.6.0.1H), 4.12 (m 3.00 (td, 3 = 12.0, 5.1, IH), 2 IH), 2.37 (ddd, 3-14.0,11.9 2.02 (m, IH), 1.81 (m, 2H) .1 4.7, IH), 1.49 (m, 4H) .Ul (13.0.8.9, IH).Ass° u / ) 6 8.74 (dd, 3 = 5.4,, 8.32 (d, 3- 1.2. IH),1 (d, 3 = 8.2, IH), 7.71 (3H), 3.74 (m, 3H), 49 (td, J = 12.1,4.2,, 5.0.3H), 2.16 (m, IH),, 63 (ddd, 3 - 14.4,8.7, m, IH), 0.80 (dt, 3 = 555. {[5-iodo-6- (trifluoronnetyl) pindin-3yl] metiIX {2 - [(9R) -9- (pyridin-24l) -6oxaes | ãro [4.5 | decan-94l] ettl}) amineÕ H - / Χζ Ν r O
    159
    Compound Name NMR Structure and / or Spectrum 556. {[5-methyl- € - (trifiuororn0til) pindin-3IOm € tiíX {2 - [(9R) -9- (pliidln-2-ll) -6oxa «spiro [4.5] decan-9-yl] etiQ) emina 557. a5-4netoxy-eqtrifluoromethyl) pyridyl-3yl] methyl} ({2 - {(9R) -94pindin-2-yl) -6oxasplro [4.5] decan-94l] ethyl)) amine 558. 5 - [({2 - {(9R) -9- (pirldin-2-yl) -6-oxaH »spiro [4.5] decan-9ll] ethyl} amlno) metll] '2 (trifluoromethyl) pyridine-3-cartx> nitrile-XN, kCF s L ff xi li ul · /559. {[5,6-bis (trifluoromethyl) pyridin-3yl] metll} ({2-[(9R) -9- (plrldin-24l) -6-oxaspospiro [4.5] decan-9-IQetII}) amlnaÇUjsJUÇ,560. [(5-fluoro-6-methylpyridin-3-yl) methyl] ({2- [(9R) »9 *(plridln-24l) -6-ox «esplro {4.5] decan-9ii] ethyl)) amine 561. [(5-chloro-6-methylpyridin-3-yl) methyl] ({2 [(9R) -9-(pyridin-24l) -6-oxaspospiro [4.5]decan-9-iQotil}) amlnazsSXό'Ey562. [(5-bromo-6-methylpyridin-34l) methyl] ({2 · [(9R> 9-(pyridin-24l) -6-oxMsplro {4,5] decan-9-yl] ethyl}) amlna
    160
    Compound Name NMR Structure and / or Spectrum 563. [(5-iodo-6-methylpyridin-3-yl) methyl] ({2 [(9R) -9- (ploto-2-4l) -6-oxasposp (4.5] decan-9-yl] ethyl}) amine 564. ((S, 6-dimethylpyridm ^ -yl) methyl] ({2 [(9R) -9-(pyridin.24l) -6-oxaspospiro (4.5]decan-94l] * til}) amlna4 2 a Γ ¥ n A / '- N ^ AA565. [(5-methoxy-6-methylpyridin-3yl) methyl] ({2 - [(9R) -9 · (plridin-2oH) <8-oxasplro [4.5] decan-9-yl) ettl)) amineCUjX566. 2 ^ netll-5 <«2- (C9R) -® ^ pHdin-2-IIHoxasplro [4.5] decan-9yl] ethyl) amino) methyl] pyridine-3carbonylL ff H f II%567. {[6-methyl-5- (trifluoromethyl) pyridin-3yl] metll} ({2q (9R) -9Hplrinin-2-IIH. Oxaespirò (4.5] decan-9-yl] etii}) amine 568. [(5 * fluoro «6 * metoxtplridln» 3 * il) nwtilJ ({2 - {(9R) -94piridin-2-ll) -6oxaespirx <4.5] decan-9 * il] etll}) amlna MS: 400.31H NMR (400 MHz, CD3CN) 1.2, IH), 8.25 (s, IH), 8.12 (td (d, J = 1.9, IH), 7.67 (d, J-8. 6.8, 5.7, 1H), 7.44 (dd, J-11.6.7, 5H), 3.62 (m, 2H), 2.86 (d 2.26 (m, 4H), 2.05 (dd, J “12. 1 = 9.5.8.0.44.2H), 1.69 (dd < 6 8.63 (dd, J · 5.3, J - 8.0.1.6, IH), 7.832, IH), 7.57 (dd, J =1.2.0, IH), 3.88 (dJd, J - 11.5, 7.1, IH), 7, 5.0, IH), 1.69 (ddd,1, J-9.5.8.0.4.4.2H), IH).
    161
    Compound Name NMR Structure and / or Spectrum 569. [(5-chloro-6-methoxypyridin-3yl) metho «2 <(9R) -9 (pyridin-2-yl) -6-oxasposp [4.5] decan4MI] etll}) amlna MS: 416.21H NMR (400 MHz, CO3CN) 8.21 (ί, IH), 8.18 (d, 1 · 8.0.1 1H), 7.72 (m, 2H), 7.63 (t, J362 (m, 2H), 2.85 (dd , 1-11.4H), 2.07 (d, J 4.9, I HX1.9I (m, 2H), 1.39 (m, 5H), 1.10 (ir 13.2.1H).'tSx' ...............4 j ü JL 1 8 8.65 (d, J = 5.4, IH), HX 7.96 (d, 1 = 2.1, 6.4, IH), 3 ^ 7 (m, 5H), 5, 7.2, IH), 2.27 (m,(d. J 14.1, IH), 1.69 i, JHX0.69 (d, J = 570. [(S-bromo-6-methoxypyridin-3yl) methyl] ((2 - {(9R} -9 (pyridin-2-yl) -0-oxasposp [4.5] decan-9-yl] ethyl}) amine MS: 460.2IHNMR (400 MHz, CDCI3) <1H), 8.43 (td, J- 8.0.1.7, IH) 7.98 (d, 1 = 2.1, 1HX .92 (d, JJ = 7.6, 5.7.1.0, IH) , 5.63 (brs 3.75 (m, 2H>, 2.96 (m, 1Ηχ 2. · 2H), 2.33 (dJ-14.1.2H), 2.2 14.2, IH), 1.83 (m, 2H), 1.64 (4.4, 1H), 1.50 (m, 4H), 1.23 (n 12.9. 8.9, IH)...............Lí h r í 5 8.79 (dd, 1 = 5,7,1.3,, 8.11 (d, J “2.1, IH),» 8.2, 1HX 7.86 (ddd, s lHX3.97 (m, 5H), 42 (dq, J- 12.2 , 4.1, 1 (m, lH), 2.06 (dJddd, J 19.4, 10.1, η, 1H), 0.82 (dt, J = 571. [(5-iodo-6-methoxypindm-3-yl) fnotil] ((2 [(9RHE(pyridin-2-yl) -6-oxaspospiro (4.5] decan4HI] ethyl}) amlna QçhXí,572. [(6-methoxy-5-methylpyridin-3II) methyl] ({2 - [(9R) -9 · (pyridin-2-yl) -6-oxasposp [4.5] decari-94l] ethyl}) amine MS: 396.31H NMR (400 MHz, CDCI3)1H), 8.38 (td, 1 “8.0.1.7, IH) 7.88 (d, J» 8.2, lHX7.8l (ddc 7.49 (d, 1 = 1.5, IH), 5.36 (brs 3.74 (m. 2H) , 2.95 (dd, J-IL 4H), 221 (dd, J = 13.2,5.4,1F (d, J-14.2, IH), 1.82 (m, 2H) (m, 4H), 1.21 (ddd, J = 10.5.6 - 12.9, 8.8, IH). 58.78 (dd, J »5.6, IJ,, 7.96 (d, 1 = 2.2, IH), Μ“ 7.6.5Λ, I O, IH). :IH), 3.93 (m. 5H), 4.7.7, IH), 2.39 (m, I). 2.14 (m, 3HX 2.05, 1.63 (m, IH), 1.50 .1.2.5.1HX0.8I (dt, J
    162
    Compound Name NMR Structure and / or Spectrum 573. [(5,6-dimethoxypyridin-3-yl) methyl] ({2 | (9R) -9- (pÍridín-2-yl) - € -oxasespíro [4.5] decan-9-íl] etll}) amine 574. 2-methoxy-S - [(p <(9R> 9- (pirtdin-24l) -6oxaspospiro [4.5] decan-9il] etiqamlno) metiqpirldlna-3 · carbonitrileQ dU575. {[6-metoxy <«4trifluoromedqpÍridin-3iqmetilX {2 - [(9R) -9- (pyridin-24l) -6oxaes | Mro [4.5] decan-9-iqetiq) amineQ OÔT
    Example 14: Opioid receptor ligands
    The following compounds in table 3 can also be prepared according to the procedures described above from appropriate starting materials and appropriate reagents and would also be expected to have similar therapeutic properties and effects as the other compounds described here. In addition, for the specific structure shown the other isomers or enantiomers are included with the description here. The compounds that were made relate NMR data and prophetic examples do not relate to NMR.
    Table 3: Opioid Receptor Ligands
    163
    Compound Name Structure 576 K5-ctoroplrWiri «3yl) methyl] ({2 - [(9} -9-phenyl-6oxasespíro [4.5] decan-9 <· yl] ethyl)) amine .THE577 {2 - [(9R) -9-phenyl-6oxaspospiro [4.5] decan-9-IWI} «(5 · (trifluoromethyl) pyridin-3yl] methyl}) amine 578 {2 - [(9R) -9-phenyl-6oxasposp [4.5] decan-9ll] etll} ({4 · (trifluoromethyl) pyridin-3if] metiQ) amine Η η T n kb579 ((9R) -9-phenyl- & oxaspiro [4.5] decan-9il] ethyl}) amine FCl a xi uZ /580 [(3-metitphenyl) methyl] ({2 [(9R) -9-pheniMoxaesplro [4.5] <tecan * 9 · yl] ethyl}) amine 581 ((5-c! Oropyridin-3H) meBg ({2 <(9RM44ftuorafenll) -6oxasposp (4.5] decan-9if] ethyl}) amlna
    164
    Compound Name Structure 582 {2 - [(9R) -9 <4-fluorophenyl) .6oxaspospiro [4.5] decan-9il] ethyl} ({5 (trifluoro * netyl) pyridin-3ll] metll}) amlna 583 {2 - [(9R) -9- (4-fluorophenyl) -6oxaspospiro [4.5] decan-9ll] etllX {[4.(trfluoromethyl) pyridin-3ll] metll}) amine H FjC r>584 [(3,5-difluorophenyl) methyl] ({2í (9R) -9- (4fluorophenll} -6oxasposp [4.5] decan-9il] ethyl}) amine ΑχXjCtoJ xXa 585 [(5-chloropyridin-3ll) metll] ({2 - ((9R) -9- [4 (trifluoromethoxy) phenyl] -6oxa spectrum (46) decan-9il] etiJ}) amlna Cl 586 (2 - [(9R) -9- [4 (btfluoromethax)) pheniq-6oxasposp [4.5) decan-9iljetyl} ({[5 (trifluoromethyl) pyridin-3> l] methyl}) amine çf 3 TI a Γ Π587 {2 - [(9R) -9- [4-(trifluoromethoxyl) feniq-6oxasposp [4.5) decan-9il] ethyl} ({[4-(trifluoromethyl) pyridin-3yl] methyl}) amine ÉjCO ^ x ^ Ρ » Ο <^ Χ 1 1 H FM% nyy 1 .......................)tIS1
    165
    Compound 1 Name Structure 588 [(3,5-difluorophenyl) methyl] {{2 · [(9R) -9- [4 (trifluoromethoxyl) phen11] -6oxasposp (4.5] decan-9ll] etll}) amlna FOcuJJi,589 ((3-methylphenyl) methyl] ({2 [(9R) -9- [4 (trifluoromethoxy) phenyl] -6oxasposp [4.5] decan-9Il] ethyl}) amine 590 [(5-chloropyridin-3yl) imtil] ({2 - ((9R) -9- (p «ridin-3il) -6-oxasposp [4.5] decan-9il] ethyl}) amlna Cll ll H in591 {2 - [{9R) -9- (pyridin-3-yl) -6oxaspospiro (4.5] decan-9ll] etll} ({[5.(trifluoromethyl) pyridin-3H] meÜI}) amlna ι | H ffl592 (24 (9R) -Ô- (plr1dln4-IIX6oxasospiro [4.5] decan-9ll] etll} ({[4 ~ (tnfluoromethyl) pyridin-3yl] metll} | amine 593 [(3,5-difluorophenyl) methyl] ({2 [(9RWplridln-3yl) -6-oxaspiro [4.5] decan-9ll] ethyl}) amine F1 | H F |
    166
    167
    Compound Name Structure 600 [(5-chloropyridin-3ll) metiq ({2 «{(9R} -9> (3« methylphenyl) -6oxaspospiro [4.5] decan-9IQ «til}) amine Me G601 {2 - [(9R) -9- (3-methylphenyl) -6oxaspospiro [4.5) decan-9il] ethyl} «[5 (trifluoromethyl) pyridin-3il] maei}) amlna Me CF 3 602 {2 - {(9R) -9- {3-metltfenll} -6oxaspospiro [4.5] decan-9 · IQetIIXa * -(trffluoromethyl) pirtoln-3yl] methyl}) amine Me Γ | l μ T n k ° ti /603 [(3,5-dffluorofanll) * n »tll] ({2 [(9RHH3-metllfenll) -6oxaspospiro [4.5] decan-9il] etll}) amine Me Ffll Η Λ604 {2 - [(9R) -9- (3-methylphenyl) -6oxaspospiro [4. $] decan-9il] etll} [3 methylphenyl) methyl] amine Me Tb '' 0 '·605 [(5-chloropyridin-3ll) me «l] ({2 <(9R) -9- {3 (trtfluoromatoxy) fanllHoxaa« piro [4.5] daean4 · IQetll}) amlna OCFj Cl •
    168
    Compound Name Structure 606 {2 - [(9RH) T3. (trffluoromethoxyKenitJ-βoxaesplro | 4.5] decan-9-(trtnuoromethyl) plridln-3 · ll] metll}) amine OCFj CFjCo607 (2- «9RH943 (trifluoromethoxy) phenyl] -6oxaspospiro [4.5] decan-9H] ethylX {[4.(trifluoromethiQpiridin-3yl] methyl}) amine QCFaécAXi608 [(3,5-difluorofsnil) matll] ({2 [(9R) -9- [3 (trifluoromethoxy) phenyl] -6oxaspiro [4.5] decan-9il] ethyl}) amine OCFj FOh ^ sXlp609 [(3-me «lphenyl) metiQ ({2 [(9RHH3-(trifluorom »t6xl) feniq-6oxaesplro [4.5] decan-9 · 'il] etll}) amtna ocf 3 OkçJ '* xAA CH3 MO610 [(5-chloropyridin-3ll) metll] ({2 - [(9R) -9- [4 (tnfluorometii) phenyl] -6oxasplro [4.5] decan-9il] etll>) amine 1 ll H f 1 MK / NN 611 {2 <(9R) -9- [4 (trifluoromethyl) phenyl] -6oxasposp [4.5] decan-9ll] ethyl} ({[5-{triflu <xxxnetyl) plrldin-3yl] methyl}) amine
    169
    Compound; Name Structure 612 {2 - [(9R) -9- [4 (trifluoromethyl) phenyl] -6oxasposp [4.5] decan-9il] ethyl} {{[4 {trifluoromethy) pyridin-3yl] methyl}) amine 613 [(3,5-difluorophenyl) methyl (({{2R9R ^ - {4 (trifluoromethyl) phenyl] -6oxaspiro [4.5] decan-9H] ethyl}) amine FΓ 11 hr a • 614 [(3-meÜlfenll) methyl] ({2 ((9R) -H4 (trtfluoronietyl) phenyl] -6oxasposp [4.5] decan-9yl] ethyl}) amine XIA XIUH; 615 [(5 * chloro-lldldin * 3 »ll) methyl] ({2q9R) -9- (3fluorophenll) -6 * oxaspiro [4.5] decan-9II] etiQ) amine Ο-inzx616 (24 (9R) -9q3-flow <x> phenyl)> 6oxaspospiro [4.5] decan-9H] ethylX {[5.(trifkioro «netii) pirid! n-3yl] methyl}) amine 1 Γ 5 617 {2 - [{9R) -943-fluorophenyl) -6oxaspospiro [4.5] decan-9ll] etll} ({[4 ·(trifluoromatil) pyridin-3yl] methyl}> amlna ç
    170
    Compound 1 Name Structure 618 [(3,5-difluorophenyl) methyl] ({2 [(9RHH3-fluorophenll) * € ~ oxaspospiro [4.5] decan-9il] ethyl}) amine 1 FF rSi h 619 {2 - [(9R) -943-fluorophenll) - € oxaspiro [4.5] decan-9il] ethyl} [(3metllphenyl) metll] amine F620 [(5-chloroplrídin-3II) methyl] ({2- (9R) -9- {3 (trifluoromethyl) phenyl] -6 · oxaspiro [4.5] decan-9ii] ethyl}) amine ÇFi Cl621 {2 - [(9R) * 9- [3 (trifluoromethyl) phenyl] -6oxasplro [4.5] decan-9il] etll} ({(5 (trtfluoromatll) pyridin * 3ll] metfl}) amine I CF3 UÉ3ULçJ. „Ó622 {2 - ({9R) -9- [3 (trifluoromethyl) fentl] -6oxasespíro [4.5] decan-9il] etll} ({[4 (trifluorom »tll) pyridin-3ll] methyl}) amlna 1 T 5 Rb623 [<3,5-dtfluorophenll) methyl] ({2 ((9RHH3 (trifluorom «tll) fenll] -6 · oxaspiro [4.5jdecan-9Ü] atH}) amine çf 3 f
    171
    Compound Name
    Structure
    624 [(3-methylfeoyl) methyl] ({2. [(SR) -943 (trifluoromethyl) phenyl] -6oxasposp (4.5] decan-9ll] ethyl}) amlna
    625
    626 [(5-chloropyridin-3H) metN] (methylH2 <(9R) - «(plridin-24l) -6oxasposp {4.5] decan-9H] etlQamlna
    1H NMR (400 MHz, CD3CN) 6 8.77 (dd, 3 »5.6, 1.3, IH), 8.67 (d, 3 = 2.0, IH), 8.53 (s, 1H), 8.41 (td, 3« 8, 0.1.6, 1H), 7.93 (m, 2H), 7.85 (m, 1H), 4.18 (s, 2H), 3.76 (ddd, 3 - 12.4, 11.3, 5.5.2H), 3.09 (d, J = 5.1 , IH), 2.65 (s, 3H), 2.55 (m, 2H). 2.33 (m, 3H), 2.08 (d, 3 “14.2, IH), 1.84 (m, 2H), 1.53 (m, 5H), 1.21 (m, IH), 0.77 (d, J = 13.2, IH ).
    methyl ({2 - [(9R) -9- (pyridin-2-ll) 6-oxasposp [4.5] decan-9il] etii}) ([5 (trifluoromethyl) pyridin-3yl] methyl) amine
    MS: 434.3
    IH NMR (400 MHz, CD3CN) δ 8.99 (S, IH), 8.84 (», 4H), 8.77 (m, IH), 8.40 (td, 3 8.0, 1.6, IH), 8.23 ($, IH), 7.91 (d, 3 - 8.2, IH), 7.84 (dd, 3 = 6.9.6.3, IH), 4.26 (s, 2H), 3.77 (m, 2H), 3.11 (d, 3 - 4.8, 1HX 2.63 (s. 3H), 2.57 (ddd, J = 17.4.12.8.8.9.2H), 2.34 (dd, J = 19.0.9.6.3H), 2.09 (d, 3 - 14.2.1H), 1.86 (m, 2HX 1.54 (m , 5H), 1.20 (dd, J = 9.5,3.8, IH), 0.77 (dd, J “9.0.4.1, IH).
    172
    Compound
    627
    Name (2H2) 1 {24 (9RWplrldin-2-ll) 6-oxaspira [4.5} decan-9il] etit) amine
    Structure
    MS: 3882
    IH NMR (400 MHz, CD3CN) ó 9.51 (s, IH), 8.48 (d, J - 1.9, IH), 8.45 (d, J - 2.3, IH), 8.42 (ddd, J = 4.8,1.8,0.8, IH), 8.06 (m, IH), 7.64 (td, J - 7.8, 1.8.1H), 7.33 (d, J = 8.1.1H), 7.12 (ddd, J = 7.4,4.8,0.7, IH), 3.57 (m, 2H), 2.74 (td, J = 12.0,4.7, IH), 2.21 (m, 4H), 1.96 (dt, J = 12.4,6.1, IH), 1.76 (d, J - 13.8, IH), 1.63 (dd, J 9.9, 5.9, IH), 1.40 (m, 6H), 0.95 (m, IH), 0.59 (m, IH).
    628 ({2 - {(9R) -9- (plrldln-2-W} 45oxasposp [4.5] decan-9ll] etll}) {[5 (tnfluoromethyl) pyridin-3 · iqmetiH2H2)} amlna
    MS: 422.3 l H NMR (400 MHz, CD3CN) δ 944 (s, 1H), 8.82 (d, J - 1.9, IH), 8.78 (d, J - 1.2, IH), 8.40 (ddd, J = 4.8,1.8,0.9, IH), 8.31 (m, IH), 7.61 (m, IH), 7.31 (m, IH), 7.09 (ddd, J - 7.4,4.8,1.0, IH), 3.57 (m, 2H ), 2.74 (m, IH). 2.24 (m, 3H), 2.10 (m, IH), 1.95 (dd, J = 12.5. 4.7, IH), 1.75 (d, J - 13.6, 1H), 1.44 (m, 7H), 0.96 (s, IH ), 0.59 (m, IH).
    173
    Compound 1 Name Structure 629 {2 - [{9R) -9- (plridln-2-ll) -6 · oxaspiro [4.5] decan-9il] ethyl} ({[6 (trlfluoromethyl) plrldin-2-yl] methyl)) amine MS: 420.2l H WMR. (400 MHx. CD3CN) δ 8.70 (dd. 3 - 5.2. 1.1.1HX ».5 3 (bn. 1 H>. 1II (td. 3 * 7.9,1.7. IHX1.05 (t. J - 7.9. 1HX 7.80 (d. J = 7.8.1H), 7.70 (d, 3 · »2, 1 H), 757 (ddd. 1 '83.7,5.4.4, IHX 6.51 (bn. 1 HX4 29 (m. IHX3. 73 (m. IHX 3.09 (td, J - 11.8, SJ. IHX 160 (td. 3- 11.9.4.8. IHX 2.36 (ra, 3HX 246 (m, IHX 1.9> (nx IHX 1.77 (ddd. 3- 14.0.9.0.5 I.2HX 1.62 (m, IHX1 48 (m.4HX 1.16 (466.3-1.5,7.0,3.5, lHX0.78 (dt, J = 13.1. 8.9, IH>H | flm lZ / 630 {2 - [(9R) -9- (pyridin-2-yl) -6oxasespíro [4.5] decan-9iqMiiMas.(trifluoromethyl) pyrldln-2ir) methyl}) amine MS: 420.2 l H NMR (400 MHz, CD3CN) 6 8.16 (d, J - 0.8, IH), 8.77 (dd, J - 5.4,1.2, IH), 8.20 (m, IH), 8.11 (dd, J = 8.3,1.9,1H), 7.77 (d, J - 8.2,1H), 7.66 (ddd, J - 7.6,5.4,0.9, IHX7.53 (d, J = 8.3, IHX 431 (m, 2H), 3.73 (m, 2H), 3.09 (td, J - 11.9.5.4, 1H), 2.60 (td. J - 11.9.4.6.1H), 239 (m, 3HX 2.21 (ddd, J - 13.6, 11.8,5.4, IH), 2.02 (d. J · 14.0, 1H), 1.80 (ddd, J-9.5,83,4.6,2H). 1.63 (m, IH), 1.49 (qddj »13.9, 8.5.3.5.4HX l.I9 (m,! H), 0.80 (dXJ = 13.1,8.8, IH). rBi h rnr CFl nÇxÇ ^ n
    174
    Compound ί
    Name
    Structure
    632 (2 - [(9R) -94plridln-24IMoxospira (4.5] decan-9il] ethyl) (pyridin-2llmettl) amlna
    MS: 352.3
    1H NMR (400 MHz, CD3CN) δ 10.49 (s, IH), 8.81 (dd, J »5.5.1.2, IH), 8.55 (dd, J = 3.7.0.8.1H), 8.30 (td, J = 8.0, 1.7.1H),
    7.91 (td, J - 7.8, 1.7, IH), 7.83 (d, J = 8.2, IH), 7.75 (ddd, J “7.6, 5.5.1.0, IH), 7.45 (dd, J - 11.3,6.5.2H ), 4.24 (m, 2H), 3.73 (m, 2H), 3.06 (td. J »12.0, 5.2, IH), 2.57 (td, J - 12.1,4.4, 1H), 2.39 (m, 3H), 2.24 (m, IH), 2.04 (d, J = 14.0, IH), 1.82 (m, 2H), 1.63 (m, IH), 1.50 (m, 4H), 1.19 (m, IH), 0.81 (dt, J - 12.9, 8.8, IH).
    (2 - ((9R) -9- (pyridin-2-ll) -6oxaasp | ro (4.5] decan-9ll] ethylXi> lridin ~ 3 ~ ylmethyl) amine
    MS: 352.3.
    IH NMR (400 MHz, CD3CN) δ 8.81 (s, IH), 8.74 (m, 2H), 8.32 (d, J = 8.1, IH), 8.26 (td. J - 8.0.1.7.
    1H), 7.80 (m, 2H). 7.70 (m, 1H), 4.18 (m, 2H), 3.73 (m, 2H). 3.02 (td, J = 12.0.5.1. IH), 2.51 (td, J · 12,1,4.3, IH), 2.36 (m, 3H), 2.15 (m, IH). 2.01 (dJ -14.1, IH), 1.80 (ddd. J = 9.8.8.2.4.7.2H), 1.62 (m, IH), 1.48 (m, 4H), 1.19 (m. IH), 0.80 (dt, J = 13.0.8.8. IH).
    175
    Compound I
    633
    Name {2 - [(9R) -9- (pIrldln-2-yl) -6oxa «spiro {4.5] decan-9ll] ethyl) (pyrldín-4ilmetiljamina
    MS: 352.3
    IH NMR (400 MHz, CD3CN) δ 8.73 (m, 3H), 8.20 (td, J = 8.0,1.7, IH), 7.82 (d, J = 6.5.2H1 7.76 (d, J - 8.2, IH1 7.65 (m , IH), 4.22 (m, 2H), 3.73 (tn, 2H), 3.03 (td, J - 12.0, 5.1, IH), 2.53 (td. J »12.1, 44. IH), 2.37 (m, 3H), 2.16 (m, IH), 2.00 (d, J = 14.2.1H), 1.79 (m, 2H), 1.63 (ddd, J = 12.2,8.8,4.0, IH), 1.49 (tn, 4H), Ll9 (m, 1H), 0.80 (dtj-13.1, 8.9, IH).
    634 (1 H-lmldazole * 44 methyl) ({2> ((9R) -9- (pyridin-2-yl) -6oxaspane [4.5] decan-9ll] etll}) amine
    MS: 341.2
    IHHMR (400MHi, CO3CH) 6 8 75 (dtl, J-5.4, t.2, IH), 8.S4 (d.3 · 10, IH). t.22 (td. J - 8 0. 16. I Hi 7.77 (d. J - 8.2, IH),
    7.67 (dd, 1-61. 5.6. IH). 7.47 (J, I H 4:18 (s , 2H 3.72 (m , 2H), 2.92 (td f - 12.1, 5.0, IH), 2,... 38 (m , 4H) 2.13 (m, I2.00.. (m, IHK 1.79 (tn, W). 1.63 (m, tH l. «(tn.4H). LI9 (tn, IH), 0. (2 (dt, J - 13.1,1.9.1 H >
    635 [(2-methylpyridin-4yl) methyl] ({2 - [(9R) -9- (pyridin-211) -0 .oxasposp [4.5] decan-9ll] atyl}) amlna
    MS: 366.3
    IΗ NM R (400 MHz, CDJCN) 8 8.71 (d. J - 1.9.1H). t.65 (dd.> - 5.1.1A IHX tit (dd. J - 8.2.2.1, IH). Í.02 (td. 3 - 7.9, 1.8. IHk 764 (d, J = 8.1.2H), 7.49 (dd.3-6.7, 5 2, IH), 4 13 (m. 2HX 3 71 («η. 2H). 3.00 (td. J = t ll 5.1. IH). 2.71 (». 3HX 2.50 (td, J = II .9,4.6,1H), 2.37 (m, 2H). 2.23 (tn, 1H). 2 06 (dd. J 12.0, 5.1.1 1.76 (ddt, J »Η. 1.9.4, 3.8, 3H), I 61 (dd, 3 16.6.9.7. IHk 1.49 (m, 4H), 1.16 (d, J “11.3.1 Hl 0.76 (dt. J» 13.1,8.9.1H>
    176
    Compound I Name
    Structure (2 - [(9R) -9 * (pyridin-2 * it) * eoxaesplro [4.5] decan-9ll] etll} ({[2 (trifliioromethyl) pyridin-4yl] metll)) amine
    MS: 420.2
    IH NMR («0 MH *. CD3CN) S175 (d, J - 5.1. 2H1» 30 (id, J «1.1.4, IH). 7.14 (m, 2Hl 774 (m, IHl7.63 (d. J - 4.7, 1H1 4.I3 (m. 2H13.73 (m. IH), 30 »(* k J - 11 9.5.0. IH), 2.45 (m. 4H), 2.22 (Id, J -» 3.0.5.0 , IH), 2.03 (dj - 14 |, IH). 1 11 (m. 2H), I 63 (m, 1Η), I 49 (m, 4H1 1.21 (dd, I - 9.4.5 I. I Hl 0 . »I (dt, J-12.8. I». IH)
    637 [(6-chloropyridin-3yl) methyl] ({2 - {(9R) -9- (pyrldin-2yl) -6-oxasposp [4.5] decan-9il] ethyl}) amine
    638 [(1-methyl-1 H-imidazol-2 · yl) methyl] ({2 - [(9R) -9 (pyridin-2-yl> 6oxae * plro [4.5] dacan-9yl] ethyl)) amine
    MS: 386.2
    IH NMR (400 MH *. CD3CN) 5 »69 (m, I Hl 8.38 (m, IH). I.» 2 (m, IHX 7.8I (m. I Hl 7.70 (ηχ, IH). 7.5 »(m .HI), 7.45 (m. IH), 4.43 (s, t Hl 4.06 MJ - J 3.9.2HX 3.72 (m. 2H12 98 (Id. J 11.9.5 1, IH), 2.48 (id, J - 12.0, 4.4. IH), 2.32 Im. 3Η 2.10 (m, IH). 1.98 (4.7-14, IH). 1.77 (m, 2Hl 1.61 (ddd. J = 150.8.2. 4.0.1 Hl I 48 (m. 4H). 1.16 (ddd, J - 8.7.7.1.4.1. ΙΗξ 0.77 (di. J -13.2. 8.9.1 Η)
    MS: 355.3
    IH NMR (400 MH *. CD3CN) 8 8.71 (ddd, J - 5.3.1 7.06. I «1 8 14 (14,1-80, IS, IH), 7. 3 (d, J» 8J, IHl 7.60 (ddd, J - 7 6, 53,1.0,1 Hl 7 43 (d. J = 1.9. IH17.35 (d, J - 1.9. IH). 4.33 (», 2H). 3.80 (m. 3H13. 72 (d *. J - 15 3.9.3,3.1, 2H13.0J (Id,) “12.0.4 9.1 Hl 2.59 (td. J -12 0.4.6, IH), 136 (m, 3Hl 2.15 (m. IH), 1.99 (m, IH11 8O (m.2H), | W (ddd, J- 14.4.9.9.5.3.
    IH). 1 49 (m, 4H11 I9 (m, 1H10.83 (dl, J - 13.1. »9.1H1
    177
    Compound I
    639
    Name
    Structure (naphthalen-2-llmetllX {2 [(9R) -9- (pyridin-2-yl) -6oxasposp [4.5] clecan-9il] ethyl)) amine
    MS: 401.3
    IHNMX (4OOMHz, CD3CH) 8 »J7 (dd, 3-SO 1.0, IHp.W (m. 5H1 7.59 (m. ZHk 7.54 (d, J -1.1. IH), 7.48 (4H. J - 8.5.1 7 . I Hl 7.34 (m. I Hl 4.19 (4.2H). 3.69 (Λ.> = 8.9.5.1, 3H). 3.4 «(hrs, IHX 302 (*. IH), 2 520, I Hl2. 33 (m, 2H), 2 19 (m. 1H1 2.02 (m. 1HX 1.89 (1 J - 9.4, IH). 1.70 (φ. J -9 2. 5.1. 2H), I 59 (m IH1 I 44 (m, 4H), 1.0 (I, IH), 0.69 (61.3-13.1.8 ', IH1 [(6-bromo-5-fluoropyridine-3yl) metM) ({2 - [(9R ) -9- (plridín-211) -6-oxaesplro [4.5] decan-9il] ethyl}) amine
    MS: 448.2
    IH HMR ¢ 400 MHz. CD3CH) 6 8.68 (4d, J = 5.2. 1.2.1H1 8.24 (d, J-IS, IH). »12 (id, 3-7,9.1.7. IH), 7.71 (m. 2H1 7.58 (dd, 3 * 7.1,5,7,1H14J8 (», IH). 4.08 (4, J - 14.0,2H). 3.72 (m. 2«! 2.9 »(id, 3» 11.9. 5.1.1H) .2.4 ”(id, 3-12.0.4.4, IHX232 (m, 3H). 2.11 (m, IH). 1.9” (d. 3 - 25, IH), 1.77 (m, 2H ), 1.61 (m, 1 Η). 1.4 «(m. 4H), 1.17 (m J Hl 0.77 (dt, J - 13.1.8.9. IH).
    641 [(5-methanossuWontlpiridln-3il) me «l] ({2 - [(9R) -9- (pyridin-2yl) -6-oxasplro [4.5] decan-9il] ethyl}) amine
    MS: 430.2
    IH NMIt (400 MHz. CD3CN) «9.10 (4. J“ 2.0.1 Hl 8.87 (d. 3 1.8.1H), 8.71 (dkl. J - 5.3.1.1, 1H18.37 (t, 3 “2.0, 1H), 8.18 (td. J = 8.0, 1.8.1 Hl 7.75 (d, 3 - Í.2. ÍH), 7Λ3 (ddd, J = 7.6.5.4,0.9. IH14 16 (m.2H13 73 (m, 2H), 3.14 (s. 3H1302 (Μ. J-12.0.
    5.2.1H), 2.S2 (m. IH), 2 33 (m, 3HX 2.14 (m. IH12.01 (m. I Hl 179 (n>, 2H), 1.62 (m. IH), 1 48 (m.4Hl 1.19 (m. IH1079 (dt, 3-13,1.89, IH)
    178
    Compound I
    642
    Name [2- {3-mettlfenll) eül] ({2 [(9R) -9- (pyridin-2yl) -6-oxasposp [4.5] decan-9 · [2- (3-chlorophenH) eaiK {2 [( 9R) -9- (pyridin-2yl) -6-oxasposp (4.5] decan-9 * yl) ethyl}) amine [2 * (3 * bromophenyl) ethyl] ({2 * Í (9R) -9- (pyridine) -2-yl) -6oxaesplro [4.5] decan-9il] etll}) amlna [2- (3-fluorophenyl) ethyl] ({2 [(9R) -9 * (pyridin-2IIHI-oxaespiro (4.5] decan-dll ] ethyl}) amine
    Structure

    646 {24 (9R) -9qpiridin-2-IIHoxasospiro [4.5] decan-9il] etll} ({2- [3 (trffli »ronwtil) pheniqetil}) amine
    647 [2- (3-methoxyphenyl) ethyl] ((2 [(9RH4pÍridln-2ll) -6-oxasespíro [4.5] decan-9il] ethyl}) amine

    179
    180
    Compound __
    Name
    Structure
    655
    656
    658
    659 [2- (2 * metllphenyl) ethyl] {{2 [(9R) -9- (pyridin-2ll) -6-oxasposp [4.5) decan-9iljetH}) amlna [2- (2-chlorophenyl) ethyl) ( {2 [(9R) 4- (pHdin-2il) -6-oxaesplro [4.5] decan-9 [2- (24> romofenll) etll] ([2 [(9R) -9- (plridln-2-yl) -eoxaspiro [4.5] decan-9iqethyl}) amine [2- (2-fluorophenyl) etllJ ({2 - [(9R) 9- (pyridin-2l!) - 6-oxaesplro [4.5] decan-9il) ethyl)) amine {2 - [(9R) -9 «(pyridine« 24l) · © oxaesplro [4.5] decan-9il] eti! X {2- [2 (trifluoromethyl) fe «ill] ettl}) amine
    P42-methoxyphenyl) etiq ({2 [(9R) -9- (pyridin-2yl) -6-oxasposp [4.5] decan-9ll} ethyl}) amlna

    Example____15: Synthesis of [(3-methoxyphenophen-2yl) methyl] ({2 - [(9R) -9 (pyridin-2-yl) -6-oxasposp [4.5] decan-9-yl] ethyl}) amine (compound 140).
    181
    Methyl 2-cyano-2- [6-oxaspospiro [4.5] decan-9ylidene] acetate (mixture of E and Z isomers) o
    A mixture of 6-oxaospiro [4.5] decan-9-one (13.74 g, 89.1 mmol), methylcyanoacetate (9.4 ml, 106.9 mmol), ammonium acetate (1.79 g, 26 , 17 mmol) and acetic acid (1.02 ml, 17.8 mmol) in benzene (75 ml) was heated to reflux in a 250 ml round bottom flask equipped with a Dean-Stark and a reflux condenser. After 3 h, TLC (25% EtOAc in hexane, PMA staining) showed that the reaction was complete. After cooling, benzene (50 ml) was added and the layer was separated, the organic layer was washed with water (120 ml) and the aqueous was extracted with CH2 Cl2 (3 x 120 ml). The combined organic was washed with saturated NaHCCh, brine, dried and concentrated and the residue was purified by flash chromatography (340 g of silica gel column, eluted by EtOAc in hexane: 5% EtOAc, 2CV; 5-25%, 14CV; 25-40%, 8 CV) gave a mixture of E and Z isomers: methyl 2-cyano-2- [6-oxasposp [4.5] decan-9ylidene] acetate (18.37 g, 87.8% yield, m / z 236.0 [M + H] + observed) as a clear oil.
    2-Cyano-2- [9- (pyridin-2-yl) -6-oxaspiro acetate
    182 [4.5] methyl decan-9-yl]
    A solution of 2-bromopyridine (14.4 ml, 150 mmol) in THF (75 ml) was added dropwise to a solution of isopropylmagnesium chloride (75 ml, 2M in THF) at 0 ° C under N2, the mixture was then stirred at room temperature for 3 h, copper iodide (2.59 g, 13.6 mmol) was added and left to stir at room temperature for an additional 30 min before a solution of a mixture of E and Z isomers of acetate of methyl 2-cyano-2- [6-oxaspiro [4.5] decan-9-ylidene] (16 g, 150 mmol) in THF (60 ml) be added in 30 min. The mixture was then stirred at room temperature for 18h. The reaction mixture was poured into a mixture of 200 g ice / 2 N HCl (100 ml). The product was extracted with Et2 <3 (3 x 300 ml), washed with brine (200 ml), dried (Na2SC> 4) and concentrated. The residue was purified by flash chromatography (100 g of silica gel column, eluted by EtOAc in hexane: 3% 2CV; 3-25%, 12 CV; 25-40% 6CV gave 2-cyano2- acetate [9- (pyridin-2-yl) -6-oxaspospiro [4.5] decan-9-yl] methyl (15.44 g, 72% yield, m / z 315.0 [M + H] + observed)
    183 like an amber oil.
    2- [9- (Pyridin-2-yl) -6-oxospira acetonitrile [4.5] decan-9-yl]
    Ethylene glycol (300 ml) was added to methyl 2-cyano-2- [9- (pyridin-2-yl) -6-oxasposp [4.5] decan-9-yl] acetate (15.43 g, 49 mmol) followed by potassium hydroxide (5.5 g, 98 mmol), the resulting mixture was heated to 120 ° C, after 3 h, the reaction mixture was cooled and water (300 ml) was added, the product was extracted by Et20 (3 x 400 ml), washed with water (200 ml), dried (NasSOj and concentrated, the residue was purified by flash chromatography (340 g of silica gel column, eluted by EtOAc in hexane: 3% 2CV; 3 -25%, 12 CV; 25-40% 6CV to give 2- [9- (pyridin-2-yl) -6-oxasposp [4.5] decan-9-yl] acetonitrile (10.37 g, 82% yield, m / z 257.0 [M + H] + observed).
    2 - [(9R) -9- (pyridin-2-yl) -6-oxaspospiro [4.5] decan-9-yl] acetonitrile
    184
    Racemic 2- [9- (pyridin-2-yl) -6-oxasposp [4.5] decan-9-yl] acetonitrile was separated by a chiral HPLC column under the following preparative CFS conditions: Instrument: SFC-80 (Thar , Waters); column: Chiralpak AD-H (Daicel); column temperature: 40 ° C; mobile phase: methanol / CO2 = 40/60; flow: 70 g / min; back pressure: 120 Bar; battery injection cycle time: 6.0 min; Injection loading: 225 mg; under these conditions, 2- [9- (pyridin-2-yl) -6oxasposp [4.5] decan-9-yl] acetonitrile (4.0 g) was separated to give the desired isomer, 2 - [(9R) -9 - (pyridin-2yl) -6- oxasposp [4.5] decan-9-yl] acetonitrile (2.0 g,> 99.5% enantiomeric excess) as a slow-moving fraction. The absolute configuration (R) of the desired isomer was then determined by an X-ray crystal structure analysis of compound 140.
    2- [(9R) -9- (Pyridin-2-yl) -6-oxaspospiro [4.5] decan-9il] ethan-l-amine
    Et 2 O, ml, mmol) was added to a solution of 2- [(9R) -9- (pyridin-2-yl) - 6-oxasposp [4.5] decan-9-yl] acetonitrile (2.56 g, 10 mmol) in Et2O
    185 (100 ml, Ο, ΙΜ) at 0 ° C under N 2 . The resulting mixture was stirred and allowed to warm to room temperature. After 2 h, LCMS showed that the reaction was complete. The reaction was cooled to 0 ° C and quenched with water (1.12 ml), NaOH (10%, 2.24 ml) and an additional 3.36 ml of water. The solid was filtered and the filter pad was washed with ether (3 x 20 ml). The combined organic was dried and concentrated to give 2 - [(9R) -9- (pyridin-2-yl) -6- oxasposp [4.5] decan-9-yl] ethan1-amine (2.44 g, 94% yield, m / z 260.6 [M + H] + observed) as a light amber oil.
    Alternatively, 2 - [(9R) -9- (pyridin-2-yl) -6-oxasposp [4.5] decan-9-yl] ethan-1-amine was prepared by Raney nickel catalyzed hydrogenation.
    An autoclave vessel was loaded with 2 - [(9R) -9 (pyridin-2-yl) -6-oxasposp [4,5] decan-9-yl] acetonitrile and ammonia (7N solution in methanol). The resulting solution was stirred under ambient conditions for 15 minutes and treated with Raney 2800 nickel, suspended in water. The vessel was pressurized to 21 kg / cm 2 (30 psi) with nitrogen and stirred briefly. The autoclave was ventilated and the purged with additional nitrogen was repeated twice. The vessel was pressurized to 21 kg / cm 2 (30 psi) with hydrogen and stirred briefly. The vessel was vented and purged with hydrogen two more times. The vessel was pressurized at 85-90
    186 psi with hydrogen and the mixture was heated to 25-35 ° C. The internal temperature was raised to 45-50 ° C for 3060 minutes. The reaction mixture was stirred at 45-50 ° C for 3 days. The reaction was monitored by HPLC. Once the reaction was considered complete, it was cooled to room temperature and filtered through celite. The filter cake was washed with methanol (2 x). The combined filtrates were concentrated under reduced pressure at 40-45 ° C. The resulting residue was co-evaporated with EtOH (3 x) and dried in a thick syrup of 2 - [(9R) -9- (pyridin-2-yl) -6oxasposp [4.5] decan-9-yl] etan-1 -the mine.
    [(3-Methoxyphenophen-2-yl) methyl] ({2- [(9R) -9- (pyridin-2yl) -6-oxasposp [4.5] decan-9-yl] ethyl}) amine / o.
    In a flask were added 2 - [(9R) -9- (pyridin-2yl) -6-oxasposp [4.5] decan-9-yl] ethan-1-amine (500 mg, 1.92 mmol), 18 mL of CH2Cl2 and sodium sulfate (1.3 g, 9.6 mmol). 3-Methoxythiophene-2-carboxaldehyde (354 mg, 2.4 mmol) was then added, and the mixture was stirred overnight. NaBH4 (94 mg, 2.4 mmol) was added to the reaction mixture, stirred for 10 minutes, and then MeOH (6.0 mL) was added, stirred 1 h, and finally cooled
    187 sharply with water. The organics were separated and evaporated. The crude residue was purified by prep Gilson HPLC. The desired fractions are collected and concentrated and lyophilized. After lyophilization, the residue was divided between CH2C12 and 2N NaOH, and the organic layers were collected. Then the solvent was concentrated in half the volume, 1.0 eq of IN HCl in Et2O was added, and most of the solvent evaporated under reduced pressure. The obtained solid was washed several times with Et2O and dried to give [(3-methoxythiophen-2-yl) methyl] ({2 - [(9R) -9- (pyridin-2-yl) -6-oxasposp [] monohydrochloride] 4.5] decan-9yl] ethyl}) amine (336 mg, 41% yield, m / z 387.0 [M + H] + observed) as a white solid. The NMR for compostol40 is described here.
    Example 16: Biological example
    Procedure for testing for antinociception
    The hot plate test is adapted from the procedure originally described by O'Callaghan and Holtzman (JPET, 192, 497, 1975) and is commonly used to determine the potential analgesic efficacy of opioid agonists. The antinociceptive effect of the composition (s) described here on the hot plate is expressed in% MPE (maximum possible effect).
    Rats (175-250g) or mice (20-30 g) were
    188 acclimatized in the nursery for at least 48 h before the behavioral test. The test drugs were administered via the subcutaneous route (SC). Animals were placed on the hot plate, where the temperature was fixed at 50-56 ° C, depending on the in vitro potency of the compound. A cut-off time of 30-60 seconds was used depending on the temperature of the hot plate so that the animal's paws exhibiting analgesia were not damaged by the heat stimulus. The cut-off time was considered to be 100% response to thermal insult. Before treatment with the drug, each animal was tested to determine the baseline response. Thirty minutes after drug administration, animals were tested again. Dose response experiments were performed to assess the potency of the test compound when multiple doses were administered at the point when maximum analgesia is observed.
    % MPE was calculated according to the following formula:% MPE = [(latency after drug - baseline latency) / (60 or 30 - baseline latency)] x 100
    ED 5 o values were calculated from the mean values in% MPE for each group using the logarithmic dose response curves by minus-square regression analysis.
    Table 4
    Compound ED50 or% MPE
    189
    Morphine 3.8 mg / kg SC 81 Compound 100% to 10mg / kg SC 122 Compound 1.1 mg / kg SC 28 Compound 1.2 mg / kg SC 145 Compound 5.9 mg / kg SC
    Results are shown in table 4. Native or control mice typically exhibit 10-15 second reaction times on the hot plate. The ED50 for morphine in the hot plate mouse was 3.8 mg / kg with complete efficacy observed at a dose of 10 mg / kg SC. For comparison, compound 122 and compound 28 produced potent efficacy with an ED 50 of 1.1 and 1.2 mg / kg SC, respectively. These results demonstrate that the compound
    122 and compound 28 produced a more robust analgesic effect in the hot plate test with mice compared to morphine.
    Example 17: In vivo administration to humans (prophetic example)
    One or more compounds will be administered in a range of
    190 dosage of 0.15 mg to 4 mg in human subject. The compound (s) will be administered as a continuous infusion over one hour. The dose can be scaled as deemed appropriate for pain relief. The dose escalation will generally not exceed 5 times as compared to the previous dose. Dosage amounts, however, can be repeated or decreased as deemed appropriate. Individuals will be tested for their ability to withstand or not appreciate pain as compared to a control group (placebo).
    The cold pain test was shown to be a reproducible and sensitive measure of the effect of opiates and other centrally acting drugs (Van F and Rolan PE. The utility of the cold pain test to measure analgesia from intravenous morphine. Br. J. Clin. Pharmacol. 1996; 42: 663-664; Posner J. Pain Models in Healthy Volunteers. In: Nimmo WS, Tucker G, eds. Clinical Measurement in Drug Evaluation. 1991, Wolfe Publishing Limited, UK.; Wotherspoon HA, Kenny GNC, McArdle CS. Analgesic Efficacy of Controlled-Release DihydroCodeine. Anesthesia 1991; 46: 915-917. Lamb RJ, Mercer AJ, Posner J. The effect of lamotrigine (3 00 mg) and dipipanone (4 mg and 8 mg), alone and in combination, on the cold-pain test in healthy volunteers. Br. J. Clin. Pharmacol. 1994; 39: 539-588P.).
    191
    In the test, an individual's hand is immersed in cold water cooled to a range of 1 to 3 ° C. The initial sensation of cold is replaced by discomfort from a deep burn in the hand, which is mediated by nociceptors in the veins. The discomfort gradually grows to a plateau over approximately 90 seconds and then either persists or subsides slightly. The stimulus is easily controlled and the response is reproducible. The technique has been shown to be sensitive to different doses of analgesic drugs.
    During the cold pain test, the individual will sit down and place their non-dominant hand in a shaking water bath, thermostatically controlled at about 2 ° C. With the other hand, the individual can adjust a visual analog scale on a computer screen using the arrow keys on the keyboard. The scale is labeled painless on one end and maximum pain on the other end. The pointer will initially be at the pain-free end and the subject will move the pointer across the line to classify their feelings continuously during the test period. At the end of 2 minutes, the computer will automatically instruct the individual to remove their hand, which can then be dried. The cold pain test has been used extensively in studies with healthy volunteers and is non-invasive.
    192
    It will be expected that administration of the compound (s) will allow the human subject to feel no pain or feel less pain compared to the control group.
    Although the compounds described herein have been described with reference to the examples, those skilled in the art recognize that various modifications can be made without departing from the spirit and scope of the same.
    All of the above US patents, US patent application publications, US patent applications, foreign patents, foreign patent applications and non-patent publications mentioned in this report and / or listed in the Order Data Form are incorporated herein by reference, in their in total, including, but not limited to, US provisional application number 61 / 596,808, filed on February 9, 2012, and US provisional application number
    61 / 466,809, filed on March 23, 2011.
    权利要求:
    Claims (6)
    [1]
    1. Compound f characterized by the fact that it has the Formula IV-1 structure:

    [2]
    2) {2- [z-ethyl-4-H-fluorophenyl) ~ 2 ~ methyloxan-4-yl] ethyl) amino) methyl] phenol

    [3]
    3) {2 - [2,2-dimethi 1-4- / 4-methyl 1 phenyl) ox.an-4i 1] ethyl} f H ~ methoxyphenyl) methyl] amine • meth 1 f en i 1) o xa π - 4

    [4]
    7) 2 ~ [({2- [2 ~ etii-4- (4 ~. Fluorophenyl) “2-methylxanamino) methyl] phenal

    [5]
    11) ethyl] amine

    [6]
    14) [(3,4-dimethylphenyl) methyl] ({2- [2-ethyl-4 ~ (2 methoxyphenyl) ~ 2-methylzan-4 ~ .11] ethyl}) amine

    4 - [({2- [4- (2-methoxyphenyl) ~ 2,2-dimethylQxan ~ 4 methyl} -Ν, Ν-dimethylaniline

    MH-— · '
    4- (4-fluorophenyl dimethyloxan-4-yl] ethyl})

    2 "dimethyl-4- (4-methylphenyl) oxan-4-;
    etill (1-phenylethyl)

    IS) [2- (2,2 — dimethyl-4-phenyloxan-4 — i methoxyphenyl1) methyl] amine

    (4- (4-Fluorophenyl) -2 f 2-dim.et i loxan-4 i1] eti1} [(4-methoxypheni1) methi1} amine and
    20) [{3,4-dimethoxyphenyl) methyl] [2- (2,2 ~ dimethyl ~ 4 ~ phenyloxan ~ 4-yl) ethyl] amine


    19. Compound according to claim 18, characterized by the fact that the aryl groups or the cyclo groups have 1-3 heteroatoms, in which the heteroatoms are selected from the group consisting of O, N and S.
    20. Compound according to claim 18 or 19, characterized in that each aryl group or each cycle group is independently substituted with one or more substitution groups selected from the group consisting of F, Cl, Br, CH 5f CH2CH3 , CH 2 F, CHFs, CF , n-Pr, n ~ Bu, i-Bu, sec-Bu, i-Pr, t-Bu, CR, OH, OMe, ÓEt, Q-iPr, OCF3, methoxycarbonyl, methanesulfonyl, Ph, benzyl, formyl, and acetyl.
    A compound according to any one of claims 18-20. characterized by the fact that each arila group is independently selected from among the group consisting of :.



    5 where Χχ and the cycle are independently selected from the group consisting of 0, S, N, bH, and NRie, where Ris is selected from the group consisting of cyan, halogen, hydroxyl, alkyloxy, alkyl, branched alkyl, alkyl halogenated, halogenated alkyl
    10 branched, aryl, arylalkyl, carbocyclic, carbocycloalkyl, alkylcarbonyl, branched alkylcarbonyl, halogenatedcarbonyl, halogenated alkylcarbonyl, atylcarbonyl and alkoxycarbonyl
    23. Composed according to any of the
    15 claims 18-23, characterized by fact A; ; and A «are connected by a carbon bridge.
    24. Composed according to. claim 23, characterized in that the bridge comprises -CH:. · - or -CH 2 .CH 2 ~.
    25. A compound according to any one of claims 18-24, characterized by the fact that d® that when carbon is connected to D ; . is fused with another ring, Ai, As, Α ·>, fp, A ·:, form a ring selected from the group consisting of benzene, pyridine, pyrimidine, furan ·, 25 thiophene and pyridazine »
    26. Compound according to claim 25, characterized in that the ring formed by Aj, A 2 , Ã 3 , A 4 As is independently substituted multiple times with a member of the group consisting of cyan, halogen, 5 alkyl , branched alkyl, halogenated ilkyl, hydroxyl, alkyloxy, formyl, acetyl., amino, alkylamino, diakylamino, mercaptanyl, and alkylamerca.ptanila.
    27 »Compound according to any one of claims 18-26, characterized by the fact that Ri, .0 Rzr Ksr & S, R , Rg, Rs, R1C, Ru, R'2, Rn, R14f Rj..g, R <g, R18, R ^, and Rae are independently selected from the group consisting of F, Cl, Br, CH 3 , CH 2 CH 3 , Cfí 2 F, CHFl, CF 3 , np.ropila, n-butyl, isobutyl, sec-butyl, isopropyl, tert-butyl, CN, OH, OCHj OCH2CH3, Hi-propyl, methoxycarbonyl, 5 phenyl, benzyl , CHO, and COCH -, .
    28. Composed according to. any of claims 18-27, characterized by the fact that Ri and R 2 , R§ and Rg, R to Rg, Rs and Rio, Ru and R 22 , R13 and R14, Ris and Rjg, Rj.se R; m, · or Rm and Ris, independently, form a cycle
    0 monocyclic or heterocycle.
    29. The compound according to any one of claims 18-28, characterized in that each aryl is independently substituted multiple times with groups selected from cyano, halogen, alkyl, branched alkyl, halogenated alkyl, hydroxyl, al il ôx i., amino, here quino. 1 amino, di a qui lamino, me reap ta n il a, a1qu11amer captani1a, aliqu1s u1fon11a, ami sso ss u1fon i1a, a 1 qu 1.1 am i no ssu 1 foni 1 a, a 1 qui 1 a car bon i 1 a, 1 cox 1 ca rboni 1 a, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aryl, arylalkyl, cycle and cycloalkyl.
    30. Compound according to any one of claims 18-29, characterized by the fact that each cycle is independently substituted multiple times with groups selected from cyan, halogen, alkyl,
    5 branched alkyl, halogenated alkyl, hydroxyl, alkyloxy, amino, alkylamino, dialkylamino, mercaptanyl, alkylamercaptanyl, alkylsuitonyl, aminosulfonyl, alkylamlnosulfonyl, - alkyloarbonyl, alkoxycarbonyl, aminocarbonyl ia, aIquylcarbonyl
    10 dialkylaminecarbonlla, aryl, arylalkyl, cycle and cyclic.
    31. Compound according to any one of claims 18-30, characterized by the fact that the connections between Αχ and Aa, Aa and A. , A 3 and A, 5 , A, 3 and A§., Ag and A $, Ag
    15 and Ai and Ag and A they are independently a single link or a double link.
    3: 2. Compound according to any one of claims 18-31, characterized by the fact that the connections between Aj and sp, A 3 and Aj, Aj and As, A «and Ag, A , and Ag, · Ag 20 and Ai e Age Ά they are not simultaneously double bonds.
    33. The compound according to any one of claims 18-32, characterized by the fact that te, Ra, Rs LOL R '>, Rg, Rg, Ria, Rn, Rn, Ria, Ru <Ri-s-, Ris Ris, R 3 .. ô , and R 2 ( j are independently selected from the group
    25 consisting of F, Cl, Br, CH 3 , CH, CH 3 , CB S F, CHF ,, CF 3 , npropyl, n-butyl, isobutyl, sec ~ butyl, i-propyl, t ~ butyl, CF, OH , OCH-a, QCH. ; jCH 3 , O-i-propyl, methoxycarbonyl, phenyl, benryl, formyl, and acetyl.
    34. A compound characterized by the fact that it
    30 Formula II structure:

    on what:
    Αχ- is selected from the group consisting of CHs, CHR.j & CRj.Ríjí
    5 A.} is selected from the group consisting of
    CHx # CHR *, CRsRjo and an Oiclo of the formula C (CHj aif where n «= 2-5;
    R s , Re, R $ and Rio are independently selected from the group consisting of CH , CH S CH 3 , 0 CH 3 F, CHFíz CF 3 , n ~ Pr, n-Bu, i ~ Bu, sec-Bu , i ~ Pr, t ~ Bu and phenyl;
    B is selected from the group consisting of H, alkyl, branched alkyl, aryl, arylalkyl, carbonyl, carbonyl, carbonated,
    5 arylcarbonyl, alkoxyearbonyl and alkylsulfonyl;
    B. 3 is selected from the group consisting of nuio, CHj f He CO;
    B $ is selected from the group consisting of alkyl, branched alkyl, carbocyclic. alkyl Q substituted with carbocycle, aryl s arylalkyl; and
    D it's arila.
    35. A compound according to claim 34, characterized in that each aryl group is independently substituted with one or more of Γ, Cl, Br, .5 CHj, C.HjCH , CH F f CHFx, CF 3 , n ~ Br, n-Bu, i ~ Bu, sec-Bu, i-Pr, t-BU, CN, OH, OMe, OEt, Õ-iPt, OCF 3 , NH 2. , NHMe, PMe a , methoxycarbonyl, methanesulfonyl. Ph, benzyls, fornula and acetetyl.
    35. Composed according to claim 34, characterized by the fact that N is not directly linked to a heteroatamus.
    37, Composed according to claim 3.4,
    5 characterized by the fact that fp and R ^, or ío. and Rio form a mcnocyclic carbocycle.
    38. Compound according to claim 34, characterized by the fact that A;> and A, are connected by a carbon bridge,
    39. A compound according to claim 38, characterized in that the bridge comprises ~ CH 2 - or -CHClU ;: ~.
    40 ... Composed according to. claim 34, characterized by the fact that each aryl or cycle 15 independently has 1 ~ 3 heteroatoms, wherein the heteroatoms are selected from the group consisting of Cf N and S, are not stmatttuxdos, or. su.ost.x <.: Uiuos with substitution groups selected from the group consisting of F, Cl, Br, CH 3 , CH2CH3, CH 2 F, .CHF 2 , CF 3 , n-Pr r n ~ Bu, i -Bu, 20 See-Ba, i ~ Pr, t ~ Bu, CN, OH, ÔMe, OEt, .O ~ iPr, QCF3, methoxycarbonyl, methanesulfonyl, Ph, benzyl, form.ila, and acetyl.
    41. Composed of. according to claim 34, characterized by the fact that each aryl is
    25 independently selected from the group consisting of:




    A't * '



    CHz, CHRg structured

    on what:
    A 2 is selected from the group consisting of and CR5R5;
    is selected from the group consisting of
    CH 2'CHRG, CRyRiíj and a cycle € formula (0¾) ^ where π =
    2-5;
    r 5 , R.5, r »and R 1S are independent and selected from the group consisting of CH S , CH CH,
    5 CH 2 F, CH5, CF - n-Pr, n-Bu, i-Bu, sec-Bu, i-Pr, t-Bu and phenyls;
    B 3 is selected from the group- consisting of H, alkyl, branched alkyl, aryl, arylalkyl, alkylcarbonyl, branched alkylcarbonyl,
    10 arylcarbonyl, alkoxycarbonyl and alkylsulfonyl;
    Bs is selected from the 6th group consisting of null, CHs, CHR; ($, CR ^ R1 and Cl);
    B s is selected from the group consisting of alkyl, branched alkyl, carbocycle, alkyl substituted with. carbocycle, aryl and arylalkyl; and
    Di is an arila.
    43. A compound according to claim 42, characterized in that each aryl group is independently substituted with one or more of F, Cl, Br,
    20 CH ; s, CHsCHs, CHF 2 , CF 3 , π-Pr, n-Bu, i ~ Bu, sec-Bu, i-Pr, t-Bu, CN, OH, OMe, OEt, O-iPr, OCFj, NH2, NHMe and NMe 2 , methoxycarbonyl, methanesulfonyl, Rh, benzyl, formyl, or acetyl>
    44. A compound according to claim 43,
    25 characterized by the fact that N is not directly connected to a net e.roa tome.
    45. A compound according to claim 42, characterized by the fact that R s and R i , or R 3 and form a monocyclic carbocycle.
    30 € 4. Compound according to claim 42, characterized by the fact that A- and A. are connected by
    12
    a carbon bridge.
    47. Composed of according to claim 46,
    characterized by the fact that the bridge comprises -CHg- or -ch 2 çh 2 -.
    48. The compound according to claim 42, characterized by the fact that the aryl groups and / or cycle groups have. 1-3 heteroatoms, in which heteroatoms are selected from among. group consisting of 0, N and S.
    49. Composed of according to claim 48,
    characterized by the fact that each aryl group and / or cycle group is independently substituted with one or more of F, Cl, Br, CHj, CH; ãCH 3 , CH S F, CHF 2 < CF 2í n-Pr, n-Bu , i ~ Bu, see-
    Bu, i-Pr, t ~ Bu, Cd, OH, OMe, OEt, 0 ~ iPr, OCFi,
    methoxycarbonyl, methanesulfonyl, Ph, benzyl, formula, and acetyl.
    58. Composed of according to claim 42,
    characterized by the fact that each arila is independently selected from the group consisting of:



    ®s · ds. A xz x g z
    I / dr
    1V-3, or

    where Rn and Rzz are independently H pu CHy
    The á is selected from the group consisting of
    CHg, CR9R1.0 and a cycle of formula 2) Λ , where n = 2 ~ 5;
    R 9 and Rio are independently CH3 or CH2CH3;
    B.3 is H r CH3, or “(CHzlCHz, where n = 2 ~ 3;
    B «is selected from the group consisting of null, CH; ·, CC. ·: Alkyl, CH CH; : or -C.HCH3 3 $ is selected from the group consisting of - CCHs) K CH 3 , where n - 2 ~ 3, ~ C (CHj) 3, cyclohexyl, cyclopentyl, aryl and arylalkyl;
    Di is phenyl or 2-pyridyl, where phenyl or 2-pyridyl can be independently mono or multiple times substituted with a member of the group consisting of F, Cl, · Br, CF, OCF and CH; and in which the aryl group is selected from the group consisting of


    characterized by the fact that each armpit group, feared, c 2 ~ oyridyl is independently replaced with one or more of F, Ci, Br, CH, Cd, OH, OMe, OEt, CF, OCF, c




    Η

    wherein Eh is an optionally mono or multiple times substituted aryl;
    Bs is a cprj ”'alme.n.te ®no or multiple substituted aryl or carbocele;
    in which aryl is selected from the group consisting of:


    where the carteeicio is cyclohexyl, cyclohexenyl. cycopentyl cu,
    54 * compound according to claim 53 r characterized by the fact that D; 5 is phenyl, 2-pi.ridila, t 3pirídila or 4-pyridyl opcionalment.e independently mono- or multiply substituted.
    55. Compound according to claim 53 or 54, characterized by the fact that D ; is οροί ona Imente independent emente substituted with one or more of F, Cl, Sr,
    5. I, QCF 3 , cn 3 , or CF, .
    56. Compound according to claim s 53 or 54, characterized in that Eh is not replaced.
    57. Compounds according to any of claims 53-56, characterized by the fact that B s is
    0 independently optionally mono or multiple times substituted



    58. Composed according to any of the
    5 claims 53-57, characterized by the fact that it is independently substituted with one or more of Cl, Br, F, I, OMe, CN, CH'3, CF 3 , or methane sulfonyl.
    59. Composed according to. any one of claims 53 ~ 58 f characterized by the fact that S 'is independently substituted with two n more than Cl., Br, F, I, OMe, CN, CH3, CF3, or sulford la methane.
    60. Compound, characterized by the fact that it is selected from the group consisting of:
    [(4-c.lorophenyl) methyl] ([2- (4- (4-methoxyphenyl) ~ 2,2 ~ .dimethyl.xan-4-yl] ethyl}) amine;
    Π 3,4 ~ dimethoxyphenyl] [2- (2,2 ~ dimethyl ~ 4 phenyloxan ~ 4-yl) ethyljamine
    2 ~ [([2 ~ [2-ethyl-2-met 11-4- (4-methylphenyl) ox.an-411] et11} amine) met11] phenol;
    [2- (2,2-dimethyl-4-phenylGxan-4-i.l) ethyl] [(2-fluoropheni.1.} Methyl] amine;
    4 - [((2- [4 ~ (2-methoxyphenyl} ~ 2,2-dimethyloxan-411] et11} amino) methyl] -Ν, Ν- dlmetilaniXina;
    2- [({2- [2-et 11.-4- (4-fluerophenyl) -2-methyloxan-4 yl] ethyl} a.mino) methyl] phenol; and [(3-metoxythophen ~ 2-yl) methyl] {{'2- [(9R) ~ 9 ~ (pyridin.-2-yl) -6-oxaspiro [4.5} decan-9-11] ethyl} ) the mine.
    Ό 61. Compound, characterized by the fact that the structure of:


    62. Pharmaceutical composition, characterized in that it comprises one or more compounds according to any of claims 1-61 and carrier
    5 pharmaceutically acceptable.
    63. The pharmaceutical composition according to claim 62, characterized by the fact that it still comprises at least one analgesic or analgesic which is not an opioid of postponing a .1.
    64. Pharmaceutical composition according to claims 62 or 63, characterized in that it still comprises at least one additional anti-constipation agent.
    65. Method of treating pain, characterized in that it comprises administering to a subject or an individual in need thereof, a compound according to any one of claims 1-61 or a composition according to any one of claims 62-64.
    66. Method according to claim 65, characterized in that the compound is selected from the group consisting of [(4 ~ chlorophenyl] methyl] ({2- [4- (4 ~ methoxyphenyl.) -2,2dimethyloxan -4. · - · 11] ethyl) :) amine;
    [(3,4-dimethylziphenyl) met.11] [2 ~ (2,2-dimethyl-45 phenyloxan-4-yl) ethyl] amine
    2- [({2- [2 ~ ethyl ~ 2 ~ methyl “4 ~ - (4-methyl 1 phenyl) oxan-4i11 et11) amino) methyl] phenol;
    (.2- (2,2-dimethyl-4-phen.yloxan-4-yl) ethyl] [(2 fluorophenyl; methyl] amine;
    10 4 ~ [({2- [4 ~ (2-methoxyphenyl) -2,2-dimethyloxan ~ 411] ethyl) amino) methyl] -N, 'N-dimethylaniline;
    2- [({2- [2-ethyl ~ 4- (4-fluorophenyl) -2 ~ methyloxan ~ 411] ethyl) · amino) methyl] phenol; and [(3-methoxythio-2-yl) methyl] ({2- [(9R) - 9-- (pyridin15 2-11) -6-oxaspi.ro [4 · .5] decan-9-11]] ethyl }) the mine"
    67. Method according to claims 65 or
    66, characterized by the fact that two or more compounds are administered.
    68. Method according to any of 20 claims 65-67, characterized in that the compound is co-administered simultaneously or sequentially with an additional analgesic.
    69. The method of agreeing with any of claims 65-66. characterized by the fact that the
    The compound is oo-administered simultaneously or sequentially with an anti-constipating agent.
    70. Process for the preparation of a compound according to any one of claims 1-62, characterized by the fact that it comprises:

    Mbt iM-Wl
    Ssjswçfc HPle «uir &
    MS

    ,. ^^. ^^ λν. ,,,,, · ,.
    and «ÍB * Ô, S! v®jss . &
    SS

    K (JM. Fcsasess gSea
    Cak »

    »7

    MS:>,! ·, I
    R ~ ísMs. tersiís s «cstóu <sSs smi sn $ s sutssuwkís, p« iiíSss. iwntMa suastisite, | ten & oente fteter & sfii »sararas] <.3! & 0 <.Clt, l MíiSWX-S & í »f # S, i:
    Scoring from aSHrlnwdlslkno to scmsr < oarbonn center cpmem & rto


    the s & u «
    Mfc

    yeah M

    R e S 'sso <M «pe <xJe * Me <$
    R «ê :, Wfiía. ísesSia srasSiiiwíis js «í», S'U SMSÍsMíSS SrtrtiW ytXÍSS iufestiívíí hí & SNSB> W, ^ ÍSsWSrô »
    JWrase: ». 3 ®te

    by understanding to administer to an individual in need of him a therapeutically effective amount of one or more of the following compounds:
    [. (4-chlorophenyl) methyl] (- {2- [4- (4-methoxyphenyl) -2 / 2-dimethyloxan ~ 4-yl] ethyl)) amine [((3,4-dimethoxy phenyl) methyl] [2- (2 , 2-d1met11 -4 phenyloxan ~ 4-yl.) Ethyl] amine
    2- [({2 ~ [2-ethyl-2-methyl-4- {4 ~ methyl.lfenll) oxan-411 max 11> amine} mar, rr] phene 1 [2- (2,2 ~ dimethyl-4-phenylxan ~ 4-i1) ethyl] [(2flucrophenyl) methyl] amine
    4- [({'2- [4- (2-methoxyphenyl) -2 1 2-dimethyloxan-4yl] axyl} amino) methyl] -2, K-dimethylanlline [({2- [í-ethyl-í- ( 4-fluoro.fen.yl) -z-methyloxan-alkyljetyl) amino / methyl] phenol; and [{3-methoxythiophen ~ 2-yl) methyl] ({2-i (9R) -9 (pyridin-2-yl) -6-oxaspiro [4,5] decan-9-yl] ethyl]) amine.
    72. A defined compound or composition in any one of claims 1 to 64, characterized in that it is for preventing or treating pain in a mammal.
    73. The compound or composition defined in any one of claims 1 to 64, characterized in that .10 is for the manufacture of a medicament to prevent or treat a mammal.
    74. Use of any compound or composition as described in any one of claims 1 to 64, characterized in that it is to prevent or treat pain.
    15 a fierce moral.
    75. Use of any compound or composition as described in any of claims 1 to 64, characterized in that it is in the manufacture of a medicament to prevent or treat pain in. a mammal.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112013024136A2|2020-01-14|opioid receptor ligands and methods of using and making them
    ES2620446T3|2017-06-28|New bicyclic heterocyclic compound
    US20210023043A1|2021-01-28|Methods of Treating Hyperalgesia
    WO2017106547A1|2017-06-22|Combinations of opioid receptor ligands and cytochrome p450 inhibitors
    WO2012075232A1|2012-06-07|Opioid receptor ligands and methods of using and making the same
    NZ713143B2|2017-08-29|Opioid receptor ligands and methods of using and making same
    NZ615993B2|2016-03-01|Opioid receptor ligands and methods of using and making same
    同族专利:
    公开号 | 公开日
    IL272165A|2021-07-29|
    JP2021176885A|2021-11-11|
    KR20140047599A|2014-04-22|
    US9642842B2|2017-05-09|
    EA201391332A1|2014-04-30|
    US9849119B2|2017-12-26|
    EP2688403B1|2017-05-31|
    AU2012230761A1|2013-05-02|
    AU2017200745B2|2018-02-22|
    US20120245181A1|2012-09-27|
    PL3290415T3|2021-07-19|
    US9309234B2|2016-04-12|
    IL272165D0|2020-03-31|
    CY1119057T1|2018-01-10|
    KR101991327B1|2019-06-20|
    AU2012230761B2|2016-11-03|
    JP2014508811A|2014-04-10|
    WO2012129495A1|2012-09-27|
    KR20190072665A|2019-06-25|
    HRP20171021T1|2017-09-22|
    KR20180100453A|2018-09-10|
    IL284407D0|2021-08-31|
    KR101991326B1|2019-06-20|
    JP2016155843A|2016-09-01|
    HUE054055T2|2021-08-30|
    US8835488B2|2014-09-16|
    LT2688403T|2017-07-25|
    HUE032948T2|2017-11-28|
    ME02754B|2018-01-20|
    EA025456B1|2016-12-30|
    US11077098B2|2021-08-03|
    ES2632009T3|2017-09-07|
    NZ615993A|2015-11-27|
    US20160250199A1|2016-09-01|
    CN103702561B|2017-02-22|
    JP2018048193A|2018-03-29|
    CA2830742A1|2012-09-27|
    US20190343819A1|2019-11-14|
    NZ713143A|2017-05-26|
    IL228506D0|2013-12-31|
    US20180311222A1|2018-11-01|
    RS56111B1|2017-10-31|
    HK1250984A1|2019-01-18|
    EP2688403A4|2014-10-15|
    PT3290415T|2021-03-29|
    JP2020073570A|2020-05-14|
    PT2688403T|2017-07-13|
    JP6649341B2|2020-02-19|
    IL228506A|2016-11-30|
    EP3290415B1|2020-12-30|
    US10588898B2|2020-03-17|
    CN103702561A|2014-04-02|
    US20130331408A1|2013-12-12|
    DK3290415T3|2021-03-22|
    AU2017200745A1|2017-02-23|
    SI2688403T1|2017-08-31|
    EP3290415A1|2018-03-07|
    ES2857549T3|2021-09-29|
    JP5912169B2|2016-04-27|
    US9044469B2|2015-06-02|
    US20170326124A1|2017-11-16|
    EP3872076A1|2021-09-01|
    JP6243949B2|2017-12-06|
    IL243318D0|2016-02-29|
    EP2688403A1|2014-01-29|
    US20150246904A1|2015-09-03|
    DK2688403T3|2017-07-24|
    JP6923683B2|2021-08-25|
    KR102129247B1|2020-07-06|
    IL243318A|2020-02-27|
    PL2688403T3|2017-09-29|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    JPS5825980B2|1976-02-12|1983-05-31|Yamasa Shoyu Kk|
    US4602035A|1983-12-07|1986-07-22|Hoechst-Roussel Pharmaceuticals Inc.|Antidepressant alkylamines|
    US5223530A|1990-07-31|1993-06-29|Sri, International|Arylcycloalkanepolyalkylamine ligands|
    US5401629A|1990-08-07|1995-03-28|The Salk Institute Biotechnology/Industrial Associates, Inc.|Assay methods and compositions useful for measuring the transduction of an intracellular signal|
    WO1996005166A1|1994-08-11|1996-02-22|Yamanouchi Pharmaceutical Co., Ltd.|Substituted amine derivative and medicinal composition containing the same|
    EP0833622B8|1995-06-12|2005-10-12|G.D. Searle &amp; Co.|Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor|
    US6071918A|1999-07-21|2000-06-06|Dupont Pharmaceuticals Company|Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence|
    GB0130261D0|2001-12-18|2002-02-06|Pfizer Ltd|Lactams as tachykinin antagonists|
    TW200307539A|2002-02-01|2003-12-16|Squibb Bristol Myers Co|Cycloalkyl inhibitors of potassium channel function|
    PT1562595E|2002-09-19|2008-07-28|Lilly Co Eli|Diaryl ethers as opioid receptor antagonists|
    AU2004278414B2|2003-10-01|2012-05-24|Adolor Corporation|Spirocyclic heterocyclic derivatives and methods of their use|
    US20100022637A1|2005-09-29|2010-01-28|The Trustees Of Columbia University In The City Of New York|Identification of anti-cancer compounds and compounds for treating huntington's disease and methods of treatment thereof|
    WO2007081966A2|2006-01-09|2007-07-19|University Of Southern California|Small molecules for treating cancer and abnormal cell proliferation disorders|
    US7645767B2|2006-08-31|2010-01-12|Trinity Laboratories, Inc.|Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy|
    EP2094692B1|2006-11-01|2012-11-28|Bristol-Myers Squibb Company|Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof|
    US8198311B2|2006-11-01|2012-06-12|Bristol-Myers Squibb Company|Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof|
    US20090028873A1|2007-07-27|2009-01-29|Auspex Pharmaceuticals, Inc.|Substituted cyclohexanols|
    DK2260042T3|2008-03-27|2011-10-31|Gruenenthal Gmbh|Substituted spirocyclic cyclohexane derivatives|
    FR2939136B1|2008-12-02|2010-12-03|Galderma Res & Dev|NOVEL 4- -BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN HUMAN MEDICINE AND COSMETICS|
    EP2415471A1|2010-08-03|2012-02-08|Laboratorios Del. Dr. Esteve, S.A.|Use of sigma ligands in opioid-induced hyperalgesia|
    FR2967672B1|2010-11-22|2012-12-28|Sanofi Aventis|NITROBENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATIONS THEREOF|
    LT2688403T|2011-03-23|2017-07-25|Trevena, Inc.|Opioid receptor ligands and methods of using and making same|LT2688403T|2011-03-23|2017-07-25|Trevena, Inc.|Opioid receptor ligands and methods of using and making same|
    CA2840095A1|2011-07-06|2013-01-10|Gilead Sciences, Inc.|Compounds for the treatment of hiv|
    TWI694071B|2013-03-01|2020-05-21|美商基利科學股份有限公司|Therapeutic compounds for treating a retroviridae viral infection|
    WO2015130964A1|2014-02-28|2015-09-03|Gilead Sciences, Inc.|Therapeutic compounds|
    US10626081B2|2015-09-16|2020-04-21|Metacrine, Inc.|Farnesoid X receptor agonists and uses thereof|
    WO2017049177A1|2015-09-16|2017-03-23|Metacrine, Inc.|Farnesoid x receptor agonists and uses thereof|
    JP6905530B2|2015-09-16|2021-07-21|メタクリン，インク．|Farnesoid X receptor agonist and its use|
    HUE048032T2|2015-10-15|2020-05-28|Jiangsu Hengrui Medicine Co|Oxa spiro derivative, preparation method therefor, and applications thereof in medicines|
    CN106588899B|2015-10-15|2019-11-15|江苏恒瑞医药股份有限公司|6- oxaspiro [4.5] decane analog derivative, preparation method and its application in medicine that pyridyl group replaces|
    US10588889B2|2015-12-14|2020-03-17|Trevena, Inc.|Methods of treating hyperalgesia|
    WO2017105881A1|2015-12-15|2017-06-22|NeuForm Pharmaceuticals, Inc.|Deuterated compounds for treating pain|
    JP2019503351A|2015-12-17|2019-02-07|トレベナ・インコーポレイテッドＴｒｅｖｅｎａ， Ｉｎｃ．|Combination of opioid receptor ligand and cytochrome P450 inhibitor|
    CN107098876B|2016-02-23|2021-04-06|江苏恒瑞医药股份有限公司|Phenyl propionamide derivative, preparation method and medical application thereof|
    JP6889186B2|2016-07-01|2021-06-18|ノイフォルム・ファーマシューティカルズ・インコーポレイテッドＮｅｕｆｏｒｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ．|Deuterium compounds for treating pain|
    EP3597646A1|2016-08-19|2020-01-22|Gilead Sciences, Inc.|Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection|
    WO2018108319A1|2016-12-16|2018-06-21|Laboratorios Del Dr. Esteve, S.A.|Tetrahydropyran and tetrahydrothiopyran amide derivatives having multimodal activity against pain|
    JP2020508301A|2017-02-17|2020-03-19|トレベナ・インコーポレイテッドＴｒｅｖｅｎａ， Ｉｎｃ．|Delta-Opioid receptor modulating compounds containing 7-membered azaheterocycles, methods of use and methods of manufacture|
    US11236071B1|2017-03-15|2022-02-01|Metacrine, Inc.|Farnesoid X receptor agonists and uses thereof|
    JP2020514333A|2017-03-15|2020-05-21|メタクリン，インク．|Farnesoid X receptor agonists and uses thereof|
    US20200054594A1|2017-04-14|2020-02-20|Jiangsu Hengrui Medicine Co., Ltd.|Pharmaceutical composition containing mor agonist and kor agonist, and uses thereof|
    CA3057383A1|2017-04-14|2018-10-18|Jiangsu Hengrui Medicine Co., Ltd.|Opioid receptoragonist salt, fumarate salt i crystal form thereof and preparation method thereof|
    CN108727347B|2017-04-14|2020-06-16|江苏恒瑞医药股份有限公司|Crystal form of opioid receptoragonist and preparation method thereof|
    CN109206417A|2017-07-04|2019-01-15|四川海思科制药有限公司|opioid receptor agonist and its application|
    AR112413A1|2017-08-17|2019-10-23|Gilead Sciences Inc|SOLID FORMS OF AN HIV CAPSID INHIBITOR|
    AR112412A1|2017-08-17|2019-10-23|Gilead Sciences Inc|CHOLINE SALT FORMS OF AN HIV CAPSID INHIBITOR|
    WO2019052557A1|2017-09-18|2019-03-21|上海华汇拓医药科技有限公司|μ-OPIOID RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF IN FIELD OF MEDICINE|
    AU2018341782A1|2017-09-28|2020-04-16|Jiangsu Hengrui Medicine Co., Ltd.|Method for preparing oxaspirocycle derivative, and intermediate thereof|
    AU2018349930A1|2017-10-13|2020-04-16|Shandong Luye Pharmaceutical Co., Ltd.|2,6-dioxaspirodecane derivatives and preparation method therefor and pharmaceutical applications thereof|
    CA3083028A1|2017-12-06|2019-06-13|Jiangsu Hengrui Medicine Co., Ltd.|Use of kor agonist in combination with mor agonist in preparing drug for treating pain|
    KR20200136384A|2018-02-05|2020-12-07|알케르메스, 인코포레이티드|Compounds for the treatment of pain|
    CA3089590A1|2018-02-15|2019-08-22|Gilead Sciences, Inc.|Pyridine derivatives and their use for treating hiv infection|
    AU2019222559B2|2018-02-16|2022-01-20|Gilead Sciences, Inc.|Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection|
    CN111836807A|2018-04-28|2020-10-27|四川科伦博泰生物医药股份有限公司|Oxaspiro compounds, preparation method and application thereof|
    TW202015678A|2018-05-14|2020-05-01|大陸商江蘇恆瑞醫藥股份有限公司|Pharmaceutical composition of mor receptor agonist|
    TW202024052A|2018-09-18|2020-07-01|美商梅塔克林公司|Farnesoid x receptor agonists and uses thereof|
    WO2020073984A1|2018-10-12|2020-04-16|江苏恒瑞医药股份有限公司|Crystal form of opioid receptoragonist and preparation method thereof|
    CN112638907A|2018-10-12|2021-04-09|江苏恒瑞医药股份有限公司|Crystalline form of an opioid receptoragonist and methods of preparation|
    CN112334465A|2019-01-17|2021-02-05|上海海雁医药科技有限公司|Tricyclic substituted oxaspiro derivatives, preparation method and medical application thereof|
    CN111662284B|2019-03-06|2021-08-10|上海海雁医药科技有限公司|Biheterocyclic substituted oxaspiro derivative, preparation method and medical application thereof|
    WO2021143803A1|2020-01-17|2021-07-22|上海海雁医药科技有限公司|Optically pure oxaspiro-substituted pyrrolopyrazole derivative, preparation method therefor and pharmaceutical use thereof|
    CN113214264A|2020-01-21|2021-08-06|上海海雁医药科技有限公司|Dihydropyrrolo five-membered heteroaryl substituted oxaspiro derivatives, preparation method and medical application thereof|
    WO2022033380A1|2020-08-10|2022-02-17|成都苑东生物制药股份有限公司|Mor receptor agonist compound, preparation method therefor, and use thereof|
    法律状态:
    2020-01-28| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2020-02-04| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|
    2020-06-16| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
    2021-03-09| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|
    2021-03-16| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|
    2021-03-16| B15K| Others concerning applications: alteration of classification|Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 43/16 , A61K 31/35 Ipc: C07D 311/96 (2006.01), A61K 31/35 (2006.01), A61K |
    2021-03-30| B07B| Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]|Free format text: ANULADA A PUBLICACAO CODIGO 7.5 NA RPI NO 2619 DE 16/03/2021 POR TER SIDO INDEVIDA. |
    2021-10-13| B350| Update of information on the portal [chapter 15.35 patent gazette]|
    优先权:
    申请号 | 申请日 | 专利标题
    US201161466809P| true| 2011-03-23|2011-03-23|
    US201261596808P| true| 2012-02-09|2012-02-09|
    PCT/US2012/030327|WO2012129495A1|2011-03-23|2012-03-23|Opioid receptor ligands and methods of using and making same|
    [返回顶部]